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Abstract 
The highly specialised brain capillary endothelial cells (BCEC) that constitute the 
blood brain barrier (BBB) exhibit high resilience to the penetration of xenobiotic and 
biologic therapeutics, making drug delivery to the central nervous system (CNS) a 
challenging feat. Endogenous BCEC receptors such as transferrin receptor (TfR) 
have been proposed as exploitable targets for therapeutic payload transport into the 
CNS, and have been successfully targeted using monoclonal antibodies to deliver 
therapeutic molecules into the brains of rodents and non-human primates via 
receptor mediated transcytosis (RMT). 
The overall aim of this study was to develop a BCEC drug delivery system using 
alternative domains to antibodies e.g. peptides and ssDNA aptamers, as a means of 
exploiting endogenous receptor transport mechanisms to deliver macromolecular 
drugs into the CNS via RMT. 
The expression of three receptor candidates, TfR, low-density lipoprotein receptor 
(LDLR) and low-density lipoprotein-related receptor protein 1 (LRP1) were 
characterised for use as selectable targets on the cell surface of Immortalised 
human brain endothelial cells (hCMEC/D3) by flow cytometric analysis. Aptamers 
and cyclic peptide domains were then selected via in vitro selection techniques. 
The present findings highlight the selection of 13 peptides that demonstrate species 
cross-reactivity to human, mouse and rat TfR as determined by phage ELISA. 
Moreover, the lead candidate Pep1 was identified to share homology with a 
conserved ‘DCSGNFCLF’ motif found on transferrin. When expressed as a bivalent 
peptide-Fc fusion molecule, Pep1 was shown to internalise within the mouse and 
human brain endothelial cell lines, bEnd.3, and hCMEC/D3. Additionally, the overall 
enrichment of hTFR specific aptamers was demonstrated following twelve rounds of 
selection and high throughput sequencing of selected pools, data that warrants 
further investigation. 
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1.1. Burden of Neurological Diseases 
Given today’s globally aging population we are witnessing high rates of 
morbidity due to debilitating neurological conditions. According to the global burden 
of disease study 2010, neurological and cerebrovascular diseases are estimated to 
represent 7.1% of the overall global disease burden for all age groups (Murray et al., 
2012). Recently, it has been suggested that these figures are largely underestimated 
due to the categorisation of mental illnesses, with true figures estimated to be 13% 
(Vigo et al., 2016). In the UK alone, it is regarded that the economic burden of 
dementia is equivalent to 23.5 billion pounds per year. This estimated financial 
burden is expected to more than double by 2051 due to the growing aging population 
in the UK (Pool, 2015). 
Despite the development of many drugs with therapeutic potential, very few 
treatments are clinically approved for treating disorders of the central nervous 
system (CNS), and this is primarily due to the impermeable nature of the blood brain 
barrier (BBB) (Gribkoff and Kaczmarek, 2017). The BBB excludes the majority of 
large and small molecule drugs from reaching the CNS at therapeutically relevant 
concentrations, and this poses major limitations for the systemic delivery of neuro-
therapeutics to the CNS via non-invasive delivery methods. The impermeability of 
the BBB to therapeutics has meant that even with today’s advancements in medicine 
and targeted drug delivery, an efficient transport mechanism for delivering 
macromolecular drugs into the CNS at pharmacologically relevant concentrations 
remains to be established (Stanimirovic et al., 2015). 
1.2. Blood-Brain Barrier Historical Aspects 
Pioneering experiments carried out in 1885 by the German physician Paul 
Ehrlich demonstrated that intravenously injecting dyes into an animal’s circulation 
caused staining of all peripheral organs with the exception of tissues of the CNS 
(Serlin et al., 2015). This finding was initially attributed to a low affinity of the alkaline 
dye to CNS tissues. However, this initial assumption was later discredited in 1913 
with successive studies carried out by Edwin Goldmann. Goldmann found that 
injecting trypan blue into the cerebro-spinal fluid (CSF) of rats caused exclusive 
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staining of the CNS and not the peripheral organs. This study enabled Goldmann to 
conclude that the exclusive staining of the CNS was due to the presence of a barrier 
between the circulatory system and the CNS (Abbott et al., 2010). 
The introduction of electron microscopy (EM) techniques further enhanced our 
understanding of the BBB, by allowing the differentiation of intercellular regions 
between endothelial cells and the surrounding perivascular region. Seminal work by 
Reese and Karnovsky (1967) demonstrated that intravenous injection of horseradish 
peroxidase (an electron dense marker) did not cause permeation of endothelial cells. 
Through the use of transmission electron microscopy (TEM) at magnifications 
greater than 135,000x, the authors also documented the cause of reduced solute 
permeability to the CNS as being due to tight junctions located within the intercellular 
clefts of cerebrovascular endothelial cells. 
1.3. Blood-Brain Barrier Structure and Function 
The CNS is a highly delicate system that is susceptible to damage by a wide 
variety of blood-borne and exogenous substances. A highly regulated neuronal 
extracellular microenvironment is therefore necessary for effective neuronal and glial 
function. Three principle barriers exist between the blood and brain tissue; the blood-
brain barrier, the blood-CSF barrier, and the arachnoid barrier, these are shown in 
Figure 1.3.1.  
The BBB constitutes the largest surface area for exchange between the blood 
and the brain interfaces. Functionally, the BBB maintains CNS homeostasis by 
regulating the movement of ions, solutes, proteins and migrating immune cells 
(Abbott et al., 2010). This mechanism protects the CNS from entry of potentially 
neurotoxic agents and provides a highly regulated transport system that facilitates 
the supply of necessary nutrients to the brain parenchyma, whilst simultaneously 
sustaining the ionic concentration gradient within the CNS for optimal neuronal 
function (Abbott, 2013).  
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Figure 1.3.1: Barriers of the brain (adapted from Abbott, et al. 2010). 
Schematic representation of the three principle barriers found between the blood and brain 
interfaces. The blood-brain barrier (A) is formed via specialised tight junctions between brain 
capillary endothelial cells and is the largest surface for exchange of solutes and drugs. The blood-
cerebrospinal fluid barrier (B) is located at the lateral third and fourth ventricles of the brain and 
tight junctions are found at the CSF apical surface of epithelial cells. The arachnoid barrier (C) is 
located below the dura at the multilayered arachnoid cells. Tight junctions are located between the 
arachnoid cells of the inner layer. Although this region is avascular, the CSF can exchange with the 
blood via arachnoid villi, that project into the nearest source of blood located at the sagittal sinus. 
 
BBB integrity is mediated and maintained through a number of structural and 
cellular components, which are shown in Figure 1.3.2. Alterations in these 
components through various mechanisms results in BBB disruption, which has been 
associated with several CNS pathological conditions, including Alzheimer’s and 
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Parkinson’s diseases, multiple sclerosis and stroke (Chung et al.,2013; Haarmann et 
al., 2015; Halliday et al., 2016; Liu et al., 2012, Wan et al., 2015). 
 
 
 
Figure 1.3.2: Schematic representation of the neurovascular unit (Adapted from Abbott, et al. 
2010) 
Figure showing cellular interactions of the BBB functional unit. Pericytes form part of the 
perivascular basal lamina. Astrocytic endfeet processes surround the basal lamina and provide 
structural integrity to the vascular unit. 
 
The BBB primarily consists of single cell thick layer of brain capillary 
endothelial cells (BCEC). These highly polarised microvascular endothelial cells are 
anatomically flat and possess oval nuclei that form the thickest region of the capillary 
wall. A luminal or apical endothelial membrane interacts with the blood interface, 
while the opposing abluminal or basolateral endothelial membrane interacts with the 
CNS. Adjacent BCEC are connected via a belt like region of specialised intercellular 
tight junctions (TJ) and adherens junctions, which form a physical barrier through 
interaction of several intercellular anchoring proteins (Bauer et al., 2014). In addition 
to sealing the paracellular space, tight junctions alongside multi-protein complexes 
based on the proteins Par, Crumbs and Scribble, play a role in establishing apico-
basal polarity and the specific distribution of membrane components at distinct sites 
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of the plasma membrane (Artus et al., 2014; Lee and Streuli, 2014). Polarisation of 
cells is vital for correct functioning of endosomal trafficking pathways and the 
transport of proteins to the correct membrane surfaces (Apodaca et al., 2012; 
Cramm-Behrens et al., 2008). The tight junctional proteins expressed in BCEC are 
outlined in Figure 1.3.3. 
 
 
Figure 1.3.3: Structural tight junctions at the BBB (adapted from Abbott, et al. 2010) 
Figure outlining the tight junctional protein complex between adjacent BCEC. Claudins 3 and 5 are 
primarily responsible for barrier impermeability to paracellular diffusion, through direct association 
across the intercellular cleft. Occludin also forms self-associations across the intercellular cleft, 
however these are less tight. Claudins and occludin both form intracellular linkages to cellular 
scaffolding proteins (ZO-1, 2, and 3). ZO scaffolding proteins form further interactions with actin-
associated proteins such as cingulin. VE cadherin anchors adjacent cells and provides structural 
integrity. JAMs are thought to interact with leukocytes during leukocyte adhesion. 
 
As observed with epithelial cells in other tissues, the TJs between BCEC 
consist of the transmembrane proteins, occludin, claudins and junctional adhesion 
molecules (JAMs) (Morita et al., 2003). The tight junctional protein complexes 
formed produce phenotypically unique endothelial cells that restrict paracellular 
permeability of solutes. Claudins 3 and 5 are primarily responsible for barrier 
impermeability to paracellular diffusion, by forming homophilic and/or heterophilic 
tight interactions with each other across the inter-cellular cleft (Yamamoto et al., 
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2008). Claudins and occludin form additional intracellular associations with the 
cytoplasmic scaffolding proteins zonula occludens (ZO-1, ZO-2 and ZO-3), these 
successively form linkages with actin cytoskeletal associated proteins such as 
cingulin (Luissint et al., 2012). It has been shown that calcium influx can modulate 
the efficacy of tight junctional barriers by promoting cross-bridge movement of actin 
and myosin filaments (De Bock et al., 2012). This generates a contractile force, 
which pulls adjacent cells apart resulting in a reduced trans-endothelial electrical 
resistance (TEER) and increased paracellular permeability (Schnittler et al., 1990). 
The BBB exhibits highly dynamic barrier properties (variable regulation of TJ 
and receptor protein expression). This feature is due to close interactions of the 
endothelial cells with several other cell types. Indeed, BCEC alongside pericytes, 
perivascular neurons, and astrocytic end feet projections constitute the functional 
neurovascular unit as shown in Figure 1.3.2. This intimate relationship allows for 
biochemical modulation and regulation of endothelial cell permeability according to 
various pathological and physiological situations (Persidsky et al., 2006). 
BCEC are surrounded by the basal lamina, a three-dimensional basement 
membrane, 20 – 200 nm in thickness, that provides a support for attachment and 
interaction of all cellular components of the neurovascular unit. It is composed of the 
structural proteins collagen and elastin as well as fibronectin, laminin, proteoglycans 
and cell adhesion molecules (CAM) (Thomsen et al., 2017) 
The basement membrane is essential for maintenance of BBB integrity. 
Deletion of laminin α2 derived from astrocytes causes impaired vascular smooth 
muscle cells and haemorrhage within the brain (Chen et al., 2013). Basement 
membrane digestion by matrix metalloproteinases, has been shown to disrupt 
cytoskeletal anchoring of BCEC, causing a reduced tight junctional integrity and 
increased barrier permeability (Cardoso et al., 2010). Upregulation of matrix 
metalloproteinases and the plasminogen activator system following stroke has been 
shown to lead to degradation of the vascular basement membrane, compromising 
the BBB, and leading to infiltration of the brain parenchyma by neutrophils, 
macrophages and monocytes (Katsu et al., 2010; Fukuda et al., 2004). Additionally, 
amyloid beta (Ab) peptide deposition in the basement membrane during cerebral 
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amyloid angiopathy, has be associated with basement membrane thickening and 
changes in its protein composition (Held et al., 2017; Hawkes et al., 2013). Similarly, 
basement membrane remodelling and thickening has been reported with multiple 
sclerosis and this is thought to play a role in the further recruitment of inflammatory 
cells via the transforming growth factor- β1 (TGF- β1) (van Horssen et al., 2006; 
2005).  
Surrounding up to 32% of the abluminal side of BCEC in microvessels, 
pericytes are embedded within the para-cellular basal lamina. Pericytes provide 
structural support to BCEC, via integrin mediated endothelial cell-pericyte and 
pericyte-extracellular matrix adhesive interactions. Pericytes have also been 
identified to regulate capillary blood flow (via contractile activity of cytoskeletal 
filaments), angiogenesis and immunogenic responses to the brain (Kamouchi et al., 
2011). Additionally, pericytes are also responsible for the synthesis of most 
components of the basal lamina and play an essential role in endothelial cell 
differentiation, migration and proliferation (Kamouchi et al., 2011).  
Astrocytic end feet projections surround 95% of BCEC and their associated 
basal lamina. Alongside pericytes, astrocytes have been shown to regulate the 
synthesis of proteoglycans that maintain the charge selectivity of the BCEC. In vivo 
studies have identified that selected loci removal of astrocytes leads to a delayed 
loss of vascular function, with subsequent vascular repair processes remaining 
effective even in the absence of astrocytic contact (Willis et al., 2004). Furthermore, 
astrocytes have been demonstrated to play an important role in controlling the active 
and passive uptake of K+ from the interstitial space. Studies have shown that K+ 
concentration is maintained at a consistent 3 mM, irrespective of fluctuations in 
plasma K+. Additionally, K+ concentrations return to the aforementioned 3 mM 
concentration following acute elevations induced by neuronal activity and seizures 
(Schielke et al., 1990). Astrocytic endfeet are enriched in the gap junctional proteins 
connexins 30 and 43 (Cx30 and Cx43) which are responsible for the trafficking of 
ions within the perivascular space. Knockout of these connexins in mice has been 
shown to lead to astrocytic endfeet oedema (via the loss of the water channel 
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aquaporin-4) and reduced anchorage of astrocytic endfeet to the basal lamina (via 
the loss of the transmembrane protein β-dystroglycan) (Ezan et al., 2012). 
1.4. Transport mechanisms present at the Blood-Brain Barrier 
Several active and passive transport mechanisms are present on the cell 
surface of brain endothelial cells that are essential for transport of nutrients to the 
CNS and removal of cellular metabolic waste products. These transport mechanisms 
vary in their transport capabilities and are outlined in Figure 1.4.1. 
 
 
Figure 1.4.1: Schematic representation of endogenous transport mechanisms present on the 
cell surface of BCEC (Adapted from Abbott, et al. 2010) 
Figure outlining potentially exploitable transport mechanisms for CNS drug delivery at the cell 
surface of brain capillary endothelial cells. The paracellular diffusion pathway is effectively sealed 
due to the presence of tight junctional complexes. Transcellular diffusion is limited to small lipophilic 
molecules no larger than 500 Da. Efflux transporters actively expel passively diffusing substrates. 
Solute carriers allow the active bi-directional transport of solutes and nutrients across a 
concentration gradient. Transcytosis mechanisms rely on vesicular cargo transport across the BCEC. 
Receptor mediated transcytosis relies on receptor specific binding and transport of a ligand, whereas 
adsorptive mediated transcytosis relies on the non-specific binding of a positively charged molecule 
to the negatively charged plasma membrane. Both mechanisms subsequently undergo endocytic 
internalisation and subsequent trafficking through the cell to the abluminal membrane where they 
may be released and made available to the CNS. 
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The simplest form of transport across the BBB is passive diffusion. Para-
cellular diffusion of hydrophilic compounds is highly prohibited due the unique tight 
junctional protein complexes anchoring neighbouring BCEC in close proximity. 
Transcellular diffusion is possible, however limited to lipophilic compounds no larger 
than 400-500 Da in size (Airan et al., 2017). Transcellular diffusion is further 
complicated by the capability of a given compound to form hydrogen bonds at the 
BCEC cell membrane. Molecules that can form greater than six hydrogen bonds and 
have a polar surface area greater than 80 Å2 are less likely to transition from 
aqueous phase into the lipid phase of the plasma membrane due to increased free 
energy requirement (Clark, 2003; Mahar Doan et al., 2002). 
 Carrier-mediated transport involves the active transport of compounds in a 
direction opposing to the concentration gradient. The activity of these transporters is 
adenosine triphosphate (ATP)-driven and sensitive to fluctuations in temperature. 
Moreover, these carriers may function either as influx transporters, efflux 
transporters or a combination of both (Ohtsuki and Terasaki, 2007). Several active 
efflux carriers are present at the BBB. These transporters are responsible for the 
elimination of hydrophilic metabolic substrates from the brain into the circulation 
(Terasaki and Hosoya, 1999). Alongside their natural ligands, many efflux 
transporters also bind and eliminate CNS drugs preventing their accumulation within 
the CNS (Groenendaal et al., 2007; Leggas et al., 2004; Yang and Liu., 2008). 
Examples include the ABC efflux unidirectional transporters, P-Glycoprotein (Pgp) 
and breast cancer resistance protein (BRCP), and the bi-directional multi drug 
resistance associated protein family (MRP 1-5) (Begley, 2004). The most 
characterised of these efflux transporters, Pgp, is localised to the apical membrane 
and eliminates large, cationic, hydrophobic molecules (de Lange, 2013; Urquhart 
and Kim, 2009). Solute carriers facilitate the bi-directional transport of nutrients such 
as amino acids, glucose, nucleosides, and monocarboxylic acids (Ohtsuki and 
Terasaki, 2007). The rate of transport of these carriers is dependent on the 
concentration of ligand present, and can also be modulated by competitive and non-
competitive inhibitors (de Lange, 2013). As a targeted drug delivery approach carrier 
mediated transport has a large transport capacity but is restricted by cargo size, 
stereo-selective (only binding endogenous substrates), and plasma concentration 
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which can reach saturation and faces significant competition with endogenous 
substrates (Ohtsuki and Terasaki, 2007).  
 Two vesicular transcytosis mechanisms are also responsible for the transport 
of large macromolecules, adsorptive-mediated transcytosis (AMT) and receptor-
mediated transcytosis (RMT). AMT involves the non-specific endocytosis and 
subsequent transcytosis of polycationic compounds through binding to 
electrostatically generated anionic regions on the plasma membrane within the 
glycocalyx, a lattice of glycoproteins, glycosaminoglycans and proteoglycans which 
line the vascular endothelium (Zhu et al., 2017). RMT allows for the transport of 
large, polar macromolecular proteins and peptides via receptor specific ligand 
binding and subsequent endocytosis, intracellular trafficking and exocytosis at the 
abluminal cell membrane (Demeule, Currie, et al., 2008; Haqqani et al., 2017). The 
detailed cellular trafficking mechanisms are discussed in section 1.5. The most 
prevalent ligands that have been shown to endocytose at BCEC are transferrin 
(Manich et al., 2013), insulin (Gray et al., 2017) and low-density lipoprotein (LDL) 
(Demeule, Currie, et al., 2008). RMT mostly occurs at clathrin-coated pits, which are 
primarily localised at the luminal membrane suggesting that transcytosis occurs 
predominantly in the blood to brain direction (Simionescu et al., 1988). 
The large network of capillaries within the brain make the exploitation of 
vascular delivery mechanisms highly favourable. The average inter-capillary distance 
is 40 µm and therefore the body of a neuron is never more than 10 – 20 µm from the 
nearest capillary (Duvernoy et al., 1983; Schlageter et al., 1999; Wong et al., 2013). 
Established transport mechanisms provide potentially exploitable means of targeted 
drug delivery to the brain (Gaillard et al., 2012). The present study will focus on RMT 
as an exploitable mechanism of crossing BCEC and overcoming the transport 
restrictions of the BBB. In order to comprehend RMT we must explore the cellular 
trafficking mechanisms present at the BBB. 
1.5. Cellular trafficking at the BBB 
The cellular plasma membrane is impervious to many biological components 
within the blood. Endocytosis is a vital mechanism by which all mammalian cells can 
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acquire nutrients, proteins and solutes from their extracellular environment (De Bock 
et al., 2016). In addition to nutrient uptake, endocytosis is vital for activation of 
cellular signalling pathways, membrane component recycling and degradation 
(Kurgonaite et al., 2015; Fletcher et al., 2014) . Furthermore, these established 
endocytic mechanisms have been exploited by viruses, bacteria and parasites in 
order to gain access to the intra-cellular environment of the cell (Abraham et al., 
2010; Ahmad et al., 2017; Asmat et al., 2014; Bonazzi et al., 2012; Botero-Kleiven et 
al., 2001; Romero et al., 2000). 
Macromolecules that are too large or polar to traverse the hydrophobic 
phospholipid bilayer can be taken up by cells from the extracellular environment via 
several pinocytotic pathways that are subdivided into clathrin-dependent and 
clathrin-independent endocytosis mechanisms, and macropinocytosis (De Bock et 
al., 2016).  
These highly regulated pathways begin at specific regions in the plasma 
membrane (clathrin coated pits, non-coated lipid rafts and caveolae) and lead to the 
formation of endocytic vesicles, distinguishable via their size and vesicular markers 
(Xu et al.,2017). The trafficking fate of internalised vesicles and their content is 
further determined according to the subcellular endosomal compartments with which 
they fuse, i.e. early or recycling endosomes, late endosome or lysosome (Kalaidzidis 
et al., 2015).  
1.5.1. Macropinocytosis 
Macropinocytosis, is a non-specific, fluid phase endocytosis process that 
occurs via rearrangement of cytoskeletal components that lead to the formation of 
membrane protrusions. These subsequently fold back to the plasma membrane to 
encapsulate extracellular fluid (Müller-Greven et al., 2017). Unlike clathrin-coated 
and caveolae internalised vesicles, macropinosomes are distinguishable via their 
large size (0.2 – 5 µm) and lack of vesicular coating (Preston et al., 2014). Whilst in 
theory macropinocytosis can mediate transcytosis across cells, it faces significant 
hurdles as a drug delivery mechanism at the BBB, primarily due to lack of specificity 
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and reduced pinocytotic uptake at healthy BCEC (Lim and Gleeson, 2011; Reese 
and Karnovsky, 1967). 
1.5.2. Caveolae-dependant endocytosis 
Caveolae are morphologically and functionally distinct from clathrin-coated 
vesicles. They consist of flask-shaped invaginations within the plasma membrane 
and once internalised their vesicles are 50-100 nm in size and have a neutral pH. 
The plasma membrane regions that form caveolae are enriched in saturated 
phospholipids, sphingolipids, cholesterol and ethanolamine plasmalogens (Andreone 
et al., 2017). Caveolae vesicles are formed through interaction of the cavin family of 
cytosolic proteins and caveolin coat proteins (Cav1, Cav2 and Cav3) (De Bock et al., 
2016).  
Typically, BCEC possess few caveolae (Soares et al., 2016). However, 
several receptors have been identified at the BBB that function via this mechanism. 
Low-density lipoprotein receptor (LDLR) has been shown to function via this 
mechanism at the BBB and more recently on human umbilical vein endothelial cells 
(HUVEC) (Candela et al., 2008; Bian et al., 2017). Another receptor which mediates 
the transport of Aβ, receptor for advanced glycation end-products (RAGE), has also 
been shown to function via caveolae-mediated transport (Candela et al., 2010; D. 
Zhu et al., 2018). More recently, a novel BBB receptor, CD98 heavy chain (CD98hc), 
has also been suggested to function via caveolae-mediated transport at the BBB 
since it was identified to co-localise with caveolin-1 (Zuchero et al., 2016). 
1.5.3. Clathrin-dependant endocytosis 
The most defined mechanism, clathrin-dependant endocytosis, occurs at 
clathrin-coated invaginations within the plasma membrane termed clathrin-coated 
pits. These pits are enriched in extracellular receptor proteins that mediate the 
transport of their constitutive ligands via endocytosis (Neutra et al., 1985).  
The formation of clathrin-coated vesicles consists of five steps; initiation, 
cargo selection, cargo vesicle budding, vesicle scission, and uncoating. The process 
is outlined in Figure 1.5.1.  
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Figure 1.5.1: Formation of clathrin-coated pits and vesicle internalisation 
Schematic representation of the process clathrin-coated pit formation and clathrin-mediated cargo 
internalisation at the plasma membrane.  During the initiation and cargo selection stages (A and B), 
adapter proteins such as AP-2 are recruited to nucleation regions within the plasma membrane 
which contain uncoated pits produced through membrane bending effectors. AP-2 then associates 
with endocytic signaling motifs within the cytoplasmic domains of transmembrane proteins. Clathrin 
triskelions are recruited and can bind adaptor proteins which initiates lattice assembly. During cargo 
vesicle budding (C), additional adaptor proteins are recruited for polymerisation and assembly of the 
clathrin coat. (D) The process of vesicle scission is mediated via the large GTPase dynamin resulting 
in an internalised clathrin-coated vesicle. (E) The clathrin coat is uncoupled from the vesicle allowing 
it to fuse with the early endosomal compartments. 
 
The initiation stage involves nucleation modules which determine the loci on 
the plasma membrane where vesicles will bud. The process involves the binding of 
F-BAR domain-containing Fer/Cip4 homology domain-only (FCHo) proteins to 
regions in the plasma membrane that are rich in phosphatidylinositol 4,5-
bisphosphate (PIP2). Epidermal growth factor receptor pathway substrate 15 
(EPS15) and intersectins are recruited to FCHo and this initiates formation of a pit 
via the introduction of membrane bending forces (Ma et al., 2016). Previous studies, 
have shown that depletion of FCHo 1 and 2 results in reduced membrane clathrin-
ABCD
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InitiationCargo selectionVesicle scission
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coated vesicle budding and endocytosis events (Henne et al., 2010). However, a 
more recent study by Wang et al. (2016) has also demonstrated that EPS15 and 
FCHo function in a partially redundant manner. 
Clathrin cannot directly bind to the membrane or cargo, instead it relies on a 
set of adaptor proteins known as clathrin-associated sorting proteins (CLASPs) and 
their complexes for recruitment. CLASPs mediate intracellular sorting and are 
recruited to the plasma membrane through interactions with sorting signals within the 
intracellular domains of transmembrane cargos and via specific interaction GTPases, 
phosphoinositide lipids and other CLASPs (Traub and Bonifacino, 2013). Following 
initiation, the cargo selection stage involves the recruitment of the heterotetrameric 
adapter protein 2 (AP-2) complex. AP-2 is the primary adapter protein that clathrin 
engages at the plasma membrane (Boucrot et al., 2010). AP-2 recognises endocytic 
signalling motifs such as the simple tyrosine motif (YXXØ, where Ø represents a 
hydrophobic residue) or the di-leucine motif [DE]XXXL[LI] within the cytoplasmic 
regions of transmembrane cargo destined for endocytic internalisation (Byland et al., 
2007; Collawn et al., 1990; Owen and Evans, 1998). The tyrosine motif was shown 
to bind to the µ2 subunit of AP-2 at an affinity between 10 – 70 µM, and this binding 
was reported to be strongest when AP-2 formed complexes with clathrin (Rapoport 
et al., 1997). Structural interaction studies have also shown that the tyrosine motif 
adopts a linear conformation and binding occurs via the hydrophobic pockets within 
the µ2 subunit that interact with tyrosine and leucine in the peptide (Owen and 
Evans, 1998).  
AP-2 may also directly or indirectly form interactions with other adaptors, 
which are themselves directly associated with particular cargo proteins. Some of 
these adaptor proteins (e.g. AP180/CALM, ARH, Epsin, β-arrestin) have also been 
shown to directly bind to PIP2 and clathrin, and may function in mediating clathrin 
recruitment, via a mechanism independent of AP-2 (Motley et al., 2003). Depletion of 
AP2 prevents clathrin recruitment but does not stop the formation of the nucleation 
complex (Motley et al., 2003). Signal adapter interaction with AP-2 leads to the 
concentration of endocytic cargo proteins within clathrin-coated pits. Early studies 
Chapter 1: 
 16 
have shown that multiple species of receptor cargo bound to their respective ligands 
could occupy a single clathrin coated pit (Carpentier et al., 1982; Neutra et al., 1985). 
The clathrin structure consists of three heavy chains associated with three 
light chains, forming a ‘three-legged structure’ termed triskelion. During the vesicle 
budding stage, the triskelia of clathrin polymerise into hexagonal and pentagonal 
lattice assemblies around the AP-2 complex forming the coat assembly. The 
polymerisation stabilises the curvature of the forming vesicle, whilst curvature 
effectors such as EPS15 and epsin develop the budding vesicle (Avinoam et al., 
2015; McMahon and Boucrot, 2011). A recent study by Kukulski et al. (2016) has 
highlighted that in addition to facilitating in vesicle budding, clathrin is also involved in 
the timing of the scission event and hence regulating the overall size of the endocytic 
vesicles that are formed. Clathrin-coated vesicles are typically 70 – 150 nm in size, 
and can be as large as 200 nm (De Bock et al., 2016). 
Vesicle scission is mediated via the large GTPase dynamin, which in itself is 
recruited by BAR domain-containing proteins, where it polymerises around neck of 
the vesicle and induces scission following GTP hydrolysis. Mutational studies of 
dynamin results in halted vesicle formation following clathrin polymerisation (van der 
Bliek et al., 1993). Once internalised, the clathrin lattice surrounding the vesicle is 
dismantled via ATPase, heat shock cognate 70 (HSC70) and auxilin (Morgan et al., 
2013; Yim et al., 2010).  
1.5.4. Intracellular trafficking 
Internalised vesicles undergo a complex process of intracellular trafficking and 
delivery to various endocytic compartments, (e.g. early endosomal, late endosomal 
and lysosomal compartments). The process is summarised in figure 1.5.2.  
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Figure 1.5.2: Vesicular trafficking at the BBB. 
Cellular uptake of molecules occurs via clathrin-dependent endocytosis and clathrin-independent 
endocytosis (macropinocytosis and caveolae-mediated endocytosis) mechanisms. Internalised 
vesicles fuse with early endosomes, where they are sorted and destined for recycling/ transcytosis 
or degradation. This process is mediated through various Rab proteins that are located on the 
cytoplasmic surface of distinct intracellular compartments. Cargo destined to recycling endosomes 
may be recycled back to the luminal membrane or to opposing abluminal membrane (transcytosis). 
Cargo within late endosomes may fuse with acidic lysosomes for degradation, or through a process 
of intra-vesicular budding, develop into a multivesicular body (MVB) and fuse with the plasma 
membrane releasing vesicular content as microvesicles and exosomes. 
 
Nearly all endocytosed vesicles fuse with mildly acidic early endosomes, that 
serve as sorting stations for all internalised cargo and are predominantly localised in 
the cell periphery (Kalaidzidis et al., 2015). Early endosomes are pleomorphic 
organelles that consist of vacuolar and tubular components, which separate cargo to 
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be degraded from cargo to be recycled back to the cell surface, respectively 
(Zeigerer et al., 2012). These early endosomes may be identified for their positive 
expression of the small GTPase Ras-related protein (Rab) 5, and early endosomal 
antigen 1 (EEA1). Rab proteins are the largest GTPase sub-family, that function by 
cycling between GDP-bound (inactive) and GTP-bound (active) states (Mishra et al., 
2010). They regulate intracellular trafficking mechanisms by interacting with effectors 
such as EEA1 and adaptor protein containing PH domain and leucine zipper motif 1 
(APPL1), which facilitate endosome fusion, tethering and vesicular transport 
(Christoforidis et al., 1999; Mishra et al., 2010; Zhu et al., 2004). Studies have shown 
that early endosomes expressing EEA1 and APPL1 are distinct populations, 
however a proportion of the population express both effectors due to their ability to 
exchange content (Kalaidzidis et al., 2015). 
Early endosomal sorting occurs via one of three pathways; recycling pathway, 
late endosomal and subsequently lysosomal pathway, and transcytotic pathway (De 
Bock et al., 2016). The slightly acidic microenvironment of early endosomes (pH ~5.7) causes internalised receptors to change conformation, releasing their bound 
ligand (Haqqani et al., 2017). Receptor cargos localised within the tubular regions of 
the early endosome are recycled primarily to the luminal membrane or transcytosed 
across polarised BCEC to the abluminal membrane. Furthermore, in polarised cells 
such as BCEC, endocytosis can occur at both the apical and basolateral sides of the 
plasma membrane, with each face possessing distinct early endosomal sorting 
compartments, but not lysosomal compartments (Brown et al., 2000; Sheff et al., 
1999; Wilson et al., 2000). 
Rab5 and Rab7 are the most highly characterised small GTPases, and are 
expressed on early endosomes and late endosomes, respectively (Rink et al., 2005). 
Rab5 is essential for endosomal organisation and in conjunction with soluble N-
ethylmaleimide sensitive factor attachment protein receptor (SNARE) proteins, is 
responsible for mediating early endosomal biogenesis and fusion (McBride et al., 
1999). When cargo is destined for degradation, early endosomes are transferred to 
late endosomes via a process of Rab conversion from Rab5 to Rab7. The 
mechanism is regulated by class C VPS/HOPS complex which interacts with the 
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Rab5 and recruits Rab7 during the conversion (Rink et al., 2005). Late endosomes 
are 0.25 – 1 µm in diameter and are localised within the perinuclear region of the 
cell. Late endosomes may form multivesicular bodies through the budding of late 
endosomal membranes which leads to the formation of a multivesicular body. These 
multivesicular bodies may subsequently fuse with the cell membrane releasing their 
vesicular cargo in the form of microvesicles (100 – 1000 nm diameter) and 
exosomes (50 – 120 nm diameter), (Hung and Leonard, 2015). Additional Rab 
proteins also mediate various intracellular trafficking and exocytosis processes. For 
instance, Rab4 mediates the release of recycled cargo from early endosomes whist 
recycling vesicles are targeted to plasma membrane mediated via Rab11 (S. W. 
Park et al., 2014; Zhao et al., 2015). Lysosomal-associated membrane protein 1 
(LAMP1) is also localised on the vesicular membrane of lysosomes and plays a role 
in protecting the lysosomal membrane from proteolysis (Qingqing Wang et al., 2017).  
1.6. Receptor mediated transcytosis at the BBB 
Transcytosis is defined as the transport of endocytosed cargo across the cell 
cytoplasm to the opposing plasma membrane where it exits the cell via exocytosis. 
The rate of cellular trafficking occurring at the BBB is substantially lower than that 
from other endothelial cells. BCEC have been shown to possess only 15% the 
number vesicles observed within muscular capillary endothelial cells (Coomber and 
Stewart, 1986; Preston et al., 2014). Despite this finding, the BBB retains selective 
permeability to key nutrients such as iron-bound transferrin and lipoproteins, which 
are transported and acquired in the CNS via RMT.  
RMT at the BBB has been suggested to primarily occur via a clathrin-
mediated mechanism. Clathrin-coated pits are highly abundant at the luminal 
membrane suggesting that clathrin-dependant transcytosis occurs predominantly in 
the blood to brain direction, as is the case with Tf/TfR transport (Bien-Ly et al., 
2014). In contrast, caveolae have been identified on both luminal and abluminal 
membranes and has been associated with bi-directional transport of cargo (Candela 
et al., 2010). 
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Several receptors have been identified on BCEC which mediate the transport 
of their constitutive ligands via RMT these include transferrin receptor, insulin 
receptor, leptin receptor, diphtheria toxin receptor and members of the low-density 
lipoprotein receptor (LDLR) family, LDLR and LDLR-related protein 1 (LRP1) (Uchida 
et al., 2011; Ohtsuki et al., 2013; Ueno et al., 2010; Ping Wang et al., 2010). These 
receptors have all been exploited for the transcytotic delivery of cargo across the 
BBB.  
Researchers are continuously pursuing the ideal RMT strategies for drug 
transport across the BBB. One recently proposed approach describes the possibility 
of increasing the transcellular transport capacity of BCEC for drug delivery (Wang et 
al., 2016). It has been suggested that an exploitable pharmacological mechanism for 
increasing RMT delivery exists via the sodium-dependent lysophosphatidyl-choline 
(LPC) symporter 1 (NLS1) or Mfsd2a. NLS1 is a BCEC specific transporter that is 
expressed by pericytes and has been shown to play two critical roles at the BBB. 
Firstly, the transporter itself has been shown to facilitate the transport of LPC-DHA, 
an essential omega-3 fatty acid required for proper neural function (Nguyen et al., 
2014). Secondly, NLS1 regulates transcellular delivery at the BBB through inhibition 
of transcytosis (Ben-Zvi et al., 2014). The group outlined the potential for targeting 
this transporter for delivery of small molecule drugs coupled with DHA or via the 
inhibition of NLS1 to temporarily attenuate suppression of transcytosis and therefore 
increase the uptake of RMT drug shuttles. 
1.6.1. Insulin receptor 
Insulin receptor (IR) is expressed at the BBB and throughout the various 
regions of the brain, and mediates the transport of insulin via RMT. This has made it 
an attractive target for exploitation of CNS drug delivery. Utilising the endogenous 
ligand insulin resulted in short serum half-life and demonstrated hypoglycaemic 
adverse effects (Lajoie and Shusta, 2015), thus subsequent targeting approaches 
have focused on the use of antibodies to IR. One promising antibody approach 
utilises a humanised antibody HIRMAb derived from a mouse anti-IR antibody (83-
14). This antibody has shown promising pre-clinical results for the delivery IDUA for 
the treatment of mucopolysaccharidosis type I (Boado et al., 2016; Boado and 
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Pardridge, 2017; J. Z. Lu et al., 2011). HIRMAb has also been engineered as a 
quadrivalent fusion molecule proposed for the treatment of Alzheimer’s disease, in 
which the HIRMAb antibody was fused to an anti-Ab single-chain variable fragment 
(scFv) at the CH3 region of the Fc domain (Boado et al., 2007). The anti-Ab acts as 
the therapeutic arms of the molecule whilst HIRMAb mediates the transcytosis 
across the BBB. The fusion molecule was shown to traverse the BBB in rhesus 
monkeys, with 1% of the injected dose reaching the CNS (Boado, Lu, et al., 2010). 
1.6.2. Lipoprotein receptor family 
Several members of the LDLR family have been identified on the surface of 
BCEC including LDLR, LRP1 and LRP2 (Gosselet et al., 2009; Molino et al., 2017). 
Functionally, LDLR is responsible for the transport of cholesterol via the cholesterol 
binding low-density lipoprotein (LDL). LDLR is also capable of binding to secondary 
form of LDL lipoprotein, beta very low-density lipoprotein (β-vLDL), which unlike LDL, 
contain multiple copies of Apolipoprotein-E (Apo-E), (Lane-Donovan and Herz, 
2017). 
The targeting of LDLR and LRP1 has predominantly consisted of the use of 
apolipoprotein ligand such as ApoB and ApoE (or their peptides components) 
coupled to nanoparticles (Dal Magro et al., 2017; Portioli et al., 2017; Wagner et al., 
2012; Zensi, Begley, Pontikis, Legros, Mihoreanu, Wagner, Büchel, Briesen, and 
Kreuter, 2009a; Kreuter et al., 2002). The success of these nanocarrier ApoE 
conjugates has also led some groups to develop apolipoprotein-a-L-iduronidase 
(IDUA) fusion molecules for the enzyme replacement treatment of 
mucopolysaccharidosis type I (El-Amouri et al., 2014; Böckenhoff et al., 2014; Daren 
Wang et al., 2013). 
Another promising lipoprotein receptor targeting approach utilises Angiopep-2 
peptide, which targets LRP1 through the Kunitz domain found on ligands which bind 
the LDLR family (Demeule, Régina, et al., 2008; Demeule, Currie, et al., 2008). 
Since its identification, Angiopep-2 peptide has been conjugated to paclitaxel 
(ANG1005) and is currently in phase II clinical trials for the treatment of glioma 
(Drappatz et al., 2013). Angiopep-2 has since been conjugated to various 
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nanocarriers and shown to translocate the BBB in vitro and in vivo (F. Lu et al., 2017; 
Figueiredo et al., 2016; Kafa et al., 2016; Velasco-Aguirre et al., 2017). 
Whilst LDLR has been shown to be expressed at the luminal membrane of 
BCEC and clearly mediates the transport of its ligands via RMT, its expression within 
the cerebral cortex is low, thus severely hindering it capacity for further target the 
subset of cells within the CNS (Molino et al., 2017). LRP1 has been shown be 
associated with BCEC transcytosis through a mechanism that does not involve 
acidification of cargo and is capable of mediating uptake in CNS cells, thus is a more 
viable RMT receptor for drug delivery at the BBB than LDLR (Tian et al., 2015). 
However, the use of LRP1 as an RMT drug delivery receptor has some potential 
disadvantages. Firstly, its expression has been shown to decrease in BCEC and 
total brain with aging (Silverberg et al., 2010). Furthermore, its expression is further 
reduced with Alzheimer’s disease (Storck et al., 2016). These finding suggest that 
LRP1 may not be the most suitable RMT target for developing a drug delivery 
system, since neurodegenerative disorders are increasingly prevalent within the 
aging population (Gallagher et al., 2017).  
Instead this thesis will explore the targeting of transferrin receptor, a widely 
targeted and highly expressed receptor on the surface of BCEC that has been 
shown to mediate the transport of its ligands via RMT at the BBB (discussed in 
section 1.7)  
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1.7. Transferrin receptor (TfR) 
Transferrin receptor (TfR) is responsible for mediating the transport of iron 
into cells via endosomal internalisation of the iron-binding, carrier glycoprotein and 
natural ligand, transferrin (Tf) (Aasa et al., 1963). Serum Tf consists of two 40 kDa 
subunits (N and C lobes), and is primarily synthesised in hepatocytes. Each lobe 
contains an iron binding site and is capable of binding Fe3+ at a high affinity 
(Holmberg and Laurell, 1946). The oxidisation of Fe2+ in the portal circulation 
produces free circulating Fe3+ ions which are capable of inducing cell toxicity through 
the generation of free radicals and the formation of insoluble polymers (Eckenroth et 
al., 2011). Functioning as a carrier molecule, Tf therefore also indirectly prevents cell 
toxicity by ‘mopping up’ circulating Fe3+.  
 Structurally TfR (CD71) is a homodimeric type II transmembranous 
glycoprotein consisting of two 760 amino acid monomers linked together via two 
disulphide linkages. The structure of TfR is shown in Figure 1.7.1. Each subunit is 
90-95 kDa in size and is capable of binding a single Tf molecule. X-ray 
crystallography studies carried out by Lawrence et al. (1999) at 3.2 Å resolution set 
the novel foundations for structural work on TfR and also proposed a model of Tf 
binding to the TfR. The TfR monomer is composed of three distinct regions, a 
globular extracellular region (AA residues 90 – 760), a hydrophobic 
intramembranous region (AA residues 62 – 89) and an N-terminal intracellular 
cytoplasmic region (AA residues 1 – 61). The extracellular region is further 
subdivided into three distinct regions, the protease-like (AA residues 121 -188 and 
384 – 606), apical (AA residues 189 – 383) and helical (AA residues 607 – 760) 
domains (Eckenroth et al., 2011). 
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Figure 1.7.1: Extracellular structure of hTfR as determined by X-ray crystallography at 3.2 Å 
resolution. 
Figure depicting the extracellular structure of the homodimeric TfR protein, anchored in the plasma 
membrane at the N-terminal region (A). The apical (B), helical (C), and protease-like (D) domains 
that make up each monomer of hTfR are also shown. Figure produced using PDB structure 1CX8 and 
JSmol software. 
 
At the N-terminal intracellular region, an endocytosis motif consisting of amino 
acids tyrosine, threonine, arginine, and phenylalanine (YTRF) allows the correct 
orientation of the large ectodomain with respect to the plasma membrane. A 
phosphorylation site for protein kinase C is also present at serine24 (Davis et al., 
1986). However, mutagenic studies have suggested that phosphorylation of serine24 
does not induce an endocytosis signal (McGraw et al., 1988). 
Two palmitoylation sites are located within the intramembranous region at 
cysteine residues 62 and 67, with cysteine 62 being the primary site for 
palmitoylation (Jing and Trowbridge, 1987). These sites enhance hydrophobicity 
through covalent attachment to fatty acids, thus anchoring the protein into the 
plasma membrane.  
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The stalk region (AA residues 89 – 120) contains a site for O-linked 
glycosylation (Threonine104), which is likely important for TfR transport to the 
plasma membrane (Do and Cummings, 1992; Hayes et al., 1992). At the plasma 
membrane side of the extracellular stalk, two intermolecular disulphide bonds are 
located at cysteine residues 89 and 98 (Jing and Trowbridge, 1987).  
Multiple proteolytic sites have been identified within the extracellular stem 
region of TfR (Kaup et al., 2002; Rutledge et al., 1998; Turkewitz, Amatruda, et al., 
1988). Although the most highly susceptible proteolytic cleavage site is present 
between arginine 100 and Leucine 101(Shih et al., 1990). Cleavage at this site 
results in the release of a solubilised form of the TfR extracellular domain into the 
circulation. This solubilised form consists of 660 AA per monomer and has been 
shown to stably maintain 95% homology to the extracellular protein structure of TfR 
(Turkewitz, Schwartz, et al., 1988). More importantly, its capability to bind Tf was 
also retained. Furthermore, Alvarez et al. (1989) revealed that dimerisation of the 
cleaved fragment occurred independent of the disulphide linkages, suggesting that 
homodimerisation occurs spontaneously through the helical domain of the globular 
extracellular region. Soluble TfR (sTfR) has also been observed as a component of 
serum under normal physiological conditions. This fragment was found to inversely 
correlate with iron storage levels within the body (Rutledge and Enns, 1996). 
The extracellular domain contains the Tf binding site. Three N-linked 
glycosylation sites, (asparagine 251, 317 and 727) are also present and play a 
significant role in proper molecular folding. Mutation of these N-linked glycosylation 
sites leads to impaired Tf binding activity of TfR (A. M. Williams and Enns, 1991; 
Lawrence et al., 1999). 
TfR is ubiquitously expressed in most cells of the body at low levels. Under 
physiological conditions, its expression is highest in cells that require high iron 
concentrations for cellular processes such as proliferation and the generation of 
mitochondrial ATP. However, although BCEC are non-proliferating cells, their 
expression of TfR remains high. This is due to the high demand for iron within the 
CNS for processes such as dopaminergic neurotransmitter synthesis and 
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myelination (Mills et al., 2010). In contrast, endothelial cells of the vasculature do not 
express detectable levels of TfR (Jefferies et al., 1984). 
TfR is also highly expressed in various cancer cells. Iron requirement is 
increased within rapidly dividing cancer cells as it functions as a co-factor for 
ribonucleotide reductase enzyme in the DNA replication process. Moreover, the 
expression of TfR on various cancer cells has been correlated with advanced stage 
disease, as well as poor prognoses (Yang et al., 2001). 
1.7.1. Iron transport at the BBB 
The TfR mediated endocytotic internalisation of iron-bound Tf was first 
described by Cienchanover, Dautry-varsat, and Lodish (1983); prior to this discovery 
it was incorrectly assumed that iron was released from bound transferrin upon 
formation of the Tf/TfR complex at the cell surface (Jandl et al., 1959). The process 
of TfR mediated RMT at the BBB is outlined in Figure 1.7.2. 
 
Figure 1.7.2: TfR mediated transcytosis and endocytosis of Tf/TfR complexes at the BBB. 
Figure outlining the two proposed mechanisms for TfR mediated iron transport at the BBB, RMT (A) 
and receptor mediated endocytosis, followed by DMT1 mediated release of iron and subsequent 
receptor recycling (B). Both mechanisms initiate by binding of diferric transferrin to the TfR at the 
cell surface pH of 7.4. Binding of the ligand induces the invagination of the cell membrane into a 
clathrin-coated pit, which internalises via clathrin-dependent endocytoses and subsequently fuses 
with the early endosomal compartment (A1, B1). RMT involves the complete traversal of the BCEC 
to the abluminal side exclusive of intra-endosomal release of iron bound Tf (A2). Exocytosis of the 
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endosome at the abluminal side leads to the release of iron from Tf at the reduced pH of the 
interstitial fluid (A3). The alternative and generally accepted mechanism for TfR mediated iron 
transport within the majority of cells involve proton pumps in endosomal membrane. These pumps 
facilitate the influx of H+ ions into the endosome reducing the pH to 5.6 (B2). Iron is then released 
from transferrin into the cytosol (B3). The Tf/TfR complex is recycled via the fusion with a recycling 
endosome (B4). Most recycling occurs to the luminal membrane via this mechanism. However, some 
recycling may also occur to the abluminal membrane. 
 
Cienchanover et al (1983) showed that at the neutral cell surface pH of 7.4 
only iron-bound Tf (monoferric and diferric) is capable of binding to the TfR. The 
unbound form, apotransferrin (apoTf) is ignored, thus preventing the competitive 
binding between the ubiquitously abundant apoTf species in contrast to the less 
abundant bound species. Furthermore, diferric Tf was shown to demonstrate a 30-
fold increase in TfR association constant in contrast to monoferric Tf (Young et al., 
1984). Following receptor association, the Tf/TfR complex is internalised via clathrin-
coated pit formation, clathrin-dependant internalisation, and subsequently fusing with 
an early endosomal vesicle (described in section 1.5.3). The internal pH 
microenvironment of the endosome is then reduced via proton pumps to a pH of 
approximately 5.6, at which point iron is unbound from transferrin, reduced to Fe2+ 
and is transported across the endosomal membrane into the cytosol, via the aid of 
the divalent metal transporter 1 (DMT1). The residual apoTf/TfR complex is then 
sorted and re-localised to the luminal membrane where apoTf is released 
extracellularly into the plasma and can consequently bind iron at a neutral pH.  
Although the aforementioned mechanism appears to be the primary 
mechanism for iron internalisation in the majority of cells within the body, it does not 
seem to be the case in BCEC. There has been conflicting evidence with regards to 
the exact mechanism by which TfR mediates the transport of iron into the CNS 
(Burdo et al., 2001; Moos and E. H. Morgan, 2000; Moos et al., 2006; Siddappa et 
al., 2002). Studies have previously demonstrated TfR transcytotic transport across 
BCEC to the abluminal side in endosomes (Bickel et al., 1994). More specifically, 
using OX26 (anti-rat TfR IgG2a antibody) coupled to gold nanoparticles and TEM, 
Bickel et al. (1994) demonstrated TfR to be mostly sub-localised to the luminal 
membrane and intracellularly in vesicles. Some expression was also observed on 
the abluminal membrane. However, it was not clear whether iron remained bound to 
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Tf and released at the abluminal membrane or transported into the cytosol following 
endocytosis via DMT1.  
Utilising a bovine BCEC and astrocyte co-culture model Descamps et al. 
(1996) were able to study the uptake of labelled TfR. Endosomal internalisation was 
found to be temperature dependant, as endosomal uptake showed complete 
inhibition at lower temperatures. The group also observed no signs of intra-
endothelial degradation of Tf, and therefore they concluded that the TfR 
internalisation pathway avoids the lysosomal degradation compartment. Moreover, 
by labelling both Tf and iron the group also demonstrated iron can be transported 
across the BCEC abluminal membrane bound to Tf. Interestingly they quantified 
10% of Tf was recycled to the luminal membrane while the remaining 90% was 
found to recycle to the abluminal membrane. In support of these findings more 
recent studies by Moos et al. (2006) have also proposed a DMT1 independent 
mechanism for the transport of iron-bound Tf.  
In contrast to the aforementioned mechanisms, iron uptake at BCEC may be 
more complex than initially thought and is likely to occur via various non-TfR 
dependant mechanisms. Mice that are severely deficient of circulating Tf have been 
reported to maintain normal brain iron content, thus suggesting alternative brain 
uptake mechanisms exist at the BBB (Beard et al., 2005). Tf homologous proteins 
such lactoferrin and melanotransferrin can also act as iron transporters across the 
BBB (Fillebeen et al., 1999; Rolland et al., 2009; Rothenberger et al., 1996; Ji et al., 
2006). A study by Kumar et al. (2012) has identified that under situations of iron 
depletion, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) can also function 
as a Tf binding protein, mediating iron uptake into non-TfR expressing CHO cells. 
Fe3+ bound ferritin has also been shown to act as a ligand for proteins such as 
Scara5 and Tim-2 (J. Y. Li et al., 2009; Todorich et al., 2008).  
Regardless of the conflicting views over iron delivery to the CNS, TfR 
mediated transcytosis demonstrates great potential for clinically significant 
accumulation of a TfR targeted therapeutic within the CNS and this has been 
demonstrated in various pre-clinical studies, in vitro and in vivo (Webster et al., 2017; 
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Macdonald, Houghton, et al., 2016; Zuchero et al., 2016; Yu et al., 2014; 
Niewoehner et al., 2014; Manich et al., 2013; Macdonald, Henri, et al., 2016). 
1.8. Targeting the BBB for drug delivery 
Targeted drug delivery is the process of increasing the concentration of a drug 
in a specific site of action, mediated via delivery vectors and targeting moieties (e.g. 
antibodies). The targeted delivery of drugs improves their therapeutic index, a 
measure of the ratio of the therapeutically effective dose to the toxic dose of a 
therapeutic agent, thus reducing undesirable side effects due to non-target site 
interactions (Guo et al., 2012). 
Several strategies have been used to overcome the transport limitations of the 
BBB. These can largely be divided into invasive and non-invasive approaches. 
Invasive approaches include transcranial surgical methods  as well as methods that 
disrupt the BBB in order to increase drug permeability (Vykhodtseva et al., 2008). 
Non-invasive methods usually involve drug delivery approaches that utilise 
endogenous mechanisms such as pharmacological approaches (small lipophilic drug 
analogues and their endogenous transporters) (Pardridge, 2007) and biological drug 
delivery strategies (Lichota et al., 2010; L. B. Thomsen et al., 2012), the latter of 
which will be the focus of this study.  
1.8.1. TfR targeted drug delivery 
The most extensively targeted receptor for RMT drug delivery at the BBB is 
TfR (Yu et al., 2014; Pardridge, 2015; Webster et al., 2017). Many animal studies 
have demonstrated the use of TfR as an effective RMT delivery strategy for the 
transport of drug payloads across the BBB. The targeting of TfR for drug delivery has 
primarily consisted of two approaches. The first approach utilises the natural ligand 
Tf or a competitively binding domain that targets the same epitope (Pang et al., 
2011; Staquicini et al., 2011; Huang et al., 2007). The second more popular 
approach has so far predominantly utilised antibodies for targeting an epitope 
independent of the ligand binding region (Bickel et al., 1994; Lee et al., 2000; Yu et 
al., 2014; Bien-Ly et al., 2014; Niewoehner et al., 2014; Webster et al., 2017) 
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Drug delivery using the natural transferrin ligand has so far predominantly 
consisted of nanocarrier conjugates and some of these have shown success in pre-
clinical studies(Huang et al., 2007; Wiley et al., 2013). Huang et al. (2007) have 
previously shown that transferrin-polyamidoamine (PAMAM) conjugates can be 
successfully used for TfR-mediated uptake of gene vectors into the brain. Within this 
study the group demonstrated a 2.5-fold increase with PAMAM-PEG-Tf conjugates 
in comparison to the controls. Another study by Wiley et al. (2013) demonstrated the 
brain uptake of Tf-coated gold nanoparticles (45nm and 80nm in size). These gold 
nanoparticles were systemically administered in mice and assessed for accumulation 
in the brain parenchyma. The group concluded that the uptake of Tf-coated 
nanoparticles was avidity dependant on the density of Tf on gold nanoparticles. One 
recent notable example of Tf mediated RMT involved the use of an iron mimicking 
cyclic heptapeptide, CRTIGPSVC. This peptide competes with iron for binding to 
apoTf and was demonstrated to significantly reduce the brain tumour size in a 
mouse model of glioma (T. Kang et al., 2015; Staquicini et al., 2011). Although some 
studies have shown promising in vivo brain uptake using Tf as a RMT delivery 
vector, it is not an ideal targeting approach. This drug delivery strategy faces 
significant competition from circulating Tf which is present in the blood at 25 µM 
concentration (Qian et al., 2002).  
The alternative approach of using a targeting molecule which binds to TfR at a 
ligand independent site is a more therapeutically viable option. Pioneering work by 
Pardridge et al. (1991) initially highlighted the concept of exploiting TfR mediated 
RMT for the delivery of macromolecular drugs across BCEC via a process later 
designated ‘molecular Trojan horse delivery’ (Pardridge, 2002). Although initially 
described for TfR, the same approach has also been applied to multiple target 
receptors that function via RMT (Dehouck et al., 1997; Demeule, Currie, et al., 
2008). The process involves the use of a receptor specific molecular targeting 
domain, which is coupled to a therapeutic payload. The targeting domain binds TfR 
and is subsequently transported alongside the Tf/TfR complex via RMT to the 
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abluminal membrane of BCEC, where it can theoretically be released and made 
available within the CNS. 
The concept was demonstrated using OX26, an IgG2a mouse monoclonal rat 
TfR-specific antibody generated against an extracellular region that does not 
interfere with Tf ligand binding and thus avoids any issues with competitive binding 
(Pardridge et al., 1991). Through an in vivo study in rats, OX26 was shown to only 
result in a 0.44% concentration of injected dose within the parenchyma. Studies 
have since described the conjugation OX26 to various payloads and demonstrated 
their capacity to be transported across the BBB via rat in vivo studies. Some of these 
payloads include, brain-derived neurotropic factor (BDNF), recombinant human CD4, 
vasoactive intestinal peptide analogue, nerve growth factor (Yun Zhang and 
Pardridge, 2006; Walus et al., 1996; D. Wu and Pardridge, 1996; Kordower et al., 
1994). More recently, OX26 has increasingly been used in conjunction with nano-
carriers to deliver various drug cargos across the BBB, these approaches are 
summarised in table 1.8.1. 
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Table 1.8.1: Recent OX26 Nano-carrier drug delivery approaches at the BBB. 
Nano-carrier Drug cargo Proposed disease treatment 
Study format 
(in vitro/ in 
vivo) 
Reference 
γ-PGA and l-
PAE co-polymer 
(PHRO) 
Ginsenoside 
Rg1 
diabetic cerebral 
infarction In vivo (Shen et al., 2017) 
liposomes oxaliplatin 
No proposed disease 
(generalised BBB drug 
delivery) 
In vitro and in 
vivo (Johnsen et al., 2017) 
Pegylated 
liposomes Dopamine Parkinson’s disease In vivo 
(Y.-S. Kang et al., 
2016) 
poly(lactic-co-
glycolic acid) 
(PLGA) 
nanoparticles 
iAβ5 
peptide 
(LPFFD) 
Alzheimer’s disease In vitro (Loureiro et al., 2016) 
Pegylated 
liposomes 
α-
synuclein Parkinson’s disease In vitro (Loureiro et al., 2015) 
Pegylated 
cationic solid 
lipid 
nanoparticles 
Baicalin Cerebral ischemic injury In vivo (Z. Liu et al., 2015) 
Pegylated 
liposomes chlorotoxin Glioma 
In vitro and in 
vivo (Yue et al., 2014) 
Pegylated 
liposomes ApoE3 
No proposed disease 
(generalised BBB drug 
delivery) 
In vitro and in 
vivo 
(Markoutsa et al., 
2014) 
 
Two rat anti-mouse TfR specific monoclonal antibodies, 8D3 and R17-217 
have also been described within the literature (Kissel et al., 1998; Lesley et al., 
1984). When comparing the brain uptake of both these antibodies, 8D3 exhibited a 
higher percentage uptake than R17-217 (3.1% and 1.7% injected dose/g, 
respectively) (Lee et al., 2000). However, upon further assessment R17-217 was 
observed to exhibit greater specificity towards the brain than to 8D3. 
Although many in vitro and in vivo studies utilising monoclonal antibody 
delivery vectors have been successful in demonstrating some extent of drug delivery 
across BCEC, the observed rate of delivery in vivo is often poor (<1% of injected 
dose), resulting in a weak therapeutic concentration within the CNS. More recently, 
TfR bi-specific antibody targeting approaches have been described by (Yu et al., 
2011). These studies propose a mechanism for TfR mediated transcytosis at the 
BBB, where antibody affinity and avidity of the targeting moiety plays an important 
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role in modulating intracellular fate of the internalised RMT vector. Through re-
engineering approaches, the group demonstrated that lower to moderate affinity 
antibodies towards TfR in conjunction with therapeutic dosing, resulted in 
significantly increased accumulation within the CNS. In support of these findings, it 
has been reaffirmed that both OX26 and 8D3 are capable of binding to BCEC, 
however these do not undergo significant transcytosis and remain sequestered 
within BCEC (Moos and E. H. Morgan, 2001; Paris-Robidas et al., 2011). Once 
again, re-engineering approaches carried out on 8D3 to generate lower affinity 
variants resulted in significantly increased accumulation within the CNS (Webster et 
al., 2017). 
1.9. Biopharmaceuticals 
Biopharmaceuticals or biologics are a growing class of therapeutics. Multiple 
definitions have been used to describe biopharmaceuticals, and these definitions 
vary according to the source (e.g. scientific or business), manufacturing process and 
the inherent nature of the product. One of the most popular classic definitions refers 
to pharmaceuticals and biopharmaceuticals as being the major subsets for drugs, 
with biopharmaceuticals being inherently biological products that can be 
manufactured through biological processes, from biological sources. In contrast, a 
pharmaceutical is a product manufactured via chemical sources and processes 
(Rader, 2008). This definition encompasses all biological products including 
engineered proteins, blood/ plasma products and vaccines. However, under this 
definition, the categorisation of certain products becomes challenging since they can 
be interpreted as both pharmaceuticals and biopharmaceuticals. For instance, 
peptides and oligonucleotide agents (e.g. aptamers, small interfering RNA and 
miRNA) are inherently biological, however they may also be synthesised and 
modified via chemical approaches (Remuzgo et al., 2014; Tang et al., 2017).  
Another definition of biopharmaceuticals, has a narrower view of the field, 
focusing only on the clinical successes of monoclonal antibodies (Mabs) and 
recombinant proteins, and this definition excludes proteins from non-recombinant 
sources, vaccines, blood/ plasma products. Instead of these aforementioned 
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definitions, it has been suggested that biotherapeutics should be defined as 
“pharmaceuticals inherently biological in nature and manufactured using 
biotechnology”, in order to avoid fragmentation of the literature (Rader, 2008). 
Examples of biopharmaceuticals described within this context include, peptides, 
recombinant proteins, enzymes, MAbs, small interfering RNA (siRNA), microRNA, 
gene therapies and aptamers (Andrews et al., 2015).  
The push towards the development of recombinant human insulin in the early 
1980’s bought about a revolutionary shift in the pharmaceutical industry that has 
changed the outlook for many patients suffering from diseases with previously very 
poor prognosis. As of 2014, a total of 212 biopharmaceuticals were marketed within 
the US and EU (Walsh, 2014). Biologics now make up approximately 45% of the 
world’s top 100 grossing drugs, and account for 25% of all pharmaceutical sales 
(Evaluate Pharma, 2015). 
For many years, monoclonal antibodies (MAbs) have dominated the biologics 
arena, generating successful treatments towards various forms of cancer (Tan et al., 
2013) and immuno-inflammatory diseases (reviewed in Willrich et al., 2015), in 
addition to contributing to the fields of disease diagnosis and bioscience research. 
Their success has primarily been attributed to their inherent target specificity. 
Although proving highly successful for research, diagnostic and therapeutic 
applications, traditional MAbs based on the IgG structure have their limitations when 
used as biotherapeutics. The large size of IgG antibodies (150 kDa) leads to poor 
tissue penetration and in what is considered both an advantage and disadvantage, 
their long plasma half-life makes patient dosing convenient, but causes difficulty in 
regulating drug clearance (M. Schmidt and Wittrup, 2009; Bai et al., 2012). 
Moreover, their development and manufacturing complexity, batch-to-batch variation 
and requirement for cold storage, adds to the overall cost of bringing these drugs to 
market (Halim et al., 2016; Patel et al., 2015; Chames et al., 2009).  
Given the shortcomings of antibodies and their clinical success, several 
engineering strategies have been employed to improve the properties of traditional 
antibodies. Many initial protein engineering attempts have focused on modifying the 
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IgG molecule e.g. bi-specific antibodies (Spiess et al., 2015), or using its modular 
fragments as independent binding domains, e.g. Fab and scFv (Holliger and 
Hudson, 2005). In addition to these approaches, several immunoglobulin-like 
molecules have been isolated from various animal sources and adapted into 
targeting domains such as camelids derived from camels and immunoglobulin new 
antigen receptor (IgNAR) derived from cartilaginous fish e.g. sharks (Rutgers et al., 
2011; Dooley et al., 2003; Goodchild et al., 2011; T. Li et al., 2016). These antibody-
like molecules differ from human immunoglobulin by being devoid of light chain 
regions (Feige et al., 2014; Hamers-Casterman et al., 1993). 
More recently, developments on several forms of non-antibody engineered 
scaffolds have been described (Stefan et al., 2011; Oganesyan et al., 2013; Tiede et 
al., 2017; Škrlec et al., 2015). These scaffolds are based on backbones of a naturally 
occurring proteins (usually human origin), which normally carry out multiple functions 
within the body and therefore have complex binding regions (Lorey et al., 2014). 
Through mutagenesis engineering approaches, a library of these proteins is 
generated with randomised amino acids within the binding region (Tiede et al., 
2014). 
The work described herein focuses on the use of peptides and aptamers as 
antibody alternative targeting domains, these are described below. 
1.10. Peptide therapeutics 
Peptides are short chains consisting of two or more amino acids. Greater than 
7000 naturally occurring peptides have been identified and many of these have 
crucial biological functions, acting as hormones, growth factors, ligands, 
antimicrobials and venoms (Murase et al., 2017; Modi et al., 2016; Orlandi et al., 
2015; Seo et al., 2016; Wenzel et al., 2016; Soares et al., 2016; Oller-Salvia et al., 
2013). Historically, peptides had been regarded as inferior to traditional chemical 
therapeutics, largely due to the fact that they are rapidly degraded by proteases 
upon intravenous administration (Julien et al., 2012; F. Xu et al., 2017). Systemically 
circulating unprotected peptides are rapidly degraded within minutes via exo-
peptidases such as amino- and carboxy-peptidases (Alsters et al., 2015; John-White 
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et al., 2017). Moreover, peptides have limited oral bioavailability due to physiological 
(poor gastrointestinal solubility and permeability), and chemical and biochemical 
(acid hydrolysis and enzymatic degradation within gastrointestinal fluids) barriers, 
resulting in <2 % of orally administered dose reaching the circulation (Uhl et al., 
2017; Diao and Meibohm, 2013). An exception to this is the approved 
immunosuppressant drug cyclosporine. This 11mer cyclic peptide (constrained via a 
disulphide bond between two cysteine residues) has greater resistance to peptidase 
degradation and demonstrates a 30 and 40% bioavailability following oral 
administration (Holt et al., 1995).  
The advent of techniques such as DNA recombination, phage display, high 
throughput screening and combinatorial chemistry approaches, allowed the efficient 
selection, identification and modification of peptides from large combinatorial phage 
display libraries ('t Hoen et al., 2012; Staquicini et al., 2011; Ru et al., 2014; Wada, 
2013). These libraries could be engineered to have structural features through the 
inclusion of fixed residues along the peptide chain (e.g. the peptide libraries used in 
this study) or via amino acids with particular properties to encourage overall 
structural and functional characteristics (O'Neil et al., 1992; Bonetto et al., 2009). 
Furthermore, the engineering of pre-identified peptides through rational design 
methods, such as alanine substitutions, structure-activity relationship studies and 
peptidomimetic modifications (Feng and B. Xu, 2016), allows the production of 
optimised protease resistant variants of peptides that maintain or improve upon 
biological and pharmacokinetic activity (Vlieghe et al., 2010). These modified 
peptides have the potential to bridge the gap between the stability and bioavailability 
of traditional small molecule drugs and the functionality and specificity of larger 
amino acid-based biologics. In total, approximately 60 peptide drugs have been 
approved, in addition to over 140 currently undergoing clinical trials (summarised in 
Fosgerau and Hoffmann, 2015; Hamzeh-Mivehroud et al., 2013). 
Initial attempts at peptide delivery across the BBB involved the use cell-
penetrating peptides originating from protein transduction domains such as TAT and 
penetratin (Cao et al., 2002; Joliot et al., 1991). Since these approaches relied on 
AMT transport, they were non-selective for the BBB and often resulted in the 
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accumulation of peptide within BCEC when not conjugated to secondary cationic 
moiety (Sharma et al., 2016). Selective peptides that target endogenous receptors 
expressed on the luminal membrane of BCEC and function through RMT, have been 
identified using in vitro phage display selections (Lee et al., 2001; Dai et al., 2014; 
Malcor et al., 2012). Studies have also employed in vivo phage display selections to 
identify brain penetrating peptides. However, this technique results in the 
identification of peptides without known target(s) and this poses many serious 
implications for safety and drug candidate development (Pasqualini and Ruoslahti, 
1996). 
Perhaps the greatest example for the viability of peptides as BBB shuttles, is 
the fact that many peptide-based venoms have evolved to circumvent the BBB and 
induce their biological effects within the CNS (Oller-Salvia et al., 2016). The ability of 
these venoms to function across a wide range of species signifies the potential for 
species cross-reactive targeting peptides. The identification of species cross-reactive 
binding domains is a highly sought after characteristic for biologic drug development, 
as it typically improves the safety, efficacy and the success rate of a drug candidate 
going forward from animal pre-clinical to human clinical studies (Irani et al., 2016; 
Farady et al., 2009; Eastwood et al., 2010).  
1.10.1. Peptides targeting TfR 
Four notable examples of peptides have been identified through phage 
display panning selections towards TfR, these are peptides B6 (GHKAKGPRK), THR 
(THRPPMWSPVWP), T7 (HAIYPRH) and BP9 (AHLHNRS) (Xia et al., 2000; Lee et 
al., 2001; Dai et al., 2014). 
The B6 peptide was identified through screening of a nonamer phage display 
library towards hTfR (Xia et al., 2000). Following sequencing of selected pools, the 
majority of sequences were identified to contain the motifs AKxxK/R, KxKxPK/R, or 
KxK. The group utilised a model of mucopolysaccharidoses type VII to study the 
capability of several variants of peptide B6 to deliver gene therapies into BCEC. 
sequences for peptide B6 were cloned into the HI loop of adenovirus type 5 fibre and 
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and were shown to be bind hTfR expressing cells and BCEC. The group also 
observed a 2- to 34- fold increase in gene transfer with cells.  
Studies by Prades et al. (2012) have re-introduced the TfR binding THR 
peptide for the purpose of drug delivery at the BBB. The 12mer linear peptide was 
initially identified via phage display panning selections and shown to bind to human 
TfR at a transferrin-independent receptor epitope, and traverse the plasma 
membrane of chicken embryo fibroblast cell lines via an endosomal pathway (Lee et 
al., 2001). The group combined this THR peptide alongside a β-sheet cleaving 
peptide, LPFFD, through conjugation to gold nanoparticles via a cysteine residue. 
The resultant THR/Ab cleaving peptide conjugated nanoparticles demonstrated 
increased permeability in vitro, using a bovine BBB co-culture model and greater 
penetration of rat brain, in vivo. More recently, the same group were able to modify 
the THR peptide using a retro-enantio rational design approach to construct a 
mirrored version of the molecule that was more resistant to protease degradation. 
This modified molecule was shown to exhibit enhanced transport capability across 
the BBB when compared to the parent molecule (Prades and Salvia, 2015).  
The BP9 peptide was identified through phage display selections of a 7-mer 
linear peptide library towards hTfR (Dai et al., 2014). Following three rounds of 
selection, 20 clones were picked and screened through phage ELISA. The group 
identified 6 clones that bind hTfR significantly higher than the negative control 
phage. Assessment of the sequences revealed the peptides share a two-amino acid 
motif ‘RS’ with transferrin. The group concluded that the negatively charged BP9 
peptide binds through electrostatic interactions with TfR. The group also generated a 
BP9-EGFP fusion and assessed the binding of BP9 towards three human 
hepatocarcinoma cell lines expressing TfR, HepG2 and SMMC-7221 cells, and 
deficient for TfR, LO-2 cells. BP9 was shown to bind to the TfR positive cells, but not 
the deficient cells. Through inhibition of cell proliferation assays, BP9 was shown to 
interfere with Tf binding. The species cross-reactivity of this peptide has yet to be 
established, since the group have only assessed the binding of BP9 towards hTfR 
expressing cells. Furthermore, the capability of BP9 to mediate transport into cells 
was not established through internalisation assays. 
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1.11. Aptamers as novel targeting biologics 
Aptamers are oligonucleotide-based targeting molecules that can bind 
molecular targets at high affinity and specificity via the three-dimensional hairpin 
structures they form through folding. The term aptamer stems from the Latin word 
aptus (to fit) and the Greek word meros (region) (Ellington and Szostak, 1990). 
Oligonucleotide aptamers consist of ribonucleic acid (RNA) or single stranded 
deoxyribonucleic acid (ssDNA) and are 20-100 nucleotides in length (5 to 25 kDa in 
weight) {Ni:2011vl}. Early studies into the human immunodeficiency virus (HIV) 
brought about the basic concept of oligonucleotide-protein molecular interaction. 
Studies carried out by Sullenger et al. (1990) to assess HIV viral replication 
established that a short RNA ligand, 5’ transactivation response (TAR) element was 
responsible for binding Tat proteins and trans-activating viral replication. 
Subsequently two groups working on aptamers in the 1990’s brought about 
the development of an in vitro system for selecting and isolating aptamers (Tuerk 
and Gold, 1990; Ellington and Szostak, 1990). This system was termed Systematic 
Evolution of Ligands by Exponential Enrichment (SELEX) (described in section 
1.12.2). The technique enabled the selective in vitro generation of specific aptamers 
to a variety of target molecules ranging from metal ions (C. H. Chung et al., 2013; 
Ling Zhang et al., 2013) and small bio-molecules, to large complex peptides, whole 
cells (Meng et al., 2010) and microorganisms (Y. S. Kim et al., 2013). The large 
range of potential target molecules provides aptamers with wide scope of 
applicational uses; some of these include diagnostic, analytical and therapeutic 
applications (Song et al., 2012). 
Since their development in the 1990’s, aptamers have only seen a significant 
surge in research over the past decade, primarily due to the expiry of key patents on 
their selection technology and use as ligands (McKeague and DeRosa, 2014). A 
recent success story for aptamers and their clinical significance came about with the 
FDA approval of the first aptamer based therapeutic, Macugen™ (pagaptanib 
sodium). This RNA aptamer-based drug offered a treatment for age related macular 
degeneration, by targeting an isoform of vascular endothelial growth factor (VEGF-
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165), that is predominantly responsible for vascular permeability and ocular 
neovascularisation (Ng et al., 2006; Vinores, 2006).  
Other aptamer-based drugs are currently undergoing clinical trials such as the 
anti-cancer drug, AS1411.  This anti-proliferative guanosine rich DNA aptamer binds 
cell surface nucleolin, is internalised and inhibits growth by halting DNA replication 
(Ireson and Kelland, 2006). The G-rich sequence of AS1411 encourages the 
formation of intermolecular and intramolecular quadruplex structures, which are 
further stabilised through G-quartet loops (Dapić et al., 2003). Soundararajan et al. 
(2008) proposed an anti-tumour cell mechanism of action for AS1411. 
Overexpression of cytoplasmic nucleolin in some tumour cells in contrast to their 
healthy counterparts is likely to play a significant role in this mechanism. 
Functionally, nuceolin acts as a post-transcriptional regulator by binding the 3’ 
untranslated region within the bcl-2 mRNA sequence, and in doing so preventing its 
degradation. This protective mechanism prevents some tumour cells from 
undergoing apoptosis. By competitively binding to nucleolin, AS1411 effectively 
inhibits bcl-2 protection and induces apoptosis in some tumour cells (Soundararajan 
et al., 2009).  
AS1411 has shown promising results with phase 1 clinical trials exhibiting no 
toxicity in human participants and is currently in undergoing phase 2 for the 
treatment of acute myeloid leukaemia (Aravind et al., 2012). Other aptamers 
currently in phase 2 of clinical trials include; REG1/RB006 (coagulation factor IXa 
inhibitor) (Ahrens et al., 2011), ARC1779 (targets A1 domain of von Willebrand 
factor) (Gilbert et al., 2007; Bae, 2012), and NU172 (thrombin inhibitor) (Zavyalova et 
al., 2013). 
The commonalities observed between aptamer and antibody- target binding 
has earned aptamers the title of ‘chemical antibodies’. For this reason, aptamers are 
increasingly being investigated for their applicability in research, diagnostic, 
therapeutic applications, in all areas where antibodies have traditionally dominated 
(Z. Luo et al., 2017; Santos do Carmo et al., 2017; Sabet et al., 2017). The most 
compelling advantage for the use of aptamers is their highly stable nature. 
Antibodies being proteins are susceptible to irreversible denaturation with elevated 
General introduction 
 41 
temperatures, leading to loss of tertiary structure. In contrast, oligonucleotide 
aptamers can be heat denatured, stored under harsh buffer conditions, and are 
capable of recovering their conformation by re-annealing (Song et al., 2012). 
Aptamers have been found to bind to their targets with similar binding 
affinities to antibodies, with dissociation constants (Kd) in the nanomolar to picomolar 
range (Meng et al., 2010). Moreover, due to their small size (5 - 25kDa), aptamers 
have the added advantage of increased tissue penetration and the ability to access 
epitopes on targets otherwise inaccessible by larger antibodies (150kDa) (Simmons 
et al., 2012). The small molecular size of aptamers enhances their clearance rate 
from the blood. The plasma clearance rates can be further fine-tuned by conjugation 
of chemical moieties such as polyethylene glycol that bulk up the size of the 
aptamer, thus increasing plasma half-life (Tucker et al., 1999). 
Nucleic acid aptamers also possess low immunogenic potential, as the 
immune system generally does not raise an immune response against nucleic acids. 
This allows aptamer drugs to be delivered at higher doses with little immunogenic 
resistance. Pre-clinical studies using pegaptanib sodium in rhesus monkeys 
presented no immunogenicity or toxicity (Drolet et al., 2000). Similar findings were 
also observed with early phase I clinical trials, where administered doses were 100-
fold higher than those clinically relevant (Eyetech Study Group, 2002). In support of 
this, a recent study characterising the pharmacological properties of two angiotensin 
II binding aptamers has shown that immunisation using both aptamers did not induce 
a humoral immune response within BALB/c mice (Heiat et al., 2016). The selection 
and production of aptamers is carried out using chemical synthesis approaches in 
vitro, thus demonstrating a relatively cost effective and standardised means of 
production (Burmeister et al., 2006). 
There is however one major limitation for the use of nucleotide-based 
aptamers as therapeutic targeting molecules in vivo. Nucleotides once injected into 
the circulation are rapidly degraded by serum and intracellular nucleases via 
catalysis of hydrolysis reactions (Kanwar et al., 2011). DNA-based aptamers are 
generally regarded as being more nuclease stable than their RNA counterparts. The 
presence of a 2’ hydroxyl group within the ribose sugar backbone of RNA aptamers 
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makes them more susceptible to nuclease degradation (X. Yang et al., 2002). 
However, the existence of this 2’ hydroxyl group offers RNA based aptamer libraries 
the added advantage of greater structural sequence diversity when compared to 
ssDNA libraries. This is due to non-Watson-Crick base pairing and to the generation 
of more complex tertiary structures (Dua et al., 2011). Generally pyrimidine 
nucleotide bases are modified to confer endonuclease stability through 2’ 
incorporations of fluorine, amino groups (NH2) or of iodide, bromide, chloride to the 
5’ end (Kanwar et al., 2011). 
Several other approaches have been utilised in order to achieve nuclease 
stability. One of these approaches utilises synthetic nucleic acid analogues (e.g. 
locked nucleic acids) that are designed with nuclease-resistant sugar backbones (Lin 
Wang et al., 2005). However, the use of such analogues is not without limitations. 
Synthesis of pre-selected aptamers using nucleotide analogues can alter the binding 
capability of the aptamer, leading to self-aggregation and non-specific binding. 
Moreover, synthetic analogues often exhibit some toxicity when administered in vivo 
(Braasch and Corey, 2001). More recently studies have also highlighted that the 
conjugation of aptamers to gold nanoparticles provides some stability against 
nuclease degradation (Chung et al., 2013). 
1.11.1. Aptamers targeting TfR 
Several studies have highlighted the selection and rationale design of RNA 
and DNA aptamers towards TfR (C.-H. B. Chen et al., 2008; Macdonald, Houghton, 
et al., 2016; Macdonald, Henri, et al., 2016). Chen et al. (2008) were first to 
demonstrate the concept of TfR targeted delivery using selected aptamers 
conjugated to proteins. The group set out to identify both RNA and DNA aptamers 
towards mouse TfR for the purpose of enzyme replacement therapy, through the 
delivery of a lysosomal enzyme conjugated to a mTfR specific aptamer, which in turn 
allows for cellular uptake via receptor mediated endocytosis. The study highlighted 
the selection of two mouse TfR specific aptamers, an RNA aptamer (FB4) and a 
DNA aptamer (GS24). Both aptamers demonstrated TfR mediated endocytic 
transport within Ltk- mouse fibroblast cells as determined by confocal microscopy. 
The GS24 DNA aptamer was also coupled to a lysosomal enzyme (a-L-iduronidase) 
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and was shown to correct glycosaminoglycan metabolism within IDua -/- cells. The 
group concluded that there was no evidence of these aptamers being involved in 
receptor mediated transcytosis and a cell selection approach may be required to 
identify aptamers that are capable of undergoing transcytosis. 
Porciani et al. (2014) later investigated how the loop structures within GS24 
relate to target TfR binding. Through the use of chromatographic based folding 
conformational analysis, the group identified two distinct structural folds (termed A-
1F and A2-F). Incubating each isolated fold with mTfR and quantifying binding 
through a fluorescence anisotropy assay, the group showed that only one of the two 
folds, A-2F, was responsible for mTfR specific binding. Moreover, the binding 
observed using the individual A-2F fold demonstrated a greater affinity towards mTfR 
than the parental GS24 molecule, thus indicating that the presence of a secondary 
inactive fold limits the efficient binding of the aptamer towards target mTfR. 
More recently, another rationale design study by Macdonald et al. (2016) 
outlined the generation a 14-mer truncated variant of the 64 nucleotide GS24 parent 
aptamer sequence. Through mutational studies of the binding region, the group 
generated 4 variants of this aptamer that demonstrated bEnd.3 cell binding at 
affinities ranging from 2.25 μM to 487.3 nM. The group characterised the functional 
ability of these aptamers to internalise within bEnd.3, and a human control cell line, 
(MOLT4), to assess any changes in target specificity. Varying levels of uptake were 
observed with the four mutant variants. Interestingly, the group found that highest 
degree of internalisation was observed with TfRA4 with a quantitated affinity towards 
the cells of 487.3 nM. However, no binding could be seen with the MOLT4 cell line, 
indicating that the epitope which these aptamer variants target is only present on 
mTfR. 
Having demonstrated successful uptake of the mutant aptamers, Macdonald 
et al. (2016) generated several bi-functional aptamer conjugates, by coupling the 
truncated 14 nucleotide mTFR specific aptamer to 17 nucleotide truncated variants 
of SYL3C, an epithelial cell adhesion molecule (EpCAM) specific aptamer. EpCAM is 
a membrane glycoprotein overexpressed on brain metastasising cancer cells. 
Through the conjugation of the mTfR binding aptamer and variants of the EpCAM 
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aptamers, the group aimed to develop a dual targeting aptamer molecule, that 
undergoes transcytosis across the BBB and further targets the subset of cancer cells 
within the CNS. It was proposed that this would reduce widespread neurotoxicity 
caused through non-specific cellular uptake within the CNS, thus increasing the 
overall safety of the therapeutic conjugate. The bi-functional aptamers were found to 
maintain target bEnd.3 internalisation and were shown to transcytose across the 
BBB in mouse in vivo studies. One limitation to both the studies performed by 
Macdonald et al. (2016; 2016) was that the binding affinity of the identified aptamers 
was only determined towards cells and not recombinant protein. With cells typically 
expressing variable levels of receptor targets under different conditions, these 
binding affinities may or may not be entirely representative of the true affinity towards 
the target protein. 
Wilner et al. (2012) have also previously highlighted the selection of a hTfR 
binding RNA aptamer which was found to bind competitively and with a similar 
affinity to transferrin. The group utilised a combinational recombinant protein and cell 
SELEX procedure in order to generate functionalised aptamers that bound under 
physiological conditions. Following just five rounds of SELEX, the group screened 13 
clones and found three clones to bind robustly to Jurkat cells, known to overexpress 
TfR. One of these three clones, the c2 clone, was minimised to optimise binding 
affinity.  Whilst the group had highlighted the potential for targeting the BBB, 
assessment of binding of the selected hTfR specific aptamer was not carried out on 
BCEC. Furthermore, the c2 clone aptamer was selected towards recombinant hTfR 
generated within the Sf9 insect cell line. This would suggest that post-translational 
glycosylation of the TfR protein used for selections would vary significantly from the 
glycosylation patterns found within mammalian cells. Although the described 
methods resulted in aptamers that functionally bound mammalian cell lines 
expressing hTfR, it is not an optimal selection approach. Some aptamers pre-
identified through screening against TfR expressed in insect cells may not bind to 
mammalian TfR during cell screening.  
Recently, Rhode et al. (2016) utilised the transferrin receptor RNA aptamer 
developed by Wilner et al. (2016) to deliver conjugated microRNA-126 and 
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demonstrated biological activity within human umbilical cord-derived venous 
endothelial cells (HUVEC) and murine endothelial cells (MEC). 
1.12. In vitro enrichment selection techniques for the identification of target 
binding biologics 
Combinatorial in vitro selection techniques provide a powerful and an efficient 
means of identifying specific molecular recognition domains towards a wide range of 
targets, from small molecules, proteins and cells to tissues and whole organisms (K. 
A. Noren and C. J. Noren, 2001; Stoltenburg et al., 2005) Target interacting 
molecules are isolated from large combinatorial libraries of random molecules with a 
theoretical diversity of up to 1016 unique species (Jijakli et al., 2016). Through 
iterative cycles of selection, amplification and purification, the selected pools become 
enriched with species that preferentially bind towards the target. These selections 
are usually performed with the target protein immobilised to an affinity matrix in order 
to allow effective separation of the unbound affinity domains from those that have 
bound to the target (Murphy et al., 2003).  
Functional selections can also be performed towards live adherent cell 
cultures or in cell suspension. Furthermore, cell selections using iterative target 
positive and non-target expressing cells can be carried out in order to select domains 
that preferentially recognise certain cell types (Ohuchi, 2012). An advantage to this 
kind of in vitro selection procedure is that no prior knowledge of the target is required 
for target-site specific recognition.  
1.12.1. Phage display 
The most established in vitro affinity screening technique is phage display. 
This method was developed by Smith et al. (1985) and relies on bioengineering 
approaches to exploit the link between genotype and phenotype (Carmen and 
Jermutus, 2002). Principally, a foreign gene encoding a protein or peptide of interest 
is inserted into the genome of a bacteriophage, a virus capable of infecting bacteria. 
The inserted gene is fused with a coat protein encoding gene of the phage virion, 
and the resultant chimeric protein or peptide is then expressed and displayed by the 
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phage on its surface. The most commonly used bacteriophage for phage display is 
the M13 filamentous phage (G. P. Smith, 1985). Unlike lytic phages, filamentous 
phages do not result in cell lysis of the infected host cell and therefore can continue 
to replicate and be released from the cell as it grows and divides (G. P. Smith, 1988). 
The genome of M13 bacteriophage incorporates a total of 11 genes, five of which 
encode phage coat proteins. All of these five coat proteins have been exploited for 
phage display, but the gene-3 minor coat protein (g3p) remains the most popular 
fusion partner, due to the possibly of fusing larger proteins (Carmen and Jermutus, 
2002).  
The use of larger proteins or peptides in fusion with g3p has one major 
limitation, it hinders efficient infection of E.coli host cells (Holliger and Riechmann, 
1997). G3p is responsible for the interaction of the phage with E.coli containing the 
F-pilus and thus the functioning of g3p is required for host cell infection (Omidfar and 
Daneshpour, 2015). In order to resolve this issue phagemid vectors were developed 
(Qi et al., 2012). These vectors are derived from filamentous phage vectors and 
typically contain the encoding material for replication origin of a plasmid, the phage 
coat protein and an antibiotic resistance marker. Whilst the phagmid DNA can be 
infected into a host cell via phage, it is not sufficient to allow the replication of phage 
particles following infection. Superinfection with a helper phage such as M13KO7 
provides all the remaining genomic information required for replication to occur within 
the host cell (Carmen and Jermutus, 2002). 
Library construction is an important aspect of phage display, since the 
diversity and quality of a library can alter the outcome of phage display selections. 
Phage display libraries typically range in diversity, demonstrating 109 - 1012 
theoretically variable sequences (Omidfar and Daneshpour, 2015). Many functional 
proteins and peptides may be displayed as fusions to g3p. The simplest form of 
library construction involves the use of random oligonucleotides inserted into the 
phage genome as a fusion to g3p. These random oligonucleotides are 
phenotypically represented as randomised linear peptides. Alternatively, through the 
inclusion of two cysteine residues surrounding a random region, it is possible to 
generate cyclic peptides via the formation of a disulphide link. Additionally, antibody 
General introduction 
 47 
libraries can be generated through the use of randomised cDNA sourced from 
immunoglobulin genes (Variable heavy and Variable light chains from immunised or 
native donors) (Pope et al., 1996; Goodchild et al., 2011).  
The selection of phage particle towards a target is often referred to as 
biopanning and is outlined in Figure 1.12.1.  
 
 
 
Figure 1.12.1: Schematic representation of soluble phage display selection. 
A phage library is incubated with recombinant protein immobilised on an affinity matrix, (1). The 
unbound phage is removed through washing steps, (2) and the bound phage is eluted and amplified 
by infection of E.coli, (3). Amplified phage is purified and utilised in subsequent rounds of selection, 
(4). Following 3 – 4 rounds of selection, phage particles that preferentially bind towards the target 
are enriched, (5). DNA from enriched phage is amplified and sequenced to determine the nucleotide 
and amino acid sequences of binding domains.  
 
Firstly, target antigen is immobilised onto a solid surface, via adsorption or 
affinity capture (e.g. streptavidin-biotin interaction) (Bakhshinejad and 
Sadeghizadeh, 2016). Subsequently, the phage library is incubated with the target, 
after which stringent washing steps are employed to remove non-binding and weakly 
binding phage. Phage is subsequently eluted from the target and used to infect E.coli 
for amplification. The amplified phage is purified and used in subsequent rounds of 
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selection towards the target. Phage particles are typically enriched to the target 
following 3 - 4 iterative selection rounds (Dai et al., 2014; J. Li et al., 2011). 
1.12.2.Systematic evolution of ligands by exponential enrichment (SELEX) 
SELEX is utilised to isolate aptamers enriched to specifically bind a given 
target from vast combinatorial oligonucleotide libraries (Ellington and Szostak, 1990). 
The general procedure consists of three steps, which are repeated cyclically to 
narrow down onto specifically binding oligonucleotides with the highest affinity 
towards the target. The number of rounds required for enrichment is dependent on 
the selection stringency and type of SELEX used, but typically ranges between 5 – 
20 rounds. The generalised procedure of SELEX is outlined in Figure 1.12.2. 
 
Figure 1.12.2: Schematic representation of typical aptamer SELEX procedure. 
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Figure outlining the typical aptamer selection cycle. A. A chemically synthesised library consisting of 
approximately 1015 theoretical sequences is incubated with target. B. The unbound sequences are 
removed through washing and the bound sequences are eluted. C. The eluted pool is amplified via 
PCR to generate an enriched pool for the subsequent round of aptamer selection. 
 
Starting material for aptamer SELEX is a chemically synthesised ssDNA or 
RNA library, theoretically consisting of approximately 1013 - 1015 varying sequences 
(Song et al., 2012). Each sequence consists of a central degenerate nucleotide 
region of a selected length (generally 30-50 nucleotides). This random region is 
flanked by adjacent primer binding sites, which facilitate amplification of bound 
sequences. The library is incubated with the target and subsequently partitioned 
from unbound sequences. Bound sequences are then eluted and amplified by PCR 
in order to enrich the pool with target binding sequences. Amplified double-stranded 
DNA is purified by eluting the template strand from the complementary strand and 
this is utilised in the subsequent round of selection in order to further enrich those 
sequences that bind with highest affinities to the target. 
Various methods and techniques have been developed and outlined in the 
literature for the selection of aptamers (Darmostuk et al., 2015). Stoltenburg et al. 
(2005) outlined a variation of the typical SELEX procedure termed fluorescence-
monitored in vitro selection (FluMag). It involved the use of target immobilised to 
streptavidin-coated magnetic beads and the use of biotin and fluorescein 
isothiocyanate (FITC)-labelled primers for affinity immobilisation and detection, 
respectively. Another form of SELEX, Cell SELEX, allows selections to be performed 
on targets in their native conformations (Sefah et al., 2010). Furthermore, performing 
selections against recombinant protein targets accelerates the selection process by 
increasing the selection scrutiny to the specific target. It is therefore advantageous to 
carry out selections using a combination of both recombinant protein and cell SELEX 
techniques, as this generates high affinity aptamers that bind specifically to a 
functionalised target (Wilner et al., 2012). 
More recently, a study by Cheng et al. (2013) highlighted the selection of 
brain penetrating aptamers via in vivo methods. The group injected a 2’-fluoro 
modified RNA aptamer library into the tail vein of C57BL/6 mice. The brain of these 
mice was harvested following 1 h circulation time and Dulbecco’s phosphate 
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buffered saline (DPBS) infusion. RNA was extracted from the mouse brain, 
amplified, transcribed and purified before being utilised for another round of in vivo 
SELEX. A total of 22 rounds of selections were performed to isolate brain 
internalising aptamers. In contrast to in vitro methods this protocol required many 
more rounds in order to produce an enriched pool of aptamers. This was 
hypothesised to be due to two factors, the large random sequence of the RNA library 
(n= 40), and the vast complexity of targets available as baits using in vivo SELEX. 
Sub-localised binding of the selected aptamer (A15). The aptamer was observed to 
bind various regions of the brain including the cortex, cerebellum, hippocampus and 
striatum. However, this method results with aptamers without initial knowledge of the 
target.  
1.13. Aims and Objectives 
The overall aim of this project was to select and identify brain endothelial 
targeting non-antibody binding domains (cyclic peptides and ssDNA aptamers) via in 
vitro selection rounds of phage display and nucleic acid enrichment (SELEX) 
towards a suitable RMT functioning receptor candidate at the BBB, in this case TfR. 
Subsequently, selected and identified domains were screened and characterised for 
binding towards recombinant TfR and immortalised in vitro BCEC lines (hCMEC/D3 
and bEnd.3 cells).  
More specifically the study set out to: 
1. Characterise cell surface receptor candidates that function via RMT at the 
BBB for use as exploitable delivery strategies across BCEC. 
a. Characterise endogenous surface receptor candidate expression in the 
hCMEC/D3 and CHO variant cell lines (CHO-TRVb). 
b. Evaluate endogenous expression of receptor candidates with long-term 
culture (cell passage), in order to determine optimal conditions for cell 
characterisation of identified domains. 
2. Characterise the CHO-TRVb and -TRVb1 cell lines for hTfR expression and 
assess their suitability for use as hTfR positive and negative targets with in 
vitro cell selections. 
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3. Select and identify TfR species cross-reactive cyclic peptides. 
a. Conduct phage display selections to identify TfR binding and BCEC 
internalising cyclic peptides. 
b. Screen cyclic peptide domains for binding towards recombinant mouse, 
human and rat TfR by means of phage ELISA and elucidate the 
sequence homology of positively binding peptide clones. 
4. Clone and express cyclic peptide lead candidates for characterisation. 
a. Clone out and express positive peptide clones as monovalent CPep-
g3p-D1 fusion domains for lead identification and characterise these 
towards recombinant mTfR, hTfR and immortalised BCEC cells 
(bEnd.3 and hCMEC/D3).  
b. Express lead peptides as bivalent Fc-fusion domains coupled to a 
therapeutic payload, for characterising the cell delivery capability of the 
lead peptides. 
5. Select and identify hTfR binding ssDNA aptamers 
a. Establish a protocol for aptamer SELEX utilising polyhistidine tagged 
recombinant protein immobilised on Ni-NTA magnetic agarose beads. 
b. Select ssDNA aptamers via rounds nucleic acid enrichment (SELEX) 
towards hTfR and CHO-TRVb1 cells (over-expressing hTfR). 
c. Carry out next generation sequencing of selected aptamer pools, 
analyse NGS data for overall enrichment with selection progression 
and identify potential lead aptamer candidates that have been highly 
enriched throughout the selection.
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2.1. Introduction 
Endogenous transport receptors expressed on the luminal surface of BCEC 
allow the movement of nutrients, proteins and other molecules across the BBB into 
the CNS for vital metabolic activities within the brain (Serlin et al., 2015; Abbott et al., 
2010). These transport receptors have been proposed as exploitable targets for the 
delivery of therapeutic cargo across the BBB into the CNS (Georgieva et al., 2014). 
The expression of many of these transporters has been extensively explored both 
within in vitro models of the BBB (Carl et al., 2010; Ohtsuki et al., 2013) and in vivo 
(Cornford and Hyman, 2005). The most notable target mechanism for the purpose of 
exploitation is receptor mediated transcytosis (RMT) (Raub and Newton, 1991). 
Normally, RMT involves the binding of a ligand to its specific receptor, resulting in an 
endocytic event which leads to cellular internalisation of the receptor and its bound 
ligand. Consequently, the complex is trafficked through the cell to the abluminal 
membrane, where it is released and made available within the CNS (Bickel et al., 
1994). By targeting an epitope on the transporter that does not interfere with ligand 
binding or internalisation, it is possible to ‘hitch-hike’ therapeutic molecules alongside 
the target transporter into the CNS. This mechanism is referred to as molecular 
‘Trojan horse’ delivery and has been utilised in the past to deliver biologics such as 
monoclonal antibodies across the BBB (reviewed in Lajoie and Shusta, 2015). 
The ideal candidate target receptor for exploitation would have the following 
characteristics. Firstly, the receptor should be specifically expressed by BCEC on 
both the luminal and abluminal membranes. It must also have a high blood to brain 
translocation capacity, to allow efficient delivery of neuro-therapeutic agents from the 
circulation. The cellular internalisation mechanism must also favour transcytosis by 
avoiding the lysosomal degradation compartment. Presently, there are no known 
receptors that meet all these criteria. Most BBB drug delivery efforts have focused on 
the exploitation of ubiquitously expressed receptors such as transferrin receptor and 
insulin receptor  
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(Yu et al., 2014; Niewoehner et al., 2014; Boado, Zhou, et al., 2010; Ulbrich et 
al., 2009; Huang et al., 2007; Lee et al., 2000; Pardridge et al., 1995; Coloma et al., 
2000; Pardridge et al., 1991; Kuo and Shih-Huang, 2013).  
Although some of these receptors are ubiquitously expressed, their 
expression is higher within BCEC than other cells, making them good candidates for 
delivery. Unfortunately, the ubiquitous nature of these receptors has also raised 
safety concerns regarding the off target side effects of their use (Ohshima-
Hosoyama et al., 2012; Couch et al., 2013). 
Although many in vitro and in vivo studies utilising monoclonal antibody 
delivery vectors have been successful in demonstrating transcytosis across BCEC, 
the rate of delivery is often poor. This amounts to a steady-state concentration of 
approximately 0.1% of circulating antibody being bio-available within the brain, thus 
resulting in a weak therapeutic concentration which does not usually elicit a 
pharmacologically relevant response (Niewoehner et al., 2014).  
In recent years, alternative non-antibody biologics such as aptamers (Mattice 
and DeRosa, 2015), engineered antibody fragments (reviewed in Roque et al., 
2004), peptides (Uhlig et al., 2014), fusion proteins (Czajkowsky et al., 2012), and 
non-antibody scaffolds (Skerra, 2007; Vazquez-Lombardi et al., 2015) have grown in 
popularity as novel targeting and therapeutic reagents. We hypothesise that the use 
of small non-antibody domains may prove advantageous alternatives to monoclonal 
antibodies in the context of delivering therapeutic cargo across the BBB.  
Prior to commencing in vitro selections of non-antibody delivery domains, it 
was necessary to establish a target cell surface receptor protein that is highly 
expressed in brain endothelial cells and functions in the translocation of its natural 
ligand into the CNS via RMT. Three receptor candidates were selected for 
characterisation, these were; transferrin receptor (TfR), low-density lipoprotein 
receptor (LDLR) and low-density lipoprotein receptor-related protein 1 (LRP1). The 
primary aim of this chapter is to characterise the expression of these receptors on 
the human immortalised microvascular endothelial cell line, hCMEC/D3. The 
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characterisations were carried out to address three preliminary questions, these 
were as follows: 
1. Are all three candidate receptors expressed on the surface of hCMEC/D3 
cells? 
2. Does the expression of the candidate receptors differ with long-term cell 
culture? 
3. Which cell surface receptor would be the most suitable candidate to exploit for 
the purpose of molecular ‘Trojan horse’ delivery of therapeutic cargo across 
the BBB into the CNS? 
Further to this main objective, it was also necessary to characterise two 
Chinese hamster ovary (CHO) transcript variant cell lines, CHO-TRVb (a hamster 
TfR deficient cell line) and CHO-TRVb-1 (the hTfR transfected form of the deficient 
cell line). These TfR variant cells were initially developed to allow the study of hTfR 
transfected CHO cells, without the interfering effects of endogenous Chinese 
hamster TfR (McGraw et al., 1987). We hypothesise that the CHO-TRVb cell lines 
could be valuable tools for accomplishing functional positive and negative cell 
selections towards TfR. 
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2.2. Materials and Methods 
2.2.1. Pre-coating culture flasks and plates with collagen type I 
Type I collagen 20x stock solution (1 mg/ml) (Sigma-Aldrich, Dorset, UK) was 
aliquoted into 1.5 ml Eppendorf tubes to reduce risk of contamination, and stored at 
4 °C. Before use, the collagen was diluted to a working concentration 50 µg/ml in 
Hank’s balanced salt solution (HBSS) with Ca2+ and Mg2+ (Sigma-Aldrich, Dorset, 
UK) and culture vessels were coated for 1 h at room temperature. Prior to cell 
seeding, the collagen was aspirated and the flasks were washed with HBSS (with 
Ca2+ and Mg2+). 
2.2.2. Cell culture of the hCMEC/D3 cell line 
Growth media for the hCMEC/D3 cell line was made up using the following 
components and volumes outlined in Table 2.2.1. Prior to media preparation, culture 
media supplements were thawed at room temperature and foetal bovine serum 
(FBS) was thawed at 37 °C. Endothelial cell growth medium-2 (Lonza™, Basel, 
Switzerland) consists of Endothelial Basal Medium-2 (EBM-2) supplemented with 
2.5% (v/v) FBS and growth factors to optimise growth.  
Table 2.2.1: Preparing complete EGM-2 Growth medium. 
 
Growth media component Volume (v/v) 
Media and 
Serum 
Endothelial Basal Medium-2 (EBM-2) - (Lonza™) 97.11% 
Foetal bovine serum (FBS) 2.5% 
Su
pp
le
m
en
ts
 
Human endothelial growth factor (hEGF) 0.025% 
Vascular endothelial growth factor (VEGF) 0.025% 
Human fibroblast growth factor (hFGF) 0.1% 
Gentamycin 0.1% 
Ascorbic acid 0.1% 
Hydrocortisone 0.4% 
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The supplemented media was inverted to mix and aliquoted into 50 ml falcon 
tubes when required to reduce risk of contamination and stored at 4 °C. 
2.2.2.1. Thawing cells from cryostorage and initial culture 
hCMEC/D3 cells were removed from cryostorage and thawed in a 37 °C water 
bath with gentle agitation. Cells were seeded into collagen pre-coated culture flasks 
containing pre-warmed EBM-2 culture media at a density of 40,000 cells/cm2 and 
subsequently transferred to a humidified incubator set at 37 °C, 5% CO2. Cell culture 
media was changed every two days until the cells were confluent. Cells were 
considered confluent when a contact inhibited monolayer was observed exhibiting 
phenotypic maturity; this took approximately 3-4 days. hCMEC/D3 cells were used 
between cell passages 23 – 35. 
2.2.2.2. Sub-culture of adherent hCMEC/D3 cells 
EBM-2 media, trypsin-ethylenediaminetetraacetic acid (EDTA) (Invitrogen, 
Paisley, UK), HBSS (without Ca2+ and Mg2+) and FBS were pre-warmed in a water 
bath at 37 °C.  Sub-culture of cells was performed by aspirating culture media from 
the culture flask, and washing cells with HBSS (without Ca2+ and Mg2+). This wash 
step removes any traces of calcium and magnesium that would otherwise inhibit the 
action of trypsin. 
Subsequently, enough trypsin-EDTA was added to cover the cell monolayer 
and the culture flask was placed in an incubator at 37°C for 2 min. Once cells had 
detached, the action of trypsin was inhibited by addition of 10% FBS in EBM-2 
culture media to the culture flasks. The complete contents of the culture flask were 
then transferred to a 50 ml falcon tube and 10 μl of cell suspension was extracted for 
cell counting using a haemocytometer at 100x magnification.  
Cells were centrifuged at 300 g for 5 min, the supernatant was discarded and 
the cell pellet was re-suspended in the appropriate volume of culture media. A 
volume equivalent to the seeding density of cells was then added to a collagen pre-
coated culture flask containing pre-warmed EBM-2 culture medium and the flask was 
placed in a humidified incubator at 37°C, 5% CO2.  
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Following sub-culture, remaining cells were prepared for cryostorage by 
addition of 10% (v/v) dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Dorset, UK). 
Volumes equivalent to 1 million cells were then aliquoted into pre-labelled cryotubes. 
The cryotubes were frozen at a rate of -1°C per minute to -80°C before being 
transferred to liquid nitrogen for long-term storage.  
2.2.3. Cell culture of CHO cell lines (TRVb and TRVb-1) 
CHO-Transferrin Receptor Variant clone b cell lines, TRVb (endogenous TfR 
deficient) and CHO-TRVb-1 (human TfR stable transfection in TRVb cells) were 
kindly provided by Prof. Tim McGraw (Cornell University, New York).  
The CHO-TRVb cell line was maintained in Ham’s F12 nutrient mix + 
GlutaMAX media (Invitrogen, Paisley, UK) supplemented with 5% FBS and 100 U/ml 
penicillin and 100 μg/ml streptomycin. The human TFR expressing form of the 
deficient cell line, CHO-TRVb-1 was maintained in similar media to TRVb cells with 
the addition of 500 μg/ml Geneticin to prevent growth of non-transfected cells. Both 
cell lines were grown in a humidified incubator at 37°C, 5% CO2. Growth media for 
each of the CHO cell lines was prepared as outlined in Table 2.2.2.  
Table 2.2.2: CHO-TRVb and TRVb-1 cell culture media. 
 TRVb (TfR 
deficient) 
TRVb-1 (hTfR 
transfected) 
Growth media component Percentage volume (v/v) 
Media 
and 
Serum 
Ham’s F12 Nutrient mix + GlutaMAX 
(Invitrogen, Paisley, UK) 93% 92% 
Foetal bovine serum (Sigma-Aldrich, 
Dorset, UK) 5% 5% 
Su
pp
le
m
en
ts
 Penicillin/ streptomycin (Invitrogen, 
Paisley, UK) 2% 2% 
Geneticin solution (50 mg/ml) (Sigma-
Aldrich, Dorset, UK) - 1% 
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2.2.4. Assessment of cell-surface protein expression using Flow cytometry 
Cell-surface receptor expression of the hCMEC/D3 and CHO-TRVb (CHO-
TRVb and CHO-TRVb1) cell lines was assayed using flow cytometry. Mouse primary 
antibodies were chosen according to the criteria that they bind an epitope within the 
extracellular domain of each of the protein receptor candidates and are validated for 
the application of flow cytometry. These primary antibodies were subsequently 
indirectly labelled with a FITC conjugated sheep anti-mouse polyclonal IgG 
secondary antibody (Sigma-Aldrich, Dorset, UK). The antibodies selected are 
outlined in Table 2.2.3.  
 
Table 2.2.3: Receptor protein specific antibodies utilised in FACS analysis. 
 
 
Cells were cultured to confluence then harvested using the relevant cell 
detachment media, trypsin/ EDTA or accutase solution, for 2 min and 4 min, 
respectively. Cells were washed in HBSS and re-suspended at a concentration of 1 x 
106 cells/ml in the relevant cell culture media.  
All subsequent protocol stages were carried out on ice. 1.5 x 106 cells were 
isolated and washed in 9 ml of HBSS. This was carried out by centrifugation at 300 g 
for 5 min then discarding the supernatant. The wash step was then repeated using 9 
Antigen Description Supplier Catalogue 
No. 
Working 
dilution 
Human TfR Mouse monoclonal 
IgG1, Clone #29806 
R&D Systems, 
Oxon, UK 
MAB2474 1 mg/ml 
Human LDLR Mouse monoclonal 
IgG1, Clone #472413 
R&D Systems, 
Oxon, UK 
MAB2148 1 mg/ml 
Human LRP1α 
chain 
Mouse monoclonal 
IgG1 
Invitrogen, 
Paisley, UK 
37-3800 1 mg/ml 
Isotype control 
antibody 
Mouse IgG1 Invitrogen, 
Paisley, UK 
MG100 1mg/ml 
Mouse IgG Polyclonal sheep 
IgG1 FITC 
conjugated 
Sigma-Aldrich, 
Dorset, UK 
F6257 1:50 (v/v) 
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ml of 1x phosphate buffered saline (PBS) to ensure removal of free protein that may 
bind primary antibody. 
Cells were subsequently fixed for 30 min at room temperature in 1 ml of 2% 
paraformaldehyde solution made up in PBS. Fixed cells were then diluted in  
9 ml of PBS and washed twice, before being re-suspended in antibody diluent 
solution consisting of 1 mg/ml bovine serum albumin (BSA) in PBS.  
Following a cell count, 3 x 105 cells were aliquoted into relevantly labelled 
Eppendorf tubes. 2 µg of primary antibody was added to each sample tube. A 
negative control was prepared by inclusion of a primary isotype-matched irrelevant 
control antibody (Invitrogen, Paisley, UK). 
Cells were incubated with primary antibody overnight on a shaker at 4 °C. The 
following day cells were washed in 1 ml of PBS twice via centrifugation at 500 g for 5 
min. Subsequently, cells were re-suspended in a secondary antibody diluent 
consisting of 1:100 polyclonal sheep anti-mouse IgG1 conjugated to FITC (Sigma-
Aldrich, Dorset, UK) in PBS and 1 mg/ml BSA. Cells were incubated with secondary 
antibody for 2 h, at 4 ˚C on a shaker, followed by another two washing steps in PBS.  
After washing, cells were re-suspended in 300 µl of HBSS and transferred to labelled 
FACS tubes before being analysed for fluorescence using a FACSCalibur machine 
and CellQuest software (Becton Dickinson, UK). The median fluorescence intensity 
of 10,000 sampled cells within a defined cell gate was acquired at a FL1 voltage of 
360 V.  
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2.2.5. Western Blotting 
Denaturing polyacrylamide gels and buffers were prepared as outlined in 
Table 2.2.4. 
Table 2.2.4: Table showing recipes for polyacrylamide gels and western blotting buffers. 
 
CHO-TRVb and TRVb-1 cells were cultured to confluence in 12 well plates, 
supplemented with their relevant culture media. Cell lysates were prepared by 
addition of 0.5 ml of cold HBSS (+Ca2+) and detached from the culture plates using a 
cell scraper. Detached cells were washed by centrifugation at 300 g for 5 min and re-
suspended in 100 µl of RIPA lysis buffer per 1 x 106 cells. The cells were then cooled 
on ice and subsequently stored at -80°C for 30 min whilst frequently agitating cells 
by gentle shaking. Cells were thawed on ice, centrifuged at 300 g for 5 min and the 
supernatant, containing the protein extract, was recovered. Following protein 
extraction, sample total protein concentration was determined using detergent-
 Composition 
Po
ly
ac
ry
la
m
id
e 
ge
ls  
Resolving gel 
 
33% Protogel (30% acrylamide, 0.8% methylene 
bisacrylamide) (National diagnostics, Hull, UK), 0.1% w/v 
SDS, 0.37M tris HCl pH 8.8, 0.03% v/v tetramethyl-
ethlenediamine (TEMED) (Sigma-Aldrich, Dorset, UK) and 
0.1% w/v ammonium persulphate (APS) (Sigma-Aldrich, 
Dorset, UK). 
Stacking gel 
16.7% Protogel (30% acrylamide, 0.8% methylene 
bisacrylamide), 0.03% w/v SDS, 0.12M tris HCl, pH 6.8, 
0.03% v/v TEMED and 0.03% w/v APS. 
Bu
ffe
rs
 
RIPA lysis Buffer 25mM Tris-HCl (pH 7.6), 150mM NaCl, 1% NP40, 1% sodium deoxycholate, 0.1% SDS 
4x SDS-PAGE (Laemmli’s) 
reducing buffer 
250mM tris HCl, 8% sodium dodecyl sulphate (SDS), 0.01% 
bromophenol blue, 40% glycerol, 10% 2-mercaptoethanol. 
Gel running buffer 25mM Tris, 192mM glycine, 1% SDS  
Gel transfer buffer 25mM Tris, 192mM glycine, 20% ethanol. 
Membrane blocking buffer 0.2% tween 20 (Sigma-Aldrich, Dorset, UK) and 5% fat free dried milk suspended in 1x PBS. 
Membrane washing buffer 
(PBST) 
0.2% tween 20 suspended in 1xPBS. 
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compatible (DC) colorimetric assay kit (Biorad, Hertfordshire, UK). This was 
performed by preparation of a standard curve using varying concentrations of the 1.5 
mg/ml BSA standard stock solution. Successively, 45 µl aliquots of each protein 
extract was then added to 15 µl of 4x Laemmli’s buffer in clean eppendorf tubes. 
This mixture was then heated to 95°C for 10 min in order to denature the 
proteins. Poly-acrylamide 8% (v/v) resolving gels were cast and allowed to set, prior 
to the addition of the 5% (v/v) stacking gel and comb. The gel was placed in an 
electrophoresis tank containing running buffer and each lane was loaded with 15 µl 
of sample alongside a multicolour high range protein ladder (26625, ThermoFisher 
Scientific, Paisley, UK). Samples were run at 100V through the stacking gel and 
150V through the resolving gel, until the bromophenol blue dye was observed to run 
off the gel. Proteins within the resolving gel were subsequently transferred onto a 
HyBond nitrocellulose membrane (Amersham, Buckinghamshire, UK) using 0.15 
Amp, overnight at 4°C. 
Following transfer, the membrane was briefly stained for 1 min in Ponceau red 
solution (Sigma-Aldrich, Dorset, UK). Staining was carried out in order to determine if 
protein and molecular marker migration was uniform. After staining the membrane 
was rinsed in water, before a 1 h incubation step with blocking buffer at room 
temperature. Post blocking, the membrane was washed and incubated overnight at 
4°C with primary mouse monoclonal anti-human TfR (MAB2474, R&D Systems, 
Oxon, UK) antibody diluted in blocking buffer (10 µg/ml). 
The following day, membranes were rinsed for 10 min in PBST washing buffer 
on a shaker. This process was repeated 4 more times using PBST washing buffer. 
The membrane was incubated with 1:80,000 dilution of polyclonal rabbit anti-mouse 
IgG HRP conjugated secondary antibody (Cat No. A9044, Sigma-Aldrich, Dorset, 
UK) at room temperature for 1 h. Following secondary incubation, the membrane 
was washed again in PBST washing buffer for 10 min (5 times) and then in 1x PBS 
for 5 min.  
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The membrane was then carefully dried on filter paper, briefly developed for 1 
min using ECL detection reagent (Amersham, Buckinghamshire, UK) and exposed to 
Hyperfilm (Amersham, Buckinghamshire, UK) for 1 min. 
2.2.6. Immunocytochemistry CHO-TRVb cell line internalisation assays 
Immunocytochemistry (ICC) was used to assess TfR mediated uptake of 
antibodies directed towards hTfR and mTfR. CHO-TRVb and CHO-TRVb-1 cells 
were maintained as outlined in section 2.2.3. Cells were sub-cultured into 96-well 
special optics flat clear bottom black polystyrene TC-treated microplates (Corning, 
High Wycombe, UK) at a seeding density of 1.5 x 104 per well. Cells were grown to 
confluence for 48 h, media was aspirated from the culture wells and cells were 
washed twice in PBS, prior to commencing internalisation assays. 
Anti-hTfR (Confidential protein, contact George Thom, MedImmune, 
Cambridge, UK) and an engineered variant of anti-mTfR (8D3) antibody 
(MedImmune, Cambridge, UK) were diluted to a working concentration of 2 µg/ml in 
1% BSA/ unsupplemented media. Confluent cells were incubated with primary 
antibody within a humidified incubator for 5 min in 1% BSA in PBS. Post-incubation, 
cells were washed three times for 5 min in 1% BSA in PBS, and permeablised using 
0.25% Triton X-100 (Sigma-Aldrich, Dorset, UK). Secondary labelling of antibodies 
was carried out using 10 µg/ml polyclonal F(ab’)2 goat anti-human IgG (Fc specific) 
Alexa 488 conjugate (Thermo-Fisher Scientific, Paisley, UK). Nuclei were labelled 
with hoechst at a dilution of 1:10,000, for 1 min at room temperature. 
Immunofluorescent imaging of labelled cells within 96-well plates was carried out 
using an ImageXpress Micro XLS system (Molecular probes, Wokingham, UK). 
Mean grey value readings were acquired using FIJI (ImageJ), normalised to the 
number of cells in each image (imageJ), and averaged from three independent 
images taken per experimental replicate (n= 3).  
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2.2.7. Statistical analysis 
Statistical analysis was performed using Graphpad Prism 6 statistical software 
on FACS triplicate sample runs by initially subtracting the irrelevant IgG1 isotype 
control median fluorescence reading. One-way analysis of variance (ANOVA) tests 
were carried out where applicable alongside Tukey’s multiple comparison post hoc-
test. A P value <0.05 was considered to be significant. 
2.3. Results 
2.3.1. Expression of candidate receptor targets by hCMEC/D3 cells. 
The initial characterisation study of the hCMEC/D3 cell line was undertaken in 
order to establish a suitable endothelial cell surface receptor candidate, and 
determine its optimal binding conditions for subsequent use as a bait during non-
antibody domain selections. This study consisted of three parts.  
2.3.1.1. Cell surface expression of TfR, LDLR and LRP1 on hCMEC/D3 cells 
 Firstly, the study set out to assess the expression of candidate receptors on 
the cell surface of the hCMEC/D3 cell line, whilst simultaneously assessing the 
binding effectiveness of the selected primary antibodies, targeted towards the 
extracellular portion of these receptors.  
Flow cytometric analysis of the three receptor targets; TfR, LDLR and LRP1, 
were carried out using three separate biological replicates on hCMEC/D3 cells 
paired alongside the primary antibody matched IgG1 isotype control. Results were 
normalised to the relevant IgG1 isotype controls and expressed as average 
fluorescence intensities +/- SEM. 
All three receptor candidates exhibited expression on the cell surface of 
hCMEC/D3 cells, Figure 2.3.1. TfR presented with higher average median 
fluorescence intensity readings than LDLR and LRP1. However, it is not possible to 
discern whether this is directly due to the expression of each receptor candidate on 
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the hCMEC/D3 cell surface or whether it is due to the varying affinities of the 
detection antibodies towards their target epitopes. 
 
 
Figure 2.3.1: Facs detection of transport receptor proteins TfR, LDLR and LRP1 on hCMEC/D3 
cells (p35) 
FACS histogram overlay data showing expression of (A) TfR, (B) LDLR, and (C) LRP1 on the hCMEC/D3 
cell line at (passage 35). Acquisition of FACS data was conducted on 10,000 gated events at an FL1 
voltage of 360 V. Primary antibody matched (IgG1) isotype control data is represented by a black 
line. Red, green and blue lines represent each of the three experimental replicates. (D) Summary of 
initial receptor candidate expression study on hCMEC/D3 cell line. Figure demonstrates expression 
of TfR, LDLR and LRP1 respectively. Median fluorescence intensity is presented as a mean ± SE of 
three experimental replicates (n= 3), with the average median fluorescence intensity of the relevant 
IgG1 isotype control subtracted.  
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2.3.1.2. Expression of TfR, LDLR and LRP1 with long-term hCMEC/D3 culture 
in vitro cultured cells de-differentiate with long-term culture, and inherently 
lose their desired phenotype through changes in gene and protein expression and 
cellular morphology (Schnabel et al., 2002). Therefore, it is essential to evaluate any 
variation in target receptor expression with increasing cell passage, in order to 
determine the optimal passage number when performing selections and binding 
assays. 
Cultures of hCMEC/D3 cells at passages 25, 30 and 34 or 26, 29 and 36 were 
thawed from three independent batches of cells for each passage and grown to 
confluency under identical culture conditions, as described in section 2.2.2.2. Cells 
were detached using Trypsin/EDTA and assessed for cell surface receptor 
expression using FACS. 
No significant changes in TfR expression were observed between passages 25, 30, 
and 34 (P >0.05, n= 3). Fluorescence readings were relatively consistent throughout 
and remained high with increasing passage, as shown in 2.3.2, A and Figure 2.3.3, 
A. 
LDLR expression was observed to significantly decrease by one third at passage 30 
when compared to passage 25 (P <0.01, n= 3) and this decrease was then 
maintained at passage 34, (2.3.2, B and Figure 2.3.3, B). 
LRP1 exhibited a dramatic increase in expression with long-term culture (2.3.2, C 
and Figure 2.3.3, C). A statistically significant three-fold up-regulation in expression 
of LRP1 was observed with passage 36 in contrast to passage 26 (P <0.01, n= 3).  A 
significant two-fold increase was also observed with passage 36 over passage 29 (P <0.05, n= 3). A greater degree of inter-variability between experimental replicates 
was observed for passage 29 (2.3.3, C).  
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Figure 2.3.3: Summarised results of TfR, LDLR and LRP1 hCMEC/D3 cell surface expression 
with long-term culture. 
Summarised receptor expression results from long-term culture study are shown in (A), (B) and (C), 
and demonstrate the expression of TfR, LDLR (passages 25, 30 and 34), and LRP1 (passages 26, 29, 
and 36), respectively. Median Fluorescence intensity is presented ± SE of three experimental 
replicates, with the average fluorescence intensity of the relevant IgG1 isotype control subtracted. 
One-way ANOVA and Tukey’s multiple comparison statistical tests were performed to assess 
statistically significant variations in receptor fluorescence intensity means. A P value of <0.05 was 
considered significant. 
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2.3.1.3. Effect of cell detachment protocol on surface TfR expression 
When considering the protein structure of the TfR monomer, multiple sites for 
proteolytic cleavage had been described within the stem region of the extracellular 
domain, including a trypsin cleavage site at arginine 100 (Kaup et al., 2002; Rutledge 
et al., 1998; Turkewitz, Amatruda, et al., 1988). Biologically, cleavage at this site 
releases the solubilised extracellular domain of TfR into the circulation. It was 
consequently appropriate to assess whether trypsin detachment of cells had a potent 
cleaving effect on the expression of the membrane bound form. To evaluate this, a 
less potent secondary cell detachment solution (Accutase) was utilised for 
comparative purposes. The technique utilised for achieving the outlined goals of this 
study was flow cytometry. 
hCMEC/D3 cells (passage 33) were cultured in six T25 flasks under the 
conditions described in section 2.2.2.2. Cells were detached using one of the two 
detachment solutions, trypsin EDTA or accutase, for the minimum incubation times 
required, 2 min or 4 min, respectively. Cells were fixed in 2% paraformaldehyde and 
evaluated for TfR cell surface expression via indirect antibody labelling and FACS 
analysis. 
 Cell membrane bound TfR expression was found to be consistent using both 
cell detachment solutions Figure 2.3.4. No observable advantage was identified with 
using Accutase detachment solution over short-term trypsin EDTA treatment. 
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Figure 2.3.4: FACS detection of TfR on cell surface of hCMEC/D3 cells after Trypsin / EDTA or 
Accutase detachment. 
FACS histogram overlay data showing expression of TfR following trypsin/EDTA detachment (A), and 
accutase detachment (B). Acquisition of FACS data was conducted on 10,000-gated events at an FL1 
voltage of 360V. Primary antibody matched (IgG1) isotype control data is represented by a black line. 
Red, green and blue lines represent each of the experimental replicates. Summarised results of 
trypsin EDTA and accutase hCMEC/D3 cell detachment study (C). Trypsin/EDTA potency on cell 
surface hTfR expression was compared to accutase detachment solution. No significant variations in 
TfR expression were observed. Median fluorescence intensity is presented as a mean ± SE of three 
experimental replicates, with the average median fluorescence intensity of the relevant IgG1 isotype 
control subtracted.  
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2.3.2. Characterising the expression of human TfR by CHO-TRVb cell lines. 
TfR expression was also assessed on two other transferrin receptor variant 
cell lines, CHO-TRVb and TRVb-1 (McGraw et al., 1987). These were initially 
developed to allow the study of hTfR transfected CHO cells, without the interfering 
effects of endogenous Chinese hamster TfR. CHO-TRVb cell lines could potentially 
be valuable tools for accomplishing both positive and negative cell selections against 
the transfected and deficient forms of the cell line, respectively. 
2.3.2.1. Expression of hTfR on CHO-TRVb cell lines 
We characterised the expression of hTfR on both the endogenous hamster 
TfR deficient cell line (TRVb), and the hTfR stably transfected form of the cell line 
(TRVb-1) using FACS. The hTfR expression of both these cell lines was also 
simultaneously compared to expression on hCMEC/D3 cells. 
Similar levels of hTfR expression were observed between the hCMEC/D3 cell 
line and the transfected CHO cell line (TRVb-1), however this similarity was not 
statistically significant, Figure 2.3.5. 
Most notably, an antibody binding signal was also observed on the negative 
TRVb cell line. The signal on TRVb cells was found to be 5-fold less when compared 
to the hTfR TRVb-1 cell line and hCMEC/D3 cells (P £0.0001, n= 3). These results 
suggest the TRVb cell line is not completely deficient and maybe a heterogeneous 
mix of hTfR expressing and hTfR deficient cells. Further assessment of the cell lines 
using the same primary antibody was performed by western blotting of the cell 
lysates. 
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Figure 2.3.5: Characterisation of TfR expression on the cell surface of hCMEC/D3, TRVb and 
TRVb-1 cells. 
FACS histogram overlay data showing expression of TfR on (A) hCMEC/D3 (p30), (B) TRVb (p12) and 
(C) TRVb-1 (p13) cell lines. Acquisition of FACS data was conducted on 10,000-gated events at an FL1 
voltage of 360V. Primary antibody matched (IgG1) isotype control data is represented by a black line. 
Red, green and blue lines represent each of the experimental replicates. Summarised results of 
surface TfR cell line comparison are shown in figure (D). Median fluorescence intensity is presented 
as a mean ± SE of three experimental replicates (n= 3), with the average median fluorescence 
intensity of the relevant IgG1 isotype control subtracted. One-way ANOVA and Tukey’s multiple 
comparison statistical tests were performed to assess statistically significant variations in receptor 
fluorescence intensity means. A P value of <0.05 was considered significant. 
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2.3.2.2. Immunoblotting of CHO-TRVb cell lysates  
Immunoblotting was used for the phenotypic characterisation of hTfR on 
TRVb-1 (hTfR transfected) cells and also to validate the previously observed 
expression of hTfR on TRVb-1 (hTfR deficient) cell line. A visible band was observed 
with TRVb-1 cell lysate immunoblot (Lane 3, Figure 2.3.6). The observed band was 
at the correct expected size of the extracellular portion of hTfR (85kDa). However, no 
visible band was observed within TRVb cell lysate immunoblot (lane 2, Figure 2.3.6). 
Non-specific background binding was also observed in both lanes containing cell 
lysates. Expression of the β-actin housekeeping control was consistent between 
both cell line lysates.  
 
 
 
 
  
 
 
 
 
  
Figure 2.3.6: Immunoblot of hTfR in TRVb and TRVb-1 cell 
lysates. 
Figure showing TfR expression (red arrow) on TRVb and 
TRVb-1 Chinese hamster ovary cells, as determined by 
immunoblotting, alongside β-actin (housekeeping control) 
expression. 
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2.3.2.3. Assessing the uptake of hTfR on CHO-TRVb and CHO-TRVb1 cell lines 
 Cell internalising antibodies, anti-hTfR (confidential protein, contact George 
Thom, MedImmune, Cambridge, UK) and an engineered variant of anti-mTfR (8D3) 
(Webster et al., 2017), were used to assess hTfR specific internalisation within CHO-
TRVb and CHO-TRVb1 cell lines, via ICC. Results of the internalisation assay are 
shown in Figure 2.3.7 and Figure 2.3.8. 
 No fluorescence was observed with anti-hTfR within CHO-TRVb, the TfR 
deficient cell line, (Figure 2.3.7. A1 and A2). In contrast, a statistically significant 3.8-
fold increase in fluorescence was observed with anti-hTfR within the hTfR over-
expressing variant, CHO-TRVb-1, when compared to the secondary antibody 
control, (Figure 2.3.7, B1 and B2, Figure 2.3.8, B). The anti-mTfR antibody 
demonstrated no fluorescence with either the CHO-TRVb or the CHO-TRVb1 cell 
lines, (Figure 2.3.7, C1, C2, D1 and D2, Figure 2.3.8, A). 
 
 
 
 
Figure 2.3.7: Uptake of anti-hTfR and anti-mTfR (8D3) antibodies in CHO-TRVb and -TRVb-1 
cell lines. 
Immunofluorescence images showing cellular uptake of anti-hTfR (A1, A2, B1, and B2), and anti-
mTfR (8D3), (C1, C2, D1, and D2) in CHO-TRVb (Chinese hamster TfR deficient), (A1, A2, C1 and C2) 
and CHO-TRVb-1 (deficient cell line stably transfected with hTfR), (B1, B2, D1, and D2) cells. Hoechst 
nuclear staining is shown in A1, B1, C1 and D1, whilst secondary anti-human IgG-Fc specific Alexa 
488 conjugate is shown in A2, B2, C2, and D2. Images were acquired at x20 magnification using a 
Molecular Probes ImageXpress XLS system and are representative of three experimental replicates 
(n= 3). Unlabeled scale bars = 100 µm. 
 
CHO-TRVb CHO-TRVb-1
An
ti-
hT
fR
An
ti-
m
Tf
R 
(8
D3
) 
B1A1 B2A2
D2C2 D1C1
Characterisation of candidate receptor targets that function via RMT at the BBB. 
 75 
 
 
 
 
 
Figure 2.3.8: Summarised results of CHO-TRVb and -TRVb-1 cell line uptake study using anti-
mTfR and anti-hTfR antibodies.  
Quantitative summary of CHO-TRVb cell line anti-TfR uptake study. The cell uptake of anti-mTfR an 
anti-hTfR antibodies, within TRVb (A) and TRVb-1 (B) cells are shown. Mean grey value is presented 
as normalised average readings of three independent images acquired through ImageJ, per 
experimental replicate (n= 3), ± SEM. **** P < 0.0001. 
2.4. Discussion 
2.4.1. TfR, LDLR and LRP1 receptors are expressed on the cell surface of hCMEC/D3 
cells 
This chapter set out to assess the expression of the three receptor candidates 
on hCMEC/D3 cells, the differentiation in expression with long-term cell culture and 
consequently to determine which cell surface receptor would potentially be most 
suitable for targeted delivery of therapeutic cargo across the BBB. Furthermore, 
since TfR is proteolytically cleaved from the cell membrane releasing soluble TfR, it 
was necessary to evaluate the effect of short-term proteolytic detachment of 
hCMEC/D3 cells on the expression of TfR (Kaup et al., 2002). 
In summary, within this chapter the expression of all three receptor candidates 
TfR, LDLR and LRP1 was confirmed on the cell surface of hCMEC/D3 cells, and 
Se
co
nd
ary
 an
tib
od
y c
on
tro
l 
An
ti-m
TfR
An
ti-h
TfR
0
5000
10000
15000
Antibody
M
ea
n 
G
re
y 
Va
lu
e 
(a
rb
itr
ar
y 
un
its
)
Se
co
nd
ary
 an
tib
od
y c
on
tro
l 
An
ti-m
TfR
An
ti-h
TfR
0
5000
10000
15000
Antibody
M
ea
n 
G
re
y 
Va
lu
e 
(a
rb
itr
ar
y 
un
its
)
****
A B 
Chapter 2: 
 76 
thus these findings support previous studies that have identified their expression at 
mRNA and protein level in hCMEC/D3 cells (Pinzón-Daza et al., 2012; Nazer et al., 
2008; Ohtsuki et al., 2013). Additionally, the expression of the three receptor 
candidates was shown to differ with long-term in vitro culture, with TfR demonstrating 
relatively stable levels of expression in contrast to LDLR and LRP1. Furthermore, 
short-term trypsin/EDTA or accutase detachment was not found to have a 
detrimental effect on TfR expression within in vitro cultures of hCMEC/D3 cells. 
The hCMEC/D3 cell line was chosen as a model of the BBB as it retains the 
majority of functional and morphological characteristics of primary BCEC in 
monoculture, and has been outlined as a good in vitro model for studying the BBB 
(Sade et al., 2014). Moreover, due to its stable expression of most transporters and 
receptors, it is a well suited model for studying therapeutic uptake and transporter 
influx (Weksler et al., 2013). However, like most in vitro BBB models, the hCMEC/D3 
cells have been shown to exhibit some transporter expressional variances, and 
these are usually most prevalent with long-term culture of the cell line (Shawahna et 
al., 2013). In vivo, BCEC interact closely with pericytes and astrocytes forming the 
functionally adaptable neurovascular unit, which as a whole is responsible for 
producing the observable BBB phenotype. Therefore, it is no surprise that BCEC 
cells cultured in vitro, away from their natural microenvironment, exhibit de-
differentiation with prolonged culture and variances in physiologically relevant 
receptor expression. Moreover, de-differentiation within in vitro cultured BCEC has 
been shown to be associated with a reduced TEER value (Patabendige et al., 2013). 
Data collected from in vitro BBB models can therefore be difficult to interpret on its 
own, and must be carefully interpreted alongside in vivo data. 
The results of the flow cytometric assessment of membrane proteins 
demonstrated here highlight the expression of TfR, LDLR and LRP1 on the cell 
surface of hCMEC/D3 cells. However, since this detection was carried out using 
monoclonal antibodies directed towards the extracellular epitopes of these receptors, 
it was not possible to discern whether the fluorescence signals observed were due to 
the level of expression of each receptor candidate or whether this was due to the 
variances in binding affinity amongst the three selected receptor antibodies. The 
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expression of TfR and LRP1 receptors have previously been quantified on the 
surface of hCMEC/D3 cells (Ohtsuki et al., 2013).  
Ohtsuki et al. (2013) previously quantified the expression of membrane 
proteins on hCMEC/D3 cells and primary BCEC. Using LC-MS/MS, the group 
quantified the membrane bound fractions for 91 target membrane proteins. They 
identified that 11 of these proteins were present at detectable levels in both cell 
types. GLUT1 and TfR were identified as exhibiting highest level of expression on 
hCMEC/D3. The group also compared the normalised expression levels between 
hCMEC/D3 cells and isolated primary human BCEC. They found TfR expression to 
be 18.5-fold higher within hCMEC/D3 cells in contrast to primary BCEC. 
Interestingly, within the same work LRP1 expression was noted to be below the limit 
of quantification in hCMEC/D3 cells, however its expression was detected in primary 
BCEC. The group concluded that differences between in vitro and in vivo conditions 
such as variances in cytokines, hormones and amino acids could be responsible for 
the variation between primary BCEC and the hCMEC/D3 cell line. The group did not 
identify the expression of LDLR on hCMEC/D3 cells or primary BCEC. A study by 
Holloway et al. (2007) has also shown that in contrast to brain endothelial cells, the 
expression of TfR is significantly lower in both dermal and lung microvascular 
endothelial cells, highlighting its great potential for BBB specific targeting over other 
endothelial cells of the body (Holloway et al., 2007).  
The results presented in this chapter, also demonstrate that TfR had the least 
variable and most stable levels of expression of the three receptor candidates with 
long-term culture in vitro. This finding is important when considering the selection 
and characterisation of TfR targeting domains, since any variability in receptor 
expression between passages and batches of cells presents a significant problem for 
the reproducibility of characterisation results. TfR is vital for the uptake of iron into 
the brain, where iron is involved in various metabolic processes such as cellular 
division, neurotransmission and myelination (LeVine and Macklin, 1990). Expression 
of TfR in BCEC is observed from an early embryonic developmental stage, and 
highlights the importance of iron for proper CNS development and function. 
Furthermore, neonatal TfR knockout mouse models have been shown to exhibit 
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severe CNS developmental defects and are incapable of maintaining life (Levy et al., 
1999). Importantly for therapeutic uptake and clearance, TfR is expressed on both 
luminal and abluminal membranes of BCEC and is also widely distributed within 
many cells of the of the CNS including; cortical neurons, oligodendrocytes and 
choroid plexus (J. Lu et al., 1995).  
TfR expression is also known to be post-transcriptionally regulated at mRNA 
level via iron response elements (IRE) and iron regulatory proteins (Rouault and 
Cooperman, 1995). During a situation of iron deficiency, iron regulatory proteins bind 
IRE hairpin structures located within the un-translated region of TfR mRNA 
sequence. In doing so, iron regulatory proteins prevent the cleavage and 
degradation of TfR mRNA (Tong et al., 2002). Iron deficiency causes elevated levels 
of iron to concentrate within the brain parenchyma via increased iron transport (E. H. 
Morgan and Moos, 2002). Interestingly however, no simultaneous increase in 
expression of TfR is observed on the cell surface of BCEC (Moos and E. H. Morgan, 
2001). It has been suggested that the observed increase of accumulated iron within 
the brain could be directly due to an increase in the cycling rate of TfR containing 
endosomes within BCEC (Moos et al., 2007). In support of this, intravenous injection 
of OX-26 anti-TfR antibody in normal and iron deficient rats did not result in 
increased binding within the iron deficient mice (Moos and E. H. Morgan, 2001). This 
theory could explain the reason why TfR expression was observed to remain 
relatively consistent with long-term culture (see Figure 2.3.3, A). Moreover, in 
support of this hypothesis, studies on primary porcine and bovine BCEC show that 
80-90% of TfR is sub-localised in endosomes within the cytosol that are mobilised in 
situations of high iron requirement (Raub and Newton, 1991; van Gelder et al., 
1995). Iron accumulation within the brain parenchyma has been shown to increase 
with age and also within the brains of individuals suffering from neurodegenerative 
conditions such as Parkinson’s disease (Sofic et al., 1988; Zecca et al., 2004). The 
reason for this is poorly understood and there is no direct evidence to suggest that 
TfR activity increases with age or neurodegeneration.  
In contrast to the relatively stable expression of TfR, the lipoprotein receptors; 
LDLR and LRP1, were both found to demonstrate varying cell surface protein 
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expression results with long-term culture. LDLR demonstrated a significant 0.3-fold 
reduction in expression between passages 25 and 30, and this significant reduction 
was maintained between passages 25 and 34. In contrast, LRP1 demonstrated a 
significant 3-fold increase in expression between passage 26 and 36.  
Molino et al. (Molino et al., 2017) recently characterised the expression of 
LDLR at both protein and mRNA level. Within rat BCEC, the mRNA expression of 
LDLR was found to be 9-fold higher than that observed within the cerebral cortex, 
however in mice this expression difference was significantly lower. Molino et al. 
(Molino et al., 2017) also assessed the apical and basolateral distribution of LDLR on 
BCEC using a sucrose density gradient. Their results demonstrated that LDLR was 
localised to the apical fraction and was delivered to a Tf positive compartments 
avoiding lysosomal degradation.  
Both LDLR and LRP1 are involved in the transport of lipoproteins and are 
known to be regulated through a feedback mechanism according to the level of LDL 
in their surrounding medium (Dehouck et al., 1994; Gosselet et al., 2009). Also, their 
expression has been shown to decrease with senescence in vivo (B. Wu et al., 
2009). Pinzon-Daza et al. (2012) showed that lowering cholesterol synthesis in 
hCMEC/D3 cells using statins lead to elevated mRNA and protein expression of 
LDLR at 24 and 48 h, respectively. Interestingly, the group also outlined the potential 
for the prophylactic up-regulation of LDLR expression (using statins), prior to 
targeting with a liposome encapsulated therapeutic, conjugated to an LDLR ligand. 
Another study by Panzenboeck et al. (2006) demonstrated that Liver-X receptor 
(LXR) and peroxisome-proliferator activated receptor (PPAR) activation promoted 
the efflux of cholesterol from primary porcine BCEC. This efflux was mainly mediated 
by ATP binding cassette transporter A1 (ABCA1) and scavenger receptor class B 
type 1 (SR-BI). ABCA1 is primarily expressed on the basolateral side of BCEC and 
mediates the transport of cholesterol into the CNS, whereas SR-BI is abundantly 
expressed on the luminal side and mediates transport into the circulation.  
The decrease in LDLR expression with long-term culture is potentially a result 
of a combination of factors. The 30% decrease is maintained at higher passages and 
could be related to LXR/ PPAR activated sterol transport pathways. The activation of 
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these nuclear receptors could be indirectly down-regulating the expression of LDLR 
via the efflux of cholesterol from endothelial cells into the culture media. In support of 
this hypothesis, Kamps and Berkel (1992) previously studied the regulatory response 
of LDLR expression within the hepatocarcinoma cell line, HepG2. They showed that 
22h incubations with non-lipoprotein bound cholesterol in albumin containing media 
induced the complete down-regulation of LDLR expression at concentrations as low 
as 50µg/ml.  
A study by Dehouck et al. (1994) has also shown LDLR expression to be 
highly regulated by astrocytes. Using a bovine BCEC and astrocyte co-culture 
model, the group identified a three-fold increase in LDL binding when compared to 
bovine BCEC alone. They proposed that this increase in LDLR expression at the 
luminal membrane of BCEC was due to the high lipid requirement of neighbouring 
astrocytes. The group concluded that receptor regulation was propagated through 
astrocyte secretory factors. The same group later confirmed that depletion of 
cholesterol from astrocytes, lead to an up-regulation of LDLR expression on the 
luminal surface of BCEC (Dehouck et al., 1997). Furthermore, unlike the traditional 
endocytotic recycling function of LDLR within most cells, LDLR on BCEC was 
observed to function through a caveolae dependant RMT mechanism. This 
specialised shift from recycling to a transcytotic mechanism is thought to be 
modulated by post-translational modifications of the cytoplasmic domain of the 
receptor. In support of their findings, previous studies have also demonstrated that 
phosphorylation of serine 664 on polymeric IgA receptor lead to an inactivation of the 
endocytosis signal allowing for transcytosis of the bound ligand (Aroeti and Mostov, 
1994). 
Similarly to LDLR, a variety of triggers within the cell also modulate cell 
surface expression of the large, multifunctional, scavenger protein, LRP1. For 
example, insulin has been shown to be involved in the regulation of LRP1 expression 
(Tamaki et al., 2007). Moreover, cellular cholesterol levels have also been shown to 
modulate the metalloproteinase dependant shedding of the extracellular ligand 
binding domain of LRP1 (Selvais et al., 2011). The relatively large size of the LRP1 
extracellular domain in contrast to the other two studied receptors deprioritises its 
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feasibility as a targeted drug delivery transporter. Selections of non-antibody 
domains can only be carried out on small clusters of the LRP1 extracellular domain. 
Having identified that TfR expression was the most stable of the three receptor 
candidates, the focus of the rest of this thesis will be on targeting of TfR as a RMT 
drug delivery approach at the BBB. 
Assessment of the effect of trypsin/EDTA detachment of hCMEC/D3 cells did 
not demonstrate any discernible difference in the expression of TfR. Trypsin is a 
membrane associated serine protease that breaks down peptide bonds through 
hydrolysis at accessible arginine and lysine residues. Alongside other membrane 
associated proteases, trypsin has been known to be involved in the shedding of 
membrane proteins (Ahram et al., 2005). Traditionally, trypsin is used alongside 
EDTA in cell culture applications to detach adherent cells from the culture vessel. 
However, trypsin detachment has been known to have detrimental effects on the 
structure of cell surface receptors and their epitopes (Deshui Zhang et al., 2012). 
Accutase was developed as a gentle alternative detachment solution to 
trypsin/EDTA. Accutase consists of a mixture of collagenolytic and proteolytic 
enzymes, which are isolated from shellfish sources (Bajpai et al., 2008). 
Interestingly, short-term detachment using trypsin/EDTA solution showed no 
significant disadvantage in cell surface TfR expression over accutase solution. This 
observation was unexpected as studies had previously shown that the use of trypsin 
and other protease treatments lead to cleavage of TfR at one of multiple amino acid 
locations within the stem region of the amino acid sequence, and arginine 100 was 
found to be the most susceptible to proteolytic cleavage (Kaup et al., 2002; Rutledge 
et al., 1998; Turkewitz, Amatruda, et al., 1988). Biologically, cleavage within the stem 
region of the extracellular domain of TfR results in the release of sTfR into the 
circulation (Kaup et al., 2002). The result of the study herein could suggest that both 
detachment solutions exhibit equal potency on the surface expression of TfR when 
used for minimum detachment incubation times of 2 min and 4 min for trypsin and 
accutase, respectively. Longer treatment times using trypsin/EDTA may lead to an 
observable reduction in cell surface TfR expression, however this would need to be 
explored further.  
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Analysis of the FASTA sequence of TfR using the ExPASy peptide Cutter 
tool, reveals a total of 83 potential cleavage sites (Supplementary Figure S1), 
(Wilkins et al., 1999). Rutledge et al. (1994) have previously shown that the removal 
of the O-linked carbohydrate at threonine 104 results in the enhanced proteolytic 
cleavage of TfR at arginine 100. Through further studies, the group also 
demonstrated that the sialic acid of the O-linked carbohydrate conferred the greatest 
protection against TfR cleavage and concluded that the removal of this carbohydrate 
could allow the cell to regulate the proteolytic cleavage and subsequent release of 
sTfR (Rutledge and Enns, 1996). 
Alternatively, the results herein could also imply that both treatments have 
equal potency towards the surface expression of TfR on hCMEC/D3 cells, but this 
finding may not be true of primary cells or other cell lines. Previous studies by Wachs 
et al. (2003) have demonstrated increased cell viability and survival rate of rat neural 
stem cells cultured as neurospheres when using accutase in contrast to trypsin. 
Accutase had no detrimental effects on the total cell viability of neural precursor cells 
immediately following detachment and following four days of culture. In contrast, 
trypsin significantly reduced the total cell viability of neural precursor cells by 66% 
following four days of culture. Several other studies have also showed the 
advantages of using accutase as a detachment solution for primary cell culture 
(Bajpai et al., 2008; Weikert et al., 2003). These studies suggest that primary cells 
are more susceptible to the damaging effects of trypsin treatment. It is not clear 
whether any observable reduction in the expression of TfR occurs in primary BCEC 
following enzymatic detachment using trypsin, and this would need to be explored 
further. 
2.4.2. The CHO-TRVb-1 cell line expresses similar surface protein levels of TfR to 
hCMEC/D3 cells. 
Functional selections using bio-combinatorial libraries against whole cells 
provides a means of selecting cell specific affinity reagents. Typically, iterative 
positive and negative selections are performed using target positive and negative 
cells in order to increase the specificity of the enriched pool to cells that highly 
express the target in its natural conformation (Ohuchi, 2012). CHO cells have long 
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been regarded as the cell line of choice for recombinant protein expression and the 
study of transfected forms of proteins due to their versatility, fast growth rate and 
long-term stable gene expression (Mariati et al., 2014).  
However, the study of transfected forms of homologous proteins can 
sometimes be affected by the background endogenous expression of the host cell 
species. Iron is a vital nutritional requirement for cell growth within most cultured cell 
lines, and this is reflected by the expression of TfR on most cultured cells. In 
addition, TfR deficient mutant cell lines are usually incapable of sustaining cell 
growth in vitro. However, early TfR mutational studies characterising iron uptake in 
CHO cells identified a secondary non-TfR dependant mechanism for iron uptake in 
these cells.  
Klausner et al. (1984) generated an endocytosis defective CHO cell line that 
was incapable of internalising and releasing iron from bound transferrin. 
Interestingly, they discovered the cells maintained sufficient iron uptake to support 
cellular growth. It was concluded that iron internalisation in these cells was also likely 
to occur via uptake of iron salts. McGraw et al. (1987) decided to exploit this feature 
by generating an endogenous hamster TfR deficient CHO cell line that could 
subsequently be stably transfected with the human form of TfR and studied without 
interfering effects of the homologous endogenous form. The group devised a 
strategy for isolating TfR-variant (TRV) CHO cells by selecting for resistance to one 
of two Tf-toxin conjugates. These chimeric Tf-toxin conjugates were generated by 
substituting the binding domain of ricin or diptheria toxin with Tf. In principle, The TfR 
deficient cells would not be able to bind the Tf-toxin conjugates and therefore would 
have a selective growth advantage over cells expressing TfR. The group 
subsequently stably transfected endogenous TfR deficient TRV cells with hTfR 
cDNA and demonstrated hTfR activity by assessing internalised 59Fe presented as 
diferric Tf.  
During our initial characterisation of hTfR expression on CHO-TRVb cell lines 
by FACS, similar levels of hTfR expression were observed on the CHO-TRVb-1 
(hTfR expressing) cells when compared to hCMEC/D3 cells. Furthermore, the TRVb 
(TfR deficient) cell line by FACS also demonstrated some positive hTfR expression 
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on the surface of these cells. Suggesting the presence of a heterogeneous 
population of cells. 
McGraw et al. (1987) had previously characterised the deficient cell line 
through functional uptake studies and shown that the cells did not internalise any 
fluorescein-Tf, suggesting that expression of endogenous TfR was absent within the 
cell line. More recently, Kumar et al. (2012) used these TfR deficient cell lines to 
elucidate alternative pathways for transferrin uptake. The same group had previously 
identified GAPDH as being a low affinity receptor for transferrin within macrophages 
and was involved in the uptake of iron bound transferrin (Raje et al., 2007). By 
knocking down GAPDH within the TfR deficient cells (CHO-TRVb), the group 
demonstrated a significant decrease in transferrin binding and also iron uptake. They 
concluded that the GAPDH mediated transferrin uptake occurred via a combination 
of clathrin-mediated and lipid raft endocytosis, in conjunction with macropinocytosis. 
Further assessment of total protein expression by western blotting showed the 
deficient cell line was negative for hTfR protein expression. Upon closer examination 
of the immunoblotting results, a high level of background exposure was observed 
(Figure 2.3.6), suggesting some non-specific binding of the primary antibody. The 
described anti-hTfR antibody (R&D Systems, MAB2474) has not been validated for 
the application of western blotting. The background reading result seen on the gel 
could be due non-optimal binding of this antibody under immunoblotting conditions. 
Nevertheless, a clear band suggesting the expression of hTfR was observed on 
CHO-TRVb-1 (hTfR positive cell line).  
To validate whether the negative cell line does express hTfR, a TfR functional 
cell uptake study was conducted using the CHO-TRVb cell lines and two antibodies, 
anti-hTfR (confidential protein, MedImmune, Cambridge, UK), and an engineered 
variant of anti-mTfR (8D3), (MedImmune, Cambridge, UK), (Webster et al., 2017). 
Cell uptake using the hTfR antibody was observed within the CHO-TRVb-1 cell line, 
but not the TRVb cell line, suggesting no expression of hTfR was present on that cell 
line. Furthermore, no cell uptake was observed with the anti-mTfR (8D3) antibody 
within both the CHO-TRVb and the -TRVb1 cell lines (Figure 2.3.7, and Figure 
2.3.8). Due to the lack of an Chinese hamster specific antibody we, we were unable 
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to determine endogenous TfR uptake in relation to wild type CHO cells. However, 
recent studies have characterised these cell lines and detailed that they are deficient 
for the expression of endogenous hamster TFRC mRNA. Mehta et al. (2015) 
characterised the expression of both Chinese hamster and human TFRC mRNA 
within the hTfR transfected form of the deficient cell line. Their characterisation 
revealed that the CHO-TRVb-1 cells expressed human TFRC mRNA, but not the 
endogenous hamster form. This was compared with wild-type CHO cells which 
expressed endogenous hamster TFRC but not human TFRC. 
Whilst we have identified hTfR expression within a small proportion of the 
CHO-TRVb cells via FACS analysis, functionally these cells do not appear to 
express TfR as identified via ICC cell uptake studies. These finding highlight that 
indeed; these cells may valuable tools for conducting positive and negative cell 
selections of non-antibody domains. Furthermore, the TfR deficient cell line would 
provide a valuable negative control for characterisation of identified domains. 
To summarise, in support of previous findings, we have demonstrated that all 
three receptor candidates, TfR, LDLR and LRP1, are expressed on the cell surface 
of hCMEC/D3 cells. Furthermore, we have shown that TfR appears to be the most 
stably expressed of the three receptor candidates with long-term in vitro culture, and 
its expression on hCMEC/D3 cells was not altered following short-term trypsin 
treatment when compared to accutase, a more gentle proteolytic solution. The CHO-
TRVb-1 cell line was observed to express similar levels of hTfR expression to 
hCMEC/D3 cells. Through uptake studies using antibodies directed to human and 
mouse TfR, the CHO-TRVb cell line was shown to be functionally deficient for the 
expression of hTfR and may be valuable tools for the selection and characterisation 
of non-antibody binding domains. 
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3.1. Introduction 
The BBB is the most significant obstacle for the delivery of neuro-therapeutic 
drugs into the CNS, thus hindering the development of successful treatments to the 
debilitating neurological disorders burdening our developed societies (Vigo et al., 
2016). Biotherapeutics, are an increasingly popular choice for the therapeutic 
treatment of many disorders, primarily due to their highly specific targeting capability 
(Yanan Cui et al., 2017).  
The leading class of biotherapeutics, MAbs, have restricted transport when 
used as RMT drug delivery shuttles at the BBB, this equates to 0.1 - 0.2% of 
circulatory antibody reaching the CNS (Yu and Watts, 2013). These limitations are 
primarily attributed to the large size and high affinity nature of antibodies, that have 
been shown to result in reduced CNS uptake via sequestration, and subsequent 
degradation within the late-endosomal and lysosomal compartments of BCEC (Bien-
Ly et al., 2014). Additionally, the high specificity of antibodies results in the lack of 
species cross-reactivity which limits the translatability between animal and human 
models. In contrast to non-CNS drugs undergoing clinical trials, CNS therapies are 
more likely to fail during every phase, but most notably during phases II and III 
(McGonigle, 2014). Clinical trial failures particularly those that fail in later stages, 
have been partly attributed to the lack of suitable animal models and species cross-
reactive molecules capable of producing translatable results (Yu et al., 2011; Irani et 
al., 2016). In addition to this, numerous factors such as poor drug efficacy, toxicity 
and the lack of understanding of complex CNS pathology, have further impeded 
progress in this research area (Ohshima-Hosoyama et al., 2012; Couch et al., 2013). 
In recent years, there has been a resurgence in the popularity of peptides as 
an alternative amino acid based platform for use as highly selective and 
physiologically efficacious biochemical therapeutics (Craik et al., 2013; Kaspar and 
Reichert, 2013). Peptides are highly suited to affinity ligand screening approaches 
such as phage display, where expression of a diverse peptide library on the surface 
of bacteriophage coat proteins allows the selection towards a target of interest (van 
Rooy et al., 2010; Bonetto et al., 2009). In this respect, with peptides being 
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inherently smaller and lower affinity than antibodies, they have great potential for use 
as RMT drug delivery vectors at the BBB. The most notable examples of receptors 
exploited via peptides for molecular Trojan horse delivery across the BBB are the 
low-density lipoprotein receptor family (LDLR and LRP1) and transferrin receptor 
(TfR), (Demeule et al., 2008; Hultqvist et al., 2017; Malinovskaya et al., 2017; 
Manich et al., 2013; Bien-Ly et al., 2014; Niewoehner et al., 2014; Sorrentino et al., 
2013; X. Tang et al., 2015; Wiley et al., 2013; Yu et al., 2014; Sakamoto et al., 
2017). 
Following the characterisation of candidate receptor targets expressed on 
human brain endothelial cells, the rationale of which is discussed in chapter two, the 
focus of this project is on TfR as a target for RMT drug delivery. We hypothesise that 
through the use of a combined target antigen and BBB cell phage display selection 
approach, we can identify novel peptide sequences that may have greater BBB 
specific transport capabilities. Additionally, the use of cyclic peptides in place of their 
linear counterparts may offer peptides with greater natural resistance to 
exopeptidases, whilst also demonstrating enhanced biological activity (Joo, 2012). In 
contrast to previously identified antibody-based BBB shuttles, peptide-based delivery 
shuttles would also likely confer greater transcytosis capacity through their inherently 
lower affinities (μM range), thus allowing the release of the delivery shuttle/ drug 
conjugate at the CNS side (Yu et al., 2011). 
The overall aims of this study were to select and identify low to medium 
affinity TfR binding and BCEC cell internalising cyclic peptides via phage display 
selections. More specifically this study endeavoured to: 
- Carry out soluble phage display selections towards mTfR and/ or hTFR 
recombinant protein antigens using three independent 16-mer cyclic 
peptide phage display libraries. 
- Conduct a final functional selection round towards a mouse brain 
endothelial cell line (bEnd.3), in order to preferentially select cell 
internalising anti-TfR cyclic peptides. 
- Screen for positive TfR species cross-reactive clones by means of a 
phage ELISA. 
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- Sequence and identify lead candidates for expression and further 
characterisation. 
- Assess homology of identified peptides to each other and to the natural 
ligand of TfR, Tf. 
3.2. Materials and methods 
3.2.1. Preparation of TfR antigens for phage display selections 
3.2.1.1. Biotinylation of recombinant transferrin receptor 
Extracellular N-terminal 6x His tagged recombinant mouse TfR (Sino 
Biological Inc. Beijing, China, Figure 3.3.1, A) was biotinylated for soluble phage 
display selections. Biotin labelling was carried out using the optimised EZ Link Sulfo-
NHS-biotin kit (ThermoFisher Scientific, Loughborough, UK) according to the 
provided protocol. Lyophilised mTfR-His6 was re-suspended in PBS at a 
concentration of 1 mg/ml. A protein:biotin molar ratio of 1:50 was used to label 200 
μg of mTfR-His6 in volume of 200 µl. The reaction was incubated at room 
temperature for 30 min and the solution was buffer exchanged using a 2 ml Zeba 
Spin desalting column (ThermoFisher Scientific, Loughborough, UK). Biotinylated 
mTfR-His6 concentration was determined by spectrophotometry at 280 nm. 
Biotinylated recombinant human TfR-His10 was kindly provided by Miguel Carvalho 
(MedImmune, Cambridge, UK), (Figure 3.3.1, B). Biotinylated rat TfR-FLAG/HIS10 
was kindly provided by Susan Fowler (MedImmune, Cambridge, UK), (Figure 3.3.1, 
C). 
3.2.1.2. Antigen presentation ELISA  
A streptavidin coated 96-well flat-bottomed microtiter plate (ThermoFisher 
Scientific, Loughborough, UK) was immobilised with triplicate serial dilution sets of 
biotinylated mTfR antigen ranging from 10 μg/ml to 0.01 μg/ml, in a dilution ratio of 
1:2. Biotinylated insulin at a concentration of 10 μg/ml was also immobilised in 
separate wells as an irrelevant control antigen, alongside a PBS negative control. 
Plates were incubated with antigens overnight at 4°C and then washed three times 
with PBS to remove unbound antigen. Antigen immobilised plates were blocked in 
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3% (w/v) skimmed milk powder in PBS (MPBS) for 1 h at room temperature. Plates 
were washed three times with PBS and incubated with 2 μg/ml of human anti-mouse 
TfR (8D3) detection antibody made up in 3% (w/v) MPBS for 1 hour at room 
temperature. Plates were washed three times in PBS with 0.1% (w/v) tween 20 
(PBST). Primary antibody was counter labelled with anti-human IgG (Fc Specific) 
horse radish peroxidase (HRP) conjugated secondary antibody (Cat No. A0170, 
Sigma-Aldrich, Dorset, UK) made up in 3% (w/v) MPBS at a dilution of 1:10,000 and 
incubated for 1 h at room temperature. Plates were washed three times in PBST and 
developed using 50 μl of 3,3',5,5'-SureBlue Tetramethylbenzidine (TMB) substrate 
(KPL, Maryland, USA) per well for 5 min at room temperature. The reaction was 
subsequently stopped by addition of 50 μl of 0.5 M H2SO4 to each well and plates 
were read using fluorescent plate reader at 450nm.  
3.2.2. Cyclic peptide library growth. 
Glycerol stocks of three pre-constructed cyclic peptide phage display libraries 
(Bonetto et al., 2009) were kindly provided by Siobhan O’brien (MedImmune, 
Cambridge, UK). Each of the three libraries encodes peptides 16 amino acid 
residues in length. However, these differ from one another through the size of the 
variable central region which is constrained via two flanking cysteine residues. Each 
library has a theoretical size of between 1.0 – 2.0 x 109 and incorporates a linker 
between the peptide and the gene-3-protein (g3p) domain in order to prevent steric 
hindrance of the peptide binding region. The amino acid formats of the cyclic peptide 
libraries are, CPEP1 (X5CX4CX5), CPEP2 (X3CX8CX3) and CPEP3 (X2CX10CX2), 
where ‘X’ denotes a random amino acid. 
Prior to soluble phage display selections (described in section 3.2.4), the 
libraries were grown and rescued as follows. For each library, 100 μl of glycerol 
stock was added to one 2 L Erlenmeyer flask containing 400 ml of 2x tryptone yeast 
media (16 g/L tryptone, 10 g/L yeast extract and 5 g NaCl) supplemented with 12.5 
μg/ml tetracycline (2xTYTET). The culture was then grown overnight at 37°C within a 
shaking incubator at 280 rpm. The following day the phage particles were recovered 
by polyethylene glycol (PEG) precipitation (as described in section 3.2.3). 
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3.2.3. Phage purification via PEG precipitation 
Cultures were transferred into two large, pre-cooled centrifuge pots and 
balanced by weight before spinning at 10,800 g for 20 min at 4°C. The supernatant 
was collected in pre-chilled 500 ml bottles before adding 120 ml of chilled 20% (w/v) 
PEG 8000/ 2.5 M NaCl to 400 ml of supernatant (3:10 ratio). The mixture was 
precipitated on ice for a minimum of 1 h. A phage pellet was concentrated by 
spinning at 10,800 g for 20 min at 4°C. The supernatant was then decanted and 
phage pellets were re-suspended in 10 ml of Tris-EDTA (TE) buffer (10 mM Tris-HCl 
and 1 mM EDTA), pH 8.0 and transferred to a 50 ml centrifuge tube. The centrifuge 
tubes were then spun in a pre-chilled rotor at 17,500 g for 15 min at 4°C and the 
supernatant containing re-suspended phage particles was collected into a fresh 50 
ml centrifuge tube. Pre-chilled 20% PEG8000 solution was subsequently added to 
the collected phage supernatant at a ratio of 3:10 (v/v), mixed by inverting, and 
precipitated at 4°C for 1 h. After precipitation, the phage stock was centrifuged at 
17,500 g for 20 min at 4°C. Supernatant was decanted, and each phage pellet was 
re-suspended in 5 ml of TE buffer, pH 8.0 and centrifuged at 17,500 g, 4°C for 10 
min. Phage supernatant was transferred into a fresh 12 ml falcon tube without 
disturbing the bacterial pellet.  
Prior to commencing phage display selections, phage input titres were 
calculated using an automated spiral petri dish plater and Acolyte colony counter 
(Synbiosis, Cambridge, UK).  
3.2.4. Soluble phage display selection 
Soluble phage display selections were carried out as outlined in Figure 3.2.1. 
The primary goal of these selections was to identify cyclic peptide domains that 
bound to both mouse and human TfR (species cross-reactive) and internalised within 
an in vitro model of the BBB, in this case, immortalised mouse brain endothelial 
cells, bEnd.3 (Montesano et al., 1990). Additionally, to encourage the selection of 
cross-species binding peptides, a cross-selection cascade was introduced at round 
3, where a switch from human to mouse TfR antigen was included. 
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Figure 3.2.1: Schematic representation of soluble phage display selections conducted using 
cyclic peptide libraries.  
Flow diagram showing cyclic peptide library selection cascades carried out against mouse and 
human TfR target antigen. A cross-selection cascade was introduced at round three to encourage 
the selection of TfR species cross-reactive peptides. The fourth round was conducted against mouse 
brain endothelial cells to encourage the selection of peptides that bind and are internalised via TfR 
expressed on the cell surface of mammalian cells. Selection output boxes highlighted in green were 
taken forward for phage ELISA screening against recombinant mouse and human TfR.  
 
3.2.4.1. Inoculation of E. coli TG1 culture 
E. coli TG1 cells were grown on a plate of M9 minimal media and a single 
colony was used to inoculate 50 ml of 2xTY media in a sterile 250 ml disposable 
flask under aseptic conditions. The flask was incubated at 37°C within a shaking 
incubator set to 300 rpm until the culture reached mid-logarithmic growth phase, as 
determined by an optical density (OD) 600 value of 0.5 – 1.0. Typically, TG1 cells 
reached an OD600 reading of 0.76 following 5 hours of culture.  
3.2.4.2. Pre-blocking of phage library and streptavidin coated magnetic agarose beads 
For the first round of selection a 50 μl aliquot of each library was added to 450 
μl of 3% (w/v) MPBS in a 1.5 ml Eppendorf tube and allowed to incubate at room 
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temperature for 1 h on a rotary shaker. For later rounds of selection, a 10 μl aliquot 
of rescued phage output from the previous round of selection was transferred to an 
Eppendorf tube containing 490 μl of 3% (w/v) MPBS and incubated at room 
temperature for 1 h on a rotary shaker. A 10 μl aliquot taken from 1 ml total rescued 
phage volume equates to approximately 1.0 x 1010 colony forming units (cfu).  
In addition to pre-blocking the phage library, streptavidin coated magnetic 
agarose beads (M-280 Dynabeads, ThermoFisher Scientific, Loughborough, UK) 
were also pre-blocked using 3% (w/v) MPBS. For each selection, a total of 100 μl of 
bead slurry was required, 50 μl for de-selection of library towards beads and 50 μl 
for capturing phage/ biotinylated antigen complexes at a later stage. Beads were 
pre-blocked in 1.5 ml Eppendorf tubes by removing the storage buffer using a 
magnetic separator, re-suspending in 1 ml of PBS, and subsequently discarding the 
PBS and re-suspending in 3% (w/v) MPBS. Beads were blocked in a rotary mixer at 
room temperature for 1 h. 
3.2.4.3. De-selection of phage library against streptavidin coated magnetic agarose beads. 
In order to limit the enrichment of peptide species that preferentially bind to 
the affinity matrix of the capture beads, a de-selection incubation step was 
performed using the pre-blocked phage library and an aliquot of pre-blocked beads. 
Pre-blocked beads were separated using a magnetic separator, the 
supernatant was discarded and beads were then re-suspended in 100 μl of fresh 3% 
(w/v) MPBS. A 50 μl aliquot of the pre-blocked beads was transferred into the pre-
blocked phage library and incubated at room temperature for 1 h. The remaining 
aliquots of beads were kept on ice for a later stage of the selection. Following de-
selection beads were separated using a magnetic separator for 2 min and the 
supernatant containing the blocked and de-selected library was transferred into a 
fresh 1.5 ml Eppendorf tube.  
3.2.4.4. Incubating de-selected phage library or rescued phage with biotinylated antigen 
Biotinylated mouse or human TfR was added to 500 μl aliquots of blocked 
phage in 1.5 ml Eppendorf tubes at a final concentration of 200 nM for rounds 1 and 
2 and 100 nM for round 3. The mixture was incubated at room temperature on a 
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rotary shaker for 2 hours in order to allow sufficient time for low affinity binding 
peptides to bind target TfR antigen. 
3.2.4.5. Capturing binding phage particles 
Following phage incubation, 50 μl of pre-blocked streptavidin magnetic 
agarose beads were added to each selection tube and allowed to equilibrate for 5 
min on an orbital shaker. Beads were washed five times in PBST solution using a 
KingFisher mL purification system (Thermo-Fisher Scientific, Loughborough, UK) in 
order to remove unbound phage, and bound phage was subsequently eluted by re-
suspending beads in 500 μl of 10 μg/ml trypsin solution and incubating on a rotary 
shaker at 37°C for 30 min. Streptavidin beads were captured using a magnetic 
separator and the eluted phage was isolated carefully in solution. Eluted phage was 
stored on ice until TG1 cells were ready at mid-logarithmic phase for infection. 
3.2.4.6. Infecting TG1 cells with eluted phage 
The total 500 μl volume of eluted phage was added to 0.8 ml of mid-log E.coli 
TG1 cells in a sterile 50 ml falcon tube and incubated at 37°C with shaking at 150 
rpm. After phage infection of TG1 cells, an aliquot of the culture was used to create a 
dilution series, which was plated using a spiral plater and used to calculate output 
titres the following day. The remaining cultures were plated on 2xTYTET bioassay 
plates, and grown overnight in a 30°C incubator.  
After calculating titres for rounds 3 and 4 outputs, the same dilution plates 
were used to carefully pick 176 individual colonies into 11 columns of two 96-well 
plates containing 100 μl of 2xTYTET. These master plates were sealed and grown 
overnight at 25°C, 250 rpm and the following morning 50 μl of 50% (v/v) glycerol 
solution was added to each well prior to storage at -80°C. The master plates were 
stored until ready to carry out phage ELISA screening.  
3.2.5. Phage selection rescue 
3.2.5.1. Harvesting cells from bioassay plates and freezing of glycerol selection outputs. 
Bioassay plates (section 3.2.4.6) were harvested in a laminar flow hood and 
handled under aseptic conditions to avoid cross-contamination of selected outputs. 
Glycerol-medium mix was prepared by mixing 2xTY with 50% (v/v) glycerol in a 2:1 
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ratio. Harvesting of E.coli TG1 colonies grown on bioassay plates was carried out by 
addition of 10 ml of glycerol-medium per plate and scraping using a sterile 
disposable spreader. The cell suspension was subsequently transferred to a sterile 
50 ml falcon tube and placed on a rotary shaker for 10 min at room temperature. For 
each selection output, two cryotubes were labelled, 1 ml of glycerol – cell suspension 
was added to the relevantly labelled cryotubes and the tubes were stored at -80°C. 
Prior to commencing the subsequent round of selection glycerol stocks were 
thawed, 7 μl of glycerol stock was used to inoculate 25 ml of 2xTYTET and the 
culture was grown overnight at 30°C, 280 rpm. The following morning, phage was 
isolated from each 25 ml culture by PEG precipitation as outlined in section 3.2.2. 
The isolated and purified phage was used to inoculate E.coli TG1 cells at mid-log 
phase, and subsequently titred to determine the input titre alongside the 
commencement of a successive round of selection.  
3.2.6. Live cell surface phage display selection 
A fourth and final round of selection was carried out against cell surface 
antigens expressed by the immortalised mouse brain endothelial cell line, bEnd.3. 
This was done in order to select phage particles that specifically bind to TfR 
expressed in its natural conformation on the surface of mammalian cells, with all the 
relevant post-translational modifications.  
3.2.6.1. Cell culture and harvesting of bEnd.3 cells 
bEnd.3 cells were maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% FBS and 100 U/ml penicillin and 100 μg/ml 
streptomycin (Invitrogen, Paisley, UK). Once cells had formed a confluent 
monolayer, they were harvested by washing in 10 ml of PBS and detached using 6 
ml of accutase solution. Following detachment, the cells were collected in 10 ml of 
growth medium in a sterile 50 ml falcon tube. A viable cell count was carried out 
using trypan blue and a 10 μl aliquot of cell suspension, and the remaining cells 
were centrifuged at 1200 rpm, for 5 min. The supernatant was discarded and the 
cells were re-suspended at 1.3 x 107 cells per ml of media.  
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3.2.6.2. Pre-blocking phage and bEnd.3 cells 
The cell suspension was blocked in 9 ml of 3% (w/v) skimmed milk powder in 
un-supplemented DMEM media for 1 h at room temperature on a rotary shaker. A 10 
μl aliquot of round 3 selected and purified phage output was also blocked in 490 μl of 
MPBS, for 1 h at room temperature. Following the blocking steps, cells were 
centrifuged at 1200 rpm for 5 min and the supernatant was discarded. The cell pellet 
was then reconstituted in 500 μl of pre-blocked phage and transferred to an 
Eppendorf tube before incubating on a rotary shaker for 1 h at room temperature. 
After incubation, the cells were centrifuged at 2000 rpm in a micro-centrifuge 
for 1 min. Unbound phage was carefully removed in solution and the pellet was re-
suspended in 100 μl of PBS using a 1 ml pipette to avoid shearing stress on the 
cells. The re-suspended cell pellet was then transferred to a fresh Eppendorf tube, 
washed 8x in 1 ml PBS and inverted to mix.  
3.2.6.3. Elution of internalised phage particles 
In order to elute cell internalised phage particles, Triethylamine (TEA) was 
used to strip cell surface antigens and thus remove membrane bound phage. Post 
washing, the cell pellet was re-suspended in 500 μl of 100 mM TEA and incubated 
for 3 min at room temperature. Subsequently, the activity of TEA was neutralised 
using 1M Tris solution (pH 8.0). The phage was then used to infect mid-log E.coli 
TG1 cells and output titres were calculated as outlined in section 3.2.4.6. 
3.2.7. Phage ELISA screening for cross-species TfR binding peptide hits 
In total, three selection outputs from each of the three cyclic peptide libraries 
were screened for binding hits towards the extracellular domain of mouse and 
human TfR as highlighted in 
Figure 3.2.1. 176 clones were picked into master plates for nine selections 
originating from rounds 3 and 4 (1584 clones in total) as shown in section 3.2.4.6. 
Prior to commencing the phage ELISA screening, biotinylated antigens 
(mTfR, hTfR and Insulin) were diluted in DPBS to a concentration of 1 µg/ml and 50 
Selection of TfR binding peptides for use as BBB drug delivery vectors. 
 97 
µl per well was used to coat streptavidin coated 96-well plates, for a total of 18 plates 
per test antigen (54 plates in total). 
Master plates were replicated into 96 deep-well plates. Selection, source plate 
and destination plate IDs are shown in supplementary Figure S3. Replication was 
then carried out using a microplate replicator, which was ethanol flame sterilised and 
cooled before being used to inoculate a labelled deep-well daughter plate containing 
500 μl of 2xTYTET per well. The daughter plate was cultured overnight at 25°C, 280 
rpm.  
The following morning phage cultures were blocked for 1 h, at room 
temperature in equal volume of 6% (w/v) skimmed milk powder in 2xPBS solution. 
Concurrent to blocking phage cultures, antigen immobilised streptavidin plates were 
blocked with 300 μl per well of 3% (w/v) skimmed milk powder in 1xPBS, for 1 h at 
room temperature. 
Following the blocking step, 96 deep-well plates containing blocked phage 
cultures were centrifuged for 5 min at 3200 rpm at room temperature. Antigen pre-
coated and blocked 96-well plates were washed three times in PBS, and 
subsequently incubated with 50 μl per well phage supernatant for 1 h, at room 
temperature. Following phage incubation, plates were washed three times in PBST 
and detection was carried out by incubating with 50 μl per well anti-M13 HRP 
conjugated secondary antibody (27-9421-01, GE Healthcare Life Sciences, Little 
Chalfont, UK) at a dilution of 1/5000 for 1 h at room temperature. 
Plates were washed three times in PBST and HRP was developed using 50 μl 
per well TMB substrate for 10 min at room temperature. To inhibit the reaction, 50 μl 
per well of 0.5 M H2SO4 was added and plates were read at 450 nm using an 
Envison fluorescent plate reader (Perkin Elmer, Beaconsfield, UK). Screening data 
was analysed using the software, Ignite (Continuity software package, MedImmune, 
Cambridge, UK).  
Prior to analysis, the criteria for the identification of weak and strong antigen 
binding hits were assigned as reference absorbance values within the software. 
Weak hits were ≥ 0.2, but < 0.5 arbitrary units, and strong hits were ≥ 0.5 arbitrary 
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units. Additionally, a hTfR and mTfR specific hit was classified as binding weakly or 
strongly towards either hTfR or mTfR, respectively and not the irrelevant control 
antigen insulin. A species cross-reactive hit was classified as binding weakly or 
strongly to both hTfR and mTfR, but not the irrelevant control antigen insulin. 
For phage ELISA repeat experiments, sequence validated clones containing 
the 16 unique peptide sequences were cultured from glycerol stocks and grown on 
2xTYTET petri plates at 30°C overnight. Three independent colonies for each of the 
unique peptides were picked and inoculated into 96-deep well plates containing 500 
µl of 2xTYTET. Colonies were grown and subjected to phage ELISA binding assays, 
as outlined within this section. 
3.2.8. Sequencing and identification of unique cross-species binding peptides. 
Source plates identified to contain cross-species TfR binding clones were 
inoculated into fresh 96-well plates containing 100 μl per well of 2xTYTET using 
Freedom EVO automated liquid handling robot (Tecan, Männedorf, Switzerland), 
and grown overnight at 25°C. The following morning, aliquots of 30 μl per well were 
transferred into fresh 96-well plates for DNA amplification and sequencing. A total of 
50 μl per well of 50% (v/v) glycerol solution was added to culture plates and these 
were stored at -80°C.  
Sequencing of peptide hits within the fdDOG phage display vector was carried 
out using the relevant forward and reverse sequencing primers, as shown in Table 
3.2.1. 
Table 3.2.1: Sequencing primers used for amplifying insert region of fdDOG phage display 
vector. 
 
 
 
3.2.9. Sequence analysis of fdDOG positive hit sequencing data 
 Sequencing data from round 3 and 4 identified selection hits was analysed 
using the software Blaze 2.0 (Continuity software package, MedImmune, Cambridge 
Primer name Sequence (5’-3’) LENGTH 
fdDOGfor seq GAAATTCACCTCGAAAGCAA 20 
fdDOGrev seq GACAGCCCTCATAGTTAGCGT 21 
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UK). All phage ELISA positive hits were assembled as fdDOG sequences and 
aligned according to the peptide insert region. After sequence alignment, identified 
unique sequences were summarised according to their sequence representation (i.e. 
number of times sequences had appeared), round of selection and library origin. 
3.2.10.  Multiple sequence alignment using ClustalW 
ClustalW multiple sequence alignments were performed using Geneious R10 
bio-informatics software package (Kearse et al., 2012). A global alignment of 
sequences with free end gaps was performed to determine the sequence homology 
amongst the 16 uniquely identified peptides. Additionally, this method was also used 
to determine the sequence homology between Pep1 and serotransferrin derived 
from human (accession №, P02787), mouse (accession №, Q921I1), and rat 
(accession №, P12346) species. 
3.2.11.  Predicting the molecular interaction of Pep1 with TfR 
The molecular interaction of Tf with TfR was assessed using the previously 
described crystal structure (PDB ID 3S9M) and PDB Protein Workshop, (Moreland et 
al., 2005). 
3.3. Results 
3.3.1. Biotinylation of recombinant mouse TfR 
Prior to initiating phage display selections using cyclic peptide libraries, it was 
necessary to introduce a secondary biotin affinity capture tag to the polyhistidine 
tagged recombinant mTfR material. This was done in order to utilise the strong biotin 
binding affinity towards streptavidin, for the purpose of antigenic immobilisation 
during soluble selections and protein binding assays. 
The recombinant mTfR protein consists of the extracellular amino acids 
Cys89-Phe763, which are fused to an N-terminal polyhistidine tag. The complete 
sequences of the recombinant mTfR, hTfR and rat TfR (the latter only used for 
phage ELISA screening), are shown in Figure 3.3.1. 
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Figure 3.3.1: Amino acid sequence of the extracellular domain of mouse TfR. 
Figure showing the amino acid sequence of the extracellular domains of recombinant mouse (A), 
human (B), and rat TfR (C). 
 
Mouse TFR extracellular domain (89-763), 
Length: 675AA 
CKRVEQKEECVKLAETEETDKSETMETEDVPTSS
RLYWADLKTLLSEKLNSIEFADTIKQLSQNTYTPRE
AGSQKDESLAYYIENQFHEFKFSKVWRDEHYVKI
QVKSSIGQNMVTIVQSNGNLDPVESPEGYVAFSK
PTEVSGKLVHANFGTKKDFEELSYSVNGSLVIVRA
GEITFAEKVANAQSFNAIGVLIYMDKNKFPVVEADL
ALFGHAHLGTGDPYTPGFPSFNHTQFPPSQSSGL
PNIPVQTISRAAAEKLFGKMEGSCPARWNIDSSCK
LELSQNQNVKLIVKNVLKERRILNIFGVIKGYEEPD
RYVVVGAQRDALGAGVAAKSSVGTGLLLKLAQVF
SDMISKDGFRPSRSIIFASWTAGDFGAVGATEWLE
GYLSSLHLKAFTYINLDKVVLGTSNFKVSASPLLYT
LMGKIMQDVKHPVDGKSLYRDSNWISKVEKLSFD
NAAYPFLAYSGIPAVSFCFCEDADYPYLGTRLDTY
EALTQKVPQLNQMVRTAAEVAGQLIIKLTHDVELN
LDYEMYNSKLLSFMKDLNQFKTDIRDMGLSLQWL
YSARGDYFRATSRLTTDFHNAEKTNRFVMREIND
RIMKVEYHFLSPYVSPRESPFRHIFWGSGSHTLSA
LVENLKLRQKNITAFNETLFRNQLALATWTIQGVA
NALSGDIWNIDNEFHHHHHH 
Human TFR extracellular domain (119 – 
761), Length: 671AA 
PAARRLYWDDLKRKLSEKLDSTDFTGTIKLLNENS
YVPREAGSQKDENLALYVENQFREFKLSKVWRDQ
HFVKIQVKDSAQNSVIIVDKNGRLVYLVENPGGYV
AYSKAATVTGKLVHANFGTKKDFEDLYTPVNGSIVI
VRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVN
AELSFFGHAHLGTGDPYTPGFPSFNHTQFPPSRS
SGLPNIPVQTISRAAAEKLFGNMEGDCPSDWKTD
STCRMVTSESKNVKLTVSNVLKEIKILNIFGVIKGFV
EPDHYVVVGAQRDAWGPGAAKSGVGTALLLKLA
QMFSDMVLKDGFQPSRSIIFASWSAGDFGSVGAT
EWLEGYLSSLHLKAFTYINLDKAVLGTSNFKVSAS
PLLYTLIEKTMQNVKHPVTGQFLYQDSNWASKVE
KLTLDNAAFPFLAYSGIPAVSFCFCEDTDYPYLGTT
MDTYKELIERIPELNKVARAAAEVAGQFVIKLTHDV
ELNLDYERYNSQLLSFVRDLNQYRADIKEMGLSLQ
WLYSARGDFFRATSRLTTDFGNAEKTDRFVMKKL
NDRVMRVEYHFLSPYVSPKESPFRHVFWGSGSH
TLPALLENLKLRKQNNGAFNETLFRNQLALATWTI
QGAANALSGDVWDIDNEFGLNDIFEAQKIEWHEG
GHHHHHHHHHH 
Rat TFR extracellular domain (100-761), Length: 684AA 
LAEAEEADKSENDETEYVPKSSRLFWADLKTLLSEKLNSIEFTDIIKQLSQNTYTPREAGSQKDENLAYYIENL
FHDFKFSKVWRDEHYVKIQVKNSVSQNLVTINSGSNIDPVEAPEGYVAFSKAGEVTGKLVHANFGTKKDFEE
LNYSVNGSLVIVRAGKITFAEKVANAQSFNAIGVLIYMDRNTFPVVEADLQFFGHAHLGTGDPYTPGFPSFNH
TQFPPSQSSGLPSIPVQTISRAAAEKLFKNMEGNCPPSWNIDSSCKLELSQNQNVKLTVNNVLKETRILNIFGV
IKGYEEPDRYIVVGAQRDAWGPGVAKSSVGTGLLLKLAQVFSDMISKDGFRPSRSIIFASWTAGDYGAVGAT
EWLEGYLSSLHLKAFTYINLDKVVLGTSNFKVSASPLLYTLMGKIMQDVKHPIDGKYLYRDSNWISKIEELSLD
NAAFPFLAYSGIPAVSFCFCEDEDYPYLGTKLDTYEILIQKVPQLNQMVRTAAEVAGQFIIKLTHDIELTLDYEM
YNSKLLSFMKDLNQFKADIKDMGLSLQWLYSARGDYFRATSRLTTDFHNAEKTNRFVMREINDRIMKVEYHF
LSPYVSPRESPFRHIFWGSGSHTLSALVENLRLRQKNITAFNETLFRNQLALATWTIQGVANALSGDIWNIDN
EFAAADYKDDDDKAAHHHHHHHHHH 
A B 
C 
Selection of TfR binding peptides for use as BBB drug delivery vectors. 
 101 
The biotinylation of mTfR was evaluated by means of a functional biotinylated 
antigen capture and presentation ELISA (Figure 3.3.2). A monoclonal anti-mTfR 
specific antibody (8D3) was used to detect the captured biotinylated mTfR on 
streptavidin coated 96-well plates. Biotinylated mTfR/8D3 binding demonstrated a 
sigmoid binding curve. Saturation of 8D3 anti-mTfR binding was observed at a bio-
mTfR concentration of 1.1 μg/ml. As expected, no binding was observed with the 
irrelevant biotin-insulin and biotin-hTfR control antigens.  
 
 
Figure 3.3.2: Validating the biotinylation of mTfR-His6 using anti-mouse TFR (8D3) antibody. 
Summary of biotinylated mTfR-His6 antigen validation as determined via antigen presentation ELISA. 
Biotinylated mTfR-His6 was immobilised onto a streptavidin coated 96-well plate in a serial dilution 
starting at 10 µg/ml. Anti-mouse TfR antibody (8D3) was then used for detection at a concentration 
of 1 µg/ml. Results are expressed as averages of three experimental replicates (n= 3) ± SEM, with the 
average secondary antibody control reading subtracted. 
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3.3.2. Cyclic peptide phage display selection summary and input/ output titres. 
A summary of the TfR CPEP library selection conditions are shown in Table 
3.3.1. In order to assess the success of a selection round, it is necessary to evaluate 
the number phage particles that are to be introduced into a selection (input titre), and 
the number of phage particles that result from a selection (output titre). By comparing 
the input to output titres between rounds, it is possible to monitor the efficiency of the 
selection and hence the level of enrichment. The enrichment factor in relation to 
round 1 was calculated by dividing the input/output titres of round 1 to that of the 
relevant successive selection rounds.  
Monitored phage input and output average titre results for the four rounds of 
selection are shown in Table 3.3.2. As expected, input titres were within the range of 
5 x 1012 cfu and 5 x 1013 cfu throughout the four selection rounds. For the first round 
of selection, input/output titres were observed within the range of 107 – 108 cfu. 
Enrichment is observable from round 2 as indicated by a decrease in the input/output 
titres and an increase in the enrichment factor. The greatest degree of enrichment at 
round 2 was observed with hTfR selections (8, 10, 12) with the CPEP2 library 
demonstrating the highest enrichment factor. 
The greatest degree of enrichment was observed at round 3 of the four 
selection rounds. Enrichment was substantially higher for the hTfR selections (14, 16 
and 18) than the mTfR selections (13, 15 and 17), with the CPEP3 library selection 
(18) demonstrating the largest increase in enrichment factor. Interestingly, the switch 
from human to mouse TfR antigen at the round 3 cross-species antigen selected 
outputs (19, 20 and 21), resulted in a reduced enrichment factor for the CPEP1 and 
CPEP2 libraries when compared to the previous round. The CPEP3 library was the 
only cross selection to result in increased enrichment (21).  
Following the fourth and final round of selection towards bEnd.3 cells, low 
enrichment factor values were observed for all sections (22 – 27) when compared to 
the relevant round 3 outputs. The lowest enrichment factor was noted with the three 
pools, 25, 26 and 27, originating from the cross antigen selected to mTfR selected 
phage pools. 
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Table 3.3.1: Cyclic peptide phage display selection round conditions. 
 
  
Selection 
ID Round 
Peptide 
Library Antigen 
Antigen 
Conc. (nM) Washes 
1 1 
CPEP1 
mTfR 200 5 
2 1 hTfR 200 5 
3 1 
CPEP2 
mTfR 200 5 
4 1 hTfR 200 5 
5 1 
CPEP3 
mTfR 200 5 
6 1 hTfR 200 5 
7 2 
CPEP1 
mTfR 200 5 
8 2 hTfR 200 5 
9 2 
CPEP2 
mTfR 200 5 
10 2 hTfR 200 5 
11 2 
CPEP3 
mTfR 200 5 
12 2 hTfR 200 5 
13 3 
CPEP1 
mTfR 100 5 
14 3 hTfR 100 5 
15 3 
CPEP2 
mTfR 100 5 
16 3 hTfR 100 5 
17 3 
CPEP3 
mTfR 100 5 
18 3 hTfR 100 5 
19 3 CPEP1 hTfR à mTfR cross 100 5 
20 3 CPEP2 hTfR à mTfR cross 100 5 
21 3 CPEP3 hTfR à mTfR cross 100 5 
22 4 CPEP1 R3 Library 1 mTfR 2 x 106 cells 5 
23 4 CPEP2 R3 Library 2 mTfR 2 x 106 cells 5 
24 4 CPEP3 R3 Library 3 mTfR 2 x 106 cells 5 
25 4 CPEP1 R3 Library 1 cross à bEnd.3 cells  2 x 10
6 cells 5 
26 4 CPEP2 R3 Library 2  cross à bEnd.3 cells 2 x 10
6 cells 5 
27 4 CPEP3 R3 Library 3  cross à bEnd.3 cells 2 x 10
6 cells 5 
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Table 3.3.2: CPEP library phage input and output titres, and enrichment factor with TfR 
selection progression. 
Table showing the average input and output titres for TfR selected CPEP libraries at each selection 
round. The input to output titre and calculated enrichment factor in relation to round 1 are also 
shown. cfu, colony forming units. 
 
  
Selection 
ID Round 
Peptide 
Library 
Input Titre 
(cfu/ml) 
output Titre 
(cfu/ml) 
Input/output 
(cfu/ml) 
Enrichment factor 
(arbitrary units) 
1 1 
CPEP1 
5.1 x 1013 6.8 x 105 7.5 x 107 1 
2 1 5.1 x 1013 6.2 x 105 8.2 x 107 1 
3 1 
CPEP2 
4.6 x 1013 5.87 x 105 7.8 x 107 1 
4 1 4.6 x 1013 6.27 x 105 7.3 x 107 1 
5 1 
CPEP3 
5.2 x 1013 5.2 x 105 1.0 x 108 1 
6 1 5.2 x 1013 3.44 x 105 1.5 x 108 1 
7 2 
CPEP1 
6.82 x 1013 1.14 x 105 5.9 x 108 0.125 
8 2 3.78 x 1013 6.21 x 106 6.0 x 106 13.514 
9 2 
CPEP2 
2.64 x 1013 9.31 x 105 2.8 x 107 2.764 
10 2 2.56 x 1013 6.13 x 107 4.1 x 105 175.675 
11 2 
CPEP3 
4.35 x 1013 3.33 x 105 1.3 x108 0.766 
12 2 2.25 x 1013 2.93 x 106 7.6 x 106 19.685 
13 3 
CPEP1 
3.77 x 1013 2.12 x 107 1.7 x 106 42.175 
14 3 2.84 x 1013 1.10 x 109 2.5 x104 3186.052 
15 3 
CPEP2 
9.08 x 1012 7.2 x 107 1.2 x 106 62.139 
16 3 1.02 x 1013 3.92 x 108 2.6 x 104 2819.527 
17 3 
CPEP3 
1.37 x 1013 2.13 x 107 6.4 x 105 155.474 
18 3 1.05 x 1013 7.69 x 108 1.3 x 104 11070.875 
19 3 CPEP1 2.84 x 1013 1.01 x 106 2.8 x 107 2.925 
20 3 CPEP2 1.02 x 1013 1.8 x 105 5.6 x 107 1.295 
21 3 CPEP3 1.05 x 1013 8.23 x 106 1.2 x 106 118.483 
22 4 CPEP1 1.23 x 1013 8.9 x 105 1.3 x 107 5.427 
23 4 CPEP2 2.03 x 1013 5.8 x 105 3.5 x 107 2.239 
24 4 CPEP3 1.02 x 1013 8.0 x 105 1.2 x 107 7.843 
25 4 CPEP1 1.15 x 1013 2.8 x 105 4.1 x 107 2.003 
26 4 CPEP2 2.33 x 1013 1.02 x 106 2.2 x 107 3.212 
27 4 CPEP3 7.17 x 1012 1.4 x 105 5.1 x 108 0.295 
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3.3.3. Identification of species cross-reactive TfR binding cyclic peptides by phage 
ELISA. 
Initial phage ELISA screening plate layout and screening reports are shown in 
supplementary Figure S4. A summary of the initial phage ELISA screen is shown in 
Figure 3.3.3. In total, of the 1584 clones that were screened for binding to mTfR, 
hTfR and the irrelevant control antigen (insulin), 875 (56%) specific TfR binding hits 
were identified across all selections. Identified hits were composed of, 197 (22.5%) 
TfR species cross-reactive, 367 (42%) human TfR specific and 311(35.5%) mouse 
TfR specific hits.  
Interestingly, the majority of species cross-reactive hits were observed to 
originate from the round 4 non-cross antigen and bEnd.3 cell selected pool (135 
hits). Moreover, this pool generated no human TfR specific binders. Most human TfR 
specific hits were observed within the round 3 antigen cross-selected pool. The 
switch from human TfR at rounds 1 and 2 towards mouse TfR antigen at round 3, did 
not result in the enrichment of many mTfR specific binders (four hits were identified). 
Also, the inclusion of a fourth bEnd.3 cell selection round to the round 3 antigen 
cross-selected pool resulted in an increase in the number of mTfR specific hits (12 
up from 4) and a reduction of the number of hTfR specific (168 down from 199) and 
species cross-reactive hits (16 down from 46). 
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Figure 3.3.3: Phage ELISA initial screen hit output summary. 
The numbers of mTfR specific, hTfR specific and species cross-reactive hits per selection cascade are 
shown. Only cross-species TfR binding hits were taken forward for sequence analysis.  
 
3.3.4. Summary of fdDOG sequence analysis and lead peptide identification. 
The phage ELISA pre-identified cross-species binding clones were 
sequenced and aligned according to the variable peptide coding region. Sequence 
alignment results are shown in supplementary figure S5. A summary of the peptide 
sequence analysis showing the amino acid sequence, nucleotide sequence and 
sequence representation is shown in Table 3.3.3. In total, 16 unique peptide 
sequences were identified. Six unique sequences were identified from CPEP1, four 
from CPEP2 and six from CPEP3. The most highly represented peptide sequence, 
Pep10, originated from the CPEP2 library which was selected against mTfR. Pep10 
was represented 104 times, accounting for more than half of the total observed hits. 
The next top 4 candidates were Pep1 (represented 36 times), Pep9 (23 times), Pep6 
(14 times) and Pep4 (5 times). Pep1 was identified from two independent selection 
cascades, Round 3 hTfR to mTfR cross-selection and the Round 4 mTfR only and 
cell selection cascade.   
Total screened: 528
hTfR Specific hits: 199
mTfR specific hits: 4
Cross reactive hits: 46
Total screened: 528
hTfR Specific hits: 168
mTfR specific hits: 12
Cross reactive hits: 16
Total screened: 528
hTfR Specific hits: 0
mTfR specific hits: 295
Cross reactive hits: 135
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Table 3.3.3: Sequence analysis summary of identified cross-species TfR binding peptide hits. 
Summary table showing the amino acid sequences, nucleotide sequences and sequence 
representation for each identified lead cross-species TfR binding cyclic peptide. Peptide sequences 
are sorted in descending order of highest sequence representation. Yellow highlights in the amino 
acid sequence show the position of the cysteine residues which form a constrained structure 
through disulphide linkages. 
 
Peptide ID Library selection round Description AA sequence Nucleotide sequence 
Sequence 
representation 
Pep10 CPEP2 Round 4 CPEP2 Non-cross mouse TfR selection LHECTYYWWGLDCSFR 
TTGCACGAGTGTACGTA
CTACTGGTGGGGGTTG
GACTGTTCCTTCCGG 
104 
Pep1 CPEP1 Round 3 CPEP1 human/ mouse TfR cross-selection WSIIDCSMNYCLYIEG 
TGGTCCATCATCGACTG
TTCCATGAACTACTGTT
TGTACATCGAGGGG 
36 
Pep9 CPEP2 Round 4 CPEP2 Non-cross mouse TfR selection ARDCLETWYGFTCWNV 
GCCCGGGACTGTTTGG
AGACCTGGTACGGCTTC
ACCTGTTGGAACGTC 
23 
Pep6 CPEP1 Round 4 CPEP1 Cross/ bEnd.3 cell selection GWHPMCNLMACSQGRP 
GGCTGGCACCCGATGT
GTAACTTGATGGCGTGT
TCCCAGGGGCGCCCG 
14 
Pep4 CPEP3 Round 4 CPEP3 Cross/ bEnd.3 cell selection LYCYPTKLPWVEYCHE 
CTCTACTGTTACCCGAC
GAAGCTCCCCTGGGTC
GAGTACTGTCATGAA 
5 
Pep3 CPEP1 Round 3 CPEP1 human/ mouse TfR cross-selection TTFPSCHPQTCYDGVQ 
ACGACCTTCCCCTCCTG
TCACCCGCAGACGTGTT
ACGACGGCGTGCAG 
4 
Pep11 CPEP1 Round 4 CPEP1 Non-cross mouse TfR selection WTIAVCGKQGCEYVWE 
TGGACCATCGCGGTCTG
TGGCAAGCAGGGCTGT
GAGTACGTGTGGGAG 
2 
Pep2 CPEP3 Round 3 CPEP3 human/ mouse TfR cross-selection IHCHPQGDQSVSFCWR 
ATCCACTGTCACCCCCA
GGGCGACCAGAGCGTC
TCCTTCTGTTGGCGG 
1 
Pep5 CPEP2 Round 4 CPEP2 Cross/ bEnd.3 cell selection ADNCQTFYPLSWCESQ 
GCCGACAACTGTCAGA
CGTTCTACCCGTTGTCG
TGGTGTGAGTCCCAG 
1 
Pep7 CPEP1 Round 4 CPEP1 Cross/ bEnd.3 cell selection LPTKTCPCLWCCAEDW 
CTCCCCACCAAGACCTG
TCCGTGCTTGTGGTGTT
GCGCCGAGGACTGG 
1 
Pep8 CPEP2 Round 4 CPEP2 Non-cross mouse TfR selection SYNCVTRWWGITCEMY 
AGCTACAACTGTGTGAC
GCGCTGGTGGGGGATC
ACCTGTGAGATGTAC 
1 
Pep12 CPEP1 Round 4 CPEP1 Non-cross mouse TfR selection TWHYQCITMNCDVLVG 
ACGTGGCACTACCAGT
GTATCACCATGAACTGT
GACGTGTTGGTGGGG 
1 
Pep13 CPEP3 Round 4 CPEP3 Non-cross mouse TfR selection WVCTPLDSEIIEICQL 
TGGGTCTGTACCCCGCT
CGACTCCGAGATCATCG
AGATCTGTCAGCTG 
1 
Pep14 CPEP3 Round 4 CPEP3 Non-cross mouse TfR selection SICRTVILDTLYLCDE 
TCCATCTGTCGCACCGT
CATCTTGGACACGCTGT
ACCTGTGTGACGAG 
1 
Pep15 CPEP3 Round 4 CPEP3 Non-cross mouse TfR selection LHCTSIWSDVVQLCDL 
TTGCACTGTACCTCCAT
CTGGAGCGACGTGGTG
CAGTTGTGTGACCTC 
1 
Pep16 CPEP3 Round 4 CPEP3 Non-cross mouse TfR selection PLCTPIFPPFVLMCEE 
CCCCTCTGTACGCCCAT
CTTCCCGCCGTTCGTGT
TGATGTGTGAGGAG 
1 
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3.3.5. Sequence homology of the 16 unique peptides 
A ClustalW sequence alignment was performed to determine whether the 
sequences of the 16 uniquely identified peptides shared any homologous amino acid 
residues or motifs (Figure 3.3.4). The two peptides Pep8 and Pep10, derived from 
the CPEP2 library, were identified to contain a highly hydrophobic, four amino acid 
motif consisting of ‘WWGϴ’ (where ϴ refers to the hydrophobic amino acid residues 
I or L). Moreover, another peptide derived from CPEP2 library, Pep9 appears to be a 
variant containing ‘WYGF’ at identical locations to the ‘WWGϴ’ motif of Pep8 and 
Pep10 (peptide AA 8 – 11). Pep10 also shares homology with Pep1 and contains a 
three amino acid sequence of ‘DCS’ combined with ‘WWGϴ’ motif and a portion of a 
previously described Tf homologous ‘FRSETKD’ (Dai et al., 2014). 
Pep4 and Pep16 were also identified to contain a highly hydrophobic set of 
residues within their loop region. Pep13, Pep15 and Pep16 and Pep4 appear to also 
show preference for the motif ‘CTPϴ’ at AA positions 3 – 6. The streptavidin binding 
motifs ‘HPQ’ and ‘HPM’ were also identified within the sequences of Pep2, Pep3 and 
Pep6, and these are predicted to be streptavidin binding clones. 
 
Figure 3.3.4: Sequence homology of 16 unique peptide sequences. 
ClustalW multiple sequence alignment of the 16 uniquely identified peptides. Amino acid key, 
negatively charged (blue), positively charged (orange), polar (green) and non-polar (red). Figure 
generated using Geneious 11 software package. 
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3.3.6. Re-evaluation of the 16 sequence validated cross-species TfR binding cyclic 
peptides 
Following the sequencing and identification of the 16 unique TfR species 
cross-reactive peptides, a repeat phage ELISA was conducted to validate the 
binding of these peptides towards mouse, human, and rat TfR antigens. Sequence 
validated clones containing the 16 unique peptide sequences were screened 
towards each of the three TfR antigens. A control antigen of similar size and charge 
to TfR was included to evaluate the specificity of the peptides towards TfR 
(confidential protein, contact George Thom, MedImmune, Cambridge, UK). A 
summary of the results is shown in Figure 2.3.5. 
All sixteen peptides did not show any observable binding towards the control 
antigen. Fourteen of the sixteen uniquely pre-identified peptides were found to bind 
to mouse, human or rat TfR with varying binding profiles. Most notably, Pep1, Pep8, 
Pep9, and Pep10 exhibited the highest absorbance readings across all TfR antigens.  
Interestingly, although initially identified as being positive for both mouse and 
human TfR, Pep2, Pep3 and Pep6 were discovered to be false positives following re-
evaluation.  
 
Figure 3.3.5: Phage ELISA screening summary of uniquely identified hits against mouse, 
human and rat TfR. 
The sixteen unique anti-TfR species cross-reactive binding peptides were re-evaluated towards 
biotinylated mouse, human and rat TfR antigens by means of a phage ELISA. Two false positive hits, 
Pep2 and Pep3, were identified upon re-evaluation. The highest absorbance readings towards 
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mouse, human and rat TfR were observed with Pep1, Pep8, Pep9 and Pep10. Results are expressed 
as means of three experimental replicates (n= 3) ± SEM. 
 
Some promising examples of peptides from the 16 unique clones were re-
evaluated via a phage ELISA towards three additional control antigens (confidential 
proteins, contact George Thom, MedImmune, Cambridge, UK). This was carried out 
in order to confirm the target specificity of these peptides towards TfR. Results of the 
phage ELISA are shown in Figure 3.3.6. 
 
 
 
Figure 3.3.6: Binding re-evaluation of Pep-g3p clones towards biotinylated TfR by phage 
ELISA. 
Peptides were re-evaluated for binding mouse, human and rat TfR in conjunction to an additional 
three control antigens, to validate specificity of the selected peptides towards TfR. Results are 
expressed as means of three experimental replicates (n=3) ± SEM. 
 
 All peptide candidates demonstrated various binding profiles towards mTfR, 
hTfR and rTfR. Once again Pep10 appears to demonstrate the highest absorbance 
readings towards the three TfR antigens. No binding was observed with any Pep-g3p 
clones towards the three control antigens, thus confirming the specificity of these 
peptide clones towards mouse, human and rat TfR.  
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3.3.7. Pep1 demonstrates homology with highly conserved residues on transferrin C-
lobe. 
To determine whether any of the identified unique peptide sequences shared 
sequence homology with the natural ligand of TfR, transferrin, a ClustalW multiple 
sequence alignment was performed using each of the 16 identified peptide 
sequences towards the sequence for human, mouse and rat serotransferrin 
(accession IDs: P02787, Q921I1, and P12346, respectively). Pep1 was identified to 
contain a homologous sequence to a highly conserved region of Tf (AA residues 633 
– 648 within multiple alignment), consisting of the nine-amino acid sequence 
‘DCSGNFCLF’, (Figure 3.3.7). 
In order to predict a potential mechanism for Pep1 binding to TfR, the crystal 
structure previously described by Eckenroth et al. (2011) was analysed using PDB 
Protein Workshop, PDB ID: 3S9M. The homologous sequence of Pep1 
(DCSGNFCLF) was identified at amino acid residues 614 - 622 and is located within 
the loop region within C1 subdomain of the C-lobe of Tf, (Figure 3.3.8). Furthermore, 
the amino acid asparagine 618 within this loop region appears to form an interaction 
with arginine 629, at ɑIII-2 helix of the helical domain of TfR, (Figure 3.3.8, B). 
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Figure 3.3.7: Sequence homology of Pep1 towards human, mouse and rat transferrin. 
ClustalW multiple sequence alignment of transferrin derived from human (accession №, P02787), 
mouse (accession №, Q921I1), and rat (accession №, P12346). The sequence of Pep1 was also 
included in the alignment. Pep1 aligned with transferrin at amino acid residues 633 – 648 and 
demonstrated strong homology with a nine-residue motif that is highly conserved across the three 
evaluated species. Amino acid key, negatively charged (blue), positively charged (orange), polar 
(green) and non-polar (red). Figure generated using Geneious 10 software package. 
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Figure 3.3.8: Predicted interaction of Pep1 with transferrin receptor monomer. 
Figure showing the interaction sites between the TfR monomer (brown) and the C-lobe and N-lobe 
of transferrin (green), A. Interaction sites on the TfR monomer are labelled in blue, whilst interaction 
sites on transferrin are labelled in red. Conserved residues between Pep1 and the C-lobe of 
transferrin are highlighted in yellow. A close up of the interacting side chains of labeled Tf residues is 
shown in, B. The nine-residue sequence of Tf that demonstrates homology with Pep1 is highlighted 
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in red and the individual residues are labelled. The disulphide bond between the two cysteine 
residues is shown in yellow. The side chain of ASN618 on the Tf C-lobe interacts with the side chain 
of Arg629 located on the TfR helical domain (also shown). Figure produced using PDB Protein 
Workshop. PDB ID: 3S9M. 
3.4. Discussion 
 
3.4.1. Biotinylated mTfR maintains anti-mouse specific 8D3 antibody binding activity. 
Phage display as an in vitro combinatorial library selection technique relies 
upon effective separation methods to partition the subset of target binding phage 
molecules from a large library of non-binding species (Carmen and Jermutus, 2002). 
In order to select molecules that bind to the target in its natural state, it is imperative 
that the solid phase immobilisation method does not interfere with the structure of 
the target molecule and that all epitopes of the molecule remain exposed for contact 
with phage particles (Koide et al., 2009). In early iterations of phage display, the use 
of non-specific adsorptive based target capture methods such as polystyrene coated 
plate surfaces, posed issues for the capture of targets and the separation of bound 
phage molecules from the unbound pool. These methods often lead to non-uniform 
immobilisation of targets (Adey et al., 1995), denaturation of target antigen (Friguet 
et al., 1984; Butler et al., 1992), blocking of target epitopes and through non-specific 
elution protocols, the recovery of phage molecules that non-specifically bound to the 
support surface (Koide et al., 2009). In order to overcome these problems, more 
specific affinity capture methods were introduced such as biotin capture using 
streptavidin. 
Target proteins are labelled with biotin through enzymatic (Barat and A. M. 
Wu, 2007; Scholle et al., 2004) or most commonly via chemical approaches, the 
latter of which utilises reactive groups connected via a linker to a biotin moiety (Elia, 
2008). Due to its small size (244 Da), biotin may be conjugated to proteins without 
disrupting biological activity (Alegria-Schaffer, 2014). In the context of phage display, 
immobilisation of biotinylated antigens to a streptavidin matrix was shown to not only 
provide greater density and bioactivity of molecules than non-specific adsorption, but 
also allowed the target antigen to be immobilised in solution phase on streptavidin-
coated agarose beads (Hawkins et al., 1992). This protocol confers several 
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advantages over panning selections. Firstly, it allows for a greater number of 
epitopes to be available for phage interaction, whilst also avoiding the loss of low 
abundance high affinity clones through the preferential selection of high avidity 
molecules. N-Hydroxysuccinimide (NHS) esters of biotin react with primary amines 
available on the surface of proteins and these are mostly from the ɛ-amino and α-
amino groups of lysine and N-terminal region, respectively (Tao et al., 2005).  
Biotinylation was performed according to the optimised conditions described 
within the manufacturer protocol, which typically result in a maximum of 4 – 6 biotins 
per protein molecule (ThermoFisher Scientific, 2016). A functional assessment of the 
biotin labelled protein was carried out via streptavidin capture and antigen 
presentation ELISA titred against a protein specific antibody. Validation results for 
the biotinylation of mTfR material using an anti-mTfR (8D3) antibody resulted in dose 
dependant sigmoid binding curve, suggesting that biotinylated protein capture and 
detection was successful. 
3.4.2. Sequence analysis resulted in the identification of thirteen cross-species 
binding sequences. 
Since its conception in 1985, phage display has evolved over the years into a 
powerful tool for the efficient screening of ligands towards protein and non-protein 
targets from a diverse library consisting of peptides or proteins expressed as fusions 
to bacteriophage coat proteins. Through a process termed bio-panning, the phage 
libraries are screened against target molecules immobilised onto a solid phase 
matrix. Although this method is highly effective at selecting target specific ligands, 
target-unrelated phage (TUP) clones are often non-intentionally enriched through the 
interaction of the phage library with components of the screening technique 
(Bakhshinejad and Sadeghizadeh, 2016). Some of these non-target components 
include, the capture matrix (streptavidin, Ni-NTA, protein A), components of the 
blocking reagent (BSA or Milk), contaminating expression by-products within target 
antigen solution and solid phase immobilisation components (agarose and 
polystyrene plastic). By far, the most commonly identified TUPs tend to be 
polystyrene binding clones. Many polystyrene binding sequences have been 
identified even when using pre-blocking protocols (Adey et al., 1995). 
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In addition, TUP clones may be more readily propagated during replication, 
and their enrichment within a selected pool does not necessarily represent their 
affinity towards the target. This is usually due to the inherent structure of the peptide 
or protein displayed on the surface of the bacteriophage and its effect on virion 
infectivity. Phage displayed peptides or proteins expressed as multivalent g3p 
fusions can result in reduced overall infectivity due to steric hindrance between the 
N2 domain and F-pilus (Carmen and Jermutus, 2002). However, the expression of 
peptides shorter than 50 residues does not have a significant impact on infectivity. 
Also, since phage display functions on the principle linkage between genotype and 
phenotype, mutations arising within the phage genome can result in increased or 
decreased propagation of certain peptides dependant on how their structure effects 
the replication process. The use of fd-tet based libraries, such as the CPep libraries 
used for our TfR selections (Bonetto et al., 2009), minimises the possibility of 
propagation-related TUP mutations (Thomas et al., 2010).   
A known example of a propagation related peptide is the HAIYPRH peptide. 
This peptide was initially discovered by Lee et al. (2001) when carrying out 
selections against human TfR using the commercially available Ph.D.-7 heptapeptide 
library, and later coined ‘T7’ peptide. Its specificity towards hTfR was later contested 
when several other labs were able to isolate the same sequence towards a host of 
different targets including, chromatin high mobility group protein 1 (Dintilhac and 
Bernués, 2002), Zn2+ ions (Brammer et al., 2008), and human umbilical vein 
endothelial cells (Maruta et al., 2003) intriguingly however, multiple studies have 
recently utilised this peptide as a glioma TfR targeting strategy and demonstrated its 
therapeutic targeting capability in vitro and in vivo (Yunke Bi et al., 2016; Yanna Cui 
et al., 2016; Yue Zhang et al., 2017).  
To summarise the selection process, three cascades using three different 
cyclic peptide libraries were conducted in order to assess which protocol and library 
would generate the most target specific hits towards TfR. The rationale behind 
utilising a combined recombinant protein and cell selection approach was to identify 
species cross-reactive peptides that are capable of binding to TfR, and are 
internalised within functional brain endothelial cells.  
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Rodent models are extensively used within pre-clinical studies to evaluate the 
toxicity, efficacy, pharmacokinetics, and pharmacodynamics of drugs (Betts et al., 
2016; Fan and Neubert, 2016; Myzithras et al., 2016) The specificity and precision 
targeting capability of biologics such as antibodies and peptides towards their target 
proteins, in most circumstances results in species specific domains that either only 
react with human protein variants, or their rodent counterparts with which they are 
evaluated. This results in difficulty with interpretation of pre-clinical data and its 
translatability to human studies (H. Park et al., 2017). The identification of species 
cross-reactive binding domains is a highly sought after characteristic for biologic 
drug development, as it typically improves the safety, efficacy and the success rate 
of a drug candidate going forward from animal pre-clinical to human clinical studies 
(Irani et al., 2016).  
Assessment of the enrichment factor as calculated via input and output titres 
of each selection round revealed information about the selection rounds and the 
CPEP library that demonstrated the highest stringency. Beginning at round 2 greater 
enrichment was observed with the hTfR selections than the mTfR selections. The 
enrichment factor of hTfR selections at round 3 was substantially higher than that 
observed with round 2. One potential reason for this high degree of enrichment 
observed with hTfR selections is the propagation of sequences with an amplification 
bias or TUP clones towards the immobilisation matrix (Thomas et al., 2010). The 
mTfR selections did not demonstrate the highest degree of enrichment, however, 
they contributed the majority of TfR species cross-reactive unique peptides, (Table 
3.3.3 and Figure 3.3.6).  
The transition from hTfR to mTfR at round 3 resulted in low enrichment for 
CPEP1 and CPEP2 libraries (enrichment factor, 2.9 and 1.3, respectively). However, 
CPEP3 libraries showed a relatively high enrichment factor (118.5), suggesting 
further enrichment had occurred with that particular library. Interestingly, the 
introduction of a cross-selection cascade at round 3 lead to reduction in output titres 
when compared with the round 3 non-cross selected outputs. This was likely due to 
increased stringency of selection introduced by the inclusion of a secondary target 
antigen species, in this case mouse TfR. Very few of the phage particles that had 
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been pre-selected towards human TfR were also mouse specific, and therefore 
these are lost from the pool leading to a reduced output titre.  
At round 4, this finding of reduced output titres is re-iterated with the 
introduction of cell selections against bEnd.3 mouse brain endothelial cells. The 
greater selection stringency requires enriched clones to not only bind to functional 
TfR expressed on cells in its natural conformation, but also to be internalised within 
cells, since a cell membrane stripping agent (TEA) was used in order to remove non-
internalising phage particles. 
Following initial phage ELISA screening we unexpectedly observed that the 
majority of cross-species binding hits originated from the round 4 non-cross antigen 
and bEnd.3 cell selected pool. This amounted to 68.5% of all cross-species binding 
hits. This finding was unexpected as this pool was preferentially partitioned towards 
mouse TfR throughout the entire selection cascade and one would expect that cross-
species binding hits would mostly originate from cross-selected cascades. This was 
later identified to be due to the enrichment of one particular peptide sequence, 
LHECTYYWWGLDCSFR, which pre-dominated within the Round 4 non-cross 
selected output. 
Sequence analysis of pre-identified species cross-reactive hits revealed a 
total of 16 unique peptide sequences. A unique peptide sequence is defined as a 
sequence that differs from another through at least one amino acid and is 
represented within a selected pool at least once. The most highly represented cross-
species binding sequence was Pep10, LHECTYYWWGLDCSFR, which had 
originated from the aforementioned Round 4 mouse TfR selection cascade. Previous 
studies have established that peptide sequences that consist largely of aromatic 
amino acids (i.e. tyrosine, tryptophan, and phenylalanine) are most likely to be TUPs 
such as plastic specific binders (Adey et al., 1995; Gebhardt et al., 1996). However, 
it is important to note that not all highly hydrophobic sequences imply TUP 
specificity. The fact that this particular peptide sequence is highly enriched, was 
observed to bind both mouse and human TfR and not the irrelevant control antigen, 
could indicate that the mostly hydrophobic amino acids within the loop structure of 
this peptide play a role in binding to a hydrophobic TfR epitope. In the past this has 
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been true of tryptophan-rich peptide sequences which have been identified towards 
the highly hydrophobic extracellular regions of HIV-1 (Conley et al., 1994; Song et 
al., 2009; Zwick et al., 2001). 
Homology between the 16 identified unique peptides was determined through 
a ClustalW multiple sequence alignment, (Figure 3.3.4). Pep8, Pep9, and Pep10 
(derived from CPEP2 library) were identified to contain the four-hydrophobic amino 
acid motif ‘WWGϴ’ or a variant thereof (as with Pep9) at positions 8 – 11 within the 
peptide sequences. These three peptides were later identified to demonstrate the 
highest TfR species cross-reactive absorbance readings with phage ELISA 
screening (Figure 3.3.5).  
During the selection of brain targeting peptides, Pasqualini et al. (1996) have 
previously highlighted the selection of a peptide sequence (CENWWGDVC) 
containing the motif ‘WWG’. This peptide was derived from a CX7C cyclic peptide 
library, and was identified alongside several other brain targeting peptides from 
various libraries, through in vivo organ selection in mice. The group intravenously 
injected the peptide library, subsequently recovered the brain and amplified phage, 
prior to subsequent rounds of selection to obtain brain enriched peptides. As isolated 
phage, the peptide was injected into mice and shown to demonstrate a 4-fold greater 
brain/ kidney tissue ratio. The disadvantage of in vivo selection methods is that the 
exact target could not be determined. The group concluded that since the peptides 
were only allowed to circulate for a few minutes the identified peptides are likely to 
be endothelial specific. Our identification of several peptides that potentially bind via 
this conserved ‘WWGϴ’ motif, could suggest that the CENWWGDVC peptide binds 
to TfR and further assessment would be needed to validate this theory.  
Further assessment of the Pep10 sequence revealed that it contained the 
shared three-amino acid motif ‘DCS’ with pep1. In addition to this sequence, Pep10 
also contained a portion of a previously described Tf region ‘FRSETKD’, which was 
shown to bind TfR via the two amino acids ‘RS’ (Dai et al., 2014), (discussed further 
in section 3.4.3). 
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Another motif ‘CTPϴ’ or variants thereof, were also identified with Pep13, 
Pep16, Pep15 and Pep4. Peptides containing ‘CTPY’ and ‘CTPL’ have previously 
been described towards MHC class I and class II molecules (Allen et al., 2001; 
Schroers et al., 2003). 
Re-evaluation of identified unique peptides was carried out through a 
secondary phage ELISA to validate the observed positive hits, (Figure 3.3.5 and 
Figure 3.3.6). Typically, phage ELISA screening provides a qualitative measure of 
binding towards a target antigen. It does not allow the affinity ranking of the screened 
clones as the expression of phage particles is not controlled, and thus some phage 
express more efficiently than others. Whilst phage ELISA screening is 
unrepresentative of affinity, a study by Watkins et al. (1997) showed that it is 
possible to perform phage ELISA screening that can provide a rough estimation of 
affinity ranking. By regulating the quantity of anti-fab capture reagent used to coat 
microtitre plates, the group were able normalise the variable E.coli expressions of 
fab fragments by saturating the immobilisation matrix. Following incubation with the 
target antigen, the group showed that absorbance readings were directly 
proportional to the relative affinity of assayed fab fragment. 
Three peptide sequences, Pep2, Pep3 and Pep6 were identified to be false 
positives following re-evaluation via a phage ELISA (Figure 3.3.5). Upon closer 
examination of the peptide sequences of Pep2 and Pep3, a consensus tripeptide 
motif ‘HPQ’ was identified. The sequence of Pep6 did not contain the ‘HPQ’ motif, 
but it does appear to contain a similar variant, ‘HPM’, (Figure 3.3.4). The ‘HPQ’ motif 
was first described by Devlin et al. (1990) through screening of a 15mer linear 
peptide library with a diversity of 107 towards streptavidin. Since then, various studies 
have also identified the ‘HPQ’ motif from screening outputs of linear (Weber et al., 
1992) and constrained (Giebel et al., 2002) peptide libraries. These peptides were 
either intentionally identified through selection towards streptavidin or avidin target 
antigens (Gissel, Jensen, Gregorius, Elsner, Svendsen, and Mouritsen, 1995a; 
Meyer et al., 2006) or non-intentionally as is the case when using streptavidin as a 
target antigen affinity capture reagent. The latter is usually unavoidable, and is often 
minimised through negative selection steps before each selection round towards 
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streptavidin, or via short incubations with 0.1 mM biotin in order to quickly displace 
any streptavidin binding phage particles without affecting the bound biotinylated 
target (I. Chen et al., 2007; Shan et al., 2016).  
In all cases, the presence of the ‘HPQ’ sequence results in streptavidin 
binding. This is due to the fact the tripeptide very effectively mimics biotin, interacting 
with the four binding sites found on the tetrameric streptavidin molecule and 
therefore directly competing with biotin for binding one of the four binding sites of 
streptavidin (Katz, 1995; Weber et al., 1992). Giebel et al. (2002) screened for 
streptavidin binding clones using a cyclic peptide library (Ph.D.-C7C) and identified 
several ‘HPQ’ containing peptide sequences. Interestingly, their findings 
demonstrated that the constrained nature of these peptides added a 2- to 3-fold 
increase in binding affinity over the previously identified linear ‘HPQ’ containing 
heptapeptide equivalents (Weber et al., 1992). This finding exemplifies the greater 
binding complexity of cyclic peptides than their linear counterparts. In addition to the 
‘HPQ’ motif, another previously reported variant ‘HPM’, has also been identified to 
bind streptavidin, though at a weaker affinity (Gissel, Jensen, Gregorius, Elsner, 
Svendsen, and Mouritsen, 1995b).  
Given that both Pep2 and Pep3 had been incubated with antigen immobilised 
onto streptavidin coated plates, no observable streptavidin binding was detected. 
One possible explanation is that all the binding sites on streptavidin are saturated 
with biotinylated antigen and due to the significantly lower affinity of these peptides 
to streptavidin, no binding was observed. The ‘HPQ’ motif has previously been 
described as having an affinity towards streptavidin in the millimolar range (T. 
Schmidt et al., 1996). This is significantly lower than that of biotin/ streptavidin 
interaction which is within the picomolar range (Lakshmipriya et al., 2016). As a 
control, it may be beneficial to re-assess these peptides towards streptavidin coated 
plates alone, in order to determine whether binding occurs in the absence of 
biotinylated antigen. 
Pep1, Pep8, Pep9 and Pep10 demonstrated the highest absorbance readings 
with phage ELISA screening. Moreover, these peptides were found to maintain 
specificity after re-assessment towards an additional three control antigens (Figure 
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3.3.5 and Figure 3.3.6). As previously described in this section, all four of these lead 
peptides share common motifs or variants of these motifs (‘DCS’, and ‘WWGϴ’), and 
these could mediate binding to TfR. 
3.4.3. Pep1 demonstrates sequence homology with a conserved motif on transferrin 
C1-lobe. 
A ClustalW multiple sequence alignment was performed for each of the identified 
peptides towards the amino acid sequence of serotransferrin from mouse, human 
and rat species. This was conducted to determine whether any of the 16 unique 
peptides shared homology with the natural ligand to TfR, Tf. Pep1 was identified to 
share strong homology with a nine-amino acid peptide (DCSGNFCLF) that is 
conserved across all three analysed species. To the best of our knowledge this 
peptide sequence has not previously been described for targeting TfR. Interestingly, 
as previously mentioned in section 3.4.2, Pep10 appears to contain a motif that is 
homologous with Pep1 and the Tf (DCS), and this motif is followed by a portion of 
previously described Tf motif ‘FRSETKD’, (Dai et al., 2014). Dai et al. (2014) 
previously highlighted the selection of a peptide designated BP9 (AHLHNRS). This 
peptide was identified through phage display selections towards recombinant hTfR, 
via biopanning of a linear 7-mer peptide library. From 20 clones that were screened 
6 clones were identified that specifically target hTfR and share the two-amino acid 
motif ‘RS’ which was homologous with a Tf motif (FRSETKD). Interestingly, the Tf 
homologous region identified by Dai et al. (2014), ‘FRSETKD’, follows directly after 
the ‘DCSGNFCL’ motif identified herein as homologous with Pep1. In our work, 
Pep10 in the form of isolated phage consistently demonstrated the highest 
absorbance values for TfR specific binding, (Figures 3.3.5 and 3.3.6), and this 
finding could be due to a combined effect of the ‘DCS’ motif in conjunction with the 
‘FR’ motif. However, this would need to be evaluated through a comparison of Pep1 
and BP9, to determine if a greater a degree of binding towards TfR is observed. 
After establishing homology of Pep1 with Tf, we sought to assess a potential 
mechanism of binding with TfR. To do so, we studied the previously described 
crystal structures for the interaction of Tf with TfR at 3.2Å (Eckenroth et al., 2011), 
(PDB ID: 3S9M), Figure 3.3.8. Eckenroth et al. (Eckenroth et al., 2011) identified 
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extensive interactions between the ⍺1 helix and β2 strand and loop regions within 
C1 lobe of Tf and the helical domain of TfR. Structurally, serum transferrin consists 
of 679 AA residues divided into two domains, N-lobe and C-lobe, which are 
connected via a short peptide linker. The N-lobe and the C-lobe can be further 
subdivided into N1 and N2, and C1 and C2 subdomains, respectively. Binding of a 
single iron ion occurs at each of the primary lobes, in between the two subdomains 
which open and close to accept and release an iron ion through a conformational 
change (Eckenroth et al., 2011). The interaction study showed that the binding of the 
Pep1 homologous sequence (DCSGNFCL) occurs via an interaction between a loop 
region located within the C1-lobe of Tf and the helical domain of TfR, Figure 3.3.8, A. 
Moreover, this binding appears to occur through the side chain of asparagine 618 on 
Tf, and Arginine 629 on the ɑIII-2 helix, of the TfR helical domain, Figure 3.3.8, B. 
The C-lobe and N-lobe of Tf, have numerous regions of interaction along the helical, 
and protease-like domains of TfR, Figure 3.3.8, A. an interaction between Glycine at 
position 617 of Tf was previously observed with Arginine 629 of TfR (Eckenroth et 
al., 2011). Pep1 binding with Arginine in this case could occur via the hydrophobic 
residue methionine at the same position as glycine within the sequence. It is not 
clear whether binding of Pep1 interferes with the binding of Tf to TfR. Further 
assessment through Tf competition assays is needed to elucidate whether Pep1 
binds competitively with Tf. 
In conclusion, combinational target antigen and cell selection strategies utilising 
the three cyclic peptide libraries were successful in identifying species cross-reactive 
peptides that bind to TfR. Following phage ELISA screening, 13 peptides were 
identified to bind specifically to TfR, with varying binding profiles towards mouse, 
human and rat TfR. Additionally, three peptide sequences were identified as false 
positive hits, and are predicted to be streptavidin binding peptides since they contain 
the consensus motifs ‘HPQ’ and ‘HPM’. The 13 peptides demonstrate regions of 
sequence homology amongst each other and with Tf. Through studying the crystal 
structure of Tf/TfR, we were able to predict a mechanism of binding for a novel 
peptide (Pep1) which showed the greatest degree of homology to Tf. 
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4.1. Introduction 
The BBB limits the effective delivery of neuro-therapeutic agents into the 
CNS, preventing potentially life changing medicines from reaching their target site 
(Pardridge, 2015). Antibody alternative, molecular targeting domains such as 
peptides, can be selected through phage display towards specific targets, and have 
the potential to overcome the disadvantages posed by antibodies within the context 
of targeting the BBB (Molino et al., 2017). 
Antibody-mediated RMT delivery shuttles are restricted in their ability to 
effectively deliver pharmacologically relevant concentrations of drugs into the CNS. 
This was later discovered to be due to the limits of the transcellular transport system 
and the binding affinity/ avidity of the BBB targeting domain (Bien-Ly et al., 2014; 
Niewoehner et al., 2014). The transport capabilities of anti-TfR antibody delivery 
molecules of varying affinities have shown that higher affinity antibody variants are 
more susceptible to lysosomal sorting and subsequent degradation than low affinity 
variants (Bien-Ly et al., 2014). Furthermore, the use of high affinity TfR binding 
antibody variants prevents dissociation at the abluminal membrane, and thus confine 
the delivery vector/ drug conjugate within BCEC (Yu and Watts, 2013; Yu et al., 
2011). Bivalent Fab-anti-BACE1 fusion domains demonstrated a greater degree of 
colocalisation with lysosomes when compared to monovalent domains. No trans-
BBB transport was observed with BCEC in vitro and in vivo transport studies and this 
was proposed to be due to receptor crosslinking of bivalent domains (Niewoehner et 
al., 2014). 
Re-engineering of BBB targeting molecules as fusion domains has been 
carried out by several groups in order to improve uptake into the CNS (Webster et 
al., 2017; Yu et al., 2011; Boado, Lu, et al., 2010). Through the use of antibody 
engineering approaches, Yu et al. (2014; 2013) were able to optimise the binding 
properties of the anti-TfR antibodies and this resulted in favourable target binding, 
intracellular trafficking (i.e. avoiding lysosomal degradation) and transcytosis 
properties of delivery molecules.  
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Most recently, Webster et al. (2017) optimised the previously described 8D3 
mouse TfR antibody through re-engineering approaches (Kissel et al., 1998). The 
group developed multiple 8D3 variants with lower affinity binding properties to mTfR. 
These antibody variants were then coupled to interleukin 1 receptor antagonist 
(IL1RA), an inhibitor of IL1 receptor, a key promoter of hyperalgesia with neuropathic 
pain. The group demonstrated CNS efficacy in a validated in vivo mouse model of 
neuropathic pain, induced through partial ligation of the sciatic nerve (Seltzer et al., 
1990; Malmberg and Basbaum, 1998; Colleoni and Sacerdote, 2010).  
Engineering approaches provide a means of enhancing the CNS uptake of 
biotherapeutic molecules. Peptides are amenable to such engineering approaches 
and can be expressed as fusions to small soluble domain or larger bivalent peptide-
Fc fusion domains for enhanced expression and avidity (Foster et al., 2017; Costa et 
al., 2014). Despite the shortcomings, the mechanism of RMT continues to be 
exploited, since it provides a viable means of overcoming the macromolecular 
transport limitations of the BBB. in this respect, with peptides being inherently 
smaller and lower affinity antibodies, they have great potential for use as RMT drug 
delivery shuttles at the BBB. 
This chapter focuses on the expression and characterisation of identified 
mouse and human TfR binding cyclic peptides for use as BBB targeting molecules 
(described in chapter 3). 
The aims of this study were to: 
- Generate a suitable periplasmic expression vector construct for expressing 
cyclic peptide g3p-domain 1 (CPep-D1) fusion proteins. 
- Sub-clone the pre-identified cross-species TfR targeting CPep candidates into 
the expression vector and carry out periplasmic expression of soluble CPep-
D1 domains. 
- Affinity rank screening of lead peptide candidates according to their ability to 
selectively bind recombinant mouse and human TfR via soluble domain 
antigen binding ELISA assays. 
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- Assess the ability of selected lead CPep-D1 candidates to bind in vitro 
cultured BCEC, bEnd.3 and hCMEC/D3.  
- Characterise the capacity of lead peptides expressed as Fc-fusion molecules 
to internalise and deliver a conjugated cargo within bEnd.3 and hCMEC/D3 
cell lines. 
- Assess the sub-cellular trafficking of CPep-Fc fusion domains within 
hCMEC/D3 cells. 
4.2. Materials and Methods 
4.2.1. Sub-cloning of cyclic peptides into pCANTAB6-D1/FLAGHIS expression vector 
4.2.1.1. Modification of pC6-D1 expression vector to introduce a NotI and FLAG tag coding 
region 
PCR primers were synthesised by the DNA chemistry team (MedImmune, 
Cambridge, UK), these are outlined in Table 4.2.1.  
Table 4.2.1: Primers used for two-step pC6-D1 vector modification process. 
Primer ID Sequence Length 
pC6-D1/FLAGHISfor CGGGCGGCCGCAGGTGGTTCTGG 23 
pC6-D1/FLAGrev CGCCGCTTTATCGTCATCGTCTTTGTAGTCAGAG
CCACCACCCTCATTTTCAGG 
54 
pC6-D1/FLAHISrev2 CCAGTGAATTCTTAATGATGGTGGTGGTGATGA
TGGTGGTGATGCGCCGCTTTATCGTCATCGTCTT
TGTAGTC 
74 
 
A total of 10 ng of pC6-D1 vector stock was used in a 100 μl PCR reaction volume 
as outlined in Table 4.2.2. The PCR reaction was run with the following programme 
parameters: Hot start 94°C (3 min), denaturation 94°C (30 s), annealing 55°C (30 s), 
extension 72°C (90 s) and final extension 72°C (5 min). Denaturation, annealing and 
extension steps were repeated for 30 cycles. An aliquot of the PCR product was 
validated on a 1.5% agarose gel to confirm the insert size. Insert DNA was digested 
using NotI and EcoRI (New England Biolabs, Hitching, UK) and purified using a 
High-Pure PCR product purification kit (Roche Applied Science, Sussex, UK) 
according to the manufacturer’s protocol. 
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Table 4.2.2. Amplification of pC6-D1 vector insert. 
Reaction component Volume (μl) 
2x Thermo Ready mix PCR master mix 46 
Nuclease free water 50 
PD1-FHfor 1 
PD1-FLrev2 1 
pC6D1 vector stock (10 ng) 2 
 
pCANTAB6 stock vector was digested using NotI and EcoRI (New England 
Biolabs, Hitching, UK). The digested vector was run on a 1% agarose gel, the double 
cut vector band was excised and gel purified using a QIAquick gel extraction kit 
(QIAGEN, Manchester, UK) according to the manufacturer’s protocol, with the 
exception that the final elution step was carried out in 50 μl of nuclease free water. 
The digested and purified vector was 5’ dephosphorylated using 1 unit of Antarctic 
phosphatase in a 55 μl reaction volume containing 5 μl of 10x Antarctic phosphatase 
buffer (New England Biolabs, Hitching, UK). Digested vector and modified insert 
were ligated using T4 DNA ligase (New England Biolabs, Hitching, UK) in a 20 μl 
reaction mix and transformed into chemically competent DH5a E.coli cells. 
Transformed cells were streaked onto 2xTYAG plates and grown overnight at 37°C. 
The following day, 8 colonies were picked and grown overnight in a shaking 
incubator at 37°C, 280rpm. Aliquots of grown up cultures were taken for sequence 
validation using the sequencing primers, CanFor 
(CCCAGGCTTTACACTTTATGCTTC) and CanRevGT 
(GTTGGGTAACGCCAGGG). Glycerol stocks of E.coli cells containing the pC6-
D1/FLAGHIS construct were prepared following sequence validation. 
4.2.1.2. Purification of pC6-D1/FLAGHIS plasmid DNA 
A 400 ml culture of pC6-D1/FLAGHIS expressing E.coli DH5a cells was 
inoculated and grown overnight in a shaking incubator at 37°C, 280rpm. The 
following morning the culture was split into two 200 ml batches and plasmid DNA 
was purified using a HiSpeed Plasmid Maxiprep kit (QIAGEN, Manchester, UK) 
according to the manufacturer’s protocol. Purified plasmid DNA was quantified using 
a Nanodrop spectrophotometer (ThermoFisher Scientific, Paisley, UK) and run on a 
1.5% agarose gel to confirm plasmid size. 
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4.2.1.3. Restriction digestion of pC6-D1/FLAGHIS and CPep DNA vector 
Purified pC6-D1/FLAGHIS DNA was restriction digested using the restriction 
enzymes NcoI and NotI (New England Biolabs, Hitching, UK). A total of 6 μg of 
plasmid DNA was digested in a volume of 100 μl with 10x NEB 3.1 buffer (New 
England Biolabs, Hitching, UK) and 2 units of NcoI. The sample was incubated with 
NcoI for 45 min at 37°C, then heat inactivated at 65°C for for 30 min. Subsequently, 
2 units of NotI was added to the reaction and incubated for a further 1 hour at 37°C. 
Restriction digested products were run on a 1.5% agarose gel and gel purified using 
a QIAquick gel extraction kit (QIAGEN, Manchester, UK) according to the 
manufacturer’s protocol. In order to prevent re-ligation of the vector, the digested 
vector DNA was 5’ dephosphorylated using Antarctic phosphatase (New England 
Biolabs, Hitchin, UK) and incubation at 37°C for 1 hour. 
Insert DNA of the 16 identified cross-species binding CPep sequences and an 
irrelevant control CPep of similar size was amplified from fdDOG vector using the 
PCR amplification primers fdpcrfor 
(CCAGCCGGCCATGGCGTCTCACAGTGCACAG) and fdpcrrev 
(TTCAACAGTTGCGGCCGCAGCGGTAGAACCAGAACCACCTTCTGCGGCCGC). 
A 40 μl PCR reaction was prepared for each of the identified clones as outlined 
Table 4.2.3. 
Table 4.2.3: PCR reaction for amplification of CPep insert DNA from fdDOG phage vector. 
Reaction component Volume (μl) 
2x Thermo Ready mix PCR master mix 20 
Nuclease free water 17 
Fdpcrfor (10 μM) 0.5 
Fdpcrrev (10 μM) 0.5 
Glycerol stock of CPep in fdDOG 
vector 
2 
 
The PCR reaction was run with the following programme parameters: Hot 
start 94°C (3 min), denaturation 94°C (30 s), annealing 55°C (30 s), extension 72°C 
(90 s) and final extension 72°C (5 min). Denaturation, annealing and extension steps 
were repeated for 30 cycles. CPep DNA inserts were purified using QIAquick 
Nucleotide removal kit (QIAGEN, Manchester, UK) according to the manufacturer’s 
protocol. At the final stage of purification, insert DNA was eluted in 50 μl of nuclease 
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free water. Purified inserts were then restriction digested using NcoI and NotI as 
described earlier with the exception of the Antarctic phosphatase step. Inserts were 
subsequently re-purified using the QIAquick nucleotide removal kit (QIAGEN, 
Manchester, UK) according to the manufacturer’s protocol. 
4.2.1.4. Ligation reaction and transformation into E.coli Z’ TG1 competent cells 
NcoI and NotI digested CPep inserts and pC6-D1/FLAGHIS vector DNA were 
ligated using 400 units of T4 DNA ligase (New England Biolabs, Hitchin, UK). For 
each of the CPep sequences, a 20 μl reaction was set up as shown in Table 4.2.4. 
Table 4.2.4: Ligation of insert into pC6-D1/FLAGHIS expression vector 
Component Volume (μl) 
10x DNA ligase buffer 2 
Nuclease free water 15 
Digested vector (55 ng/μl) 1 
Digested insert DNA 1 
T4 DNA ligase 1 
Total volume 20 
 
The ligation reactions were incubated at room temperature for 1 h and 
subsequently transformed into Z-competent E.coli TG1 cells (MedImmune, 
Cambridge, UK). Cells were immediately plated out onto pre-warmed 2x Tryptone 
Yeast supplemented with 100 μg/ml ampicillin and 2% glucose (TYAG) agar plates 
and incubated overnight at 37°C. The following morning, 8 colonies per CPep were 
innoculated into columns within 96-well plates containing 2x TYAG media and 
cultured overnight at 30°C. Aliquots were then taken for sequencing and glycerol 
was added to remaining cultures in wells and plates were stored at -80°C. 
4.2.2. E.coli periplasmic expression and affinity purification of CPep-D1 fusion 
domains. 
4.2.2.1. Buffer preparation 
In preparation for automated sample purification, buffers were prepared, 
sterile filtered and stored at 4°C. Buffers were made according to the recipes shown 
in Table 4.2.5. 
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Table 4.2.5: ASPEC purification buffer compositions. 
Buffer  Composition 
ASPEC buffer A (equilibration) 50 mM Tris-HCl, 300 mM Sodium chloride, pH 
8.0 
ASPEC buffer B (Binding) 50 mM Tris-HCl, 300 mM Sodium chloride, 40 
mM Imidazole, pH 8.0 
ASPEC buffer C (Elution) 50 mM Tris-HCl, 300 mM Sodium chloride, 400 
mM Imidazole, pH 8.0 
TES buffer 200 mM Tris-HCl, 0.5 mM EDTA, 0.5 M sucrose, 
pH 8.0 
Test-tube buffer 1 M MgCl2, 2 M Imidazole, pH 8.0 
 
4.2.2.2. Expression, culture harvest, periplasm extraction and His capture affinity 
purification. 
An agar plate was freshly streaked for each of the 16 identified CPep clones 
(including the two predicted streptavidin binding clones), in addition to an irrelevant 
control CPep of similar size and charge and grown overnight at 30°C. Starter 
cultures were then prepared by inoculating 10 ml aliquots of 2x TYAG with a single 
colony from each of the streaked plates, and these were grown overnight in a 
shaking incubator at 30°C, 300rpm. The following day, 0.3 ml was taken from each 
starter culture to prepare glycerol stocks, and the remaining cultures were used to 
inoculate 2L Erlenmeyer flasks containing 400 ml of 2x TYAG (100 μg/ml Ampicillin, 
0.1% glucose). The flasks were then incubated for 2.5 h at 30°C, 300rpm. 
Subsequently, cultures were induced by addition of IPTG to a final concentration of 1 
mM, and incubation was recommenced for a further 3 h. 
The GX-274 ASPEC automated sample purification system (Gilson, Luton, 
UK) was setup by loading Ni-Sepharose FF columns, NAP10 desalting columns and 
6 ml collection tubes. Lines were primed with the relevant buffers before use. 
Storage buffer was allowed to completely drain from the Ni-Sepharose FF and 
NAP10 column resins and the columns were allowed to equilibrate for 3 h in ASPEC 
buffers A and D, respectively. 
Cultures were harvested via centrifugation at 6084 g for 10 min at 4°C using a 
pre-chilled SLA3000 rotor and a Sorvall RC5B centrifuge (ThermoFisher Scientific, 
Paisley, UK). Following centrifugation, the supernatant was discarded and the cell 
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pellet was re-suspended in Tris EDTA sucrose (TES) buffer, transferred to a 50 ml 
falcon tube and stored on ice. To each re-suspended cell pellet, 15 ml of a 1:5 
diluted TES solution was added, mixed and stored on ice for 30 min. Subsequently, 
the samples were centrifuged at 3576 g for 30 min at 4°C and lysate was isolated. 
Sample lysates were transferred to 25 ml glass test-tubes containing 125 μl of 
test-tube buffer and samples were loaded onto the ASPEC sample purification 
system and purified overnight. Purified material was quantified via a bicinchoninic 
acid (BCA) assay (ThermoFisher Scientific, Paisley, UK) according to the 
manufacturer’s protocol. Expressed and purified peptides that resulted in 
concentrations below 25 μg/ml were considered failed expressions. 
4.2.3. SDS-PAGE purity analysis of expressed CPep-D1 fusion domains. 
Validation of expressed peptide purity and molecular weight was carried out 
via sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Non-
reducing sample buffer stock was prepared at a 1:2 (v/v) of MiliQ water to 4x LDS 
sample buffer. Sample buffer was added to a 25 μl aliquot of the expressed peptide, 
mixed, transferred to a heat block at 100°C for 3 min, and allowed to cool to room 
temperature.  
Pre-cast NuPAGE 12% Bis-Tris gels (ThermoFisher Scientific, Paisley, UK) 
were placed in a buffer tank containing NuPAGE 1x MOPS SDS running buffer 
(ThermoFisher Scientific, Paisley, UK) and 10 μl of each peptide sample was loaded 
into individual wells alongside a well containing 5 μl of SeeBlue Plus pre-stained MW 
standard (ThermoFisher Scientific, Paisley, UK). The gel was run at 200 V, 400 mA 
for 45 min. Gels were subsequently stained for approximately 60 min in InstantBlue 
stain (Expedeon, Swavesey, UK) then de-stained by thoroughly rinsing in MiliQ 
water and allowing the gel to de-stain in water on a shaker for 30 min. Gels were 
imaged using a scanner. 
4.2.4. Soluble CPep-D1 fusion TfR binding ELISA 
Biotinylated mouse TfR, human TfR and an irrelevant control antigen 
(confidential proteins, contact George Thom, MedImmune, Cambridge, UK) of a 
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similar charge and molecular weight, were immobilised onto wells within streptavidin 
coated 96-well plates (Thermo-Fisher Scientific, Paisley, UK) at a concentration of 1 
μg/ml overnight at 4°C. As a negative control, non-TfR immobilised streptavidin 
coated plates were also assayed alongside surface antigens. The following morning, 
plates were rinsed three times in PBS and wells were blocked in 3% (w/v) skimmed 
milk powder in PBS for 1 h at room temperature. Blocked plates were subsequently 
washed three times in PBS and expressed soluble CPep-D1 lead molecules were 
added to the relevant wells, at 10 μM concentration or 1:3 serial dilutions starting at 
10 μM. Labelling of bound CPep-D1 domains was carried out by initially washing 
plates three times in PBS with 0.1% (v/v) Tween 20 (PBST) and incubating with a 
mouse monoclonal anti-FLAG M2 HRP conjugated secondary antibody (Sigma-
Aldrich, Dorset, UK) at a dilution of 1:20,000 for 1 h at room temperature. Wells were 
re-washed in PBST, the reduction of HRP was catalysed by addition of TMB 
substrate for 10 min, sulphuric acid was added to stop the reaction and plates were 
read using an EnVision™ fluorescent plate reader (PerkinElmer, Beaconsfield, UK) 
at 450 nm. 
4.2.5. Immunocytochemistry based cell binding, internalisation and intracellular co-
localisation assays 
ICC was used to assess the binding of lead peptides expressed as 
monomeric -D1 fusion domains towards bEnd.3 and hCMEC/D3 cell lines. ICC was 
also used to assess cellular uptake (within bEnd.3 and hCMEC/D3 cells) and 
intracellular localisation (within hCMEC/D3 cells) of CPep-Fc/ interleukin 1 receptor 
antagonist (IL1Ra) fusion domains. 
4.2.5.1. Cell culture 
Immortalised human brain endothelial cells (hCMEC/D3) were seeded into 
collagen coated flasks and maintained in endothelial cell basal medium-2 (Lonza, 
Basel, Switzerland) supplemented with 2.5% FBS and growth factors as outlined in 
Chapter 2, section 2.2.2. Immortalised mouse brain endothelial cells (bEnd.3) were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
FBS (Thermo-Fisher Scientific, Paisley, UK). Cells were cultured within a humidified 
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incubator at 37°C, 5% CO2. All experiments were carried out with cell lines at 
passages 25 – 30. 
For binding and internalisation assays, cells were sub-cultured into 
fibronectin- and collagen-coated Nunc Lab-Tek II 8-well glass chamber slides 
(ThermoFisher Scientific, Paisley, UK) or 96-well special optics flat clear bottom 
black polystyrene TC-treated microplates (Corning, High Wycombe, UK) at a 
seeding density of 5 x 104 per chamber or 1.5 x 104 per well, respectively. Cells were 
grown to confluence for 48 h, media was aspirated from the culture wells and cells 
were washed twice in PBS, prior to commencing cell binding and internalisation 
assays. 
4.2.5.2. Cell binding assays 
Cells were fixed in 4% p-formaldehyde in PBS, pH 7.4 for 15 min at room 
temperature. Post fixation, buffers were kept on ice and all subsequent steps were 
carried out at 4°C. Cells were washed three times in pre-chilled PBS and blocked in 
5% BSA in PBS solution, 30 min at 4°C. Post blocking, cells were washed three 
times in PBS and incubated with expressed lead CPep-D1 fusion domains diluted to 
a concentration of 2 μM in 1% BSA in PBS, for 4 h at 4°C. Post Incubation, cells 
were washed three times in 1% BSA in PBS for 5 min at 4°C. Cell bound CPep-D1 
domains were counter stained using a two-step secondary antibody labelling 
protocol. Cells were incubated for 1 h with 1 μg/ml secondary mouse anti-His 
monoclonal antibody (Millipore, Watford, UK) and subsequently 1:50 sheep anti-
mouse IgG FITC conjugated polyclonal antibody (Sigma-Aldrich, Dorset, UK) diluted 
in 1% BSA in PBS. Post labelling, cells were washed and chamber slides were 
mounted to glass coverslips in DAPI Fluoromount-G mounting media 
(SouthernBiotech, Birmingham, USA).  
Cells were imaged using a TCS SP5 confocal microscope (Leica, Milton 
Keynes, UK) and z-stack images were acquired using LAS AF software package. 
Max fluorescence intensity overlays were prepared from z-stack images using FIJI 
(imageJ). Mean grey value readings were acquired using FIJI (imageJ), normalised 
to the number of cells within each image and averaged from three independent 
images taken per experimental replicate (n= 3).  
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4.2.5.3. Cell internalisation and intracellular co-localisation assays 
CPep-Fc/ interleukin 1 receptor antagonist (IL1Ra) fusion domains and 
human anti-mTfR specific 8D3 antibody were expressed, purified, and validated by 
the protein purification team (MedImmune, Cambridge, UK). 
CPep-Fc/IL1Ra and anti-mTfR 8D3 antibody were diluted to a working 
concentration of 2 μM and 2 μg/ml in 1% BSA/ unsupplemented media, respectively. 
Confluent bEnd.3 or hCMEC/D3 cells were incubated with primary CPep-Fc/IL1Ra or 
anti-mTfR antibody within a humidified incubator at 37°C for 5, 15, 30, 60 and 120 
min time intervals. Post-incubation, cells were washed three times for 5 min in 1% 
BSA in PBS, and permeabilised using 0.25% Triton X-100 (Sigma-Aldrich, Dorset, 
UK). Secondary labelling of CPep-Fc/IL1Ra domains and anti-mTfR antibody was 
carried out using 10 μg/ml polyclonal F(ab’)2 goat anti-human IgG (Fc specific) Alexa 
488 conjugate (Thermo-Fisher Scientific, Paisley, UK).  
Intracellular co-localisation assays were carried out with hCMEC/D3 cells. In 
addition to CPep-Fc/IL1Ra labelling, cells were also labelled for EEA1 or LAMP1 
using rabbit anti-EEA1(#3288, Cell Signalling Technology, Leiden, Netherlands) or 
anti-LAMP1 (#9091, Cell Signalling Technology, Leiden, Netherlands). Counter-
staining of rabbit antibodies was carried out using goat anti-rabbit IgG (H+L) Alexa 
647 conjugated secondary antibody (Thermo-Fisher Scientific, Paisley, UK). Nuclei 
were labelled with hoechst at a dilution of 1:10,000, for 1 min at room temperature. 
Immunofluorescent imaging of labelled cells within 96-well plates was carried out 
using an ImageXpress Micro XLS system (Molecular probes, Wokingham, UK). 
Normalised mean grey value reading were acquired as outlined in section 4.2.5.2. 
4.2.6. Statistical analysis 
Statistical analysis was conducted using Graphpad Prism 6 statistical 
software. Unpaired t-tests and one-way analysis of variance (ANOVA) tests were 
carried out where applicable, alongside Bonferroni’s multiple comparison post-test. A 
p-value <0.05 was considered to be significant. 
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4.3. Results 
4.3.1. Flag and His10 coding region successfully inserted into pC6-D1 expression 
vector. 
The expression and purification of the small sized cyclic peptide (CPep) 
domains (approximately 1.8 kDa) poses a significant challenge for stability and 
effective purification. The solubility of peptides is typically poor due to the lack of a 
defined structure. This makes peptides susceptible to degradation by peptidases, 
and complicates their expression and purification steps through the formation of 
inclusion bodies and aggregates, respectively (Yuan Bi et al., 2006). To alleviate 
these issues, peptides may be expressed as fusion domains (Anderluh et al., 2003). 
A modified expression vector based on the pCANTAB6 phagemid vector (Figure 
4.3.1), pCANTAB6-D1 (pC6-D1), was used to express monovalent cyclic peptides 
fused to the small and soluble N-terminal region of g3p-domain 1. 
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Figure 4.3.1: Circular vector map of stock pCANTAB6 expression vector. 
Schematic representation of pCANTAB6 stock vector, showing the GIIIp encoding region, alongside 
the Myc tag, His6 tag and Pelb signaling regions. The insert region lies between NcoI and NotI 
restriction sites. Sourced from MedImmune (Cambridge, UK). 
 
The pC6-D1 vector incorporates a LacZ promoter which drives the expression 
of CPep-D1 fusion domains to the periplasmic space through a pelB signalling 
peptide sequence (AQPAMA). To prevent steric hindrance of the peptide, this vector 
construct features a linker encoding region between the N-terminal domain of g3p-
domain 1 and the peptide. The expression of peptides alongside a fusion partner 
also allows for the incorporation of affinity tags (Crowe et al., 1994; D. B. Smith and 
Johnson, 1988). The pC6-D1 expression vector encodes a His10 tag, which in turn 
generates CPep domains that incorporate a His tag for purification.  
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The presence of His tags on both the recombinant antigens and the 
expressed peptide domains poses an issue for the detection of peptide binding with 
ELISA based binding assays. Moreover, whilst the expression cassette within this 
vector incorporates a NcoI restriction site upstream of the peptide cloning region, it 
does not contain a unique downstream secondary restriction site. An alternative 
construct, pC6-D1/FLAGHIS, was therefore generated through a two-step PCR 
protocol in order to introduce a flag tag for detection of bound peptides and a NotI 
site for cloning. 
Amplification of pC6-D1 expression cassette insert DNA via the two-step PCR 
modification primers resulted in an observable band at the expected size of 258bp, 
Figure 4.3.2, A, lane 3. Restriction digestion of the stock pCANTAB6 expression 
vector using EcoRI and NotI resulted in three observable bands relating to three 
independent DNA fragments, Figure 4.3.2, B. The largest fragment observed at 4544 
bp represents the complete length of the pCANTAB6 stock expression vector and 
signifies the single digested vector product. The second largest band represents the 
double-digested vector product of interest and is observed at the expected size of 
3250 bp. The smallest observable band relates to the size of the digest site and is at 
the expected size of 1300 bp.  
Sequence validation of the modified pC6-D1/FLAGHIS vector revealed that 
the FLAG and NotI encoding sequences were successfully incorporated into the 
modified pC6-D1/FLAGHIS expression vector (Figure 4.3.3). The approximate 
molecular mass of a CPep-D1 fusion domain expressed using this construct is 13 
kDa, with the peptide itself accounting for ≃ 1.8 kDa. 
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Figure 4.3.2: Validation of pC6-D1 FLAG modified insert DNA product and digested pCANTAB6 
stock expression vector fragments via agarose gel electrophoresis. 
Figure showing gel electrophoresis images of amplified insert DNA (A, lane 3) and restriction 
digested pCANTAB6 stock expression vector (B, lane 3). All gels were run alongside a 1 kbp DNA 
ladder. 
 
 
Figure 4.3.3: Sequence validation of the modified insert region of pC6-D1/FLAGHIS expression 
vector. 
Schematic representation of the insert region within pC6-D1/FLAGHIS expression vector as 
determined by sequencing. The Flag and His10 coding regions were both validated in addition to the 
NotI restriction site introduced downstream of the peptide insert region.  
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4.3.2. Periplasmic expression of the CPep-D1 fusion domains resulted in variable 
yields of the uniquely identified peptides. 
After establishing mouse and human TfR binding of uniquely identified CPep 
domains via phage ELISA, CPep-D1 domains were expressed via periplasmic 
expression for the subsequent characterisation of monovalent peptides expressed as 
fusions to g3p-domain 1. SDS-PAGE gel validation results are shown in 4.3.4. 
Results revealed that not all of the CPep candidates expressed well as g3p-
domain 1 fusions (4.3.4, A and B). Of the 16 identified peptide sequences that were 
expressed within this format, 14 peptides expressed to some extent as demonstrated 
by observable bands on SDS-PAGE gels 1 and 2 at 13kDa. Both Pep10 and Pep16 
failed to express, showing no visible bands on the SDS-PAGE gel (4.3.4, A, lanes 12 
and 19). Additionally, Pep2, Pep4, Pep12, Pep13 and Pep15 exhibited low 
expression which prevented their use in further studies, as they did not meet the 
minimum starting concentration of 10 μM required for soluble recombinant TfR 
binding assays (4.3.4, A, lanes 4, 6, 14, 16 and 18). 
All Cpep-D1 fusion domains that expressed within this format demonstrated 
visible bands on SDS-PAGE gels within the expected region of 13 kDa (lanes 3-11, 
13, 14, 16, 17 and 18, respectively). In addition to the 13 kDa band, the majority of 
these peptides showed secondary banding as noted with Pep1 – Pep3, Pep5 – Pep9 
and Pep14 (lanes 3 – 5, 7 – 11 and 17, respectively). The secondary bands 
observed with Pep3, Pep5, Pep6, Pep7 and Pep14 (lanes 5, 7, 8, 9 and 17, 
respectively) are approximately 26 kDa in size. As well as demonstrating a 
secondary band at 26 kDa, Pep7 (lane 9) also demonstrated two additional bands 
which appear to be approximately 13 kDa apart and are visible at approximately 38 
kDa and 52 kDa. Pep1, Pep8 and Pep9 demonstrate a secondary band that is within 
the range of 15 – 16 kDa (lanes 3, 10 and 11, respectively). 
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A 
B 
  
Figure 4.3.4: Validation of expressed His10 
tagged monovalent CPep-D1 fusion 
molecules by SDS-PAGE. 
SDS-PAGE analysis of expressed monovalent 
CPep-D1 fusion molecules (A). CPep-D1 fusion 
domains were expressed in E.coli TG1 cells, 
purified on Ni-NTA affinity columns and run 
on a 12% Bis-Tris SDS-PAGE gels, which were 
later stained using Coomasie blue. The 
expected molecular weight of the CPep-D1 
domain is 13 kDa. A summary table of peptide 
lane order and concentration as determined 
by BCA assay is shown in (B). The 
concentration column within the table also 
highlights peptides which failed to express 
and those that expressed below the usable 
requirement for further analysis via ELISA 
based screening assays i.e. 10 μM.  
 
 
 
 
131 2 3 4 5 6 7 8 9 10 11 12
28 kDa
17 kDa
14 kDa
6 kDa
38 kDa
49 kDa
62 kDa
98 kDa
13 kDa
13 14 15 16 17 18 19
Gel 1 Gel 2
Gel Lane Lane content Concentration (µg/ml) 
Gel 1 
1 Empty N/A 
2 SeeBlue Plus2 
protein standard 
N/A 
3 Pep1 246 
4 Pep2 46 (Low) 
5 Pep3 212 
6 Pep4 27 (Low) 
7 Pep5 205 
8 Pep6 151 
9 Pep7 241 
10 Pep8 277 
11 Pep9 209 
12 Pep10 Fail 
13 Pep11 314 
Gel 2 
14 Pep12 48 (Low) 
15 SeeBlue Plus2 
protein standard 
N/A 
16 Pep13 29 (Low) 
17 Pep14 224 
18 Pep15 39 (Low) 
19 Pep16 Fail 
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4.3.3. Four lead peptides identified to exhibit recombinant mouse and human TfR 
specific binding over the control antigen. 
 Characterisation of cyclic peptides expressed as monovalent fusions to g3p-
domain 1 was carried out in order to establish lead candidates to be taken forward 
for cell binding studies and affinity ranking peptides towards mouse and human TfR. 
Lead peptides were selected according to criteria that they demonstrate higher 
absorbance readings towards both mouse and human TfR than those observed with 
the streptavidin and peptide controls. 
Initial assessment of CPep-D1 domains was carried out at 10 μM 
concentration to establish lead peptide candidates. Results are summarised in 
Figure 4.3.5. Due to the poor periplasmic expression yields of some CPep-D1 
domains and the large quantity required for further ICC cell binding studies, initial 
affinity screening of monovalent domains was carried out using two experimental 
replicates. Contrary to previous phage ELISA results (Chapter 3, Figure 3.3.3.), 
Pep7 did not bind mouse and human TfR when expressed within the CPep-D1 
fusion format, as demonstrated by the lack of increased absorbance over the 
irrelevant control peptide. The predicted streptavidin binding clones containing the 
consensus ‘HPQ’ and ‘HPM’ motifs, Pep3 and Pep6, showed greater absorbance 
readings towards streptavidin than to the irrelevant control and TfR antigens.  
Pep1, Pep8, Pep9 and Pep14 were all shown to exhibit greater absorbance 
readings with mouse and human TfR when compared with the irrelevant control 
antigen and were therefore taken forward for further study. In the case of Pep14, the 
absorbance readings observed appear to be only marginally greater than 
background absorbance of the irrelevant control peptide. Pep1 and Pep8 
demonstrated similar absorbance readings towards both human and mouse TfR. 
Additionally, Pep1 and Pep8 also show a two-fold increase in non-specific binding 
towards the irrelevant control antigen when compared with the control CPep at 10 
μM concentration. 
To determine the binding profiles of lead peptides, Pep1, Pep8, Pep9 and 
Pep14 were all titred against biotinylated recombinant mTfR and hTfR antigens and 
an irrelevant control antigen (confidential protein, contact George Thom, 
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MedImmune, Cambridge, UK) at a 1:2 serial dilution starting from 10 μM 
concentration. Summarised results of the antigen presentation ELISAs are shown in 
Figure 4.3.6. All four lead peptides were observed to bind to mTfR and hTfR at 
greater absorbance readings than the control CPep. Pep1 demonstrated TfR specific 
binding at concentrations higher than 1.25 μM (Figure 4.3.6, A). Additionally, Pep1 
also demonstrated greater absorbance readings towards hTfR at concentrations 
above 5 μM and this is consistent with previously observed results at 10 μM 
concentration, Figure 4.3.4. 
Pep8 exhibits TfR specific binding at concentrations greater than 0.63 μM, 
(Figure 4.3.6, B). Overall, Pep1 and Pep8 demonstrate the highest absorbance 
values when compared to the irrelevant control antigen for both mouse and human 
TfR. However, with increasing concentration, Pep1 and Pep8 also show high levels 
of non-specific background binding as indicated by the gradual increase in 
absorbance readings observed with the irrelevant antigen and streptavidin controls 
(Figure 4.3.6, A and B). Moreover, a greater degree of non-specific binding towards 
the irrelevant control antigen and streptavidin coated plates was observed with Pep8 
when compared to Pep1. Non-specific binding was also observed to gradually 
increase between 0.63 μM and 5 μM, with a more significant increase observed at 
10 μM concentration.  
Pep9 exhibits a greater affinity towards mTfR than hTfR (Figure 4.3.6, C). A 
gradual increase in mTfR specific binding was observed ranging from 0.63 μM to 10 
μM concentration. Pep14 demonstrated a very weak affinity to mTfR and presented 
greater affinity towards hTfR at 5 μM and 10 μM concentrations (Figure 4.3.6, D). 
Contrary to Pep1 and Pep8 results, both Pep9 and Pep14 exhibited less non-specific 
binding towards the control antigen and streptavidin coated plates. However, overall 
absorbance values were lower for Pep9 and Pep14, suggesting significantly lower 
binding affinities than Pep1 and Pep8. 
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Figure 4.3.5: Summary of soluble CPep-D1 antigen binding ELISA and lead identification. 
TfR binding ELISA performed with 10 μM of purified soluble CPep-D1 fusion domains titred against 1 
μg/ml biotinylated human and mouse TfR immobilised onto streptavidin coated plates. Pep1, Pep8, 
Pep9 and Pep14 were identified as lead candidates and carried forward for further study. 
Summarised results are presented as averages of two experimental replicates, (n= 2). 
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Figure 4.3.6: Titration summary of lead CPep-D1 soluble peptide binding to mouse and human 
TfR. 
Titration of expressed CPep-D1 lead peptides, Pep1 (A), Pep8 (B), Pep9 (C) and Pep14 (D), towards 1 
μg/ml biotinylated recombinant mTfR, hTfR, control antigen and non-TfR immobilised streptavidin 
coated plates, as determined by soluble peptide ELISA. Experiments were performed at a 1:2 serial 
dilution of CPep-D1 domains starting at 10 μM concentration. Summarised results are presented as 
averages of two experimental replicates, (n= 2). 
 
4.3.4. Lead peptide candidates bind to immortalised mouse and human brain 
endothelial cell lines, bEnd.3 and hCMEC/D3. 
ICC based cell binding assays were carried out using the four lead peptides 
Pep1, Pep8, Pep9 and Pep14 to establish whether CPep-D1 domains were capable 
of binding to TfR antigen expressed on the surface of brain endothelial cells, with all 
the relevant post-translational modifications (Davis et al., 1986; Jing and Trowbridge, 
1990; Do and Cummings, 1992; Hayes et al., 1992; A. M. Williams and Enns, 1993).  
Summarised results of the CPep-D1 cell binding assays are shown in Figure 
4.3.7. All four lead CPep-D1 fusion domains were found to bind both mouse and 
human immortalised brain endothelial cell lines, bEnd.3 and hCMEC/D3, respectively 
(Figure 4.3.7, A). In order to quantitatively assess the extent of CPep-D1 domain 
binding towards bEnd.3 and hCMEC/D3 cells, mean grey value readings were 
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analysed using FIJI (ImageJ) from three images taken at random locations for each 
experimental replicate. The acquired mean grey value readings were multiplied with 
the number of cell nuclei within each image to normalise for cell density. A summary 
of the quantified results is shown in Figure 4.3.7, B and C. 
The extent of cell binding was consistent with previous recombinant TfR 
affinity ranking ELISA based assays (Figure 4.3.6), thus confirming the binding 
profiles of lead candidates towards TfR. Pep1 and Pep8 exhibit the highest levels of 
cell binding with bEnd.3 and hCMEC/D3 (Figure 4.3.7, A and B). Pep9 and Pep14 
also demonstrate cell binding towards mouse and human cell lines, (Figure 4.3.7, A 
and B). 
Both Pep1 and Pep8 demonstrated a statistically significant 4.4- and 4.3-fold 
increase in binding towards bEnd.3 cells, when compared to the control CPep, 
respectively, (P= <0.0001), (Figure 4.3.7, A). In contrast, Pep9 and Pep14 
demonstrated 2- and 1.7-fold increase in binding when compared to the control 
CPep, however these were not statistically significant, (Figure 4.3.7, A).  
Pep1 and Pep8 exhibited a statistically significant 10.7- and -13.5-fold 
increase in binding towards hCMEC/D3 cells when compared with the control CPep, 
respectively, (P= <0.0001). Pep14 also demonstrated a statistically significant 3.8-
fold increase in binding over the control CPep (P= 0.001 to 0.01). Pep9 
demonstrated a 2.8-fold increase in binding in relation to the control, however this 
finding was not statistically significant. 
 
  
Expression and characterisation of lead TfR binding peptides. 
 147 
 
Figure 4.3.7: CPep-D1 bEnd.3 and hCMEC/D3 cell binding assay as determined by 
immunocytochemistry. 
Figure summarising the results of the CPep-D1 brain endothelial cell binding study. bEnd.3 and 
hCMEC/D3 cells were grown in chamber slides for 48 hours, fixed in 4% PFA and incubated with 2 
μM of monovalent Pep1, Pep8, Pep9 and Pep14 -D1 domains at 4°C for 4 hours. Secondary labelling 
was carried out with a mouse anti-his antibody and a goat anti-mouse FITC conjugated antibody. Z-
stack images were acquired using a Leica SP5 confocal microscope, and max intensity images are 
shown (A). DAPI nuclear staining is represented by the blue channel, whilst CPep-D1 binding is 
represented by the green channel. A quantitative summary of ICC based CPep-D1 binding assays 
carried out against bEnd.3 (B) and hCMEC/D3 (C) is also shown. Mean grey value is presented as 
normalised average readings of three independent images acquired through ImageJ, per 
experimental replicate, ± SEM. ** P 0.001 to 0.01, **** P < 0.0001. 
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4.2.7. Pep1-Fc/IL1RA fusion molecule demonstrates mouse and human brain 
endothelial cell internalisation. 
Pep1 and Pep8 were expressed as bivalent Fc-fusion proteins coupled to 
interleukin-1 receptor antagonist (IL1RA), (expressed by protein expression team, 
MedImmune, Cambridge, UK), in order to investigate the capacity these peptides to 
deliver a coupled cargo into mouse and human brain endothelial cells. To assess the 
optimal incubation time for peptide-Fc fusion domain internalisation within brain 
endothelial cells, an ICC time-course internalisation assay was carried out on bEnd.3 
cells ranging from 5 min to 120 min time points. To quantitatively determine uptake 
at each internalisation time-point, the mean grey value readings were acquired via 
FIJI (ImageJ), and normalised to the number cells as outlined in section 4.2.5.2. 
Summarised results of the internalisation time course and the quantitative 
mean grey value summary are shown in Figure 4.3.8 and Figure 4.3.9, respectively. 
As expected no staining was observed with the negative control CPep-Fc/IL1RA, 
Figure 4.3.8, A. Pep1-Fc/IL1RA demonstrated observable internalisation from the 15 
min time point, saturating within cells by the 60 min time-point, Figure 4.3.8, B, and 
Figure 4.3.9. Unlike Pep1-Fc/IL1RA, Pep8-Fc/IL1RA demonstrates low levels of 
internalisation within bEnd.3 cells when compared to control CPep-Fc/ILRA, Figure 
4.3.8, C, and Figure 4.3.9. In contrast, positive control anti-mTfR 8D3 antibody was 
internalised and saturated within cells after the 5 min time point Figure 4.3.8, D, and 
Figure 4.3.9. Since Pep8 demonstrated low bEnd.3 cell internalisation when 
expressed within the -Fc/IL1RA format, it was not carried forward for further studies. 
Internalisation and sub-cellular co-localisation of Pep1-Fc/IL1RA was 
assessed towards hCMEC/D3 cells by means of ICC using labelled antibodies 
directed to the Fc domain of the fusion protein, a cellular early endosomal marker 
(EEA1) and a cellular lysosomal marker (LAMP1). Results are summarised in, Figure 
4.3.10. 
As expected control CPep-Fc/IL1RA did not present any internalisation within 
hCMEC/D3 cells as indicated by the lack of observable green staining (Figure 
4.3.10, A, B, E and F). Pep1-Fc/IL1RA was observed to internalise within hCMEC/D3 
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cells (Figure 4.3.9, C, D, G and H). No distinct co-localisation was observed with 
EEA1 or LAMP1 at 60 and 120 min time points (Figure 4.3.10, G and H). 
 
  
Figure 4.3.8: CPep-Fc/IL1RA bEnd.3 cell internalisation time course at 5, 15, 30, 60 and 120 min 
time points. 
bEnd.3 cell internalisation of control CPep-Fc/IL1RA (A), Pep1-Fc/IL1RA (B), Pep8-Fc/IL1RA (C) and 
anti-mTfR 8D3 antibody (D). CPep-Fc fusions were incubated with cells at 5 μM concentration, whilst 
anti-mTfR 8D3 antibody was incubated at a concentration of 2 μg/ml. Blue channel represents 
nuclear staining. Green channel represents internalised CPep-Fc/IL1RA (A, B, C) or anti-mTfR 8D3 
MAb (D). Enlarged representations of Pep1-Fc/IL1RA and Pep8-Fc/IL1RA internalisation at the 60 min 
interval are shown in (E) and (F), respectively. Images were acquired at x20 magnification using a 
Molecular Probes ImageXpress XLS system. Results are representative of three experimental 
replicates (n= 3).  
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Figure 4.3.9: Quantified average mean grey values of CPep-Fc/IL1RA bEnd.3 internalisation 
assay.  
A quantitative summary of the ICC based CPepFc/IL1RA internalisation time course carried out 
towards bEnd.3 cells. Mean grey value is presented as normalised average readings of three 
independent images acquired through ImageJ, per experimental replicate (n= 3), ± SEM.  
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Figure 4.3.10: Pep1-Fc/IL1RA hCMEC/D3 cell internalisation and intracellular co-localisation 
assays. 
Immunofluorescence images of hCMEC/D3 cells showing staining for control CPep-Fc/IL1RA (A, B, E 
and F) and Pep1-Fc/IL1RA (C, D, G and H) internalisation (green), with or without visible nuclear 
staining (blue). Intra-cellular trafficking of Pep1-Fc/IL1RA fusion domains was assessed using early 
endosomal antigen-1 (EEA1), (A, B, C, and D) or lysosomal-associated membrane protein 1 (LAMP1), 
(E, F, G and H) and are both represented by red staining. Control CPep-Fc/IL1RA and Pep1-Fc/IL1RA 
fusion molecules were both assessed at 60 and 120 min intervals. Images were acquired at x63 
magnification using a Molecular Probes ImageXpress XLS system. Results are representative of three 
experimental replicates, (n= 3). 
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4.4. Discussion 
4.4.1. Construction of pC6-D1/FLAGHIS expression vector and sub-cloning of CPep 
sequences. 
Identified peptide candidates were initially screened as pentavalent g3p fusion 
domains which resulted in the observed multivalent binding towards target mouse 
and human TfR antigens (described in chapter 3). In order to evaluate the relative 
affinity of each peptide in the absence of avidity effects, peptides must be produced 
and characterised for binding as monovalent domains. Typically, the production of 
peptides can be achieved using solid phase chemical synthesis techniques. 
However, these techniques can be costly, which poses a problem for the efficient 
affinity ranking of large numbers of peptide candidates (Yuan Bi et al., 2006). 
Cellular expression systems provide a more viable approach to the production of 
relatively large quantities of recombinant peptide, whilst also allowing the simple 
incorporation of polypeptide affinity tags (Lindhout et al., 2003).  
The most commonly utilised expression system, E.coli, has been exploited 
using a variety of expression vectors and is typically well suited for the expression of 
soluble domains under 60 kDa in size, although successful expression of larger 
proteins has also been reported (Rosano and Ceccarelli, 2014). The reducing 
environment of the cytoplasm, prevents the formation of di-sulphide linkages and 
often requires further steps to refold proteins in vitro (Rouet et al., 2012). However, 
researchers have overcome these issues by expressing proteins and peptides within 
the periplasmic space found in gram negative bacteria, an oxidising environment that 
is suitable for the formation of disulphide linkages (Lindhout et al., 2003). The direct 
expression of peptides remains challenging due to poor solubility and protease 
stability. The expression of peptides with a stable and highly soluble fusion partner 
domain can ameliorate these concerns (Amarasinghe and Jin, 2015). Typically, the 
yield of peptide obtained from E.coli periplasmic expression is dependent of the 
molecular weight of the coupled fusion partner. Smaller fusion partners tend to result 
in higher expression yields (Yuan Bi et al., 2006). 
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The pC6-D1 phagemid expression vector was chosen for the expression of 
peptide fusions to g3p-domain 1 as a means of enhancing solubility, reducing 
proteolytic degradation and facilitating cell expression and purification of the single 
domain peptides (Malik, 2016). This vector is based on the pCANTAB6 vector used 
to express single chain fragment variable (scFv) antibody domains (McCafferty and 
Johnson, 1996; Qi et al., 2012). The vector incorporates the complete coding region 
for g3p-domain 1 (g3p-D1), followed by a short flexible linker, a His10 tag and an 
ochre stop codon. 
Structurally the 66 amino acid globular g3p-D1 is comprised of six stranded β-
sheets that form a barrel unit which is capped at the N-terminal region with a short a-
helix (Holliger and Riechmann, 1997; Holliger et al., 1999). Importantly for its use as 
fusion partner, g3p-D1 is a highly stable domain with a melting temperature of 
66.8°C due to the presence of two disulphide linkages, and a N-terminal a-helical 
cap. The use of a short flexible GGSG linker between the peptide and the g3p-D1 
fusion protein prevents steric hindrance of the cyclic peptide, allowing for greater 
freedom of interaction. The use of a suitable linker has also been shown to prevent 
protein mis-folding, whilst improving expression yields and bioactivity of the fusion 
domains (X. Chen et al., 2013). 
For the purpose of this study, an alternative variant construct of the pC6-D1 
vector, was generated in order to introduce a unique NotI restriction site to facilitate 
efficient sub-cloning of peptide sequences, and a FLAG tag for detection of peptide 
binding within ELISA based recombinant TfR binding assays. Although many affinity 
tags have been developed with varying sizes and functional properties (reviewed in 
Terpe, 2003), the FLAG tag was chosen in this case since it consists of a short, 
hydrophilic sequence and like the polyhistidine tag, does not usually interfere with 
the native folding and function of the fused protein (Einhauer and Jungbauer, 2001). 
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Results of the pCANTAB6 stock vector digestion with NotI and EcoRI showed 
a large proportion of the digested vector remained at its full length, as demonstrated 
by the band seen at 4544 bp (Figure 4.3.2, B). This observed band likely represents 
the single NotI digested product and is a result of the inefficiency of the EcoRI 
enzyme in NEBuffer 3.1 buffer, which only exhibits 50% activity in contrast to NotI 
which demonstrates 100% activity. Following ligation of the modified insert, the pC6-
D1/FLAGHIS vector was transformed into competent E.coli DH5a cells and 
sequence validated, results are shown in. As expected the modified vector contained 
the inserted NotI restriction digest site downstream of the peptide insert region, in 
addition to the correct FLAG sequence, DYKDDDDK.  
The precise FLAG sequence is vital for antibody recognition. Several 
monoclonal anti-FLAG antibodies have been identified towards the FLAG peptide 
sequence, namely anti-FLAG M1, M2 and M5, with each antibody having specific 
binding epitopes and properties (Einhauer and Jungbauer, 2001). The most 
commonly used and versatile of these antibodies is the mouse monoclonal anti-
FLAG M2, which is capable of recognising the FLAG motif expressed at the N-, Met-
N-, C- termini, and also within internal sites of the fusion protein, through a calcium 
independent manner. Utilising a peptide phage display library, Srila et al. (2013) 
carried out biopanning selections against anti-FLAG M2 to elucidate the consensus 
binding motif of this antibody. The group found that the consensus motif ‘DYKxxD’ 
was essential for proper binding of the FLAG peptide. Moreover, the group also 
discovered that C-terminal hydrophilic amino acid residues flanking this motif were 
preferentially selected towards the anti-FLAG M2 antibody, suggesting those 
residues also conferred some binding advantage towards anti-FLAG M2.  
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4.4.2. Periplasmic expression of monovalent CPep-D1 domains. 
Although expression yields were within the expected range for nine of the 
expressed peptide candidates, the remaining candidates showed consistently low 
yields (Pep2, Pep4, Pep12, Pep13 and Pep15) or failed expressions (Pep10 and 
Pep16) with multiple expression attempts (Figure 4.3.3).  
The poor or failed expressions observed with these peptides are likely to be 
due to the inherent sequence structure of the cyclic peptide and its effect on 
periplasmic expression within the E.coli host. Several factors have been shown to 
lead to poor or failed expressions (Rosano and Ceccarelli, 2014). The expressed 
peptide sequence may have a detrimental effect on a host cell function, which can 
lead to cell toxicity (Saïda, 2007). A lower yield may also be a result of low mRNA 
stability (Tegel et al., 2011) or mRNA secondary structure formation, which limits 
efficient translation. Furthermore, mRNA codons encoding the heterologous protein 
are not all equally translated within cellular hosts such as E.coli and this can lead to 
low or failed expression where minor codon usage is present within the peptide 
sequence (Kane, 1995). This results from an inherent frequency bias of codon use 
within E.coli and their cognate tRNA levels. Several factors lead to expression 
deficits with minor codon usage, these include the formation of truncated proteins via 
disrupted translation, reduced cell growth and frame shift mutations (Kleber-Janke 
and Becker, 2000). Kane et al. (1995) previously highlighted 18 minor codons with 
less than 1% frequency usage within E.coli. Of the 18 minor codons, 7 of the least 
prevalent codons are most commonly reported to interfere with heterologous 
expressions within E.coli, these are shown in Table 4.4.1.  
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Table 4.4.1: Most commonly reported minor codons and their frequency representation by 
E.coli (adapted from: Kane et al. 1995). 
Minor codon Encoded Amino acid Frequency (per 1000 codons) 
AGG Arginine 1.4 
AGA Arginine 2.1 
CGA Arginine 3.1 
CUA Leucine 3.2 
AUA Isoleucine 4.1 
CCC Proline 4.3 
CGG Arginine 4.6 
GGA Glycine 7.0 
 
Closer examination of the seven peptide sequences that exhibited low or 
failed expression revealed that four peptide sequences contained minor codons, with 
Pep2 and Pep16 containing two codons within their short 16 codon sequence 
(highlighted codons in Table 4.4.2). The minor codons that appear within the peptide 
sequences are CCC (Proline) and CGG (arginine). Previous studies have shown that 
minor codon presence close to the initiation codon of an mRNA sequence can 
significantly reduce its translational efficiency, through ribosomal stalling at minor 
codons and the limited availability of the less abundant tRNAs (G.-F. T. Chen and 
Inouye, 1994). These minor codons are commonly observed within the first 25 
codons of E.coli genes, and are thought to be intrinsically involved in E.coli gene 
regulation via growth rate restriction. 
Table 4.4.2: Minor codon usage within the variable peptide encoding region of poorly 
expressing CPep-D1 domains. 
CPep ID AA sequence Nucleotide sequence (5’ – 3’) 
Pep2 IHCHPQGDQSVSFCWR ATC CAC TGT CAC CCC CAG GGC GAC CAG AGC GTC TCC TTC TGT TGG CGG 
Pep4 LYCYPTKLPWVEYCHE CTC TAC TGT TAC CCG ACG AAG CTC CCC TGG GTC GAG TAC TGT CAT GAA 
Pep12 TWHYQCITMNCDVLVG ACG TGG CAC TAC CAG TGT ATC ACC ATG AAC TGT GAC GTG TTG GTG GGG 
Pep13 WVCTPLDSEIIEICQL TGG GTC TGT ACC CCG CTC GAC TCC GAG ATC ATC GAG ATC TGT CAG CTG 
Pep15 LHCTSIWSDVVQLCDL TTG CAC TGT ACC TCC ATC TGG AGC GAC GTG GTG CAG TTG TGT GAC CTC 
Pep10 LHECTYYWWGLDCSFR TTG CAC GAG TGT ACG TAC TAC TGG TGG GGG TTG GAC TGT TCC TTC CGG 
Pep16 PLCTPIFPPFVLMCEE CCC CTC TGT ACG CCC ATC TTC CCG CCG TTC GTG TTG ATG TGT GAG GAG 
 
The 16 codons that make up the peptide sequence all fall within the first 25 
codons downstream of the initiator codon, any presence of minor codons within 
these peptide encoding sequences is therefore likely to interfere with efficient 
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translation. In the case of Pep16 which shows two CCC codons at the 5’ region of 
the sequence, this resulted in a failed expression. 
Several approaches have been used to overcome the translational issues 
posed by minor codon usage within recombinantly expressed proteins. The simplest 
method, codon optimisation, involves replacing minor codons with those more 
frequently represented in E.coli and code for the same amino acid residue (Marlatt et 
al., 2010; Tiwari et al., 2010).  
Expressed CPep-D1 domains were primarily observed as soluble monomers 
at a size of 13 kDa on SDS-PAGE gels (Figure 4.3.4, A). However, nine of the 
expressed peptide candidates also demonstrated secondary bands on SDS-PAGE 
gels. The secondary band observed at approximately 15 kDa with Pep1, Pep8 and 
Pep9 could be due to translational read-through the ochre stop codon, resulting in 
the expression of a c-terminal extended fusion protein. The secondary bands 
observed at 26 kDa are likely due to dimerisation of the individual CPep-D1 domains. 
In addition to exhibiting a dimer band at 26kDa, Pep7 also demonstrated bands at 38 
kDa and 52 kDa. These three bands appear to correspond to multimeric forms of the 
fusion protein, i.e. dimer, trimer and tetramer.  
Protein aggregation is defined as the amalgamation of monomeric domains in 
their native or non-native states to form soluble or insoluble multimeric units (Moussa 
et al., 2016). The formation of aggregates during protein production is a multifactorial 
process, which initiates with the non-covalent interaction of proteins that form soluble 
reversible aggregates under the influence of a stressor or non-optimal storage 
conditions (e.g. temperature, pH, agitation, concentration). These reversible 
aggregates can subsequently act as foci for insoluble aggregate formation via a 
nucleation growth process. The formation of protein aggregates poses major 
challenges for the production of therapeutic proteins, since these aggregates often 
cause a loss in biological activity and have been shown to cause immunogenic 
responses, as demonstrated both in vitro and in vivo  (Daha et al., 1982; Fradkin et 
al., 2009; Hermeling et al., 2006; Q. Luo et al., 2011; Joubert et al., 2012) .The 
intrinsic heterologous protein structure, expression vector, expression host cell and 
purification methods all play a significant role in the susceptibility of a protein to form 
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aggregates. These numerous factors make identifying the source of aggregation 
problematic and time-consuming. Although, the use of a fusion domain has been 
shown to minimise the formation of spontaneously occurring aggregates, studies 
have shown that hydrophobic regions within the fusion proteins are likely to also play 
role in aggregate formation (Lebendiker and Danieli, 2014). The intrinsic structure 
Pep7 appears to be the most susceptible to aggregation, since it resulted in the 
formation multimeric aggregates of varying sizes, as demonstrated by visible 
banding in increments of 13 kDa. 
Although unnecessary at this stage of lead candidate discovery, it is possible 
to isolate and sequence the secondary band(s) via N-terminal sequencing (Edman 
sequencing) to identify the exact sequence of these contaminating bands (Joo et al., 
2006).  
4.4.3. Four CPep candidates bind specifically to recombinant mouse and human TfR 
expressed as CPep-D1 fusion domains. 
Four cyclic peptide candidates (Pep1, Pep8, Pep9 and Pep14) were identified 
to bind specifically towards mouse and human TfR as soluble monovalent CPep-D1 
domains (Figure 4.3.5). Detection of bound flag tagged CPep-D1 domains in this 
case was carried out via an anti-FLAG M2 antibody. In contrast to phage ELISA 
screening conducted using phage supernatant, the absorbance readings observed 
with these results are more insightful into the binding profiles of the monovalent 
peptide domains, and thus any variances in the overall binding curves of the 
peptides towards either mouse or human TfR, could reflect the relative binding 
affinity of the peptide towards the antigens. However, it is important to note that the 
binding affinity cannot be deduced using ELISA techniques, since the immobilisation 
of antigens via biotin tags onto streptavidin plates likely results in the steric 
hindrance of some epitopes (Underwood, 1993). 
The precise binding affinity can be determined using more sensitive 
biomolecular interaction techniques such as surface plasmon resonance (SPR). 
These techniques rely on the use of optical-based biosensors to determine the one-
to-one interaction of molecules in real-time without necessitating the need for labels 
Expression and characterisation of lead TfR binding peptides. 
 159 
(Nguyen et al., 2015). The incorporation of a label to a biomolecule can in some 
cases detrimentally impact the overall structure and function of a given biomolecule, 
resulting in disrupted molecular interaction properties. The use of SPR therefore 
provides a means quantitatively assessing Kon and Koff kinetics for native 
biomolecular interactions, under label-free conditions (D. Yang et al., 2017). 
Due to the aforementioned restrictions in CPep-D1 expression yields and cell 
binding assay requirements, ELISA screening of monovalent CPep-D1 domains was 
carried out using two experimental replicates. Contrary to phage ELISA screening 
results, Pep7 does not appear to bind mTfR, hTfR, or the control antigen when 
expressed within the CPep-D1 format, Figure 4.3.4 At first glance this appears to 
indicate that the peptide is a false positive clone identified via phage ELISA 
screening. However, since this peptide was observed to bind as a pentavalent 
fusions on phage particles throughout several experiments (Figure 3.3.5, and Figure 
3.3.6), it is likely to be a weak affinity peptide that exhibits binding due to avidity 
effects of multivalent expression, a commonly observed phenomenon with phage 
display selections conducted in the g3p pentavalent fusion format (Gabryelczyk et 
al., 2015). Alternatively, with Pep7 being identified as the peptide most susceptible to 
aggregation, the lack of observed binding may be related to the presence of 
multimeric aggregate forms of the Pep7-D1 fusion protein observed on the SDS-
PAGE gel (Figure 4.3.3), which may impede binding or interfere with effective 
detection of the FLAG tag. A study by Jannssen et al. (2015) have previously 
highlighted that the presence of oligomers within a protein sample can interfere with 
the accuracy of ELISA measurements. Using Aβ as an aggregate protein model, the 
group showed a decreased detection signal with highly oligomerised Aβ samples. 
Furthermore, disaggregating the oligomerised Aβ by treatment with trifluoroacetic 
acid and hexafluoroisopropanol, resulted in a recovery of the detection signal, which 
was not observed when monomeric protein was subjected to the same pre-
treatment.  
Pep3 (TTFPSCHPQTCYDGVQ) and Pep6 (GWHPMCNLMACSQGRP) both 
demonstrated higher absorbance readings towards streptavidin than mouse and 
human TfR, thus confirming they are TUP clones enriched throughout phage display 
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selections towards the streptavidin affinity capture matrix (Thomas et al., 2010). As 
previously predicted with phage ELISA positive clone sequence analysis, Pep3 binds 
to streptavidin via the consensus ‘HPQ’ motif within its sequence (Section 3.4.2). 
Interestingly, the ‘HPM’ motif binds streptavidin with a lower affinity than that seen 
with ‘HPQ’, as demonstrated by the lower absorbance reading seen with Pep6 in 
contrast to Pep3 (Figure 4.3.4), and these results are consistent with a previous 
study demonstrating the affinity of the two motifs (Gissel, Jensen, Gregorius, Elsner, 
Svendsen, and Mouritsen, 1995b). Binding could also be observed within the mTfR, 
hTfR and control antigen coated wells of Pep3 and Pep6 assays. This binding is 
likely to be towards non-occupied binding epitopes on streptavidin molecules, rather 
than non-specific binding. As discussed in chapter 3, avoiding the enrichment of TUP 
clones throughout phage display selections is difficult, even when de-selection steps 
are employed. The remaining peptide sequence surrounding the tripeptide ‘HPQ’ 
motif plays little to no role in mediating streptavidin binding, however preferential 
enrichment of phenylalanine, glycine, asparagine and valine residues have been 
reported following the glutamine residue of the ‘HPQ ‘motif (Menendez and Scott, 
2005). 
According to the CPep-D1 titration results, it appears that all four lead 
peptides, Pep1, Pep8, Pep9 and Pep14 demonstrate weak affinity profiles (Figure 
4.3.5). When compared to the CPep-D1 control, all four lead peptides exhibit specific 
binding within the micro-molar range. This finding was anticipated, since peptides 
selected in this phage display format tend to be significantly weaker affinity than 
antibodies also selected via phage display. Additionally, selections were conducted 
in manner to encourage the identification of lower affinity peptides by maintaining 
higher concentrations of target TfR antigen throughout later selection rounds. 
Theoretically, the identification of low to medium affinity peptides in the context of 
targeting the BBB would be advantageous since it has been shown to positively 
influence the fate of transcellular trafficking across the BCEC by avoiding lysosomal 
degradation (Bien-Ly et al., 2014). 
Once again, Pep1 and Pep8 exhibited the highest degree of binding towards 
mouse and human TfR of the four lead candidates. Interestingly, even though 
Expression and characterisation of lead TfR binding peptides. 
 161 
blocking steps were carried out, both of these lead peptides also demonstrated non-
specific binding, which was observed at higher concentrations towards the irrelevant 
control antigen and streptavidin coated plates. In contrast, non-specific binding was 
not observed when these peptides were expressed as pentavalent g3p fusions 
during phage ELISA screening, Figure 3.3.6.  
The poor potency of these peptides, in combination with the crude purification 
method used to generate the monovalent g3p-domain 1 fusions, may be one reason 
for the observed non-specific binding. However, it appears that the inherent amino 
acid makeup of the peptides also plays a role in non-specific activity since Pep8 
appears to be more pre-disposed to non-specific binding than Pep1, as 
demonstrated by the increased non-specific binding from 0.63 – 10 μM 
concentrations. 
4.4.4. Lead cyclic peptide candidates bind bEnd.3 and hCMEC/D3 cells 
CPep cell binding assays were conducted towards bEnd.3 and hCMEC/D3 
cells in order to assess whether the four identified lead peptide candidates could 
recognise TfR expressed natively on the cell surface of in vitro cultured immortalised 
brain endothelial cells. TfR undergoes significant post-translational modifications 
within the mammalian cell (Davis et al., 1986; Jing and Trowbridge, 1990; Do and 
Cummings, 1992; Hayes et al., 1992; A. M. Williams and Enns, 1993). These 
modifications are not always reflected correctly with expressed recombinant protein. 
The validation of peptide binding towards cells is therefore important for the 
identification of functionally relevant peptides.  
The four lead peptide candidates Pep1, Pep8, Pep9 and Pep14 all bound with 
various binding profiles towards the two cell lines when compared to the CPep-D1 
control, (Figure 4.3.7). As anticipated, the highest fluorescence intensities were 
observed with Pep1 and Pep8 for both cell lines. These results are consistent with 
previous recombinant TfR binding assays, where Pep1 and Pep8 persistently 
demonstrate the highest degree of binding towards recombinant mTfR and hTfR, 
(Figure 3.3.5 and Figure 3.3.6).  
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Due to time and reagent limitations, it was not possible to determine whether 
cell binding occurs competitively with Tf. As previously discussed in section 3.3.5, 
the sequences of Pep1 and Pep10 share a homologous ‘DCS’ motif with Tf, and this 
motif amongst others (‘WGG’ and FR) may mediate the identified peptides to TfR.  
Eckenroth et al. (2011), have previously shown that arginine 646 which 
located within a canonical ‘RGD’ sequence (arginine 646, glycine 647, and 
asparagine 648) of TfR is vital for binding to Tf. Furthermore, it was suggested that 
these residues are within binding range of Tf residues 356, 359 and 366 located 
within the C1-lobe of Tf and are vital for Tf binding to TfR. The group concluded that 
the remaining van der Walls interactions between the C1-lobe of Tf and TfR likely 
show limited conservation with the specificity for binding between Tf and TfR. This 
finding alongside the proposed site of binding discussed in section 3.4.3, could 
suggest that binding of Pep1 to TfR residue arginine629 may or may not interfere 
with Tf interaction, and this would need to be demonstrated experimentally. One 
means of assessing this, would be to incubate cells with Pep1 and recombinant TfR 
protein at equimolar concentration, and determine whether there is a reduction in 
binding when compared to Pep1 alone.  
4.4.5. Pep1-Fc/IL1RA internalises within bEnd.3 and hCMEC/D3 cells 
Targeting TfR has been extensively shown to be an effective strategy for the 
delivery of macromolecular drugs and large nano-carrier conjugates into cancer cells 
and across the BBB (Q. Ye et al., 2012; Yue Zhang et al., 2017; Yu et al., 2014; T. 
Kang et al., 2015; Webster et al., 2017). Ligands that are multivalent or contain 
multiple pharmacophores, can synergistically interact with targets and this leads to 
an apparent increase in their ‘functional affinity’ or more commonly referred to as 
avidity. Naturally occurring multivalent immunoglobulins, such as IgG typically have 
strong affinities towards their targets due to their bivalent structure. The increased 
avidity is a result of cross-linkages formed between two target antigens. When one 
pharmacophore binds towards a target site, the local co-presence of the secondary 
pharmacophore within close proximity leads to a higher local concentration and 
increased residency time, which results in an increased probability of secondary site 
binding and rebinding of the dissociated, tethered pharmacophore (Vauquelin and 
Expression and characterisation of lead TfR binding peptides. 
 163 
Charlton, 2013). Researchers have exploited the multivalent nature of IgG antibodies 
by generating highly engineered Fc-Fusion molecules which mimic the bivalent 
structure of IgG. The first instance of fc-fusion use was described in 1989 
(Czajkowsky et al., 2012). Since then, many Fc-fusion domain therapies have been 
researched, developed and approved, with one example etanercept reaching 
‘blockbuster drug’ status (Willrich et al., 2015; Beck and Reichert, 2014).  
An engineered Fc-fusion molecule is typically constructed by fusing a peptide 
or protein encoding sequence to the N-terminal encoding sequence of the Fc-
domain, via the use of a linker. The appropriate choice of linker can vary with the 
required structural properties and pharmacokinetic characteristics (X. Chen et al., 
2013). However, typically the most versatile are the flexible glycine-rich repeat linker, 
e.g. (G4S)n of a suitable length to avoid steric hindrance or interaction of the effector 
molecule with the Fc-domain. The primary advantage for the fusion of an effector 
molecule to the Fc-domain is the ability to take advantage of extended half-life 
through the pH dependant binding to FcRn, and averting degradation in endo-
lysosomal compartments (Beck and Reichert, 2014; Strohl, 2015). Furthermore, 
expression of the effector domain as an Fc-fusion also facilitates with protein or 
peptide stability, expression and label-free purification via protein A affinity 
chromatography (Stanislaus et al., 2017; Zwolak et al., 2017). Whilst FcRn mediated 
receptor recycling extends the half-life of Fc containing therapeutics, studies have 
demonstrated that FcRn expressed on BCEC primarily functions in the efflux of IgG 
from the CNS into the blood via a process of ‘reverse transcytosis’ (Cooper et al., 
2013; Deane et al., 2005; Schlachetzki et al., 2002). Nevertheless, the inclusion of 
an Fc-domain does confer an advantage for the transcytosis of macromolecules 
across the BBB. Haqqani et al. (2017) recently reported that the inclusion of an Fc 
domain to single domain antibodies results in a redistribution from late endosomes 
and lysosomes to early endosomes and multi-vesicular bodies, which increases 
transcytosis to the abluminal side of the BBB.  
In order to improve avidity and also determine the capability of the lead 
peptides (Pep1 and Pep8) to deliver a cargo into BCEC, the lead peptides were 
engineered as CPep/Fc-fusion domains. These domains were also expressed 
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coupled to IL1RA on the C-terminal CH3 region of the Fc domain (the rationale of 
which is discussed later on in this section). The overall structure of the CPep-
Fc/IL1RA molecule is shown in Figure 4.4.1. 
 
Figure 4.4.1: Schematic representation of CPep-Fc/Il1Ra structure. 
Figure depicting the engineered structure of CPep-Fc/IL1RA. The molecule consists of the peptide 
fused to the N-terminal hinge region of the Fc domain via a flexible (G4S)3 linker. IL1RA is fused to 
the C-terminal, CH3 region of the Fc domain. Image not to scale. Approximate size of molecule is 70 
kDa. 
 
A bEnd.3 cell internalisation time course ICC assay was carried out in order to 
assess the optimal cellular uptake time for lead peptides, Pep1 and Pep8, expressed 
as CPep-Fc/IL1RA domains, (Figure 4.3.7 and Figure 4.3.8). A stark difference in 
fluorescence was observed between Pep1 and Pep8. When expressed as an Fc-
IL1RA fusion domain, it appears Pep8 no longer maintains its potent activity as 
demonstrated by the disperse faint fluorescence observed throughout Pep8 time 
points and the lower normalised mean grey value readings as determined through 
quantification of images. Furthermore, none to very little specific internalisation can 
be seen within cells. The reason for this is unclear, since the specific binding of Pep8 
as a monovalent CPep-D1 fusion had already been successfully demonstrated 
towards bEnd.3 and hCMEC/D3 cells, (Figure 3.3.5, Figure 3.3.6, Figure 4.3.4, and 
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Figure 4.3.5). Additionally, Webster et al. (2017) have previously reported that the 
expression of monoclonal antibodies fused to IL1RA demonstrated no observable 
effect on binding activity of Fab domains.  
The variation in biological activity observed for Pep8 expressed as –g3p, –D1 
and –Fc fusion formats could be due to the inherent structure of Pep8, the way it 
interacts with the –Fc/IL1RA domain and the feasibility of expression within 
mammalian cells. Whilst mammalian expression systems generate proteins that are 
properly folded with post-translational modifications, the overexpression of these 
proteins within the mammalian cell can overwhelm protein folding mechanisms, 
leading to the production of misfolded or partially processed proteins which are 
prone to aggregation (Schröder et al., 2002). Strand et al. (2013) have previously 
studied the aggregation mechanisms of glycosylated Fc-fusion domains produced in 
CHO cells. The group utilised the high molecular weight species of activin receptor-
like kinase 1 Fc-fusion protein as a model for soluble aggregate formation, and 
highlighted the existence of two populations of aggregates. The majority of 
aggregates were found to be covalently linked via non-native intermolecular 
disulphide linkages, whilst the smaller population associated via non-covalent 
interactions. The group also demonstrated that secondary structure and glycan 
micro-heterogeneity of proteins differ according to the overall size of the aggregates. 
Another study has also suggested that Fc-fusion protein aggregates are formed 
through free thiol cross-linking at the peptide moiety of the fusion protein (Wei Wang 
and Roberts, 2010). 
Conversely to Pep8, Pep1 shows a linear increase in specific internalisation 
from 5 min to 30 min, saturating at 60 – 120 min time points as indicated through 
quantification of normalised mean grey value readings (Figure 4.3.9). At the 5 and 15 
min time points, internalisation appears to be primarily localised to outer regions of 
cells with few internalised vesicles visible. In contrast to the anti-mTfR 8D3 antibody 
control, Pep1 mediated uptake occurs at a slower rate. He et al. (2015) have 
previously studied the trafficking of TfR within an engineered CHO cell line 
expressing TfR-EGFP fusions. Through live cell ICC assessment, the group were 
able to study the time-dependant internalisation of a hTfR specific antibody. The 
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group highlighted the fast turnover of TfR through co-localisation of EGFP with 
EEA1, which was detected after 5 min and LAMP1 following 30 min. The results 
described herein show that the high binding affinity 8D3 antibody and the fast 
turnover of TfR lead to saturated internalisation in less than the minimum 5 min time 
point. In contrast to Pep1- and Pep8- Fc/IL1RA, no linear increase in internalisation 
was observed with the quantified 8D3 antibody mean grey values, (Figure 4.3.9). 
These results further highlight the low binding affinity of these peptides, which even 
when expressed as higher avidity bivalent fusion domains, retain a slow rate of cell 
uptake in contrast to antibodies. As previously described by Yu et al. (2011), the use 
of high affinity antibodies and therapeutic dosing strategies, detrimentally effects the 
fate of internalised vesicles by triggering the carriage transfer from late endosomes 
to acidic lysosomes, which results in protein degradation, and reduced transcellular 
transport. In this case, the observed reduced rate of internalisation of Pep1-Fc/IL1RA 
may be a favourable trait for transcellular delivery, however this would need to be 
explored further using BCEC cell transcytosis studies.  
In order to assess the capacity of Pep1-Fc/IL1RA molecules to internalise 
within hCMEC/D3 cells and examine their intracellular fate, an ICC internalisation 
and preliminary co-localisation study was carried out at 30 and 60 min time points, 
Figure 4.3.10. As observed with bEnd.3 cells, internalisation of Pep1-Fc/IL1RA was 
observed with both time points in hCMEC/D3 cells. However, no distinctive co-
localisation was observed with LAMP1 or EEA1. This initial finding is promising as it 
indicates that at these late time points in TfR trafficking cycle no distinct co-
localisation is visible between Pep1-FcIL1RA and lysosomes. However, imaging for 
this study was conducted using epifluorescence microscopy rather than confocal 
microscopy and this does not provide the relevant information on whether the two 
fluorescently labelled molecules of interest are co-localised or whether they overlap 
within the Z-dimension (Dunn et al., 2011). Further intracellular trafficking studies 
conducted via confocal microscopy are needed to determine the exact mechanism of 
uptake for Pep1-Fc/IL1RA.  
Our knowledge of intracellular trafficking is expanding at a rapid rate. Recent 
evidence has emerged to suggest that regardless of the entry and trafficking routes 
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taken by vesicles, exocytosis occurs via a dedicated cellular mechanisms which are 
mediated via several proteins including, Rab proteins (Rab27, Rab11 and Rab35), 
soluble NSF attachment protein (SNAP) and the transSNARE complex formed via 
interaction of vesicular SNAREs (e.g. synaptobrevin) and target SNAREs (e.g. 
syntaxin) (Biesemann et al., 2017; H H Wang et al., 2016; van Breevoort et al., 2014; 
Zhao et al., 2015; Q. M. Zhu et al., 2015; L. Yang et al., 2012; Naskar and Puri, 
2017). These function to translocate vesicles to within close proximity of the plasma 
membrane. Further categorisation of endosomal co-localisation and subcellular 
trafficking can be elucidated via the use of antibodies directed towards more specific 
markers of early endosomes (Rab5), late-endosomes (Rab 7), recycling endosomes 
(Rab 4 and 11) and transcytotic endosomes (Rab 27) (De Bock et al., 2016). 
Furthermore, labelling of CD133 would also confirm whether these peptides are 
being taken up through an additional non-specific macropinocytosis mechanism 
(Müller-Greven et al., 2017).  
The conjugation of IL1RA to Fc domain was carried out in anticipation of 
further work to demonstrate the capacity of the peptides to deliver a therapeutic 
cargo and elicit a detectable response in vivo. IL1 (a and β) are pro-inflammatory 
and regulatory cytokines that are involved regulating acute inflammatory responses, 
in a wide variety of cells by exerting their effects through binding to IL1 receptor 
(IL1R). Within the peripheral nervous system, these cytokines are involved in the 
induction and propagation of pain and as such have warranted drug targeting for the 
treatment of neuropathic pain, a condition that does not respond well to traditional 
analgesics (Webster et al., 2017). IL1RA (kineret) is a natural antagonist of IL1R and 
an anti-inflammatory regulator which has been shown to block the effects of the IL1 
in vitro and in vivo (Arend and Guthridge, 2000). 
A pilot study of in vivo CNS uptake was performed using a C57BL/6 mouse  
pre-clinical neuropathic pain model induced through partial sciatic nerve ligation, 
(Thom and Hatcher, 2016). The mouse model had been adapted from the original rat 
model reported by Seltzer et al. (1990), and its viability for use as a model for 
studying the uptake of biologics into the CNS has recently been validated by 
Webster et al. (2017). Partial nerve ligation (PNL) results in a neuropathic pain 
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phenotype, the extent of which is quantifiable through mechanical pressure at the 
ipsilateral paw (Malmberg and Basbaum, 1998).  
Results of the study are shown in Supplementary Figure S5. PNL of the 
sciatic nerve resulted in mechanical hyperalgesia which demonstrated a significant 
reduction in ipsilateral/contralateral (ipsi/contra) ratio on day 7 and 10, in comparison 
to the sham + PBS control. Operated mice treated with PBS did not show any 
variation in the level of mechanical hyperalgesia from pre-dose levels, suggesting no 
effect of the PBS control. Administration of Pep1- and Pep8-FcIL1RA resulted in a 
brief but statistically significant reversal in mechanical hyperalgesia that was only 
observable at 4 hours post dose, and rapidly diminished thereafter. The control 
CPep-Fc/IL1RA showed no significant effect. Further optimisation of the peptides for 
increased affinity may be necessary to improve their uptake and therapeutic delivery 
capability across the BBB. 
In conclusion, when expressed as soluble CPep-D1 fusion domains Pep1 and 
Pep8 were shown to bind specifically towards recombinant mouse and human TfR 
and also demonstrated statistically significant binding with both in vitro cell models of 
the BBB (bEnd3 and hCMEC/D3). Furthermore, Pep9 and Pep14 demonstrated 
weak affinity binding towards recombinant mouse and human TfR protein, in addition 
to bEnd.3 and hCMEC/D3 cells. When expressed as a peptide-Fc/IL1RA fusion 
domain, Pep1 and Pep8 were both shown to internalise within bEnd.3 and 
hCMEC/D3 cells. In contrast to an anti-mTfR antibody (8D3), uptake within bEnd.3 
cells were observed to occur at slower rate, saturating at the 60 and 120 min time 
points in contrast to 5 min observed with the antibody. When administered in a 
validated CNS uptake model of neuropathic pain, Pep1- and Pep8-Fc/IL1RA 
demonstrated significant short-term reversal of mechanical hyperalgesia, suggesting 
CNS uptake, (Thom and Hatcher, 2016). 
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5.1. Introduction  
Biologic based delivery molecules such as antibodies, peptides and 
engineered proteins have been extensively researched for use as delivery shuttles, 
via exploiting RMT at the BBB and these have shown some success in pre-clinical 
studies (Yu et al., 2014; Demeule, Currie, et al., 2008; Haqqani et al., 2017). Novel 
molecular delivery approaches diversify our capacity to access previously 
inaccessible targets, and are highly sought after within the context of targeting the 
BBB.  
Aptamers are an emerging class of targeting molecules, which consist of 
ssDNA or RNA and have several proposed advantages over traditional biologics (J. 
Zhou and Rossi, 2017). Much like antibodies, aptamers are capable of binding 
epitopes on targets with a high affinity and avidity, through the adoption of three-
dimensional hairpin-loop structures (Porciani et al., 2014). Target binding aptamers 
are identified from large combinatorial libraries through an in vitro selection 
technique, termed SELEX, which much like phage display, relies on the enrichment 
of target binding aptamers through iterative rounds of selection towards the target. 
Multiple adaptations to the traditional SELEX technique have been developed and 
utilised to select target binding aptamers (Stoltenburg et al., 2005; Soldevilla et al., 
2017; Duan et al., 2017; Renders et al., 2017). 
By far the most significant advantage for the use of aptamers as drug delivery 
shuttles across the BBB, is their low immunogenic potential. The toxicity concerns 
related to the use of anti-TfR and anti-IR antibodies have been highlighted (Couch et 
al., 2013; Ohshima-Hosoyama et al., 2012). Unlike, amino acid based biologics, 
aptamers have been shown to mostly avoid immunogenic response at clinically 
relevant concentrations (Drolet et al., 2000; Heiat et al., 2016). Furthermore, in 
contrast to protein based biologics, aptamers are chemically synthesised through a 
consistent and cost effective chemical synthesis process, which eliminates the safety 
implications of batch-to-batch variability (Lakhin et al., 2013). Moreover, the small 
size of aptamers (average 10 - 25 kDa) in contrast to MAb results in increased tissue 
penetration and accessibility of smaller epitopes (Catuogno et al., 2016). 
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Transferrin receptor is the most commonly researched target receptor for 
biologic drug delivery across the BBB via RMT (discussed in chapters 1 and 2), and 
its over expression on highly proliferating cells has also made it a desirable target for 
cancer therapies (Dai et al., 2014; T. Kang et al., 2015; Yue Zhang et al., 2017).  
The major body of current literature on TfR targeting using aptamers is 
derived from two parental aptamer sequences, GS24 ssDNA aptamer and the c2 
RNA aptamer (C.-H. B. Chen et al., 2008; Wilner et al., 2012). Subsequent studies 
have predominantly focused on the truncation and optimisation of the GS24 ssDNA 
aptamer (Porciani et al., 2014; Macdonald, Houghton, et al., 2016). Thus, novel 
aptamers that target TfR and mediate uptake into cells are needed. 
The overall aim of this study was to select DNA aptamers that specifically 
target human TfR, through a combinatorial approach towards recombinant protein 
and cell SELEX. DNA based aptamers were chosen for hTfR aptamer selections. 
DNA is significantly more stable than RNA, facilitating lab handling procedures and 
improving the potential therapeutic aptamer bioavailability when administered in vivo, 
without the requirement for chemical modifications. 
More specifically the study endeavoured to:  
- Characterise the optimal immobilisation capacity of Ni-NTA magnetic agarose 
beads for recombinant polyhistidine tagged human TfR.  
- Establish an aptamer SELEX protocol that utilises recombinant TfR material 
immobilised onto Ni-NTA magnetic agarose beads. 
- Conduct aptamer selections using a combined approach of recombinant hTfR 
and CHO-TRVb-1 cells overexpressing the hTfR (described in chapter 2). 
- Screen selected pools for enrichment and identify potential lead aptamer 
sequences through next generation sequencing (NGS). 
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5.2. Materials and Methods 
5.2.1. Western blotting 
Denaturing polyacrylamide gels and buffers were prepared as outlined in 
chapter 2, table 2.2.4. Carrier free, N-terminal polyhistidine tagged recombinant hTfR 
(2474-TR, R&D Systems, Oxon, UK) aliquoted in 1 μg, 2.5 μg, 5 μg and 10 μg 
amounts was re-suspended in a final volume of 500 μl of protein binding/ wash 
buffer (Table 5.2.1). Storage media was removed from 100 μl aliquots of 5% Nickel-
Nitrilotriacetic acid (Ni-NTA)-coated magnetic agarose bead suspensions (36111, 
Qiagen, Manchester, UK) by separating with a magnetic separator for 1 min and 
disposing the supernatant using a pipette. The beads were then washed twice in 
protein binding/ wash buffer, and re-suspended in the relevant 500 μl hTFR-His6 
protein solution. Beads were incubated with recombinant hTfR-His6 on a rotary 
mixer for 1 h at room temperature.  
 
Table 5.2.1 : Composition of buffers used for Ni-NTA Magnetic agarose bead aptamer 
selections.  
Buffer Composition 
Protein binding/ 
Wash buffer 
- 50 mM NaH2PO4 
- 300 mM NaCl 
- 20 mM imidazole 
- Corrected to pH 8.0 
Interaction 
buffer 
- 50 mM NaH2PO4 
- 50 mM NaCl  
- 20 mM imidazole 
- Corrected to pH 8.0 
Elution buffer - 50 mM NaH2PO4 
- 300 mM NaCl 
- 20 mM imidazole 
- Corrected to pH 8.0 
 
Following incubation, the beads were separated using a magnetic separator 
and the supernatant containing unbound material was isolated into a fresh 
Eppendorf tube and stored at 4°C. For each experimental tube, 500 μl of protein 
binding buffer was then added to immobilised beads and the volume was split into 
two aliquots of 250 μl. The first aliquot was used to assess protein loss and elution 
efficiency following one wash step, whilst the second aliquot was used to assess the 
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same criteria following three wash steps. This was accomplished by washing once or 
three times in wash buffer and eluting immobilised beads by re-suspension in 40 μl 
of SDS-PAGE sample buffer and heating to 95°C for 5 min. Similarly, 100 μl of SDS-
PAGE sample buffer was added to the unbound supernatant, and these were also 
heated to 95°C for 5 min. 
The remaining western blotting protocol was carried out as outlined in Chapter 
2, section 2.2.5, from the poly-acrylamide casting step onwards.  
5.2.2. ssDNA aptamer SELEX 
Aptamer selections were carried out using a N30 ssDNA library (TriLink 
Biotechnologies, California, USA). The library was supplied as a random 30 
nucleotide region, flanked by two primer binding sites, each 23 nucleotides in length 
(overall aptamer length 76bp). The ssDNA library, forward and reverse primer 
sequences used in the SELEX procedure are outlined below: 
- Trilink (n=30) ssDNA library: 5' TAG GGA AGA GAA GGA CAT ATG AT(N30) 
TTG ACT AGT ACA TGA CCA CTT GA 3' 
- Trilink (n=30) forward primer: 5’ TAG GGA AGA GAA GGA CAT ATG AT 3’ 
- Trilink (n=30) reverse primer: 5’ TCA AGT GGT CAT GTA CTA GTC AA 3' 
Two aptamer selection protocols were carried out in a combinational 
approach for the selection of receptor specific aptamers. Selections were primarily 
conducted towards hTFR-His6 (2474-TR, R&D Systems, Oxon, UK) for a total of 12 
rounds. However, at round 5 a functional cell selection round was introduced 
towards CHO-TRVb-1 cells overexpressing human TfR in the absence of 
endogenous hamster TfR (described in chapter 2).  
Recombinant protein SELEX was performed using hTfR-His6 immobilised 
onto Ni-NTA-coated magnetic agarose beads (Qiagen, Manchester, UK). The 
procedure described for recombinant protein selections was a modification of the 
original “Flu-Mag SELEX” magnetic bead based aptamer selection protocol outlined 
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by Stolenburg et al. (2005). The cell selection round towards CHO-TRVb-1 cells was 
carried out according to the cell SELEX protocol outlined by Sefah et al. (2010).  
5.2.2.1. Recombinant hTfR aptamer SELEX 
The procedure used for recombinant protein SELEX is outlined in Figure 
5.2.1. Ni-NTA washing/ binding, interaction and elution buffers were prepared as 
suggested within the QIAGEN Ni-NTA magnetic agarose beads handbook (QIAGEN, 
2001), (outlined in Table 5.2.1). Prepared buffers were autoclaved and stored at 4˚C. 
Prior to incubation, 10 nmoles of the lyophilised ssDNA library was re-constituted in 
370 μl of binding buffer. The re-suspended library was then heated to 95˚C and 
cooled on ice to encourage ssDNA folding and the formation of secondary structures 
(Sefah et al., 2010).  
For each selection round, the relevant volume of Ni-NTA magnetic agarose 
bead slurry was transferred into a clean Eppendorf tube (outlined in Table 5.2.1), the 
storage buffer was removed and the beads were washed in washing buffer. Pre-
washed beads were subsequently immobilised by incubating with 5 μg of hTfR-His6 
on a rotary shaker for 1 h at room temperature.  
A de-selection step was employed at the start of each round using the pre-
folded library stock (round 1) or pre-folded, and reconstituted aptamer pool 
(subsequent rounds), incubated with non-immobilised Ni-NTA magnetic agarose 
beads. This was achieved by incubating the ssDNA pool with 100 μl of pre-washed 
beads in binding buffer for 1 h on a rotary shaker at room temperature. The beads 
were then pulled down using a magnetic separator and the non-bound supernatant 
was transferred onto pre-washed and target hTfR-His6 immobilised beads. The 
immobilised beads and de-selected library were incubated at room temperature for 
the relevant incubation times shown in Table 5.2.2.  
Following incubation, the beads were pulled down with a magnetic separator, 
the unbound ssDNA pool was transferred into a clean Eppendorf tube and stored at -
20°C. The beads were subsequently washed in washing buffer with increasing wash 
volumes and number of wash steps as the selection progressed (outlined in Table 
5.2.1). Bound aptamers were sequentially eluted in five 100 μl volumes of elution 
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buffer (Table 5.2.1) for the first round, and three 100 μl volumes for subsequent 
rounds. At round 5 onwards multiple selections were simultaneously carried out in 
order to achieve appropriate yields of ssDNA for selection progression. 
 
 
Figure 5.2.1: Schematic representation of DNA aptamer selection using recombinant protein 
immobilised on Ni-NTA coated magnetic agarose beads. 
1. The chemically synthesised random oligonucleotide library is incubated with Ni-NTA magnetic 
agarose beads immobilized with polyhistidine tagged recombinant protein. 2. Magnetic beads are 
separated and unbound sequences are removed with the supernatant. Wash steps are performed in 
washing buffer and remnant unbound and poorly bound sequences are removed. 3. Binding 
sequences are detached and collected from protein-bound beads in elution buffer. 4. Amplification 
steps are carried out to amplify the bound sequences within the selected pool. A biotin tag is 
incorporated to the 3’ end of the non-template strand via a specific biotinylated primer 5. The non-
biotinylated strand is separated from the template strand via alkaline denaturation and affinity 
purification methods, utilising streptavidin-coated beads. 6. The enriched and purified pool is 
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utilised in the following round of selection and the cycle is repeated. 7. Following 6 – 15 rounds, the 
selected pool is sequenced to identify the exact nucleotide base sequences for selected aptamers. 
 
Table 5.2.2: Table showing an overview of selection conditions for recombinant hTfR-His6 
SELEX. 
 
 
 
 
 
 
 
 
 
 
 
5.2.2.2. CHO-TRVB-1 cell SELEX 
Cell SELEX washing and binding buffers were prepared as follows: 
o Washing buffer: 4.5 g of glucose and 5 ml of 1M MgCl2 were added to 
1 L of DPBS (Sigma-Aldrich, Dorset, UK).  
o Binding buffer: 4.5 g of glucose, 100 mg of baker’s yeast tRNA 
(Sigma-Aldrich, Dorset, UK), 1 g BSA (Sigma-Aldrich, Dorset, UK), and 
5 ml of 1 M MgCl2 were all added to 1 L of DPBS. 
Target TRVb-1 CHO cells were cultured to confluence according to the cell 
culture protocol outlined in chapter 2, section 2.2.3. Adherent cells were dissociated 
via a short-term trypsin treatment (2 min), the action of trypsin was inhibited using 
culture media. Following cell detachment and counting, cells were washed and 1 x 
107 cells were isolated for cell selection. The isolated cells were washed twice in 3 
Selection 
Round Target 
Ni-NTA 
Bead 
slurry 
Incubation 
time 
(minutes) 
Wash 
volume 
(μl) 
Wash 
steps 
1 hTfR-His6 100 60 500 3 
2 hTfR-His6 100 60 500 3 
3 hTfR-His6 100 60 500 3 
4 hTfR-His6 100 60 500 3 
5 CHO-TRVb-1 cells N/A 60 500 3 
6 hTfR-His6 85 60 500 4 
7 hTfR-His6 70 50 500 4 
8 hTfR-His6 55 40 750 5 
9 hTfR-His6 40 30 750 5 
10 hTfR-His6 40 30 900 5 
11 hTfR-His6 40 30 900 5 
12 hTfR-His6 40 30 900 5 
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ml of washing buffer and re-suspended in 330 μl of binding buffer. The purified and 
desiccated ssDNA pool from round 4 was re-suspended in binding buffer at a 
concentration of 1000 nM, added to the cell suspension, and incubated on a rotary 
shaker at 4 ˚C for 1 h. 
Post incubation, cells were centrifuged at 150 g for 3 min at 4˚C; the 
supernatant containing unbound ssDNA sequences was then carefully collected and 
stored at -20˚C. The remaining cell pellet was carefully washed three times in 3 ml of 
washing buffer and elution of bound aptamers was accomplished by re-suspending 
the cell pellet in 500 μl of DNase free water, heating to 95˚C for 10 min, and 
centrifuging the suspension at 13,100 g for 5 min. Cell membrane bound and 
internalised aptamers were isolated by carefully collecting the supernatant. 
5.2.3. PCR amplification of selected aptamer pool outputs 
5.2.3.1. Initial PCR amplification of Round 1 selected pool 
Following the first round of selection, the entire first round selected pool was 
used as a template for a 1000 μl PCR reaction mixture. A master mix was prepared 
as outlined in Table 5.2.3. The purpose of this initial amplification was to increase the 
frequency of bound ssDNA sequences for the preparative PCR amplification step to 
follow.   
Table 5.2.3: Initial PCR amplification of entire first round selected pool. 
PCR reaction component Reaction Mixture 
Volume (μl) 
DNase free water 290 
MyTaq 5x PCR reaction buffer (Bioline, UK) – 
Containing dNTPs and MgCl2 
200 
Forward/ Reverse Primer Mix (100 μM) 10 
MyTaq Hot start DNA polymerase (5 units /μl) 3 
Template ssDNA – Round 1 selected pool 500 
 
The total reaction mixture was separated into 20 x 50 μl aliquots in PCR 
reaction tubes. Amplification was carried out using a Bio-Rad icycler PCR machine, 
(Bio-Rad, Hertfordshire, UK). PCR reaction conditions used are outlined in Table 
5.2.4. 
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Table 5.2.4: PCR amplification programme reaction conditions. 
Step Temperature (°C) Time (s) 
Hot start 95 150 
Amplification - 10 cycles for first round or optimised cycle 
number for later rounds 
     Denaturation 95 30 
     Annealing  49 30 
     Extension 72 30 
Final extension 72 180 
Hold 4 ¥ 
 
The melting temperature of the primer pair was calculated using 
OligoAnalyzer 3.1 software (Integrated DNA technologies, Leuven, Belgium). Initial 
amplification of the first round selected pool was performed for 10 cycles to minimise 
the formation of non-specific amplicons. Following amplification, all reaction mixtures 
were pooled. 
5.2.3.2. Optimisation PCR 
A 250 μl reaction master mix was prepared alongside a negative control as 
outlined in Table 5.2.5. The reaction mix was split into 5 x 50 μl aliquots in PCR 
reaction tubes. Reaction tubes were removed incrementally at cycle number ranges 
determined from the previously selected optimal cycle number for amplification. For 
amplification of round one selected pool, 4, 6, 8, 10, 12 cycles were used. In later 
rounds, cycle numbers in the range of 12 – 22 cycles were used. The negative 
control tube was amplified for the maximum number of cycles carried out for the 
optimisation PCR. For cell selection rounds, 5 μl supernatant of cell lysate was 
included within the amplification negative control. 
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Table 5.2.5: Optimisation PCR reaction setup. 
Reagents Reaction mixture volume (μl) Control (μl) 
MyTaq 5x reaction buffer (Bioline, UK) – containing 
dNTPs and MgCL2 
25 5 
Forward/ Reverse Primer mix (10 μM) 25 5 
DNase-free water 166.75 35 
Template DNA – Amplified selected pool (10% of 
reaction volume) 
25 - 
MyTaq Hot start DNA polymerase (5 units/ μl) 0.75 0.15 
 
PCR products were separated on a 3% agarose gel containing 2.5 μg 
ethidium bromide. 10 μl aliquots of each PCR amplification product was mixed with 2 
μl of 6x loading dye (Promega, Southampton, UK) and loaded on the gel alongside a 
25 bp DNA ladder (Promega, Southampton, UK). Agarose gel electrophoresis was 
performed in 1x TAE buffer at 100 V for 45 min. Visualisation of gels was carried out 
on a gel doc G:Box system (Syngene, Cambridge, UK). The optimal cycle number 
for the preparative PCR was determined as the brightest single observable band, 
lacking non-specific amplification bands. 
5.2.3.3. Preparative PCR 
Large scale amplification was carried out using an unmodified forward primer 
in conjunction with a biotinylated reverse primer to allow affinity capture, separation 
and purification of the single stranded complementary DNA identical to the original 
aptamer strand. A 1000 μl reaction mix was prepared as outlined in Table 5.2.6, with 
the selected aptamer pool serving as 10% of the reaction mix. The reaction was then 
distributed into 10 x 100 μl aliquots in PCR tubes and pooled following amplification. 
A 10 μl aliquot was run on a 3% agarose gel to verify efficient amplification. 
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Table 5.2.6: Preparative PCR amplification reaction setup. 
Reagents 
Reaction 
mixture 
volume (μl) 
MyTaq™ 5x PCR reaction buffer (Bioline™, UK) – Containing 
dNTPs and MgCl2 
200 
Forward primer (100µM) 5 
Biotinylated Reverse primer (100µM) 5 
Template DNA - Amplified Round 1 selected pool (10% of 
reaction mixture) 100 
DNase-free water 690 
MyTaq™ Hot start DNA polymerase 3 
 
5.2.4. Purification of ssDNA from PCR product 
 Separation and isolation of the non-biotinylated strand from the dsDNA PCR 
product was performed using alkaline denaturation and affinity purification 
techniques. DNA synthesis columns (Glen-Research, Virginia, USA) were prepared 
by inserting a filter into the lower end of the column. A plunger from a 10 ml syringe 
was removed, and the empty syringe was inserted into the top of the column. 200 μl 
of streptavidin sepharose bead suspension (GE Healthcare Life Sciences, Little 
Chalfont, UK) was loaded into the syringe. The plunger was then gradually inserted 
to allow the storage buffer to drain out of the filter. Between each draining step, the 
DNA synthesis column was disconnected prior to removal of the syringe plunger. 
The beads were subsequently washed using 2.5 ml of Dulbecco’s PBS (DPBS) and 
the round 1 preparative PCR product was run through the column three times. The 
beads were washed again in 2.5 ml of DPBS, prior to elution of the non-biotinylated 
strand using 500 μl of 200 mM NaOH solution. The eluate was gradually collected in 
a clean Eppendorf tube. 
5.2.5. Desalting, quantification and lyophilisation of purified ssDNA  
 Desalting was performed using Illustra NAP5 columns containing G25 
Sephadex (GE Healthcare Life Science, Little Chalfont, UK). The NAP5 column was 
completely drained of storage buffer and then the column was equilibrated using a 
minimum of 15 ml of nuclease free water, in 3 ml volumes. 500 μl of eluted ssDNA 
was then added to the column and allowed to drain into the gel completely. The 
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purified and desalted ssDNA pool was then eluted off the NAP5 column into a clean 
Eppendorf tube using 1 ml of DNase free water. The concentration of purified ssDNA 
was determined at a UV absorbance of 260 nm, on a nanodrop spectrophotometer 
(ThermoFisher Scientific, Paisley, UK). Following quantification, the aqueous sample 
was vacuum desiccated at 60°C in an Eppendorf concentrator plus (Eppendorf, 
Stevenage, UK) for 6 h. The lyophilised ssDNA pool was re-constituted at a 
concentration of 200 nM for subsequent selection rounds. 
5.2.6. Next-generation sequencing of aptamer selected pools 
5.2.6.1. DNA pool preparation for Illumina MiSeq sequencing 
The round 5 cell selected, round 6, 7, 9, 10, and 12 hTfR-His6 selected, and 
the round 1 unbound pool (negative control), were all amplified by carrying out 
preparative PCR amplification steps (as outlined in section 5.2.3.3) using unmodified 
n30 Trilink library amplification forward and reverse primers, (outlined in section 
5.2.2). Following preparative PCR amplification, the dsDNA products were 
lyophilised using an Eppendorf concentrator plus (Eppendorf, Stevenage, UK) and 
re-constituted in 65 μl of DNase free water. A 10 μl aliquot was taken for validation 
on a pre-cast 4% Hi-ReSolution agarose E-gel (G501804, ThermoFisher Scientific, 
Paisley, UK). Purification of dsDNA product was carried out using a nucleotide 
removal kit, according to the manufacturer protocol. Elution from the purification 
column was carried out in 60 μl of DNA free water. Quantification of purified samples 
was carried out using a Qubit 3.0 Fluorimeter (ThermoFisher Scientific, Paisley, UK) 
and a Qubit dsDNA High Sensitivity assay kit (Q32851, ThermoFisher Scientific, 
Paisley, UK).  
5.2.6.2. Enrichment analysis of NGS sequencing Data 
A sequence count analysis was performed by Colin Hardman (MedImmune, 
Cambridge, UK). Paired reads were assembled using PandaSeq (Masella et al., 
2012). Viable assembled reads were then aligned according to the forward and 
reverse primer binding regions as outlined below: 
AGGGAAGAGAAGGACATATGAT ({30}) TTGACTAGTACATGACCACTTGA 
The random regions were then clustered according to uniqueness. 
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5.3. Results 
5.3.1. Assaying recombinant hTfR immobilisation onto Ni-NTA agarose beads. 
An immunoblot was carried out to validate the size of the recombinant 
polyhistidine tagged hTfR (R&D Systems, Oxon, UK), and also to assess the optimal 
binding capacity and immobilisation integrity of Ni-NTA magnetic agarose beads to 
be used as bait in subsequent SELEX protocols. This was performed by incubating 
100 μl of bead slurry with varying amounts of recombinant hTfR (1 μg, 10 μg, 2.5 μg 
and 5 μg). 
Results of the 1 μg and 10 μg immobilisation study are shown in A and B, 
respectively. No protein was observed in the supernatant of the 1 μg incubation 
following magnetic separation (Figure 5.3.1, A, lane 4). However, in contrast to the 1 
μg incubation, the 10 μg incubation presented a significant quantity of unbound 
protein within the supernatant (Figure 5.3.1, A, lane 7).  
The beads were washed once and three times in order to assess the loss of 
bead-bound recombinant hTfR. Remaining bound protein was eluted off the beads 
and quantified. For the 1 μg sample a faint band was observed bound to the Ni-NTA 
agarose beads following one wash step and elution (Figure 5.3.1, A, lane 2). A 
fainter band was observed with three washing steps, suggesting greater loss of 
recombinant protein had occurred with three wash steps in contrast to one wash 
step. (Figure 5.3.1, A, lane 3). Incubation, subsequent washing and elution of beads 
with 10 µg of recombinant TfR produced two intense bands of similar thickness. This 
finding suggests a large proportion of protein remained bound to the beads after 
washing steps and were successfully isolated following elution. Observable bands 
appeared at the correct expected length of 85 kDa. 
A follow up experiment was performed using 2.5 μg and 5 μg of recombinant 
TfR to determine a quantity of protein that exhibited optimal saturation of beads with 
minimal protein wastage (Figure 5.3.1, B). During this experiment Eppendorf protein 
Lo-bind (Eppendorf, Stevenage, UK) tubes were used in an attempt to reduce bead 
to tube adhesion. At 2.5 μg some protein remained unbound within the supernatant 
(Figure 5.3.1, B, lane 1), This observation was more notable with 5 μg of supernatant 
Selection of hTfR binding DNA aptamers for use as alternative BBB shuttles. 
 183 
(Figure 5.3.1, B, lane 2). Following one and three wash steps, the 2.5 μg eluted 
samples showed no visible variation in hTfR recovery. However, observable bands 
were faint indicating a small quantity of protein had been eluted from the beads 
(Figure 5.3.1, B, lanes 3 and 4). Likewise, at 5 μg little to no protein loss was 
observed with three wash steps in contrast to one wash step (Figure 5.3.1, B, lanes 
5 and 6). However, significantly more protein was eluted from the beads, when 
compared with the 2.5 μg eluted samples. Overall, 5 μg gave the most efficient 
levels of recovery of eluted hTfR, without excessive protein loss. 
hTfR-His6 was validated at the correct size of 76 kDa. Interestingly, the 10 μg 
sample wash and supernatant also contained a faint secondary band at a size of 
approximately 150 kDa, indicating the presence of TfR in the dimeric form.  
Figure 5.3.1: Assessing immobilisation of recombinant hTfR to Ni-NTA magnetic agarose 
beads. 
Immunoblot assessment of hTfR was performed by incubating (A) 1 μg, 10 μg or (B) 2.5 μg and 5 μg 
of recombinant hTfR with 100 μl of bead slurry. Unbound protein was measured in supernatant. Loss 
of protein with one and three protocol wash steps was also assessed by eluting beads following 
relevant wash steps. Recombinant hTFR-His6 was observed at the expected size of the soluble hTFR 
monomer (76 kDa). Bands were also noted at a size equivalent to the dimeric form (152 kDa) with 
the 10 μg samples. Due to an error in technical handling of the membrane, secondary exposure 
bands are visible in lanes 6 and 7. 
  
85 kDa 
85 kDa 
150 kDa 
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5.3.2. Adapted SELEX protocol for the selection of hTfR binding ssDNA aptamers 
immobilised on Ni-NTA beads. 
Optimisation PCRs were performed in order to determine the optimal PCR 
amplification cycle numbers to carry out for large scale preparative amplifications of 
the selected ssDNA pool, without over-amplification or the formation of non-specific 
amplification products. The amplified preparative pool would then be purified and 
used for the successive SELEX round. 
Optimisation PCR gel electrophoresis results are shown in Figure 5.3.2. The 
determined optimal cycle number used for preparative PCR amplifications is 
highlighted in blue. Throughout the selection a primary band representing the n30 
library can be seen at the expected size of 76 base pairs (bp). Initial amplification of 
the round 1 selected pool only required 6 cycles to produce a clean single visible 
band on agarose gels. However, for rounds two and three the number of cycles 
required was increased to 14 cycles. From round four onwards, the number of cycles 
required to amplify a clean PCR product fluctuated between 18 and 22 cycles.  
An observable non-specific secondary band can be seen at round 11 on the 
optimisation PCR gel at a size of 50 bp. Although the presence of this band could not 
be detected on agarose gel runs of the preparative PCR amplified product, the non-
specific band prevented further progression of the selection past selection round 12, 
where its presence was as prevalent as the primary PCR product in all optimisation 
PCR cycles (results not shown). 
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Figure 5.3.2: Optimisation PCR amplification results. 
Figure showing optimisation PCR gel electrophoresis runs for each round of selection. The 
amplification cycle numbers used are shown in each lane. The red line indicates the position of the 
75 bp marker on the 25 bp incremental marker DNA ladder. The optimal cycle number determined 
for each round is highlighted in blue. 
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5.3.3. Enrichment observed following 12 rounds of SELEX 
Following 12 rounds of ssDNA aptamer SELEX, high throughput sequencing 
(HTS) in the form of Illumina Miseq sequencing, was carried out to assess the pools 
for overall enrichment. The sequencing output results would also be used for 
subsequent screening and identification of conserved aptamer sequences that have 
been enriched throughout the selection process. A summary of the count analysis 
conducted on NGS data is shown in Figure 5.3.3. In total, out of 13 million reads, 
approximately 9.6 million reads could be aligned and sorted according to the forward 
and reverse primer binding sites. This equates to 74% of total reads.  
As expected, the R0 unbound library control showed complete diversity, with 
all sorted sequences being represented once as indicated by the total number of 
unique sequences within that pool (Figure 5.3.3, A and B). As the selection 
progresses from round 0 onwards, the number of unique sequences and therefore 
diversity of the selected pools is gradually reduced up until round 9. From round 9 to 
round 10 a 30% reduction in the diversity of the selected pool was observed. A 
reduction of approximately 15% was also noted from round 10 to round 12. Overall, 
a 62% reduction in pool diversity was observed between round 0 and round 12. 
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Figure 5.3.3: Summary of NGS count analysis as an overall assessment of aptamer 
enrichment. 
Figure showing a summary of the count analysis conducted using NGS data. (A) For each of the 
sequenced selection rounds, the number of raw sequences (blue), the number of primer aligned 
sequences (orange) and the number of unique sequences within the n30 random region (grey) are 
shown. A unique sequence in this case is defined as a sequence that differs from another by at least 
one nucleotide. (B) Figure showing the percentage diversity presented as a ratio of primer aligned to 
unique sequences. Significant enrichment is observed at round 10, with further enrichment 
observed at round 12. 
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5.4. Discussion 
5.4.1. hTfR-His6 efficiently immobilised to Ni-NTA magnetic agarose beads  
Validation of hTfR-His6 on an SDS-PAGE gel revealed a band at the correct 
size of the hTfR extracellular domain (76 kDa). Moreover, at 10 μM concentration, 
some of this material was also observed in the dimeric form (152 kDa). The 
extracellular domain of TfR has previously been identified to be natively present in a 
soluble form that arises through trypsin proteolytic cleavage of the TfR stem region. 
This extracellular domain has been shown to maintain the dimeric globular structure 
and functionality of transferrin binding, via the spontaneous dimerisation of 
monomeric helical domains (Aisen, 2004; Mason et al., 2009).  
Ni-NTA magnetic agarose beads were assessed for their ability to immobilise 
hTfR-His6. Additionally, the capacity of these beads to maintain hTfR-His6 with 
multiple wash steps was also assessed (Figure 5.3.1). Results show that the beads 
were capable of effectively capturing recombinant hTfR-His6. Optimal binding was 
determined at 5 μg of hTfR-His6, since immobilised beads showed equal amounts of 
protein following elution after one or three wash steps, with minimal recombinant 
protein usage in the process.  
Binding of the polyhistidine tag occurs to a Ni-NTA chelated atom, with an 
affinity of KD = 10-6 M (Nieba et al., 1997). Although immobilisation via streptavidin 
and biotin interaction would allow the target protein to remain bound to the beads 
with a stronger affinity interaction (KD = 10-14 M), it also makes elution of target 
aptamers together with their bound interaction partners (in this case, hTFR-His6) 
impossible without the use of denaturing conditions (A. Holmberg et al., 2005). 
Furthermore, due to the size of biotin, and the biotin labelling process, there is 
potential to block epitopes on the target protein, thus limiting the availability of 
accessible epitopes for aptamer interaction (Murphy et al., 2003). His-tag 
immobilisation to beads also allows the homogenous native (n-terminal) orientation 
of TfR protein on the surface of magnetic agarose beads for selections. 
A key component of aptamer selection relies on the efficient separation and 
purification of the relevant strand from the complementary strand. The use of Ni-NTA 
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for the immobilisation of target protein in this case also allows the subsequent 
utilisation of streptavidin as an affinity capture matrix during separation and 
purification stages of SELEX, as carried out for this study. 
A similar approach to aptamer SELEX and ssDNA purification had previously 
been described for the successful selection of high affinity thyroid transcription factor 
(TTF) specific aptamers (Murphy et al., 2003). In support of the practicality of this 
SELEX approach, several other aptamer SELEX studies have also described the 
use of the polyhistidine tag in order to effectively immobilise and select target 
specific aptamers (Wilner et al., 2012; Tanaka et al., 2009; Barfod et al., 2009). 
5.4.2. Analysis of PCR amplification steps 
Aptamer selection by the various forms of SELEX is liable to failure due to 
several inherent issues including, the retention of non-target specific aptamers due 
to inefficient pool partitioning methods, interaction of the primer binding sites with the 
random region of the library leading to by-product amplification, and the enrichment 
of non-target specific aptamers towards affinity capture matrix (Tolle et al., 2014; 
Ouellet et al., 2015). The failure of aptamer SELEX via these factors results from an 
increased number of rounds required for enrichment of target specific aptamers or 
the complete takeover of the amplified pool with non-specific by-products. 
In total, 12 rounds of aptamer SELEX were carried out. The summary of the 
PCR amplification steps and relevant cycle numbers used for preparative PCR are 
shown in Figure 5.3.2. At round 11 the presence of truncated secondary band 50 bp 
in size was observed. This band indicates the presence of a non-specific 
amplification product. The formation of aptamer amplification by-products is a well-
established phenomenon that interferes with aptamer enrichment and reduces library 
specific amplification (Ouellet et al., 2015). Tolle et al. (2014) have previously 
examined the process of by-product formation during the amplification stages of 
aptamer SELEX. The group reported two distinct forms of amplification by-products, 
termed ladder and non-ladder, and proposed a mechanism by which these by-
products were formed. The ladder class of by-products result from the annealing of 
the 3’ end fixed region of one strand to a complementary sequence within the 
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random region of another strand. This annealing and amplification process results in 
a double reverse primer PCR product that can subsequently be further amplified to 
form copies with multiple reverse primer binding sites. The non-ladder class of by-
products occurs when there is incomplete annealing of the reverse primer to the 
random region, which results in a gap that prevents further re-annealing and the 
production of a slightly larger, single sized PCR product. 
Both these types of by-products describe larger amplicons which were not 
observed within our optimisation and preparative PCR stages. The smaller 
amplification product observed within the round 11 pool may instead be due to 
primer-primer hybridisation, a major cause of by-product formation within 
conventional PCR methods (Tolle et al., 2014). Furthermore, calculated annealing 
temperature for the library amplification primers was low (49°C). Although a low 
primer melting temperature has been demonstrated to significantly reduce 
preferential PCR amplification biases (Sipos et al., 2007), it has also been well 
established to increase non-specific annealing of primers to non-target sequences 
and can lead to a reduction in the yields of the desired product. The low annealing 
temperature of the primers could have also contributed to the formation of non-
specific amplification by-products observed with the round 11 PCR step.  
The presence of this by-product prevented further progression past round 12, 
during which, there was a clear amplification of the two visible bands at equal band 
intensities (result not shown). Re-selection attempts were carried out starting from 
the round 9 selection output pool, with increased selection stringency (via increased 
wash steps and volumes). However, the same amplification by-products re-emerged 
by round 12.  
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5.4.3. Significant enrichment observed following 12 rounds of hTfR SELEX 
Although NGS was initially developed for whole genome sequencing its use 
has been expanded to many other research areas, including the screening of ligands 
following library selections carried out via phage display and SELEX (Blind and 
Blank, 2015). Screening via HTS is highly advantageous in this respect, as it has 
previously been shown to allow the identification of low abundance, target binding 
aptamers (<1%) in fewer selection rounds, whilst also allowing a highly 
representative, in depth analysis of sequenced aptamer pools (Nguyen Quang et al., 
2016). Furthermore, it also allows the tracking of aptamer species and conserved 
motifs with selection progression (Alam et al., 2015). 
The results of the NGS of hTfR selected pools demonstrate an overall 62% 
reduction in sequence diversity between the unselected pool and round 12. Although 
a significant amount of enrichment was observed, further rounds could still be carried 
out in order to further enrich the pool for aptamers with the strongest binding affinity 
towards hTfR. The level of enrichment observed with the current hTfR selection 
protocol correlates with other studies that have required on average, between 6 – 15 
rounds for enrichment. Studies have previously highlighted the selection of TfR 
specific aptamers using traditional SELEX approaches in as few as 5 to 9 rounds 
(C.-H. B. Chen et al., 2008; Wilner et al., 2012). The current study required more 
rounds to achieve enrichment, and this may have been due to several factors 
including selection stringency, which has been shown to play a significant role in the 
number of rounds required to achieve high levels of enrichment (K. M. Ahmad et al., 
2011). 
Using a similar SELEX approach to the one described here, Murphy et al. 
(2003) demonstrated the identification of high affinity aptamers towards TTP 
following 15 rounds of selection. The binding affinities of these aptamers was 
characterised and shown to be within the low nanomolar range (10-8 to 10-9). 
However, the advantage of screening earlier rounds is that this allows the 
identification of lower to moderate affinity aptamer variants which are highly sought 
after for the purpose of identifying aptamer species capable of translocating the BBB 
via RMT. Macdonald et al. (2016) have demonstrated that TfR binding aptamers with 
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a moderate affinity of approximately 500 nM exhibited the greatest degree of 
internalisation within bEnd.3 cells. Similarly, optimised antibody based BBB delivery 
molecules which also appear to have moderate binding affinities have been 
described, and these were reported as 111 ± 16 nM (Yu et al., 2011) and 130 nM 
(Webster et al., 2017). From these findings, it appears the optimal affinity for TfR 
mediated biologic targeting of RMT occurs within the range of 100 – 500 nM. 
However, this is also likely dependant on the targeted epitope and its effect on 
overall fate of transcellular trafficking within BCEC.  
Current aptamer TfR targeting approaches have focused on the rational 
design or use of pre-existing aptamers that have specificity towards either mTfR 
(GS24 ssDNA aptamer and its variants) or hTfR (c2 RNA aptamer) independently. 
As discussed in chapter 3, there is a significant requirement in the area of biologic 
therapeutics to produce species cross-reactive molecular recognition domains, that 
are capable of recognising molecules on multiple species homologues for 
translatability of pre-clinical to clinical studies and improved biologic safety and 
efficacy rate (Irani et al., 2016). Further work into identifying novel TfR species cross-
reactive aptamers is needed. 
In conclusion, this study has highlighted the enrichment of a heterogeneous 
pool of aptamers, that have been preferentially selected towards recombinant target 
hTfR protein and hTfR overexpressed on CHO-TRVb1 cells. Through the use of high 
throughput sequencing, it was possible to establish the extent of enrichment with 
selection progression from round 0 to round 12. 
Aptamers are proving to be promising alternatives to antibodies for many 
applications including drug delivery. However, they have yet to become as 
established as antibodies, partly due to a lack of awareness and commercial 
backing. Further research into the pharmacokinetic, pharmacodynamic and safety 
profiles of aptamer-based therapies is required in vivo to meet the increased demand 
for delivery of DNA and RNA based therapies such as siRNAs and miRNAs. 
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Through the course of this thesis, we have explored the use of phage display 
and SELEX for the selection of TfR binding cyclic peptides and aptamers, 
respectively. Specifically, we aimed to utilise the selected domains as the targeting 
moiety for a generalised drug delivery system, capable of transporting a conjugated 
macromolecular therapeutic cargo e.g. protein, miRNA, siRNA or drug carriers (gold 
nanoparticles and liposomes) across the BBB into the CNS. To achieve this goal, 
endogenous receptors that are localised on the cell surface of BCEC and function in 
transcellular transport were exploited. 
6.1. Assessment of receptor targets that function via RMT at the BBB 
It was necessary to identify a suitable receptor candidate for exploiting the 
mechanism of RMT prior to conducting selections of binding domains, therefore 
chapter two focused on the characterisation of three receptor candidates; TfR, LDLR 
and LRP1, which were selected based on the criteria that they transport their natural 
ligands across the BBB via RMT. Although, these receptor candidates are not 
exclusively expressed by BCEC and by definition are not target specific in nature, 
they have been successfully targeted for the delivery of therapeutic cargos across 
the BBB (Yu et al., 2014; Hultqvist et al., 2017; Demeule, Currie, et al., 2008; Zensi, 
Begley, Pontikis, Legros, Mihoreanu, Wagner, Büchel, Briesen, and Kreuter, 2009b). 
Three principle research aims needed to be addressed within this chapter; are 
the receptor candidates expressed on the surface of the hCMEC/D3 cell line? If so, 
to what extent is their expression stable with long-term culture? Does the proteolytic 
detachment of cells impact the expression of TfR? 
Cell surface protein expression of TfR, LDLR and LRP1 was demonstrated on 
hCMEC/D3 cells and the suitability of these receptors as potential targets for RMT 
mediated drug delivery across the BBB was assessed. Concurrent with the literature 
we found that all three receptors were expressed on hCMEC/D3 cells (Ohtsuki et al., 
2013; Pinzón-Daza et al., 2012). TfR was found to exhibit the most stable levels of 
expression with long-term in vitro culture. In contrast to TfR expression, LDLR and 
LRP1 expressions appeared to vary significantly with long-term culture. Additionally, 
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although TfR has been shown to have a functional trypsin cleavage site at arginine 
100 within the stem region of its extracellular domain and is bio-available in a soluble 
form within the circulation, use of trypsin/ EDTA as a short-term cell detachment 
solution did not appear to affect the cell surface expression of TfR on hCMEC/D3 
cells. Considering our findings, in conjunction with previous studies that have shown 
the expression of TfR to be amongst the most highly expressed membrane receptors 
on BCEC both in vitro and in vivo, together with the observed fast endocytotic 
turnover of TfR (He et al., 2015), we decided to pursue TfR as our receptor 
candidate of interest (He et al., 2015; Ohtsuki et al., 2013; W. M. Yang et al., 2011). 
Within chapter two, we had also set out to evaluate the hTfR protein 
expression of two CHO-transcript variant cell lines, CHO-TRVb (TfR deficient) and -
TRVb-1 (deficient cells transfected with hTfR) and assess their applicability for use 
as target cells for accomplishing positive and negative in vitro selections. Through 
flow cytometric analysis, the human TfR transfected form of the deficient cell line 
(TRVb-1) was observed to express similar levels of hTfR to hCMEC/D3 cells.  
Similarly to the work presented herein, Mehta et al. (2015) have also 
demonstrated the cell surface hTfR expression of CHO-TRVb1 cells by FACS 
analysis. The group highlighted that TfR expression remained consistent following 5 
g/L holotransferrin treatment at 24h and 48h time points, and expression was 
observed in 70% of the cell population. In contrast, the group found that the HepG2 
cell line demonstrated a 2-fold reduction of hTfR following the same holotransferrin 
treatment, and its expression of hTfR was seen in 30% of cells at 24h and 15% of 
cells at 48h. However, considering the higher levels of hTfR the group did not see an 
increase in uptake of iron within these cells, suggesting that iron may be regulated 
through increased expression of slc40a1 which mediates the efflux of iron from these 
cells.  
Within our work, we identified some expression of hTfR by FACS analysis on 
the deficient cell line suggesting presence of a heterogeneous population of cells. 
However, our assessment of TfR uptake within these cell lines showed no 
observable uptake of anti-hTfR or anti-mTfR within the deficient cells suggesting they 
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are functionally deficient of hTfR. This finding corresponds to existing evidence 
showing TfR mediated uptake with these cell lines (McGraw et al., 1987).  
Further exploration of these cell lines was not within the remit of our work. 
Being functionally deficient for the expression of hTfR, these cells may prove to be 
useful tools for selecting and characterising conformationally relevant TfR cell 
binding domains, and this would need to be explored further. Such selections could 
be performed through positive and negative cell selections towards the hTfR 
expressing and the hTfR deficient cells, a commonly used approach for identifying 
target cell specific domains (Cerchia et al., 2009; M. Lu et al., 2015). 
Further characterisation of TfR expression under various culture conditions 
such as serum starvation within hCMEC/D3 cells has yet to be established and 
would be beneficial in deducing the optimal conditions for cell selections, when 
expression of TfR is highest. Utilising live cell imaging of Hela cells, Tacheva-
Grigorova et al. (2013) demonstrated a substantial increase in the expression of 
surface TfR following incubation with ligand at 4°C and subsequent re-initiation of 
endocytosis at 37°C. It has not yet been established whether a similar increase in 
TfR expression is observed with BCEC under the same culture conditions and this 
could be explored further. 
Also, another under-explored area with BBB cell models is the circadian 
regulation of genes. The levels of iron found in the brain fluctuate in diurnal patterns, 
and these have been shown to be associated with Alzheimer’s disease, Parkinson’s 
disease and restless leg syndrome (Simpson et al., 2015). In iron-deficient mice, 
brain iron levels were found to be to be reduced by 25% (in relation to control fed 
mice), during the light phase when compared to the active dark phase (Unger et al., 
2009). The circadian regulation of TfR could be one of the factors involved in the 
observed diurnal variations in brain iron content. A previous study utilising 
hexapeptide (dalagrin) conjugated nanoparticles has demonstrated a dose and time 
dependant antinociceptive effect and this was suggested to potentially be due to an 
increased rate of endocytosis and exocytosis occurring within BCEC during the rest 
phase (Ramge et al., 1999; Kreuter, 2015). Characterisation of the diurnal profiles of 
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BCEC receptors with in vitro and in vivo models of the BBB could be an important 
factor for future drug transport studies. 
6.2. Selection and identification of TfR binding cyclic peptides 
Following the identification of TfR as a suitable drug delivery candidate 
receptor that functions through RMT on BCEC, a study was set up to select and 
identify suitable peptides targeting TfR. Chapter three focused on the selection and 
identification of cyclic peptides capable of recognising TfR variants from multiple 
species. 
The primary research goal of this chapter was to devise a phage display 
selection strategy that would facilitate the identification of low to medium affinity TfR 
species cross-reactive cyclic peptides. Secondly, this study endeavoured to utilise a 
suitable screening method for the identification of species cross-reactive peptides. 
Lastly, identified species cross-reactive peptides were compared for sequence 
homology.  
Multiple phage display selection cascades were performed using three CPEP 
libraries towards biotinylated target human and mouse TfR immobilised on 
streptavidin-coated magnetic agarose beads. A cross-selection cascade was 
performed to encourage the identification of species cross-reactive domains. 
selections towards target receptors from multiple species, aid in the identification of 
species cross-targeting peptides, which are likely to fare more positively during the 
later stages of clinical trials, where the transition from animal models to human 
participants is the major cause of clinical trial failure (Eastwood et al., 2010). This is 
particularly important in the case of CNS biotherapeutics, where the lack of suitable 
BBB in vitro models and species cross-reactive domains has been amongst the 
reasons for the clinical trial failure of CNS candidates (Stanimirovic et al., 2015). 
Similar phage display methods have previously been utilised to select and 
identify species cross-reactive domains to various targets including VEGF receptor, 
serum albumin, and notch receptors (Henry et al., 2015; Popkov et al., 2004; Y. Wu 
et al., 2010).  
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Furthermore, functional cell selections towards bEnd.3 cells were also carried 
out in a manner to encourage the identification of cell internalising domains. In a 
partially similar approach, a previous study has highlighted the selection of BBB 
crossing camelid single domain antibodies through phenotypic phage display 
selections towards cells (Muruganandam et al., 2002). This method relied on de-
selection steps against lung endothelial cells to remove non-BBB specific domains. 
Subsequently, multiple rounds of cell selection were performed in order to identify 
human BCEC binding domains. The enriched pool of binding domains was 
phenotypically screened to identify cell internalising domains, in a similar approach 
to that described within our phage display selection strategy. 
Interestingly, to identify a subset of cell transmigrating domains 
Muruganandam et al. (2002) further subjected the enriched pool to cell transcytosis 
assays using an in vitro model of the BBB consisting of human brain endothelial cells 
grown in transwell filters. The group identified two transmigrating domains Fc5 and 
Fc44, that demonstrated 4.5 ± 2.7% and 2.9 ± 1.7% brain uptake when intravenously 
administered as phage in mice, respectively. Whilst this approach resulted in BBB 
transmigrating domains, the exact binding receptor could not be determined without 
further studies (Abulrob et al., 2005). This is undesired, since identification of the 
unknown target(s) post-selection can be cumbersome and may hinder drug 
development due to a lack of understanding of the specific mechanism of action. 
This is further exemplified through the in vivo selection study carried out by 
Pasqualini et al. (1996), where  intravenous injection of a peptide phage library and 
isolating the brain at each round led to the enrichment of cyclic peptides without a 
known target, and this target has not yet been elucidated. In contrast, our selection 
approach utilised a pre-selection to recombinant TfR protein prior to further 
enrichment through functional cell selections. This combined selection strategy 
avoids the selection of binding domains to unknown targets whilst also conferring 
functionally relevant domains. 
From screening three phage output pools, we have identified 13 lead peptide 
sequences that were all shown to exhibit specific binding towards mouse, rat and 
human forms of TfR, as determined through phage ELISA studies using crude phage 
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supernatants. Moreover, the antigen cross-selection strategy was successful in 
identifying three species cross-reactive candidates (Pep1, Pep4 and Pep7). 
Furthermore, mTfR only selections were also successful in identifying species cross-
reactive domains. In addition to the identification of TfR binding peptide candidates, 
three TUP clones that bind streptavidin through the consensus ‘HPQ’ and ‘HPM’ 
motifs were also observed. 
 Homology assessment of the 16 unique peptides revealed various conserved 
motifs that likely confer binding of peptides towards TfR including ‘DCS’, ‘CTPϴ’, and 
a hydrophobic motif ‘WWGϴ’.  Two of these motifs, ‘CTPϴ’ and ‘WWG’ have 
previously been described within peptides that bind MHC molecules and an unknown 
brain targeting protein, respectively (Allen et al., 2001; Pasqualini and Ruoslahti, 
1996; Schroers et al., 2003). Since the brain targeting peptide described by 
Pasqualini et al. (1996), (CENWWGDVC), shares the ‘WWG’ motif with three of the 
strongest binding domains as identified by phage ELISA (Pep8, Pep9 and Pep10), 
we predict that it could be targeting the brain via TfR mediated uptake across BCEC. 
Further work would be required to elucidate the binding of ‘CENWWGDVC’ to 
recombinant TfR and BCEC targets. 
Through homology studies with the natural ligand transferrin, Pep1 was identified 
to share strong homology with a nine-residue motif (DCSGNFCL) located within the 
sequence of Tf (AA 614 – 622). This sequence was conserved across human mouse 
and rat TfR and has not previously been described for targeting of TfR. Through 
studying the previously described crystal structures and interactions of Tf with TfR 
(Eckenroth et al., 2011), we have identified a potential mechanism of binding for 
Pep1. The corresponding peptide motif to Pep1 was identified on Tf C1 subdomain 
of the C-lobe and was shown to bind through electrostatic interactions between Tf 
and Arginine 629 of TfR. Dai et al. (2014) have previously described a phage display 
selected linear peptide (BP9) that contains two amino acid motif (FR) and bears 
homology with Tf Herein, we have shown that the ‘FR’ motif lies downstream of our 
identified homologous sequence (DCSGNFCL). It is not clear whether both of these 
peptide interact with TfR through a consensus epitope and this would need to be 
explored further through competition binding assays utilising both peptides. 
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During the course of our phage ELISA screening analysis, we also identified 
hTfR and mTfR specific positive clones that could not be investigated further due to 
time constraints (see supplementary Figure S3). Whilst this project has solely 
focused on the identification of TfR species cross-reactive peptides, it may also be 
interesting to sequence, express and characterise these unique TfR binding clones 
for their ability to internalise and traverse BCEC. Furthermore, whilst these peptides 
were identified to be species specific via phage ELISA screening, they may still be 
useful candidates for obtaining species cross-reactive peptides. Studies have 
previously shown that it is possible to confer species cross-reactivity through affinity 
maturation and computational design approaches of the binding region of peptides 
and antibodies (Garcia-Rodriguez et al., 2007; Farady et al., 2009). 
Additionally, due to time constraints, only a small number of clones were 
screened per output pool (528 clones). It may therefore be valuable to re-screen the 
output pools using a greater number of clones. Typically, several thousands of 
clones are screened per output pool in order to obtain a representative overview of 
the entire pool and identify binding sequences with low representation (Lee et al., 
2004; Kehoe et al., 2006). Although phage ELISA screening methods are the most 
extensively reported methods in the literature for phage clone screening, the difficulty 
in initially recognising whether affinity molecules exhibit TUP binding properties and 
the time-consuming protocols involved for screening a large number of clones has 
led some researchers to transition to alternative screening methods. In recent years, 
some groups have transitioned to high throughput sequencing as an alternative 
means of predicting sequences that may potentially be involved in target specific 
binding ('t Hoen et al., 2012). This is done through the alignment of millions of 
sequence reads from a heterogeneous selection output pool and the study of 
conserved sequence motifs across the most highly enriched sequences. Sequence 
enrichment can also be monitored with selection round progress, allowing for 
correlations to be made with preserved sequences seen in later rounds. 
Subsequently, lead sequences can be synthesised and assayed for binding towards 
the target antigen. 
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Ngubane et al. (W. M. Yang et al., 2011) compared the results of both random 
clone picking and HTS as screening approaches when carrying out phage display 
selections towards Mycobacterium tuberculosis using a cyclic heptapeptide library 
(CX7C). The group discovered that target specific clones could be identified following 
just one round of selection when using HTS. Moreover, the most highly enriched 
sequence identified using the HTS approach demonstrated a greater binding affinity 
towards the target than the three identified leads discovered via the random colony 
screening approach. Interestingly, the most highly enriched sequence discovered via 
HTS (80% representation), was not identified using the random colony screening 
approach.  
Further work on assessing the physiochemical properties of the identified 
peptide sequences is needed. The functional groups of amino acids confer distinct 
physical properties that determine the overall solubility and charge of a peptide. The 
isoelectric point (pI) of a peptide or a protein is the pH at which the molecule has a 
net charge of zero (Kozlowski, 2016). Peptides and proteins have poor solubility at 
the isoelectric point making them more likely to precipitate and bind non-specifically 
(McDonald et al., 2009). Additionally, short positively charged or hydrophobic 
peptides are more susceptible to passive adsorption to polystyrene surfaces (Kogot 
et al., 2012). Importantly, determining the pI of a peptide will allow the calculation of 
its charge at physiological pH of 7.4 which can give an indication of its specificity and 
solubility within circulation (Kohn et al., 2007). The lipophilicity of a peptide is also an 
important factor to consider. Highly hydrophobic peptides are more prone to bind 
plasma proteins such as albumin within the circulation significantly increasing serum 
half-life and reducing elimination (Plum et al., 2013).  
6.3. Characterisation of binding and internalisation of lead peptides 
Following the identification of 13 positive cross-species binding peptides from 
phage ELISA screening towards TfR, peptides needed to be expressed as soluble 
domains for characterisation. Chapter four focuses on the expression and 
characterisation of lead peptides towards recombinant protein and BCEC targets. 
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The primary research aim of this chapter was to characterise the binding and 
cell uptake of peptide candidates expressed as soluble fusion domains, towards 
recombinant TfR and BCEC cells derived from both mouse and human species. 
For the initial characterisation towards recombinant TfR and BCEC cell lines, 
peptide candidates were cloned into a modified pCANTAB6-D1/FLAGHIS10 vector 
and expressed as soluble monovalent fusion domains to g3p-D1 via periplasmic 
expression. Subsequently, promising lead candidates that expressed within the g3p-
D1 fusion format were taken forward for further characterisation as bivalent CPep-Fc 
fusion domains. Finally, the internalisation and subcellular trafficking of CPep-Fc 
lead domains was assessed on bEnd.3 and hCMEC/D3 cells. 
Periplasmic expression of monovalent CPep-D1 fusion domains resulted in 
the efficient expression of 9 of the 16 peptides identified through phage ELISA 
screening. Five peptides demonstrated poor periplasmic expression yields, (Pep2, 
Pep4, Pep12, Pep13 and Pep15) and two peptides (Pep10 and Pep16) failed to 
express completely with the current periplasmic expression protocol. The most 
significant peptide that failed to express was Pep10, which consistently 
demonstrated the highest specific absorbance readings during phage ELISA 
screening towards all three species of TfR and was the most highly enriched 
sequence identified throughout the selection process. Some fusion molecules have 
been known to be problematic to expressed within E.coli and it has been suggested 
that this may be due to the inappropriate physiochemical properties of microbial 
hosts (H.-J. Kang et al., 2017). 
Due to time constraints, it was not possible to optimise the re-expression 
conditions for the CPep-D1 domains that exhibited low yields or failed to express. 
Further optimisations of growth conditions using different growth temperatures, IPTG 
concentrations, and induction times may be necessary to optimise yields (Rouet et 
al., 2012). Additionally, optimisations of minor codon usage within peptide coding 
sequences and the use of E.coli strains that re-introduce less abundant tRNA may 
also ameliorate heterologous expression issues (Nouri et al., 2016). Another 
approach would be to utilise an alternative fusion domain to the g3p-D1 domain 
described here. Various fusion domains have been described for the stable and 
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efficient periplasmic expression of peptides and proteins, these include the small 
ubiquitin-like modifier 3 (SUMO 3), Cytochrome b5 and Fh8 tag (Besir, 2017; 
Dormeshkin et al., 2016; Costa et al., 2013). 
 If optimisation approaches fail to yield suitable quantities of peptide, then 
chemical synthesis approaches may be necessary for characterising the remaining 
peptide candidates. Typically, the peptides are synthesised coupled to polyethylene 
glycol (PEG) in place of the fusion domain to aid in peptide stability and solubility, 
whilst also reducing immunogenicity and decreasing clearance rate (Dozier and 
Distefano, 2015).  
 Following monovalent peptide screening, four lead peptides (Pep1, Pep8, 
Pep9, and Pep14) were identified to specifically bind to recombinant mouse and 
human TfR and immortalised mouse and human BCEC (bEnd.3 and hCMEC/D3). 
Pep1 and Pep8 demonstrated the greatest degree of binding towards recombinant 
TfR and BCEC, whilst Pep9 and Pep14 appear to be very weak affinity peptides. 
Alanine scanning and other structure-based design studies may be carried out 
on the four lead peptide candidates to identify key amino acid residues involved in 
TfR binding. Rationale design approaches such as these can aid in the identification 
of peptide variants with improved binding affinity, stability and desired 
physiochemical properties (Savio et al., 2012). Furthermore, the precise binding 
affinities of these lead peptides has yet to be determined via SPR based approaches 
such Biacore (Kamat and Rafique, 2017; Yau and Shochat, 2014). 
The two promising lead peptides (Pep1 and Pep8) were subsequently 
expressed as divalent CPep-Fc/IL1RA fusions and assessed for their capacity to 
transport a conjugated cargo within BCEC. Pep1 demonstrated a specific, time 
dependant uptake within bEnd.3 and its internalisation demonstrated with 
hCMEC/D3 cells at 60 and 120 min time points. At both time-points, no observable 
co-localisation was observed with EEA1 and LAMP1 suggesting that at those 
particular time-points it was avoiding the lysosomal degradation pathway. However, 
this preliminary finding needs to be validated using confocal microscopy since 
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epifluorescence microscopy is not capable of distinguishing overlapping vesicles 
within the Z-dimension from co-localised points (Dunn et al., 2011). 
Pep8 demonstrated a low specific uptake when expressed as a -Fc/IL1RA 
fusion. A study by Daniel et al. (Danial et al., 2017) has recently reported a similar 
loss in peptide binding potency when a PEG polymer was conjugated to heptad 
repeat 2 peptide. Further work is needed to determine whether the low uptake 
observed with Pep8 was due to expression within this format. 
Results of the early in vivo pilot study carried out using the mouse neuropathic 
pain model indicate that these peptides demonstrate some promise for use as BBB 
delivery shuttles (Thom and Hatcher, 2016). A significant increase in CNS uptake as 
demonstrated via an increase in analgesic effect on the mice was observed at the 
four-hour time-point in relation to sham controls. However, the observed effects were 
rapidly diminished thereafter. It is not clear whether renal filtration is the cause for 
this rapid clearance. The threshold for glomerular filtration is a molecule size of 
approximately 60 kDa, however it has also been suggested that the radius of a 
molecule is the limiting factor for renal filtration (Meibohm and H. Zhou, 2012). The 
size of these fusion domains could suggest that renal filtration may be the cause of 
the rapid clearance, however further assessment is needed. As they currently stand, 
these peptide-Fc conjugates do not provide a viable proposition for therapeutic 
dosing, primarily due to the fact that frequent dosing strategies using biologics is not 
economically viable and increases the risks of adverse drug events.  
The use of strategies to increase the size of these molecules significantly 
beyond the renal threshold may be required for optimisation. Alternatively, the extent 
of binding of peptides towards plasma proteins such as albumin can also influence 
drug distribution in vivo, limiting the free compound available for binding and uptake 
at target cells. Dennis et al. (2002) have selected an albumin binding peptide through 
phage display that binds albumin derived from various species. The group 
demonstrated extended half-life of a short lived Fab domain after recombinant fusion 
with the peptide ‘DICLPRWGCLW’. Such an approach may be useful in reducing the 
rapid elimination of Pep1-Fc/IL1RA. 
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The transcytosis capacity of Pep1-Fc/IL1RA has yet to be explored using in 
vitro BBB transcytosis models. Transcytosis within in vitro cell models may be 
assessed two ways. Firstly, the most commonly utilised method involves the use of 
in vitro immortalised BCEC cultured in trans-well filters in order to assess apical to 
basolateral transport. However, these models are highly susceptible to significant 
para-cellular flux due to low TEER values, which mask the measurement of specific 
transcellular transport. One promising study describes an approach which 
overcomes this problem through the use of a ‘pulse-chase’ method (Sade et al., 
2014). Alternatively, the use of TEM approaches is also a well-established method 
for assessing apical to basolateral transport within in vitro models of the BBB (D. Ye 
et al., 2014). Conducting transcytosis assays using the CPep-Fc/IL1RA domains in 
addition to determining brain uptake with in vivo animal models, will greatly aid in 
evaluating the viability of CPep1 as a potential BBB drug delivery shuttle. 
6.4. Selection and enrichment analysis of aptamer selected pools 
Aptamers have recently emerged as promising alternatives to antibodies as 
molecular recognition domains (Alshaer et al., 2017; Ruscito et al., 2017). Chapter 
five focuses on the establishment of a SELEX protocol and the selection of ssDNA 
aptamers that target and bind hTfR.  
The overall aim of this chapter was to establish a protocol for the selection of 
hTfR binding aptamers and subsequently screen selected pools for the identification 
of enriched aptamer species. Several considerations were made when deciding 
upon the selection approach and SELEX library to use. Firstly, a ssDNA library was 
chosen in place of its RNA counterpart, since DNA is significantly more stable than 
RNA. This facilitates lab handling procedures and potentially produces aptamers that 
can be utilised natively in vivo (Heiat et al., 2016). Furthermore, the size of the library 
chosen for this study consisted of 30 nucleotides within the random region. Smaller 
aptamers are likely to have better tissue penetration and better accessibility of 
epitopes (Xiang et al., 2015). In order to improve the likelihood of selecting 
physiologically relevant aptamers, a combinatorial selection strategy consisting of 
selections towards recombinant hTfR and hTfR overexpressing CHO cells was 
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chosen. Such an approach has previously been described by Wilner et al. (Wilner et 
al., 2012) during the selection of hTfR binding RNA aptamers.  
The preferential separation of target binding aptamer from the unbound pool 
was carried out through the immobilisation of polyhistidine tagged hTfR onto Ni-NTA 
magnetic agarose beads, a commonly utilised affinity capture matrix for utilised for 
SELEX (Murphy et al., 2003; Wilner et al., 2012; Bartnicki et al., 2015). Prior to 
commencing with selections, it was necessary validate Ni-NTA magnetic bead 
capture of hTfR-His6 and assess whether the beads could maintain captured protein 
through multiple wash steps. Captured and eluted hTfR protein from Ni-NTA 
magnetic agarose beads following wash steps, was characterised using immunoblot 
analysis. Our findings indicate that that 5 µg was optimal for minimising loss of 
protein with one and three wash steps. 
Initially, the goal of these selections was to perform 5 rounds of aptamer SELEX 
towards recombinant hTfR-His6 and subsequently one or more rounds of cell 
selections towards CHO-TRVb-1 (hTfR overexpressing) cells. A similar number of 
rounds was previously carried out to identify target hTfR binding RNA aptamers 
(Wilner et al., 2012). A total of 6 rounds were initially carried out, five rounds of 
selection towards hTfR-His6 and one round towards CHO-TRVb-1 cells. Using a 
colony screening approach, it was not possible to identify any enriched sequences 
following the screening of approximately 88 colonies originating from each of the 
round 5 and 6 selected pools (results not shown). Selections were subsequently 
continued to round 12, where non-specific amplification products were observed to 
contaminate the amplified aptamer pool and limited further progression of the 
selection.  
As discussed in chapter 5, the formation of non-specific by-products is a 
commonly observed artefact of selections and can originate from various sources 
(Tolle et al., 2014). In the case of our selections the source of contamination likely 
originated from primer dimerisation. Some of these by-products may be overcome 
through the use of emulsion PCR, a technique that ameliorates the need for 
optimisation PCR steps, allows the amplification of small amounts of DNA and 
prevents PCR amplification bias (Tolle et al., 2014; R. Williams et al., 2006). 
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Following 12 rounds of SELEX, HTS was carried out on several selected pools 
in order to determine enrichment and allow further identification of potential lead 
candidate aptamer sequences for screening. A count analysis revealed an overall 
62% reduction in pool diversity between the unselected pool and round 12 selected 
pool. Having established enrichment following 12 rounds, further analysis of 
clustered NGS data is required to identify conserved whole sequences or regions 
within groups of aptamers. Once identified, lead candidates may then be chemically 
synthesised and screened using aptamer linked immunosorbent assays (ALISA) 
(Modh et al., 2016), Fluorescent dye-linked aptamer assays (FLAA) (Schütze et al., 
2011) or FACS analysis (Macdonald, Houghton, et al., 2016; Sefah et al., 2010) to 
identify target hTfR binding aptamers.  
The cell selection approach used at round 4 to successfully identify functional 
cell internalising peptides can be applied within the context of aptamer selections 
(described in chapter 3). This approach may be applied in order to increase selection 
stringency and preferentially identify BCEC cell internalising aptamers. A similar 
approach has previously been described with cell-internalising SELEX 
(Mallikaratchy, 2017). Following the incubation of the aptamer library with live cells, 
cells are washed in a high salt solution in order eliminate slow or non-internalising 
aptamers leaving only aptamers that have been internalised within cells. 
6.5. Conclusion and personal reflections 
This thesis has explored the use of antibody alternative biologic domains for 
use as drug delivery shuttles across the BCECs that form the primary physical 
barrier component of the neurovascular unit. TfR was confirmed as a suitable 
candidate RMT receptor at the BCEC and targeted through phage display and 
SELEX to identify cyclic peptides and aptamers, respectively.  
Through the use of a multifaceted phage display selection approach, we have 
identified 13 species cross-reactive peptides that demonstrate specific binding 
towards human and mouse TfR. Through homology sequence alignment, we have 
identified that our lead peptide candidate (Pep1) shares significant homology with a 
highly conserved nine amino acid sequence on transferrin (DCSGNFCLF), which 
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has not previously been described for targeting TfR. Furthermore, when expressed 
as a bivalent Fc-fusion domain, Pep1 demonstrated a significant time-dependant 
uptake within bEnd.3 cells and was shown to internalise within hCMEC/D3 cells at 
60 and 120 min time points. 
ssDNA aptamers, were also selected through a cascade of in vitro rounds of 
enrichment towards recombinant hTfR and CHO cells overexpressing hTfR. 
Following 12 rounds of nucleic acid enrichment, a count analysis of NGS data 
revealed that the selection resulted in 62% enrichment of the round 12 selected pool 
in contrast to the unselected pool. This result warrants further detailed assessment 
of the selected pools for sequence enriched aptamers which may be characterised 
for binding recombinant hTfR and BCEC. 
The versatile and specific nature of biotherapeutics has revolutionised the 
way we tackle the treatment of many conditions (Gasser and Waaga-Gasser, 2016). 
Non-antibody biologic domains (such as peptides and aptamers) provide an effective 
approach to circumventing the transport limitations of the BBB, and have the 
potential to overcome the longstanding limitations of traditional MAb within this 
context. There is a vastly unmet demand for the treatment of neurological disorders. 
Whilst evidently there are high financial risks involved in the pursuit of strategies that 
enhance therapeutic uptake of macromolecules at the CNS, the promise of opening 
a largely untapped pharmaceutical market has continued to push research and 
development within this area (Stanimirovic et al., 2015). With our ever-growing 
knowledge of the BBB and continued commitment to research into targeted 
therapeutic approaches, it is only a matter of time and effort before the capabilities of 
this fascinating class of drugs is realised within the area neurotherapeutic 
treatments. 
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Figure S1: PeptideCutter (ExPASy) analysis summary of predicted trypsin cleavage sites on 
the TfR sequence.  
In total, 83 potential trypsin cleavage sites were identified for the 760 amino acid sequence of 
human TfR. The position of cleavage, resulting peptide sequence, as well as peptide length and mass 
are shown.  
 
Position 
of 
cleavage 
site 
Name of 
cleaving 
enzyme(s) 
Resulting peptide sequence Peptide length [aa] 
Peptide 
mass [Da] 
Cleavage 
probability (%) 
6 Trypsin MMDQAR 6 750.886 100 % 
22 Trypsin SAFSNLFGGEPLSYTR 16 1745.909 100 % 
27 Trypsin FSLAR 5 592.696 100 % 
39 Trypsin QVDGDNSHVEMK 12 1358.446 100 % 
53 Trypsin LAVDEEENADNNTK 14 1561.579 100 % 
58 Trypsin ANVTK 5 531.610 19.4 % 
60 Trypsin PK 2 243.306 90.7 % 
61 Trypsin R 1 174.203 100 % 
90 Trypsin CSGSICYGTIAVIVFFLIGFMIGYLGYCK 29 3139.837 82.8 % 
95 Trypsin GVEPK 5 528.606 100 % 
100 Trypsin TECER 5 636.678 100 % 
109 Trypsin LAGTESPVR 9 929.041 100 % 
120 Trypsin EEPGEDFPAAR 11 1217.257 90.4 % 
121 Trypsin R 1 174.203 100 % 
128 Trypsin LYWDDLK 7 952.075 91.8 % 
129 Trypsin R 1 174.203 89.7 % 
130 Trypsin K 1 146.189 83.7 % 
134 Trypsin LSEK 4 475.542 94.7 % 
145 Trypsin LDSTDFTGTIK 11 1197.307 100 % 
155 Trypsin LLNENSYVPR 10 1204.348 100 % 
161 Trypsin EAGSQK 6 618.644 100 % 
174 Trypsin DENLALYVENQFR 13 1610.743 69.6 % 
177 Trypsin EFK 3 422.481 100 % 
180 Trypsin LSK 3 346.427 100 % 
183 Trypsin VWR 3 459.549 100 % 
189 Trypsin DQHFVK 6 772.859 100 % 
193 Trypsin IQVK 4 486.612 100 % 
205 Trypsin DSAQNSVIIVDK 12 1288.420 63.1 % 
208 Trypsin NGR 3 345.358 100 % 
224 Trypsin LVYLVENPGGYVAYSK 16 1772.031 100 % 
231 Trypsin AATVTGK 7 646.742 100 % 
240 Trypsin LVHANFGTK 9 986.139 84.4 % 
241 Trypsin K 1 146.189 84.6 % 
258 Trypsin DFEDLYTPVNGSIVIVR 17 1937.180 100 % 
261 Trypsin AGK 3 274.320 100 % 
267 Trypsin ITFAEK 6 707.825 95.7 % 
287 Trypsin VANAESLNAIGVLIYMDQTK 20 2150.475 100 % 
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325 Trypsin FPIVNAELSFFGHAHLGTGDPYTPGFP
SFNHTQFPPSR 
38 4188.630 100 % 
339 Trypsin SSGLPNIPVQTISR 14 1468.673 91.9 % 
344 Trypsin AAAEK 5 488.541 94.7 % 
358 Trypsin LFGNMEGDCPSDWK 14 1598.765 100 % 
364 Trypsin TDSTCR 6 681.719 100 % 
371 Trypsin MVTSESK 7 780.892 100 % 
374 Trypsin NVK 3 359.426 100 % 
382 Trypsin LTVSNVLK 8 873.060 92.8 % 
385 Trypsin EIK 3 388.464 100 % 
394 Trypsin ILNIFGVIK 9 1016.292 100 % 
409 Trypsin GFVEPDHYVVVGAQR 15 1672.861 100 % 
418 Trypsin DAWGPGAAK 9 871.948 100 % 
428 Trypsin SGVGTALLLK 10 958.166 100 % 
439 Trypsin LAQMFSDMVLK 11 1282.579 86.4 % 
446 Trypsin DGFQPSR 7 805.845 100 % 
477 Trypsin SIIFASWSAGDFGSVGATEWLEGYLSS
LHLK 
31 3329.713 100 % 
486 Trypsin AFTYINLDK 9 1084.237 92.8 % 
495 Trypsin AVLGTSNFK 9 936.076 89.5 % 
508 Trypsin VSASPLLYTLIEK 13 1433.708 100 % 
514 Trypsin TMQNVK 6 719.854 100 % 
531 Trypsin HPVTGQFLYQDSNWASK 17 1978.151 100 % 
534 Trypsin VEK 3 374.437 94.7 % 
574 Trypsin LTLDNAAFPFLAYSGIPAVSFCFCEDTD
YPYLGTTMDTYK 
40 4463.024 88.9 % 
579 Trypsin ELIER 5 658.753 75.6 % 
585 Trypsin IPELNK 6 712.844 100 % 
588 Trypsin VAR 3 344.414 100 % 
600 Trypsin AAAEVAGQFVIK 12 1203.404 100 % 
613 Trypsin LTHDVELNLDYER 13 1616.748 100 % 
623 Trypsin YNSQLLSFVR 10 1226.398 100 % 
629 Trypsin DLNQYR 6 807.861 100 % 
633 Trypsin ADIK 4 445.516 93.1 % 
646 Trypsin EMGLSLQWLYSAR 13 1553.796 100 % 
651 Trypsin GDFFR 5 640.696 100 % 
655 Trypsin ATSR 4 433.465 100 % 
665 Trypsin LTTDFGNAEK 10 1095.174 100 % 
668 Trypsin TDR 3 390.396 100 % 
672 Trypsin FVMK 4 523.691 78.5 % 
673 Trypsin K 1 146.189 82 % 
677 Trypsin LNDR 4 516.555 100 % 
680 Trypsin VMR 3 404.528 100 % 
693 Trypsin VEYHFLSPYVSPK 13 1565.789 90.7 % 
698 Trypsin ESPFR 5 634.690 100 % 
717 Trypsin HVFWGSGSHTLPALLENLK 19 2106.412 100 % 
719 Trypsin LR 2 287.362 100 % 
720 Trypsin K 1 146.189 83.1 % 
732 Trypsin QNNGAFNETLFR 12 1410.509 100 % 
760 end of 
sequence 
NQLALATWTIQGAANALSGDVWDID
NEF 
28 3034.288 - 
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Figure S2: Plate transfer summary of screened phage ELISA clones. 
Figure showing the series of transfers firstly from source selection plates to deep-well plates (B) and 
subsequently to the phage ELISA screening plates. Plate barcoding was used to avoid mislabeling of 
plates and plate IDs are shown for each plate. 
 
 
 
 
  
 Selection ID mTfR - biotin hTfR - biotin insulin - biotin 
Round 3 CPEP 
human to mouse 
TfR cross selection 
screen 
29 (plate 1) Y01668 Y02066 Y02153 
29 (plate 2) Y02263 Y01704 Y01740 
30 (plate 1) Y01536 Y01776 Y01516 
30 (plate 2) Y01978 Y01518 Y02371 
31 (plate 1) Y01878 Y01968 Y01847 
31 (plate 2) Y01896 Y01903 Y01749 
Round 4 CPEP cross 
selected to b.End 3 
cell selection 
screen 
35 (plate 1) Y02229 Y02481 Y02339 
35 (plate 2) Y02232 Y02019 Y01586 
36 (plate 1) Y02311 Y01583 Y01876 
36 (plate 2) Y02374 Y01529 Y02036 
37 (plate 1) Y01730 Y01675 Y01868 
37 (plate 2) Y02306 Y02020 Y02477 
Round 4 CPEP non-
cross selected to 
b.End 3 cell 
selection screen 
32 (plate 1) Y01760 Y02443 Y02447 
32 (plate 2) Y01698 Y02491 Y02497 
33 (plate 1) Y01541 Y02116 Y01827 
33 (plate 2) Y02412 Y03036 Y01761 
34 (plate 1) Y02411 Y03498 Y02079 
34 (plate 2) Y02998 Y01963 Y03386 
Selection ID Description Source plate Destination 
(Deep well) 
29 (plate 1) R3 CPEP1 h à m ZZ1I0I 00658B 
29 (plate 2) R3 CPEP1 h à m ZZ1I0J 006588 
30 (plate 1) R3 CPEP2 h à m ZZ1JTV 00659N 
30 (plate 2) R3 CPEP2 h à m ZZ1JTW 006585 
31 (plate 1) R3 CPEP3 h à m ZZ1I0G 006582 
31 (plate 2) R3 CPEP3 h à m ZZ1I0H 00657Z 
32 (plate 1) R4 CPEP1 non-cross to bEnd.3 ZZ1K3W 0064YK 
32 (plate 2) R4 CPEP1 non-cross to bEnd.3 ZZ1K3V 0064YN 
33 (plate 1) R4 CPEP2 non-cross to bEnd.3 ZZ1K3U 0064YQ 
33 (plate 2) R4 CPEP2 non-cross to bEnd.3 ZZ1K3Z 00657K 
34 (plate 1) R4 CPEP3 non-cross to bEnd.3 ZZ1K3Y 00657N 
34 (plate 2) R4 CPEP3 non-cross to bEnd.3 ZZ1K3X 00657Q 
35 (plate 1) R4 CPEP1 cross to bEnd.3 ZZ1IY1 00659E 
35 (plate 2) R4 CPEP1 cross to bEnd.3 ZZ1IY0 00659H 
36 (plate 1) R4 CPEP2 cross to bEnd.3 ZZ1IXZ 00659K 
36 (plate 2) R4 CPEP2 cross to bEnd.3 ZZ1IXY 006598 
37 (plate 1) R4 CPEP3 cross to bEnd.3 ZZ1IXX 00659B 
37 (plate 2) R4 CPEP3 cross to bEnd.3 ZZ1IXW 00657W 
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Figure S3: Plate layout and Phage ELISA screening reports 
Figure showing the well layout for 96-well plates used throughout the phage ELISA colony screening 
(A). Screening reports highlighting the weak (green) and strong (yellow) phage hits towards 
biotinylated insulin (control), human TfR and mouse TfR, from round 3 cross-selection cascade (B), 
Round 4 cross-selection to bEnd.3 cell selection cascade (C), and Round 4 mTfR to bEnd.3 cell 
selection cascade (D). 
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C 
Round 4 cross-selection to bEnd.3 cell selection 
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D 
Round 4 mTfR Selection to bEnd.3 cell selection  
Appendix 
 265 
 
 
 
  
Appendix 
  266 
 
 
 
 
 
Appendix 
 267 
 
 
 
  
Appendix 
  268 
 
Figure S4: Phage ELISA positive hits sequence alignment.  
The 197 TfR species cross-reactive hits identified from initial phage ELISA screening were sequenced 
and analysed using Blaze 2.0 (Continuity software package, MedImmune, Cambridge).  Sequences 
were assembled as fdDOG sequences and aligned according to the peptide insert region. Yellow 
highlights indicate the position of the cysteine residues which form the disulphide bond of the cyclic 
peptide. 
 
  
Blaze2™ Sequence Analysis Report fd-DOG
*
»   A11+ZZ1IOJ-A11+fdDOGf (Oust0025) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
B08+ZZ1IOI-B08+fdDOGf (Oust0014) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C08+ZZ1IOI-C08+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F07+ZZ1IOI-F07+fdDOGf (Oust0021) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C07+ZZ1IOI-C07+fdDOGf (Oust0017) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
A11+ZZ1IOI-A11+fdDOGf (Oust0012) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H10+ZZ1IOI-H10+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H09+ZZ1IOI-H09+fdDOGf (Oust0024) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
A05+ZZ1IOI-A05+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
B04+ZZ1IOI-B04+fdDOGf (Oust0013) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H11+ZZ1IY0-H11+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
G11+ZZ1IY0-G11+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C03+ZZ1IOI-C03+fdDOGf (Oust0015) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
E03+ZZ1IOI-E03+fdDOGf (Oust0020) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C06+ZZ1IOI-C06+fdDOGf (Oust0016) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
E06+ZZ1IOI-E06+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
D06+ZZ1IOI-D06+fdDOGf (Oust0019) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H05+ZZ1IOI-H05+fdDOGf (Oust0023) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F03+ZZ1IOJ-F03+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F08+ZZ1IY0-F08+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
B05+ZZ1IOJ-B05+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
D02+ZZ1IOJ-D02+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F01+ZZ1IOJ-F01+fdDOGf (Oust0027) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C11+ZZ1IOI-C11+fdDOGf (Oust0018) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F11+ZZ1IOJ-F11+fdDOGf (Oust0028) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F01+ZZ1IY0-F01+fdDOGf (Oust0035) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C11+ZZ1IOJ-C11+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H08+ZZ1IOJ-H08+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C09+ZZ1IOJ-C09+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H07+ZZ1IOJ-H07+fdDOGf (Oust0029) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
D08+ZZ1IOJ-D08+fdDOGf (Oust0026) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
A07+ZZ1IOJ-A07+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F02+ZZ1IOI-F02+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
G02+ZZ1IOI-G02+fdDOGf (Oust0022) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H06+ZZ1IY1-H06+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAOTVESCLAKPHTENSFTNVWKDD
G01+ZZ1IY1-G01+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
»   G01+ZZ1K3W-G01+fdDOGf (Oust0044) PFYSHSAQWTIAVCGKQGCEYVWEAAAETVESCLAKPHTENSFTNVWKDD
H01+ZZ1K3W-H01+fdDOGf PFYSHSAQWTIAVCGKQGCEYVWEAAAETVESCLAKPHTENSFTNVWKDD
»   H06+ZZ1IOI-H06+fdDOGf PFYSHSAQTTFPSCHPQTCYDGVQAAAETVESCLAKPHTENSFTNVWKDD
G02+ZZ1IOJ-G02+fdDOGf PFYSHSAQTTFPSCHPQTCYDGVQAAAETVESCLAKPHTENSFTNVWKDD
F10+ZZ1IOJ-F10+fdDOGf (Oust0032) PFYSHSAQTTFPSCHPQTCYDGVQAAAETVESCLAKPHTENSFTNVWKDD
B08+ZZ1IOJ-B08+fdDOGf PFYSHSAQTTFPSCHPQTCYDGVQAAAETVESCLAKPHTENSFTNVWKDD
»   A11+ZZ1IY0-A11+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
C04+ZZ1IOI-C04+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
A07+ZZ1IOI-A07+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
C05+ZZ1IOJ-C05+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
C02+ZZ1IOJ-C02+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
A03+ZZ1IOJ-A03+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
E11+ZZ1IY1-E11+fdDOGf (Oust0036) PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
B01+ZZ1IY0-B01+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
H09+ZZ1IOJ-H09+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
F09+ZZ1IOJ-F09+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
G06+ZZ1IOJ-G06+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
H05+ZZ1IOJ-H05+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
C06+ZZ1IOJ-C06+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
A03+ZZ1IOI-A03+fdDOGf (Oust0031) PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
»   H07+ZZ1K3W-H07+fdDOGf (Oust0045) PFYSHSAQSTPISWVLMVCDEIGEAAAQTVESCLAKPHTENSFTNVWKDD
»   E09+ZZ1K3X-E09+fdDOGf (Oust0048) PFYSHSAQLHCTSIWSDVVQLCDLAAAETVESCLAKPHTENSFTNVWKDD
»   A07+ZZ1K3X-A07+fdDOGf (Oust0047) PLYSHSAQSICPTIIMDTLYLCDBAAAETVESCLAKPHTENSFTNVWKDD
»   H06+ZZ1K3X-H06+fdDOGf (Oust0049) PFYSHSAQPLCTPIFPPFVLMCEEAAAETVESCLAKPHTENSFTNVWKDD
»   A10+ZZ1IXW-A10+fdDOGf PFYSHSAQLYCYPTKLPWVEYCHEGGAETVESCLAKPHTENSFTNVWKDD
B11+ZZ1IXW-B11+fdDOGf PFYSHSAQLYCYPTKLPWVEYCHEGGAETVESCLAKPHTENSFTNVWKDD
A01+ZZ1IXW-A01+fdDOGf (Oust0033) PFYSHSAQLYCYPTKLPWVEYCHEGGAETVESCLAKPHTENSFTNVWKDD
H04+ZZ1IXW-H04+fdDOGf PFYSHSAQLYCYPTKLPWVEYCHEGGAETVESCLAKPHTENSFTNVWKDD
H03+ZZ1IXW-H03+fdDOGf PFYSHSAQLYCYPTKLPWVEYCHEGGAETVESCLAKPHTENSFTNVWKDD
»   A01+ZZ1K3X-A01+fdDOGf (Oust0046) PFYSHSAQWVCTPLDSEIIEICQLAAAETVESCLAKPHTENSFTNVWKDD
»   E06+ZZ1IOH-E06+fdDOGf (Oust0030) PFYSHSAQIHCHPQGDQSVSFCWRAAAETVESCLAKPHTENSFTNVWKDD
»   G07+ZZ1K3U-G07+fdDOGf (Oust0041) PFYSHSAQLHQCTYYWWGLDCSFRAAAOTVHSCLTQSHTODSFTNLWKDN
»   B01+ZZ1K3U-B01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A01+ZZ1K3U-A01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B04+ZZ1K3Z-B04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G03+ZZ1K3Z-G03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D06+ZZ1K3U-D06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H03+ZZ1K3Z-H03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C06+ZZ1K3U-C06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B07+ZZ1K3U-B07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A07+ZZ1K3U-A07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E03+ZZ1K3Z-E03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F05+ZZ1K3U-F05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E05+ZZ1K3U-E05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H02+ZZ1K3Z-H02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D05+ZZ1K3U-D05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A03+ZZ1K3Z-A03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G02+ZZ1K3Z-G02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A06+ZZ1K3U-A06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D02+ZZ1K3Z-D02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G05+ZZ1K3U-G05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F08+ZZ1K3U-F08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H01+ZZ1K3Z-H01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D08+ZZ1K3U-D08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A09+ZZ1K3U-A09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F01+ZZ1K3Z-F01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B09+ZZ1K3U-B09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D01+ZZ1K3Z-D01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H08+ZZ1K3U-H08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B01+ZZ1K3Z-B01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C07+ZZ1K3U-C07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A08+ZZ1K3U-A08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A01+ZZ1K3Z-A01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B08+ZZ1K3U-B08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G07+ZZ1K3Z-G07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D02+ZZ1K3U-D02+fdDOGf (Oust0039) PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C02+ZZ1K3U-C02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A08+ZZ1K3Z-A08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B08+ZZ1K3Z-B08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E02+ZZ1K3U-E02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H02+ZZ1K3U-H02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D07+ZZ1K3Z-D07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G02+ZZ1K3U-G02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E07+ZZ1K3Z-E07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B03+ZZ1K3U-B03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F07+ZZ1K3Z-F07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G06+ZZ1K3Z-G06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D01+ZZ1K3U-D01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H06+ZZ1K3Z-H06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C01+ZZ1K3U-C01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A07+ZZ1K3Z-A07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B07+ZZ1K3Z-B07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C06+ZZ1K3Z-C06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H01+ZZ1K3U-H01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D06+ZZ1K3Z-D06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E06+ZZ1K3Z-E06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A02+ZZ1K3U-A02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H05+ZZ1K3Z-H05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C04+ZZ1K3U-C04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D04+ZZ1K3U-D04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B06+ZZ1K3Z-B06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E04+ZZ1K3U-E04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C05+ZZ1K3Z-C05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H04+ZZ1K3U-H04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F05+ZZ1K3Z-F05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRASAETVESCLAKPHTENSFTNVWKDD
B05+ZZ1K3U-B05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H04+ZZ1K3Z-H04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G04+ZZ1K3Z-G04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D03+ZZ1K3U-D03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B05+ZZ1K3Z-B05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F03+ZZ1K3U-F03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D04+ZZ1K3Z-D04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G03+ZZ1K3U-G03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F04+ZZ1K3Z-F04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E04+ZZ1K3Z-E04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E11+ZZ1K3Z-E11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F11+ZZ1K3Z-F11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F10+ZZ1K3Z-F10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C10+ZZ1K3Z-C10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A11+ZZ1K3Z-A11+fdDOGf (Oust0042) PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B11+ZZ1K3Z-B11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H10+ZZ1K3Z-H10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E09+ZZ1K3Z-E09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D09+ZZ1K3Z-D09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B10+ZZ1K3Z-B10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H09+ZZ1K3Z-H09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G09+ZZ1K3Z-G09+fdDOGf (Oust0043) PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F08+ZZ1K3Z-F08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D08+ZZ1K3Z-D08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B09+ZZ1K3Z-B09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A09+ZZ1K3Z-A09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H08+ZZ1K3Z-H08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H10+ZZ1K3U-H10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A11+ZZ1K3U-A11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F10+ZZ1K3U-F10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H09+ZZ1K3U-H09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G09+ZZ1K3U-G09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B10+ZZ1K3U-B10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D09+ZZ1K3U-D09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C09+ZZ1K3U-C09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E09+ZZ1K3U-E09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G11+ZZ1K3U-G11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H11+ZZ1K3U-H11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C11+ZZ1K3U-C11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E11+ZZ1K3U-E11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
»   C05+ZZ1K3U-C05+fdDOGf (Oust0038) PFYSHSAQSYNCVTRWWGITCEMYAAAETVESCLAKPHTENSFTNVWKDD
»   H11+ZZ1IXZ-H11+fdDOGf (Oust0034) PFYSHSAQADNCQTFYPLSWCESQAAAETVESCLAKPHTENSFTNVWKDD
»   A04+ZZ1K3Z-A04+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
E06+ZZ1K3U-E06+fdDOGf (Oust0040) F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
B03+ZZ1K3Z-B03+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
B06+ZZ1K3U-B06+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
E08+ZZ1K3U-E08+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
C08+ZZ1K3U-C08+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
E07+ZZ1K3U-E07+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
F07+ZZ1K3U-F07+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
D07+ZZ1K3U-D07+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
F02+ZZ1K3U-F02+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
F01+ZZ1K3U-F01+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
B02+ZZ1K3U-B02+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
A05+ZZ1K3U-A05+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
A05+ZZ1K3Z-A05+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
A04+ZZ1K3U-A04+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
D11+ZZ1K3Z-D11+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
C09+ZZ1K3Z-C09+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
A10+ZZ1K3Z-A10+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
G08+ZZ1K3Z-G08+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
C10+ZZ1K3U-C10+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
E10+ZZ1K3U-E10+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
A10+ZZ1K3U-A10+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
F09+ZZ1K3U-F09+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
»   F10+ZZ1IY1-F10+fdDOGf (Oust0037) PFYSHSAQLPTKTCPCLWCCAEDWAAAETVESCLAKPHTENSFTNVWKDD
* Sequences with highlighting in this column have warnings associated with them (F=frameshift, M=missing sequence)
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»   A11+ZZ1IOJ-A11+fdDOGf (Oust0025) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
B08+ZZ1IOI-B08+fdDOGf (Oust0014) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C08+ZZ1IOI-C08+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F07+ZZ1IOI-F07+fdDOGf (Oust0021) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C07+ZZ1IOI-C07+fdDOGf (Oust0017) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
A11+ZZ1IOI-A11+fdDOGf (Oust0012) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H10+ZZ1IOI-H10+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H09+ZZ1IOI-H09+fdDOGf (Oust0024) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
A05+ZZ1IOI-A05+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
B04+ZZ1IOI-B04+fdDOGf (Oust0013) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H11+ZZ1IY0-H11+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
G11+ZZ1IY0-G11+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C03+ZZ1IOI-C03+fdDOGf (Oust0015) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
E03+ZZ1IOI-E03+fdDOGf (Oust0020) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C06+ZZ1IOI-C06+fdDOGf (Oust0016) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
E06+ZZ1IOI-E06+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
D06+ZZ1IOI-D06+fdDOGf (Oust0019) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H05+ZZ1IOI-H05+fdDOGf (Oust0023) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F03+ZZ1IOJ-F03+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F08+ZZ1IY0-F08+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
B05+ZZ1IOJ-B05+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
D02+ZZ1IOJ-D02+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F01+ZZ1IOJ-F01+fdDOGf (Oust0027) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C11+ZZ1IOI-C11+fdDOGf (Oust0018) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F11+ZZ1IOJ-F11+fdDOGf (Oust0028) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F01+ZZ1IY0-F01+fdDOGf (Oust0035) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C11+ZZ1IOJ-C11+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H08+ZZ1IOJ-H08+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C09+ZZ1IOJ-C09+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H07+ZZ1IOJ-H07+fdDOGf (Oust0029) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
D08+ZZ1IOJ-D08+fdDOGf (Oust0026) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
A07+ZZ1IOJ-A07+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F02+ZZ1IOI-F02+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
G02+ZZ1IOI-G02+fdDOGf (Oust0022) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H06+ZZ1IY1-H06+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAOTVESCLAKPHTENSFTNVWKDD
G01+ZZ1IY1-G01+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
»   G01+ZZ1K3W-G01+fdDOGf (Oust0044) PFYSHSAQWTIAVCGKQGCEYVWEAAAETVESCLAKPHTENSFTNVWKDD
H01+ZZ1K3W-H01+fdDOGf PFYSHSAQWTIAVCGKQGCEYVWEAAAETVESCLAKPHTENSFTNVWKDD
»   H06+ZZ1IOI-H06+fdDOGf PFYSHSAQTTFPSCHPQTCYDGVQAAAETVESCLAKPHTENSFTNVWKDD
G02+ZZ1IOJ-G02+fdDOGf PFYSHSAQTTFPSCHPQTCYDGVQAAAETVESCLAKPHTENSFTNVWKDD
F10+ZZ1IOJ-F10+fdDOGf (Oust0032) PFYSHSAQTTFPSCHPQTCYDGVQAAAETVESCLAKPHTENSFTNVWKDD
B08+ZZ1IOJ-B08+fdDOGf PFYSHSAQTTFPSCHPQTCYDGVQAAAETVESCLAKPHTENSFTNVWKDD
»   A11+ZZ1IY0-A11+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
C04+ZZ1IOI-C04+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
A07+ZZ1IOI-A07+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
C05+ZZ1IOJ-C05+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
C02+ZZ1IOJ-C02+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
A03+ZZ1IOJ-A03+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
E11+ZZ1IY1-E11+fdDOGf (Oust0036) PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
B01+ZZ1IY0-B01+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
H09+ZZ1IOJ-H09+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
F09+ZZ1IOJ-F09+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
G06+ZZ1IOJ-G06+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
H05+ZZ1IOJ-H05+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
C06+ZZ1IOJ-C06+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
A03+ZZ1IOI-A03+fdDOGf (Oust0031) PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
»   H07+ZZ1K3W-H07+fdDOGf (Oust0045) PFYSHSAQSTPISWVLMVCDEIGEAAAQTVESCLAKPHTENSFTNVWKDD
»   E09+ZZ1K3X-E09+fdDOGf (Oust0048) PFYSHSAQLHCTSIWSDVVQLCDLAAAETVESCLAKPHTENSFTNVWKDD
»   A07+ZZ1K3X-A07+fdDOGf (Oust0047) PLYSHSAQSICPTIIMDTLYLCDBAAAETVESCLAKPHTENSFTNVWKDD
»   H06+ZZ1K3X-H06+fdDOGf (Oust0049) PFYSHSAQPLCTPIFPPFVLMCEEAAAETVESCLAKPHTENSFTNVWKDD
»   A10+ZZ1IXW-A10+fdDOGf PFYSHSAQLYCYPTKLPWVEYCHEGGAETVESCLAKPHTENSFTNVWKDD
B11+ZZ1IXW-B11+fdDOGf PFYSHSAQLYCYPTKLPWVEYCHEGGAETVESCLAKPHTENSFTNVWKDD
A01+ZZ1IXW-A01+fdDOGf (Oust0033) PFYSHSAQLYCYPTKLPWVEYCHEGGAETVESCLAKPHTENSFTNVWKDD
H04+ZZ1IXW-H04+fdDOGf PFYSHSAQLYCYPTKLPWVEYCHEGGAETVESCLAKPHTENSFTNVWKDD
H03+ZZ1IXW-H03+fdDOGf PFYSHSAQLYCYPTKLPWVEYCHEGGAETVESCLAKPHTENSFTNVWKDD
»   A01+ZZ1K3X-A01+fdDOGf (Oust0046) PFYSHSAQWVCTPLDSEIIEICQLAAAETVESCLAKPHTENSFTNVWKDD
»   E06+ZZ1IOH-E06+fdDOGf (Oust0030) PFYSHSAQIHCHPQGDQSVSFCWRAAAETVESCLAKPHTENSFTNVWKDD
»   G07+ZZ1K3U-G07+fdDOGf (Oust0041) PFYSHSAQLHQCTYYWWGLDCSFRAAAOTVHSCLTQSHTODSFTNLWKDN
»   B01+ZZ1K3U-B01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A01+ZZ1K3U-A01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B04+ZZ1K3Z-B04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G03+ZZ1K3Z-G03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D06+ZZ1K3U-D06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H03+ZZ1K3Z-H03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C06+ZZ1K3U-C06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B07+ZZ1K3U-B07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A07+ZZ1K3U-A07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E03+ZZ1K3Z-E03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F05+ZZ1K3U-F05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E05+ZZ1K3U-E05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H02+ZZ1K3Z-H02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D05+ZZ1K3U-D05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A03+ZZ1K3Z-A03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G02+ZZ1K3Z-G02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A06+ZZ1K3U-A06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D02+ZZ1K3Z-D02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G05+ZZ1K3U-G05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F08+ZZ1K3U-F08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H01+ZZ1K3Z-H01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D08+ZZ1K3U-D08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A09+ZZ1K3U-A09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F01+ZZ1K3Z-F01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B09+ZZ1K3U-B09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D01+ZZ1K3Z-D01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H08+ZZ1K3U-H08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B01+ZZ1K3Z-B01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C07+ZZ1K3U-C07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A08+ZZ1K3U-A08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A01+ZZ1K3Z-A01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B08+ZZ1K3U-B08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G07+ZZ1K3Z-G07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D02+ZZ1K3U-D02+fdDOGf (Oust0039) PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C02+ZZ1K3U-C02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A08+ZZ1K3Z-A08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B08+ZZ1K3Z-B08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E02+ZZ1K3U-E02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H02+ZZ1K3U-H02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D07+ZZ1K3Z-D07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G02+ZZ1K3U-G02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E07+ZZ1K3Z-E07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B03+ZZ1K3U-B03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F07+ZZ1K3Z-F07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G06+ZZ1K3Z-G06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D01+ZZ1K3U-D01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H06+ZZ1K3Z-H06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C01+ZZ1K3U-C01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A07+ZZ1K3Z-A07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B07+ZZ1K3Z-B07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C06+ZZ1K3Z-C06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H01+ZZ1K3U-H01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D06+ZZ1K3Z-D06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E06+ZZ1K3Z-E06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A02+ZZ1K3U-A02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H05+ZZ1K3Z-H05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C04+ZZ1K3U-C04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D04+ZZ1K3U-D04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B06+ZZ1K3Z-B06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E04+ZZ1K3U-E04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C05+ZZ1K3Z-C05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H04+ZZ1K3U-H04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F05+ZZ1K3Z-F05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRASAETVESCLAKPHTENSFTNVWKDD
B05+ZZ1K3U-B05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H04+ZZ1K3Z-H04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G04+ZZ1K3Z-G04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D03+ZZ1K3U-D03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B05+ZZ1K3Z-B05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F03+ZZ1K3U-F03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D04+ZZ1K3Z-D04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G03+ZZ1K3U-G03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F04+ZZ1K3Z-F04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E04+ZZ1K3Z-E04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E11+ZZ1K3Z-E11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F11+ZZ1K3Z-F11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F10+ZZ1K3Z-F10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C10+ZZ1K3Z-C10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A11+ZZ1K3Z-A11+fdDOGf (Oust0042) PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B11+ZZ1K3Z-B11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H10+ZZ1K3Z-H10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E09+ZZ1K3Z-E09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D09+ZZ1K3Z-D09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B10+ZZ1K3Z-B10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H09+ZZ1K3Z-H09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G09+ZZ1K3Z-G09+fdDOGf (Oust0043) PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F08+ZZ1K3Z-F08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D08+ZZ1K3Z-D08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B09+ZZ1K3Z-B09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A09+ZZ1K3Z-A09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H08+ZZ1K3Z-H08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H10+ZZ1K3U-H10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A11+ZZ1K3U-A11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F10+ZZ1K3U-F10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H09+ZZ1K3U-H09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G09+ZZ1K3U-G09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B10+ZZ1K3U-B10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D09+ZZ1K3U-D09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C09+ZZ1K3U-C09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E09+ZZ1K3U-E09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G11+ZZ1K3U-G11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H11+ZZ1K3U-H11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C11+ZZ1K3U-C11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E11+ZZ1K3U-E11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
»   C05+ZZ1K3U-C05+fdDOGf (Oust0038) PFYSHSAQSYNCVTRWWGITCEMYAAAETVESCLAKPHTENSFTNVWKDD
»   H11+ZZ1IXZ-H11+fdDOGf (Oust0034) PFYSHSAQADNCQTFYPLSWCESQAAAETVESCLAKPHTENSFTNVWKDD
»   A04+ZZ1K3Z-A04+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
E06+ZZ1K3U-E06+fdDOGf (Oust0040) F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
B03+ZZ1K3Z-B03+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
B06+ZZ1K3U-B06+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
E08+ZZ1K3U-E08+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
C08+ZZ1K3U-C08+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
E07+ZZ1K3U-E07+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
F07+ZZ1K3U-F07+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
D07+ZZ1K3U-D07+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
F02+ZZ1K3U-F02+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
F01+ZZ1K3U-F01+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
B02+ZZ1K3U-B02+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
A05+ZZ1K3U-A05+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
A05+ZZ1K3Z-A05+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
A04+ZZ1K3U-A04+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
D11+ZZ1K3Z-D11+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
C09+ZZ1K3Z-C09+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
A10+ZZ1K3Z-A10+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
G08+ZZ1K3Z-G08+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
C10+ZZ1K3U-C10+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
E10+ZZ1K3U-E10+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
A10+ZZ1K3U-A10+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
F09+ZZ1K3U-F09+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
»   F10+ZZ1IY1-F10+fdDOGf (Oust0037) PFYSHSAQLPTKTCPCLWCCAEDWAAAETVESCLAKPHTENSFTNVWKDD
* Sequences with highlighting in this column have warnings associated with them (F=frameshift, M=missing sequence)
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»   A11+ZZ1IOJ-A11+fdDOGf (Oust0025) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
B08+ZZ1IOI-B08+fdDOGf (Oust0014) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C08+ZZ1IOI-C08+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F07+ZZ1IOI-F07+fdDOGf (Oust0021) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C07+ZZ1IOI-C07+fdDOGf (Oust0017) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
A11+ZZ1IOI-A11+fdDOGf (Oust0012) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H10+ZZ1IOI-H10+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H09+ZZ1IOI-H09+fdDOGf (Oust0024) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
A05+ZZ1IOI-A05+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
B04+ZZ1IOI-B04+fdDOGf (Oust0013) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H11+ZZ1IY0-H11+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
G11+ZZ1IY0-G11+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C03+ZZ1IOI-C03+fdDOGf (Oust0015) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
E03+ZZ1IOI-E03+fdDOGf (Oust0020) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C06+ZZ1IOI-C06+fdDOGf (Oust0016) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
E06+ZZ1IOI-E06+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
D06+ZZ1IOI-D06+fdDOGf (Oust0019) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H05+ZZ1IOI-H05+fdDOGf (Oust0023) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F03+ZZ1IOJ-F03+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F08+ZZ1IY0-F08+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
B05+ZZ1IOJ-B05+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
D02+ZZ1IOJ-D02+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F01+ZZ1IOJ-F01+fdDOGf (Oust0027) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C11+ZZ1IOI-C11+fdDOGf (Oust0018) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F11+ZZ1IOJ-F11+fdDOGf (Oust0028) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F01+ZZ1IY0-F01+fdDOGf (Oust0035) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C11+ZZ1IOJ-C11+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H08+ZZ1IOJ-H08+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C09+ZZ1IOJ-C09+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H07+ZZ1IOJ-H07+fdDOGf (Oust0029) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
D08+ZZ1IOJ-D08+fdDOGf (Oust0026) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
A07+ZZ1IOJ-A07+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F02+ZZ1IOI-F02+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
G02+ZZ1IOI-G02+fdDOGf (Oust0022) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H06+ZZ1IY1-H06+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAOTVESCLAKPHTENSFTNVWKDD
G01+ZZ1IY1-G01+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
»   G01+ZZ1K3W-G01+fdDOGf (Oust0044) PFYSHSAQWTIAVCGKQGCEYVWEAAAETVESCLAKPHTENSFTNVWKDD
H01+ZZ1K3W-H01+fdDOGf PFYSHSAQWTIAVCGKQGCEYVWEAAAETVESCLAKPHTENSFTNVWKDD
»   H06+ZZ1IOI-H06+fdDOGf PFYSHSAQTTFPSCHPQTCYDGVQAAAETVESCLAKPHTENSFTNVWKDD
G02+ZZ1IOJ-G02+fdDOGf PFYSHSAQTTFPSCHPQTCYDGVQAAAETVESCLAKPHTENSFTNVWKDD
F10+ZZ1IOJ-F10+fdDOGf (Oust0032) PFYSHSAQTTFPSCHPQTCYDGVQAAAETVESCLAKPHTENSFTNVWKDD
B08+ZZ1IOJ-B08+fdDOGf PFYSHSAQTTFPSCHPQTCYDGVQAAAETVESCLAKPHTENSFTNVWKDD
»   A11+ZZ1IY0-A11+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
C04+ZZ1IOI-C04+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
A07+ZZ1IOI-A07+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
C05+ZZ1IOJ-C05+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
C02+ZZ1IOJ-C02+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
A03+ZZ1IOJ-A03+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
E11+ZZ1IY1-E11+fdDOGf (Oust0036) PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
B01+ZZ1IY0-B01+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
H09+ZZ1IOJ-H09+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
F09+ZZ1IOJ-F09+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
G06+ZZ1IOJ-G06+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
H05+ZZ1IOJ-H05+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
C06+ZZ1IOJ-C06+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
A03+ZZ1IOI-A03+fdDOGf (Oust0031) PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
»   H07+ZZ1K3W-H07+fdDOGf (Oust0045) PFYSHSAQSTPISWVLMVCDEIGEAAAQTVESCLAKPHTENSFTNVWKDD
»   E09+ZZ1K3X-E09+fdDOGf (Oust0048) PFYSHSAQLHCTSIWSDVVQLCDLAAAETVESCLAKPHTENSFTNVWKDD
»   A07+ZZ1K3X-A07+fdDOGf (Oust0047) PLYSHSAQSICPTIIMDTLYLCDBAAAETVESCLAKPHTENSFTNVWKDD
»   H06+ZZ1K3X-H06+fdDOGf (Oust0049) PFYSHSAQPLCTPIFPPFVLMCEEAAAETVESCLAKPHTENSFTNVWKDD
»   A10+ZZ1IXW-A10+fdDOGf PFYSHSAQLYCYPTKLPWVEYCHEGGAETVESCLAKPHTENSFTNVWKDD
B11+ZZ1IXW-B11+fdDOGf PFYSHSAQLYCYPTKLPWVEYCHEGGAETVESCLAKPHTENSFTNVWKDD
A01+ZZ1IXW-A01+fdDOGf (Oust0033) PFYSHSAQLYCYPTKLPWVEYCHEGGAETVESCLAKPHTENSFTNVWKDD
H04+ZZ1IXW-H04+fdDOGf PFYSHSAQLYCYPTKLPWVEYCHEGGAETVESCLAKPHTENSFTNVWKDD
H03+ZZ1IXW-H03+fdDOGf PFYSHSAQLYCYPTKLPWVEYCHEGGAETVESCLAKPHTENSFTNVWKDD
»   A01+ZZ1K3X-A01+fdDOGf (Oust0046) PFYSHSAQWVCTPLDSEIIEICQLAAAETVESCLAKPHTENSFTNVWKDD
»   E06+ZZ1IOH-E06+fdDOGf (Oust0030) PFYSHSAQIHCHPQGDQSVSFCWRAAAETVESCLAKPHTENSFTNVWKDD
»   G07+ZZ1K3U-G07+fdDOGf (Oust0041) PFYSHSAQLHQCTYYWWGLDCSFRAAAOTVHSCLTQSHTODSFTNLWKDN
»   B01+ZZ1K3U-B01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A01+ZZ1K3U-A01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B04+ZZ1K3Z-B04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G03+ZZ1K3Z-G03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D06+ZZ1K3U-D06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H03+ZZ1K3Z-H03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C06+ZZ1K3U-C06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B07+ZZ1K3U-B07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A07+ZZ1K3U-A07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E03+ZZ1K3Z-E03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F05+ZZ1K3U-F05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E05+ZZ1K3U-E05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H02+ZZ1K3Z-H02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D05+ZZ1K3U-D05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A03+ZZ1K3Z-A03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G02+ZZ1K3Z-G02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A06+ZZ1K3U-A06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D02+ZZ1K3Z-D02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G05+ZZ1K3U-G05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F08+ZZ1K3U-F08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H01+ZZ1K3Z-H01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D08+ZZ1K3U-D08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A09+ZZ1K3U-A09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F01+ZZ1K3Z-F01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B09+ZZ1K3U-B09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D01+ZZ1K3Z-D01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H08+ZZ1K3U-H08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B01+ZZ1K3Z-B01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C07+ZZ1K3U-C07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A08+ZZ1K3U-A08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A01+ZZ1K3Z-A01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B08+ZZ1K3U-B08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G07+ZZ1K3Z-G07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D02+ZZ1K3U-D02+fdDOGf (Oust0039) PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C02+ZZ1K3U-C02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A08+ZZ1K3Z-A08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B08+ZZ1K3Z-B08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E02+ZZ1K3U-E02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H02+ZZ1K3U-H02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D07+ZZ1K3Z-D07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G02+ZZ1K3U-G02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E07+ZZ1K3Z-E07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B03+ZZ1K3U-B03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F07+ZZ1K3Z-F07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G06+ZZ1K3Z-G06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D01+ZZ1K3U-D01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H06+ZZ1K3Z-H06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C01+ZZ1K3U-C01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A07+ZZ1K3Z-A07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B07+ZZ1K3Z-B07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C06+ZZ1K3Z-C06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H01+ZZ1K3U-H01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D06+ZZ1K3Z-D06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E06+ZZ1K3Z-E06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A02+ZZ1K3U-A02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H05+ZZ1K3Z-H05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C04+ZZ1K3U-C04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D04+ZZ1K3U-D04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B06+ZZ1K3Z-B06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E04+ZZ1K3U-E04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C05+ZZ1K3Z-C05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H04+ZZ1K3U-H04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F05+ZZ1K3Z-F05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRASAETVESCLAKPHTENSFTNVWKDD
B05+ZZ1K3U-B05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H04+ZZ1K3Z-H04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G04+ZZ1K3Z-G04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D03+ZZ1K3U-D03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B05+ZZ1K3Z-B05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F03+ZZ1K3U-F03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D04+ZZ1K3Z-D04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G03+ZZ1K3U-G03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F04+ZZ1K3Z-F04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E04+ZZ1K3Z-E04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E11+ZZ1K3Z-E11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F11+ZZ1K3Z-F11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F10+ZZ1K3Z-F10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C10+ZZ1K3Z-C10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A11+ZZ1K3Z-A11+fdDOGf (Oust0042) PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B11+ZZ1K3Z-B11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H10+ZZ1K3Z-H10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E09+ZZ1K3Z-E09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D09+ZZ1K3Z-D09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B10+ZZ1K3Z-B10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H09+ZZ1K3Z-H09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G09+ZZ1K3Z-G09+fdDOGf (Oust0043) PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F08+ZZ1K3Z-F08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D08+ZZ1K3Z-D08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B09+ZZ1K3Z-B09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A09+ZZ1K3Z-A09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H08+ZZ1K3Z-H08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H10+ZZ1K3U-H10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A11+ZZ1K3U-A11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F10+ZZ1K3U-F10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H09+ZZ1K3U-H09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G09+ZZ1K3U-G09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B10+ZZ1K3U-B10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D09+ZZ1K3U-D09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C09+ZZ1K3U-C09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E09+ZZ1K3U-E09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G11+ZZ1K3U-G11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H11+ZZ1K3U-H11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C11+ZZ1K3U-C11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E11+ZZ1K3U-E11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
»   C05+ZZ1K3U-C05+fdDOGf (Oust0038) PFYSHSAQSYNCVTRWWGITCEMYAAAETVESCLAKPHTENSFTNVWKDD
»   H11+ZZ1IXZ-H11+fdDOGf (Oust0034) PFYSHSAQADNCQTFYPLSWCESQAAAETVESCLAKPHTENSFTNVWKDD
»   A04+ZZ1K3Z-A04+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
E06+ZZ1K3U-E06+fdDOGf (Oust0040) F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
B03+ZZ1K3Z-B03+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
B06+ZZ1K3U-B06+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
E08+ZZ1K3U-E08+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
C08+ZZ1K3U-C08+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
E07+ZZ1K3U-E07+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
F07+ZZ1K3U-F07+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
D07+ZZ1K3U-D07+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
F02+ZZ1K3U-F02+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
F01+ZZ1K3U-F01+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
B02+ZZ1K3U-B02+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
A05+ZZ1K3U-A05+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
A05+ZZ1K3Z-A05+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
A04+ZZ1K3U-A04+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
D11+ZZ1K3Z-D11+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
C09+ZZ1K3Z-C09+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
A10+ZZ1K3Z-A10+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
G08+ZZ1K3Z-G08+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
C10+ZZ1K3U-C10+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
E10+ZZ1K3U-E10+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
A10+ZZ1K3U-A10+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
F09+ZZ1K3U-F09+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
»   F10+ZZ1IY1-F10+fdDOGf (Oust0037) PFYSHSAQLPTKTCPCLWCCAEDWAAAETVESCLAKPHTENSFTNVWKDD
* Sequences with highlighting in this column have warnings associated with them (F=frameshift, M=missing sequence)
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»   A11+ZZ1IOJ-A11+fdDOGf (Oust0025) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
B08+ZZ1IOI-B08+fdDOGf (Oust0014) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C08+ZZ1IOI-C08+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F07+ZZ1IOI-F07+fdDOGf (Oust0021) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C07+ZZ1IOI-C07+fdDOGf (Oust0017) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
A11+ZZ1IOI-A11+fdDOGf (Oust0012) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H10+ZZ1IOI-H10+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H09+ZZ1IOI-H09+fdDOGf (Oust0024) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
A05+ZZ1IOI-A05+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
B04+ZZ1IOI-B04+fdDOGf (Oust0013) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H11+ZZ1IY0-H11+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
G11+ZZ1IY0-G11+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C03+ZZ1IOI-C03+fdDOGf (Oust0015) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
E03+ZZ1IOI-E03+fdDOGf (Oust0020) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C06+ZZ1IOI-C06+fdDOGf (Oust0016) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
E06+ZZ1IOI-E06+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
D06+ZZ1IOI-D06+fdDOGf (Oust0019) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H05+ZZ1IOI-H05+fdDOGf (Oust0023) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F03+ZZ1IOJ-F03+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F08+ZZ1IY0-F08+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
B05+ZZ1IOJ-B05+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
D02+ZZ1IOJ-D02+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F01+ZZ1IOJ-F01+fdDOGf (Oust0027) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C11+ZZ1IOI-C11+fdDOGf (Oust0018) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F11+ZZ1IOJ-F11+fdDOGf (Oust0028) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F01+ZZ1IY0-F01+fdDOGf (Oust0035) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C11+ZZ1IOJ-C11+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H08+ZZ1IOJ-H08+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
C09+ZZ1IOJ-C09+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H07+ZZ1IOJ-H07+fdDOGf (Oust0029) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
D08+ZZ1IOJ-D08+fdDOGf (Oust0026) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
A07+ZZ1IOJ-A07+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
F02+ZZ1IOI-F02+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
G02+ZZ1IOI-G02+fdDOGf (Oust0022) PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
H06+ZZ1IY1-H06+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAOTVESCLAKPHTENSFTNVWKDD
G01+ZZ1IY1-G01+fdDOGf PFYSHSAQWSIIDCSMNYCLYIEGAAAETVESCLAKPHTENSFTNVWKDD
»   G01+ZZ1K3W-G01+fdDOGf (Oust0044) PFYSHSAQWTIAVCGKQGCEYVWEAAAETVESCLAKPHTENSFTNVWKDD
H01+ZZ1K3W-H01+fdDOGf PFYSHSAQWTIAVCGKQGCEYVWEAAAETVESCLAKPHTENSFTNVWKDD
»   H06+ZZ1IOI-H06+fdDOGf PFYSHSAQTTFPSCHPQTCYDGVQAAAETVESCLAKPHTENSFTNVWKDD
G02+ZZ1IOJ-G02+fdDOGf PFYSHSAQTTFPSCHPQTCYDGVQAAAETVESCLAKPHTENSFTNVWKDD
F10+ZZ1IOJ-F10+fdDOGf (Oust0032) PFYSHSAQTTFPSCHPQTCYDGVQAAAETVESCLAKPHTENSFTNVWKDD
B08+ZZ1IOJ-B08+fdDOGf PFYSHSAQTTFPSCHPQTCYDGVQAAAETVESCLAKPHTENSFTNVWKDD
»   A11+ZZ1IY0-A11+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
C04+ZZ1IOI-C04+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
A07+ZZ1IOI-A07+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
C05+ZZ1IOJ-C05+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
C02+ZZ1IOJ-C02+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
A03+ZZ1IOJ-A03+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
E11+ZZ1IY1-E11+fdDOGf (Oust0036) PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
B01+ZZ1IY0-B01+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
H09+ZZ1IOJ-H09+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
F09+ZZ1IOJ-F09+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
G06+ZZ1IOJ-G06+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
H05+ZZ1IOJ-H05+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
C06+ZZ1IOJ-C06+fdDOGf PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
A03+ZZ1IOI-A03+fdDOGf (Oust0031) PFYSHSAQGWHPMCNLMACSQGRPAAAETVESCLAKPHTENSFTNVWKDD
»   H07+ZZ1K3W-H07+fdDOGf (Oust0045) PFYSHSAQSTPISWVLMVCDEIGEAAAQTVESCLAKPHTENSFTNVWKDD
»   E09+ZZ1K3X-E09+fdDOGf (Oust0048) PFYSHSAQLHCTSIWSDVVQLCDLAAAETVESCLAKPHTENSFTNVWKDD
»   A07+ZZ1K3X-A07+fdDOGf (Oust0047) PLYSHSAQSICPTIIMDTLYLCDBAAAETVESCLAKPHTENSFTNVWKDD
»   H06+ZZ1K3X-H06+fdDOGf (Oust0049) PFYSHSAQPLCTPIFPPFVLMCEEAAAETVESCLAKPHTENSFTNVWKDD
»   A10+ZZ1IXW-A10+fdDOGf PFYSHSAQLYCYPTKLPWVEYCHEGGAETVESCLAKPHTENSFTNVWKDD
B11+ZZ1IXW-B11+fdDOGf PFYSHSAQLYCYPTKLPWVEYCHEGGAETVESCLAKPHTENSFTNVWKDD
A01+ZZ1IXW-A01+fdDOGf (Oust0033) PFYSHSAQLYCYPTKLPWVEYCHEGGAETVESCLAKPHTENSFTNVWKDD
H04+ZZ1IXW-H04+fdDOGf PFYSHSAQLYCYPTKLPWVEYCHEGGAETVESCLAKPHTENSFTNVWKDD
H03+ZZ1IXW-H03+fdDOGf PFYSHSAQLYCYPTKLPWVEYCHEGGAETVESCLAKPHTENSFTNVWKDD
»   A01+ZZ1K3X-A01+fdDOGf (Oust0046) PFYSHSAQWVCTPLDSEIIEICQLAAAETVESCLAKPHTENSFTNVWKDD
»   E06+ZZ1IOH-E06+fdDOGf (Oust0030) PFYSHSAQIHCHPQGDQSVSFCWRAAAETVESCLAKPHTENSFTNVWKDD
»   G07+ZZ1K3U-G07+fdDOGf (Oust0041) PFYSHSAQLHQCTYYWWGLDCSFRAAAOTVHSCLTQSHTODSFTNLWKDN
»   B01+ZZ1K3U-B01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A01+ZZ1K3U-A01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B04+ZZ1K3Z-B04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G03+ZZ1K3Z-G03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D06+ZZ1K3U-D06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H03+ZZ1K3Z-H03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C06+ZZ1K3U-C06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B07+ZZ1K3U-B07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A07+ZZ1K3U-A07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E03+ZZ1K3Z-E03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F05+ZZ1K3U-F05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E05+ZZ1K3U-E05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H02+ZZ1K3Z-H02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D05+ZZ1K3U-D05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A03+ZZ1K3Z-A03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G02+ZZ1K3Z-G02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A06+ZZ1K3U-A06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D02+ZZ1K3Z-D02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G05+ZZ1K3U-G05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F08+ZZ1K3U-F08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H01+ZZ1K3Z-H01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D08+ZZ1K3U-D08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A09+ZZ1K3U-A09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F01+ZZ1K3Z-F01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B09+ZZ1K3U-B09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D01+ZZ1K3Z-D01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H08+ZZ1K3U-H08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B01+ZZ1K3Z-B01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C07+ZZ1K3U-C07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A08+ZZ1K3U-A08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A01+ZZ1K3Z-A01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B08+ZZ1K3U-B08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G07+ZZ1K3Z-G07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D02+ZZ1K3U-D02+fdDOGf (Oust0039) PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C02+ZZ1K3U-C02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A08+ZZ1K3Z-A08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B08+ZZ1K3Z-B08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E02+ZZ1K3U-E02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H02+ZZ1K3U-H02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D07+ZZ1K3Z-D07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G02+ZZ1K3U-G02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E07+ZZ1K3Z-E07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B03+ZZ1K3U-B03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F07+ZZ1K3Z-F07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G06+ZZ1K3Z-G06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D01+ZZ1K3U-D01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H06+ZZ1K3Z-H06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C01+ZZ1K3U-C01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A07+ZZ1K3Z-A07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B07+ZZ1K3Z-B07+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C06+ZZ1K3Z-C06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H01+ZZ1K3U-H01+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D06+ZZ1K3Z-D06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E06+ZZ1K3Z-E06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A02+ZZ1K3U-A02+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H05+ZZ1K3Z-H05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C04+ZZ1K3U-C04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D04+ZZ1K3U-D04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B06+ZZ1K3Z-B06+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E04+ZZ1K3U-E04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C05+ZZ1K3Z-C05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H04+ZZ1K3U-H04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F05+ZZ1K3Z-F05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRASAETVESCLAKPHTENSFTNVWKDD
B05+ZZ1K3U-B05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H04+ZZ1K3Z-H04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G04+ZZ1K3Z-G04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D03+ZZ1K3U-D03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B05+ZZ1K3Z-B05+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F03+ZZ1K3U-F03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D04+ZZ1K3Z-D04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G03+ZZ1K3U-G03+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F04+ZZ1K3Z-F04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E04+ZZ1K3Z-E04+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E11+ZZ1K3Z-E11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F11+ZZ1K3Z-F11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F10+ZZ1K3Z-F10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C10+ZZ1K3Z-C10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A11+ZZ1K3Z-A11+fdDOGf (Oust0042) PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B11+ZZ1K3Z-B11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H10+ZZ1K3Z-H10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E09+ZZ1K3Z-E09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D09+ZZ1K3Z-D09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B10+ZZ1K3Z-B10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H09+ZZ1K3Z-H09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G09+ZZ1K3Z-G09+fdDOGf (Oust0043) PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F08+ZZ1K3Z-F08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D08+ZZ1K3Z-D08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B09+ZZ1K3Z-B09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A09+ZZ1K3Z-A09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H08+ZZ1K3Z-H08+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H10+ZZ1K3U-H10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
A11+ZZ1K3U-A11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
F10+ZZ1K3U-F10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H09+ZZ1K3U-H09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G09+ZZ1K3U-G09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
B10+ZZ1K3U-B10+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
D09+ZZ1K3U-D09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C09+ZZ1K3U-C09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E09+ZZ1K3U-E09+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
G11+ZZ1K3U-G11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
H11+ZZ1K3U-H11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
C11+ZZ1K3U-C11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
E11+ZZ1K3U-E11+fdDOGf PFYSHSAQLHECTYYWWGLDCSFRAAAETVESCLAKPHTENSFTNVWKDD
»   C05+ZZ1K3U-C05+fdDOGf (Oust0038) PFYSHSAQSYNCVTRWWGITCEMYAAAETVESCLAKPHTENSFTNVWKDD
»   H11+ZZ1IXZ-H11+fdDOGf (Oust0034) PFYSHSAQADNCQTFYPLSWCESQAAAETVESCLAKPHTENSFTNVWKDD
»   A04+ZZ1K3Z-A04+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
E06+ZZ1K3U-E06+fdDOGf (Oust0040) F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
B03+ZZ1K3Z-B03+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
B06+ZZ1K3U-B06+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
E08+ZZ1K3U-E08+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
C08+ZZ1K3U-C08+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
E07+ZZ1K3U-E07+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
F07+ZZ1K3U-F07+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
D07+ZZ1K3U-D07+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
F02+ZZ1K3U-F02+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
F01+ZZ1K3U-F01+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
B02+ZZ1K3U-B02+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
A05+ZZ1K3U-A05+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
A05+ZZ1K3Z-A05+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
A04+ZZ1K3U-A04+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
D11+ZZ1K3Z-D11+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
C09+ZZ1K3Z-C09+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
A10+ZZ1K3Z-A10+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
G08+ZZ1K3Z-G08+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
C10+ZZ1K3U-C10+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
E10+ZZ1K3U-E10+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
A10+ZZ1K3U-A10+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
F09+ZZ1K3U-F09+fdDOGf F PFYSHSAQARDCLETWYGFTCWNVAAAETXESCLAKPHTENSFTNVWKDD
»   F10+ZZ1IY1-F10+fdDOGf (Oust0037) PFYSHSAQLPTKTCPCLWCCAEDWAAAETVESCLAKPHTENSFTNVWKDD
* Sequences with highlighting in this column have warnings associated with them (F=frameshift, M=missing sequence)
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Figure S5: Effect of Pep1- and Pep8-Fc/IL1RA on the reversal of partial nerve ligation induced 
mechanical hyperalgesia - Ipsi/Contra Ratio 
Partial nerve ligation (PNL) of operated mice was conducted at the baseline time point. Mice were 
administered control or CPep-Fc/IL1RA on day 10 and were re-tested for changes in mechanical 
hyperalgesia at 4hrs post dose and also on 1, 2 and 4 days post dose. Ipsilateral to contralateral 
ratios for Sham + PBS Vehicle control (Black), Operated (Op) + PBS Vehicle control (red), Op + Pep1-
FcIL1RA (green), Op + Pep8-Fc/IL1RA, and Op + control CPep-FcIL1RA (blue) are shown. Data 
analysed using 2 way ANOVA with time and treatment as dependant factors. Subsequent statistical 
significance obtained using Tukey's Post Hoc test. Individual comparisons as shown ** P<0.01 Op + 
PBS vs Pep8; *** P<0.001 Op + PBS vs Pep1, n= 9-10 per group 
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